AUTHOR INDEX

A

Aamdal S, *see* Sundstrøm S
Aapro MS, *see* Bernhard J
see Repetto L
Aaronson NK, *see* Detmar SB
Aasebø U, *see* Sundstrøm S
Abbruzzese JL, *see* Herbst RS
see Pentz RD
see Pisters PWT
Abdel-Rahman S, *see* Wendtner C-M
Abdel-Wanis ME, *see* Tsuchiya H
Abdi EA, *see* Denman JP
Abdolell M, *see* Kiss TL
Abdulkadyrov K, *see* Österborg A
Abe S, *see* Tsuchiya H
Abel U, *see* Kaiser U
Abrams J, *see* Harlan LC
see Sateren WB
Abrams R, *see* Shaw E
Abramson N, Aster RH. Retrospective Assessment of Hypercoagulability in Breast Cancer Prevention Trial (correspondence), 4133
Abramson N, Stokes PK, Luke M, Marks AR, Harris JM. Ovarian and Papillary-Serous Peritoneal Carcinoma: Pilot Study With Thalidomide (correspondence), 1147
Abuja PM, *see* Wölfler A
Achten R, Verhoef G, Vanuytsel L, De Wolf-Peeters C. T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Distinct Clinicopathologic Entity, 1269
Acute Leukemia Working Party of the European Blood and Marrow Transplant Registry, *see* Rocha V
Acute Myeloid Leukemia Study Group Ulm, *see* Fröhling S
Adachi I, *see* Morita T
Adak S, *see* Kemeny MM
Adamo V, *see* Scagliotti GV
Adams DJ, *see* Bass AJ
see Rizzieri DA
Adams J, *see* Orlowski RZ
see Pearson ML
Adams N, *see* DiPaola RS
Adelstein DJ, Saxton JP, Lavertu P, Rybicki LA, Esclamado RM, Wood BG, Strome M, Carroll MA. Maximizing Local Control and Organ Preservation in Stage IV Squamous Cell Head and Neck Cancer With Hyperfractionated Radiation and Concurrent Chemotherapy, 1405
Adenis A, *see* Curé H
Ades L, *see* Bergeron A
Adjei AA, see Dy GK
Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C. Comparative Pharmacokinetic Study of Continuous Venous Infusion Fluorouracil and Oral Fluorouracil With Eniluracil in Patients With Advanced Solid Tumors, 1683
Adler H, *see* Datta RV
Áfra D, *see* Pignatti F
Agarwala SS, see Kirkwood JM
Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, Gonzalez R, Hersh E, Feun L, Belt R, Meyskens F, Hellstrand K, Wood D, Kirkwood JM, Gehlsen KR, Naredi P. Results From a Random Phase III Study Comparing Combined Treatment With Histamine Dihydrochloride Plus Interleukin-2 Versus Interleukin-2 Alone in Patients With Metastatic Melanoma, 125
Agarwala SS, Hellstrand K, Naredi P. Interleukin-2 and Histamine Dihydrochloride in Metastatic Melanoma (correspondence), 3558
Agelaki S, *see* Souglakos J
Aghajanian C, *see* Barakat RR
see Dizon DS
see Hensley ML
Aglietta M, *see* Fagioli F
Agrawal M, Emanuel EJ. Attending to Psychologic Symptoms and Palliative Care (editorial), 624
Agteresch HJ, Rietveld T, Kerkhofs LGM, van den Berg JWO, Wilson JHP, Dagnelie PC. Beneficial Effects of Adenosine Triphosphate on Nutritional Status in Advanced Lung Cancer Patients: A Randomized Clinical Trial, 371
Ah-See AK, *see* Smith IC
A'Hern R, *see* Harper-Wynne CL
A'Hern RP, *see* Kolomainen DF
Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg ER, Silberfarb PM. Neuropsychologic Impact of Standard-Dose Systemic Chemotherapy in Long-Term Survivors of Breast Cancer and Lymphoma, 485
Ahmad SA, Patel SR, Ballo MT, Baker TP, Yasko AW, Wang X, Feig BW, Hunt KK, Lin PP, Weber KL, Chen LL, Zagars GK, Pollock RE, Benjamin RS, Pisters PWT. Extraosseous Osteosarcoma: Response to Treatment and Long-Term Outcome, 521
Ahmed T, *see* Seiter K
Ahn J-H, *see* Lee Jung-Hee
Ahn S-D, *see* Lee Jung-Hee
Aiello E, *see* Chlebowski RT
Aish LS, *see* Oo TH
Aisner J, *see* Berry DA
Akabani G, *see* Reardon DA
Akçali Z, *see* Saglam S

AUTHOR INDEX

A

Aamdal S, *see* Sundstrøm S
Aapro MS, *see* Bernhard J
see Repetto L
Aaronson NK, *see* Detmar SB
Aasebø U, *see* Sundstrøm S
Abbruzzese JL, *see* Herbst RS
see Pentz RD
see Pisters PWT
Abdel-Rahman S, *see* Wendtner C-M
Abdel-Wanis ME, *see* Tsuchiya H
Abdi EA, *see* Denman JP
Abdolell M, *see* Kiss TL
Abdulkadyrov K, *see* Österborg A
Abe S, *see* Tsuchiya H
Abel U, *see* Kaiser U
Abrams J, *see* Harlan LC
see Sateren WB
Abrams R, *see* Shaw E
Abramson N, Aster RH. Retrospective Assessment of Hypercoagulability in Breast Cancer Prevention Trial (correspondence), 4133
Abramson N, Stokes PK, Luke M, Marks AR, Harris JM. Ovarian and Papillary-Serous Peritoneal Carcinoma: Pilot Study With Thalidomide (correspondence), 1147
Abuja PM, *see* Wölfler A
Achten R, Verhoef G, Vanuytsel L, De Wolf-Peeters C. T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Distinct Clinicopathologic Entity, 1269
Acute Leukemia Working Party of the European Blood and Marrow Transplant Registry, *see* Rocha V
Acute Myeloid Leukemia Study Group Ulm, *see* Fröhling S
Adachi I, *see* Morita T
Adak S, *see* Kemeny MM
Adamo V, *see* Scagliotti GV
Adams DJ, *see* Bass AJ
see Rizzieri DA
Adams J, *see* Orlowski RZ
see Pearson ML
Adams N, *see* DiPaola RS
Adelstein DJ, Saxton JP, Lavertu P, Rybicki LA, Esclamado RM, Wood BG, Strome M, Carroll MA. Maximizing Local Control and Organ Preservation in Stage IV Squamous Cell Head and Neck Cancer With Hyperfractionated Radiation and Concurrent Chemotherapy, 1405
Adenis A, *see* Curé H
Ades L, *see* Bergeron A
Adjei AA, see Dy GK
Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C. Comparative Pharmacokinetic Study of Continuous Venous Infusion Fluorouracil and Oral Fluorouracil With Eniluracil in Patients With Advanced Solid Tumors, 1683
Adler H, *see* Datta RV
Áfra D, *see* Pignatti F
Agarwala SS, see Kirkwood JM
Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, Gonzalez R, Hersh E, Feun L, Belt R, Meyskens F, Hellstrand K, Wood D, Kirkwood JM, Gehlsen KR, Naredi P. Results From a Random Phase III Study Comparing Combined Treatment With Histamine Dihydrochloride Plus Interleukin-2 Versus Interleukin-2 Alone in Patients With Metastatic Melanoma, 125
Agarwala SS, Hellstrand K, Naredi P. Interleukin-2 and Histamine Dihydrochloride in Metastatic Melanoma (correspondence), 3558
Agelaki S, *see* Souglakos J
Aghajanian C, *see* Barakat RR
see Dizon DS
see Hensley ML
Aglietta M, *see* Fagioli F
Agrawal M, Emanuel EJ. Attending to Psychologic Symptoms and Palliative Care (editorial), 624
Agteresch HJ, Rietveld T, Kerkhofs LGM, van den Berg JWO, Wilson JHP, Dagnelie PC. Beneficial Effects of Adenosine Triphosphate on Nutritional Status in Advanced Lung Cancer Patients: A Randomized Clinical Trial, 371
Ah-See AK, *see* Smith IC
A'Hern R, *see* Harper-Wynne CL
A'Hern RP, *see* Kolomainen DF
Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg ER, Silberfarb PM. Neuropsychologic Impact of Standard-Dose Systemic Chemotherapy in Long-Term Survivors of Breast Cancer and Lymphoma, 485
Ahmad SA, Patel SR, Ballo MT, Baker TP, Yasko AW, Wang X, Feig BW, Hunt KK, Lin PP, Weber KL, Chen LL, Zagars GK, Pollock RE, Benjamin RS, Pisters PWT. Extraosseous Osteosarcoma: Response to Treatment and Long-Term Outcome, 521
Ahmed T, *see* Seiter K
Ahn J-H, *see* Lee Jung-Hee
Ahn S-D, *see* Lee Jung-Hee
Aiello E, *see* Chlebowski RT
Aish LS, *see* Oo TH
Aisner J, *see* Berry DA
Akabani G, *see* Reardon DA
Akçali Z, *see* Saglam S

Akechi T, *see* Morita T
Albain KS, Crowley JJ, Turrisi AT III, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston RB. Concurrent Cisplatin, Etoposide, and Chest Radiotherapy in Pathologic Stage IIIB Non-Small-Cell Lung Cancer: A Southwest Oncology Group Phase II Study, SWOG 9019, 3454
Albanell J, see Baselga J
Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J. Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition, 110
Albano JQ, *see* Howell A
Alberts DS, Markman M, Armstrong D, Rothenberg ML, Muggia F, Howell SB. Intraperitoneal Therapy for Stage III Ovarian Cancer: A Therapy Whose Time Has Come! (editorial), 3944
Alberts SR, *see* Adjei AA
Alektiar KM. In Reply (correspondence), 3930
Alektiar KM, Leung D, Zelefsky MJ, Brennan MF. Adjuvant Radiation for Stage II-B Soft Tissue Sarcoma of the Extremity, 1643
Alexander C, *see* Samnick S
Alexopoulou A, *see* Dourakis SP
Ali SM, *see* Lipton A
Allal AS, Dulguerov P, Allaoua M, Haenggeli C-A, El Ghazi EA, Lehmann W, Slosman DO. Standardized Uptake Value of 2-[^{18}F] Fluoro-2-Deoxy-D-Glucose in Predicting Outcome in Head and Neck Carcinomas Treated by Radiotherapy With or Without Chemotherapy, 1398
Allaoua M, *see* Allal AS
Allard J, *see* Lipton A
Allegra C. Thymidylate Synthase Levels: Prognostic, Predictive, or Both? (editorial), 1711
Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P, Klein P, Behan K, O'Connell MJ, Levitt R, Kugler JW, Tirona MT, Goldberg RM. Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon Cancer, 1735
Allegrini G, *see* Falcone A
Allen P, *see* Stojadinovic A
Allgayer H, *see* Heiss MM
Allgood V, *see* Herbst RS
Alloisio M, *see* Bertuzzi A
Allouache N, *see* Joly F
Allred C, *see* Singletary SE
Allred DC, *see* Love RR
Almadori G, *see* Piantelli M
Almahmeed T, *see* Rabbani F
Alonzo TA, *see* Woods WG
Aloulou S, Bosq J, Vanel D, Ribrag V. Unusual Sites of Involvement in Non-Hodgkin's Lymphoma; Case 2. Isolated Meningeal Anaplastic Large-Cell Lymphoma, 4395
Alquati P, *see* Berruti A
Altavilla G, *see* Scagliotti GV
Alvord WG, *see* Urba WJ
Amadori D, *see* Ravaioli A
Amato R, *see* Bukowski R
Amdur RJ, *see* Mendenhall WM
American Society of Clinical Oncology Bisphosphonates Expert Panel, *see* Berenson JR
American Society of Clinical Oncology Breast Cancer Technology Assessment Working Group, *see* Chlebowski RT
American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel, *see* Schuchter LM
Ames MM, *see* Adjei AA
Amodio A, *see* Vici P
Amoroso M, *see* Benedetti-Panici P
Amsterdam A, *see* Vuky J
Amunni G, *see* Benedetti-Panici P
Anagnostopoulos N, *see* Dimopoulos MA
Anaissie E, *see* Badros A
Andermann A, Thiffault I, Wong N, Gordon P, MacNamara E, Chong G, Foulkes W. Multimodal Molecular Screening Is Required to Improve the Sensitivity of *MLH1* and *MSH2* Mutation Analysis (correspondence), 1705
Anderson D, *see* Seymour LW
Anderson H, *see* Ross P
Anderson JK, *see* Orlowski RZ
Anderson JR, *see* Baker KS
Anderson K, *see* Berenson JR
Anderson PM, Wiseman GA, Dispenzieri A, Arndt CAS, Hartmann LC, Smithson WA, Mullan BP, Bruland OS. High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients With Osteosarcoma and Bone Metastases, 189
Anderson PR, *see* Freedman GM
Anderson TJ, *see* Lakhani SR
Andersson M, *see* Dores GM
Andre A, *see* Carducci MA
André T, *see* Louvet C
Andreeff M, *see* Giles FJ
Andreola G, *see* Belli F
Androutakis N, *see* Souglakos J
Angelopoulou MK, *see* Rassidakis GZ
Anker G, *see* Geisler J
Annino L, *see* Federico M
Ansari RH, *see* Schilsky RL
Ansell SM, Jelinek DF, Wettstein PJ, Witzig TE. In Reply (correspondence), 2905
Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE. Subsequent Chemotherapy Regimens Are Well Tolerated After Radioimmunotherapy

With Yttrium-90 Ibritumomab Tiuxetan for Non-Hodgkin's Lymphoma, 3885
Anselmo AP, *see* Sieber M
Antin JH, *see* Cutler C
see Loberiza FR Jr
Antman K, *see* Berry DA
Antolini A, *see* Scartozzi M
Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, Economou I, Karageorgis P, Throuvalas N. Phase II Randomized Trial of Temozolomide and Concurrent Radiotherapy in Patients With Brain Metastases, 3644
Aoyama H, Shirato H, Ikeda J, Fujieda K, Miyasaka K, Sawamura Y. Induction Chemotherapy Followed by Low-Dose Involved-Field Radiotherapy for Intracranial Germ Cell Tumors, 857
Aoyama H, Shirato H, Kashiwamura M, Ikeda J, Sawamura Y. In Reply (correspondence), 2911
Aozasa K, *see* Nakatsuka S
Apostolaki S, *see* Stathopoulou A
Appelbaum FR, see also Morrison VA
Appelbaum FR, Sandmaier B. Sensitivity of Renal Cell Cancer to Nonmyeloablative Allogeneic Hematopoietic Cell Transplantations: Unusual or Unusually Important? (editorial), 1965
Arbuck SG, *see* Tan AR
Arcese W, *see* Ringdén O
see Rocha V
Ardizzoni A, Tjan-Heijnen VCG, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, Dziadziuszko R, Burghouts J, van Meerbeeck JP, Gans S, Legrand C, Debruyne C, Giaccone G, Manegold C. Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923, 3947
Arienti F, *see* Belli F
Armand JP, *see* Raymond E
see van Kesteren Ch
Armitage JO, *see* Vose JM
see Weekes CD
Armstrong D, *see* Alberts DS
Armstrong DK, *see* Bristow RE
Armstrong KA, *see* Shih HA
Arndt CAS, *see* Anderson PM
Aro J, *see* Mäkinen T
Aronson D, *see* Czauderna P
Arroyo CD, *see* Van Poznak C
Arthur DC, *see* Woods WG
Arun B, *see* Esteva FJ
Arusell R, *see* Shaw E
Asada N, *see* Tsuchiya H
Asami T, *see* Yamamoto K
Ascani L, *see* Belli F
Aschermannova A, *see* Howell A
Ashby M, *see* Seidman A
Ashley D, *see* Gururangan S
Ashley P, *see* Singletary SE
Ashley S, *see* Powles T
see Waters JS
Asmar L, *see* Loesch D
Asselain B, *see* Rouzier R
Asselin B, *see* LeClerc JM
Asselin BL, *see* Lipshultz SE
Assouline D, *see* Page E
Aster JC, *see* Kutok JL
Aster RH, *see* Abramson N
Atala J, *see* Prieto JM
Athale UH, Stewart C, Kuttesch JF, Moghrabi A, Meyer W, Pratt C, Gajjar A, Heideman RL. Phase I Study of Combination Topotecan and Carboplatin in Pediatric Solid Tumors, 88
Athanasiadis I, *see* Stathopoulos GP
Athanasiadis N, *see* Souglakos J
Atherton P, *see* Adjei AA
Atkins D, *see* Kuball J
Atkins MA, *see* Kilbridge KL
Atula S, *see* Powles T
Au WY, see Hon C
Au WY, Ooi CGC, Li KH, Shek TW, Liang R. Challenges in Oncology; Case 1. Oncology Emergencies: A Myeloma Patient With Stridor, 866
Audisio RA, *see* Repetto L
Austenfeld JL, *see* Stanton AL
Austrian Breast and Colorectal Cancer Study Group, *see* Jakesz R
Auvinen A, *see* Mäkinen T
Auvinen MI, Sihvo EIT, Ruohtula T, Salminen JT, Koivistoinen A, Siivola P, Rönnholm R, Rämö JO, Bergman M, Salo JA. Incipient Angiogenesis in Barrett's Epithelium and Lymphangiogenesis in Barrett's Adenocarcinoma, 2971
Auvrignon A, *see* Perel Y
Averbuch S, *see* Albanell J
see Ranson M
Averbuch SD, *see* Baselga J
see Herbst RS
Aviles VM, *see* Machtay M
Ayers GD, *see* Pentz RD
Ayoub J-P, *see* O'Shaughnessy J
Ayres M, *see* Gandhi V
Azzabi A, *see* Hughes A

B

Baars JW, *see* de Gast GC
Baas P, *see* Kruijtzer CMF
Babic R, *see* Heiss MM
Bacci G, *see* Fagioli F
see Ferrari S
Bach A, *see* Modi S

Bach PB, *see* Schrag D
Bacik J, *see* Motzer RJ
see Vuky J
Backstrand KH, *see* Ng AK
Bacoyiannis C, *see* Kosmidis P
Bader JB, *see* Samnick S
Bader-Meunier B, *see* Perel Y
Badran M, *see* Kolomainen DF
Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A, Morris C, Anaissie E, Van Rhee F, Tricot G. Improved Outcome of Allogeneic Transplantation in High-Risk Multiple Myeloma Patients After Nonmyeloablative Conditioning, 1295
Badros A. In Reply (correspondence), 4268
Bafaloukos D, Gogas H, Georgoulias V, Briassoulis E, Fountzilas G, Samantas E, Kalofonos C, Skarlos D, Karabelis A, Kosmidis P. Temozolomide in Combination With Docetaxel in Patients With Advanced Melanoma: A Phase II Study of the Hellenic Cooperative Oncology Group, 420
Bagg A, *see* Tao J
Bahng H, *see* Lee Jung-Hee
Baier P, *see* Rosenberg R
Baile WF, Lenzi R, Parker PA, Buckman R, Cohen L. Oncologists' Attitudes Toward and Practices in Giving Bad News: An Exploratory Study, 2189
Bains MS, *see* Martin J
Bajetta E, *see* Littlewood TJ
Bajetta E, Zilembo N, Bichisao E. Endocrine Effects of Nonsteroidal Aromatase Inhibitors and Their Clinical Impact (correspondence), 3039
Bajorin D, *see* Dalbagni G
Bajorin DF, *see* Vuky J
Baker C, *see* Herbst RS
Baker KS, Anderson JR, Lobe TE, Wharam MD, Qualman SJ, Raney RB, Ruymann FB, Womer RB, Meyer WH, Link MP, Crist WM. Children From Ethnic Minorities Have Benefited Equally as Other Children From Contemporary Therapy for Rhabdomyosarcoma: A Report From the Intergroup Rhabdomyosarcoma Study Group, 4428
Baker M, *see* Markman M
Baker SD, *see* Bélanger K
see de Bone JS
see Giles FJ
Baker SD, Garrett E, Giles F. In Reply (correspondence), 3356
Baker TP, *see* Ahmad SA
Bakker PJM, *see* Koedoot CG
Bakri K, *see* Socinski MA
Baldelli AM, *see* Cascinu S
Baldi A, *see* Santini D
Baldwin AS, *see* Orlowski RZ
Baldwin RL, *see* Liede A
Baldwin Y, *see* Ferrari AC
Balestrini MR, *see* Massimino M
Balibrea J-L, *see* González-Quevedo R
Ballard-Barbash R, *see* Harlan LC
Ballo MT, *see* Ahmad SA
Ballo MT, Gershenwald JE, Zagars GK, Lee JE, Mansfield PF, Strom EA, Bedikian AY, Kim KBS, Papadopoulos NE, Prieto VG, Ross MI. Sphincter-Sparing Local Excision and Adjuvant Radiation for Anal-Rectal Melanoma, 4549
Balm AJM, *see* Dorresteijn LDA
Balogh J, *see* El-Sayed S
Balzarotti M, *see* Bertuzzi A
Bamat MK, *see* Pecora AL
Bamberg M, *see* Timmermann B
Bani JC, *see* Brooks BJ
Bannwarth C, *see* Weihrauch MR
Bapat B, *see* Lindor NM
Barakat R, *see* Hensley ML
see Scheuer L
Barakat RR, Sabbatini P, Bhaskaran D, Revzin M, Smith A, Venkatraman E, Aghajanian C, Hensley M, Soignet S, Brown C, Soslow R, Markman M, Hoskins WJ, Spriggs D. Intraperitoneal Chemotherapy for Ovarian Carcinoma: Results of Long-Term Follow-Up, 694
Barazzoul J, *see* Schwartz GK
Barbarano L, *see* Cesana C
Barbui T, *see* Radford JA
Bardo DME, *see* Kletzel M
Barker MA, *see* Lindor NM
Barlogie B, *see* Badros A
Barnard DR, *see* Woods WG
Barnsteiner JH, *see* Womer RB
Baron A, *see* Bremnes RM
Barón A, *see* Nieto Y
Barr FG, *see* Sorensen PHB
Barr R, *see* LeClerc JM
Barr RD, *see* Lipshultz SE
Barranger E, Grahek D, Cortez A, Uzan S, Darai E. Laparoscopic Sentinel Node Procedure in Patients With Cervical Cancer (correspondence), 2602
Barresi J, *see* Shadbolt B
Barrett AJ, *see* Levine JE
Bartelink H, *see* Dorresteijn LDA
Barth TFE, *see* Viardot A
Barthe C, *see* Mahon FX
Bartlett NL, *see* Horning SJ
see Witzig TE
Barton DPJ, *see* Kolomainen DF
Barton JH, *see* Greco FA
Baruchel A, *see* Patte C
see Perel Y
Baruchel S, *see* Furman WL
Baselga J, *see* Albanell J
see Herbst RS
Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J. Phase I Safety, Pharmacoki-

netic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types, 4292
Baselga J. Targeting the Epidermal Growth Factor Receptor With Tyrosine Kinase Inhibitors: Small Molecules, Big Hopes (editorial), 2217
Baskind P, *see* Seiter K
Bass AJ, *see* Rizzieri DA
Bass AJ, Gockerman JP, Hammett E, DeCastro CM, Adams DJ, Rosner GL, Payne N, Davis P, Foster T, Moore JO, Rizzieri DA. Phase I Evaluation of Prolonged-Infusion Gemcitabine With Irinotecan for Relapsed or Refractory Leukemia or Lymphoma, 2995
Bassett LW, *see* Singletary SE
Bast M, *see* Weekes CD
Baudis M, *see* Kaiser U
Bauer S, *see* Kaiser R
Bauernhofer T, *see* Jakesz R
Baumann MA, *see* Koduri J
Baumert J, *see* Wendtner C-M
Baur A, *see* Wendtner C-M
Bearman SI, *see* Nieto Y
Bearzi I, *see* Scartozzi M
Beasley KR, *see* Albain KS
Beattie-Palmer L, *see* Sweeney C
Beatty P, *see* Levine JE
Beauchesne P. Promising Survival and Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide (correspondence), 3180
Beck AF, *see* Bepler G
Beck BD, *see* Chetrit A
Beck J, *see* Shariat SF
Becton DL, *see* Furman WL
Bedikian AY, *see* Ballo MT
see Eton O
Bednar M, *see* Ferrari AC
Begg CB, *see* Schrag D
see Shike M
Beham-Schmid C, *see* Jäger G
Behan K, *see* Allegra CJ
Behm FG, *see* Crews KR
see Rubnitz JE
Behrens BC, *see* Bloss JD
Behrens S, *see* Hoecht S
Behringer D, *see* Gelderblom H
Beijnen JH, *See* Crul M
see Kruijtzer CMF
see Malingré MM
see Raymond E
see van Kesteren Ch
Bekradda M, *see* Keating MJ
Bélanger K, Moore M, Baker SD, Dionne J, Maclean M, Jolivet J, Siu L, Soulières D, Wainman N, Seymour L. Phase I and Pharmacokinetic Study of Novel L-Nucleoside Analog Troxacitabine Given as a 30-Minute Infusion Every 21 Days, 2567
Belani CP, *see* Ramanathan RK
Belghiti J, *see* Vauthey J-N
Belkora JK, *see* Sepucha KR
Bell RS, *see* Davis AM
Bell WN, *see* Schilsky RL
Belldegrun AS, *see* Zisman A
Beller U, *see* Chetrit A
Belli F, *see* Vici P
Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, Gallino G, Piris A, Cattelan A, Lazzari I, Carrabba M, Scita G, Santantonio C, Pilla L, Tragni G, Lombardo C, Arienti F, Marchianó A, Queirolo P, Bertolini F, Cova A, Lamaj E, Ascani L, Camerini R, Corsi M, Cascinelli N, Lewis JJ, Srivastava P, Parmiani G. Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings, 4169
Belt R, *see* Agarwala SS
Beltrán M, Colomer R. Does HER-2 Status Predict Only a Decreased Response to Hormone Therapy in Advanced Breast Cancer, or Does It Also Predict the Extent of Metastatic Disease? (correspondence), 4605
Bemis L, *see* Bremnes RM
Ben-Baruch G, *see* Chetrit A
Ben-Bassat I, *see* Raanani P
Benda J, *see* Bloss JD
Bendandi M, *see* Federico M
Bender C, *see* Kirkwood JM
Benedetti-Panici P, Greggi S, Colombo A, Amoroso M, Smaniotto D, Giannarelli D, Amunni G, Raspagliesi F, Zola P, Mangioni C, Landoni F. Neoadjuvant Chemotherapy and Radical Surgery Versus Exclusive Radiotherapy in Locally Advanced Squamous Cell Cervical Cancer: Results From the Italian Multicenter Randomized Study, 179
Benedetti-Panici P, Greggi S. In Reply (correspondence), 2909
Benito M, *see* González-Quevedo R
Benjamin RS, *see* Ahmad SA
see Eton O
Benk V, *see* Davis AM
Benner A, *see* Döhner K
Benner SE, *see* Douillard J-Y
see Shin DM
Bennett CL, *see* Rizzo JD
Bennett CL, Price DK, Kim S, Liu D, Jovanovic BD, Nathan D, Johnson ME, Montgomery JS, Cude K, Brockbank JC, Sartor O, Figg WD. Racial Variation in CAG Repeat Lengths Within the Androgen Receptor Gene Among Prostate Cancer Patients of Lower Socioeconomic Status, 3599
Benson AB III, *see* Berlin JD
see Kemeny MM
see Tepper JE
Bentz M, *see* Viardot A

Bepler G, Gautam A, McIntyre LM, Beck AF, Chervinsky DS, Kim Y-C, Pitterle DM, Hyland A. Prognostic Significance of Molecular Genetic Aberrations on Chromosome Segment 11p15.5 in Non-Small-Cell Lung Cancer, 1353
Berdzik J, *see* Khushalani NI
Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS. American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma, 3719
Beretta GD, *see* Cascinu S
Berg W, *see* Motzer RJ
Berger F, *see* Fermé C
Berger J, *see* Thies A
Berger MS, *see* Jennings MT
Bergerat J-P, *see* Herbrecht R
Bergeron A, Bergot E, Vilela G, Ades L, Devergie A, Espérou H, Socié G, Calvo F, Gluckman E, Ribaud P, Rousselot Ph, Tazi A. Hypersensitivity Pneumonitis Related to Imatinib Mesylate (correspondence), 4271
Bergman M, *see* Auvinen MI
Bergot E, *see* Bergeron A
Bergsland EK, Venook AP. Shedding Old Paradigms: Developing Viruses to Treat Cancer (editorial), 2220
Berinstein NL. Carcinoembryonic Antigen as a Target for Therapeutic Anticancer Vaccines: A Review, 2197
Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB III. Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297, 3270
Bernard-Marty C, *see* Khayat D
Bernardo MP, *see* Ng AK
Bernath A, *see* Fata F
Berney DM, *see* Oliver RTD
Bernhard J, Maibach R, Thürlimann B, Sessa C, Aapro MS, Swiss Group for Clinical Cancer Research. Patients' Estimation of Overall Treatment Burden: Why Not Ask the Obvious?, 65
Bernstein L, *see* Press MF
see Wickerham DL
Bernstein M, *see* Goorin AM
Bernstein ML, *see* Furman WL
Berruti A, *see* Sperone P
Berruti A, Bitossi R, Gorzegno G, Bottini A, Alquati P, De Matteis A, Nuzzo F, Giardina G, Danese S, De Lena M, Lorusso V, Farris A, Sarobba MG, DeFabiani E, Bonazzi G, Castiglione F, Bumma C, Moro G, Bruzzi P, Dogliotti L. Time to Progression in Metastatic Breast Cancer Patients Treated With Epirubicin Is Not Improved by the Addition of Either Cisplatin or Lonidamine: Final Results of a Phase III Study With a Factorial Design, 4150
Berry D, *see* Singletary SE
Berry DA, *see* Guidi AJ
Berry DA, Broadwater G, Klein JP, Antman K, Aisner J, Bitran J, Costanza M, Freytes CO, Stadtmauer E, Gale RP, Henderson IC, Lazarus HM, McCarthy PL Jr, Norton L, Parnes H, Pecora A, Perry MC, Rowlings P, Spitzer G, Horowitz MM. High-Dose Versus Standard Chemotherapy in Metastatic Breast Cancer: Comparison of Cancer and Leukemia Group B Trials With Data From the Autologous Blood and Marrow Transplant Registry, 743
Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G. BRCAPRO Validation, Sensitivity of Genetic Testing of *BRCA1/BRCA2*, and Prevalence of Other Breast Cancer Susceptibility Genes, 2701
Berry DA, Parmigiani G, Rubinstein W, Watson P. In Reply (correspondence), 3936
Berthelet E, *see* El-Sayed S
Bertolini F, *see* Belli F
Bertozzi AI, *see* Patte C
Bertucci D, *see* Schilsky RL
Bertuzzi A, Castagna L, Nozza A, Quagliuolo V, Siracusano L, Balzarotti M, Compasso S, Alloisio M, Parra HS, Santoro A. High-Dose Chemotherapy in Poor-Prognosis Adult Small Round-Cell Tumors: Clinical and Molecular Results From a Prospective Study, 2181
Bessell EM, López-Guillermo A, Villá S, Verger E, Nomdedeu B, Petit J, Byrne P, Montserrat E, Graus F. Importance of Radiotherapy in the Outcome of Patients With Primary CNS Lymphoma: An Analysis of the CHOD/BVAM Regimen Followed by Two Different Radiotherapy Treatments, 231
Betensky RA, Louis DN, Caimcross JG. Influence of Unrecognized Molecular Heterogeneity on Randomized Clinical Trials, 2495
Beyer BCM, *see* Heiss MM
Beyer J, *see* Bokemeyer C
see Kollmannsberger C
Beykirch MK, *see* Josting A
Bezjak A, *see* Davis AM
see Shepherd FA
Bhagat R, *see* Orlowski RZ
Bhaskaran D, *see* Barakat RR
Bhatia S, Jenney MEM, Bogue MK, Rockwood TH, Feusner JH, Friedman DL, Robison LL, Kane RL. The Minneapolis-Manchester Quality of Life Instrument: Reliability and Validity of the Adolescent Form, 4692
Bianchi F, *see* Scartozzi M
Biankin AV, Morey AL, Lee S-C, Kench JG, Biankin SA, Hook HC, Head DR, Hugh TB, Sutherland RL, Henshall SM. *DPC4*/Smad4 Expression and Outcome in Pancreatic Ductal Adenocarcinoma, 4531
Biankin SA, *see* Biankin AV
Biasin E, *see* Fagioli F

Bichakjian CK, Schwartz JL, Wang TS, Hall JM, Johnson TM, Biermann JS. Melanoma Information on the Internet: Often Incomplete—A Public Health Opportunity?, 134
Bichisao E, *see* Bajetta E
Bickert B, *see* Womer RB
Bielack SS, *see* Franzius C
Bielack SS, Jargens H. In Reply (correspondence), 2910
Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H, Winkler K, Cooperative German-Austrian-Swiss Osteosarcoma Study Group. Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols, 776
Bierman PJ, *See* Vose JM
see Weekes CD
Biermann JS, *see* Berenson JR
see Bichakjian CK
Biesma B, *see* Ardizzoni A
Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ. Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial, 3114
Bigner DD, *see* Reardon DA
Bilhou-Nabéra C, *see* Mahon FX
Billett AL, *see* Donaldson SS
see LeClerc JM
Billups CA, *see* Spunt SL
Binh NC, *see* Love RR
Birhiray R, *see* Keating MJ
Birkmann J, *see* Kaiser U
Birner P, Oberhuber G. Is Fluorescence In Situ Hybridization Really Superior to HercepTest? (correspondence), 4607
Bischoff HG, *see* Kaiser U
Bisogno G, *see* Ferrari A
Bitossi R, *see* Berruti A
Bitran J, *see* Berry DA
Bivens S, *see* Ahles TA
Bivins C, *see* Giles FJ
Bjork T, *see* Baselga J
Black PM, *see* Chakravarti A
Blackwood MA, *see* Shih HA
Blake PR, *see* Kolomainen DF
Blamey R, *see* Jonat W
Blanch J, *see* Prieto JM
Blanchon F, *see* Depierre A
Bland KI, *see* Singletary SE
Blanke CD, *see* Heinrich MC
Blay JY, *see* Viens P
Bleiberg H, *see* Louvet C
Bleiberg H, Di Leo A. Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin (correspondence), 1145
Bleiweiss IJ, *see* Guidi AJ
Blessing JA, *see* Bloss JD
see Muggia FM
Blomgren H, *see* Edler D
Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M, Benda J. Randomized Trial of Cisplatin and Ifosfamide With or Without Bleomycin in Squamous Carcinoma of the Cervix: A Gynecologic Oncology Group Study, 1832
Blumenschein GR Jr, *see* Herbst RS
Blumgart L, *see* Heffernan N
Boasberg PD, *see* Hsueh EC
Bochner B, *see* Graefen M
Bociek G, *see* Weekes CD
Boddy AV, *see* Hughes A
Bodnar L, *see* Khushalani NI
Bodurka DC, *see* Eifel PJ
see Strasser F
Boerrigter L, *see* Crul M
Boewer C, *see* Menssen HD
Boffi R, *see* Galeazzi G
Bogue MK, *see* Bhatia S
Bohlen H, *see* Weihrauch MR
Boige V, *see* Raymond E
Boiocchi M, *see* Toffoli G
Boiron JM, *see* Cany L
see Mahon FX
Bokemeyer C, *see* Kersemaekers A-MF
see Kollmannsberger C
see Mayer F
Bokemeyer C, Nichols CR, Droz J-P, Schmoll H-J, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Kanz L, Einhorn L, Hartmann JT. Extragonadal Germ Cell Tumors of the Mediastinum and Retroperitoneum: Results From an International Analysis, 1864
Bol CJ, *see* Crul M
Bolla M, *see* Pignatti F
Bomanji JB, Syed R, Brock C, Jankowska P, Dogan A, Costa DC, Ell PJ, Lee SM. Challenging Cases and Diagnostic Dilemmas; Case 2. Pitfalls of Positron Emission Tomography for Assessing Residual Mediastinal Mass After Chemotherapy for Hodgkin's Disease, 3347
Bonadonna G, *see* Rassidakis GZ
Bonazzi C, *see* Cantù MG
Bonazzi G, *see* Berruti A
Bonfante V, *see* Rassidakis GZ
Boni C, *see* Scagliotti GV
Bonner JA. Reply 2 (correspondence), 1428
Bonneterre J, Nabholtz J-M, Budzar A, Robertson J, Thürlimann B, Steinberg M, Webster A, von Euler M. In Reply (correspondence), 3749
Boogerd W, *see* Dorresteijn LDA

Bookbinder M, *see* Heffernan N
Boortz-Marx RL, *see* Smith TJ
Booser D, *see* Esteva FJ
Borbas C, *see* Keating NL
see Silliman RA
Borgen P, *see* Scheuer L
Borgen PI, *see* Singletary SE
Borner M, *see* Carmichael J
Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Müller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD. Phase II Study of Capecitabine and Oxaliplatin in First- and Second-Line Treatment of Advanced or Metastatic Colorectal Cancer, 1759
Bos AM, *see* Kehrer DFS
Bos R, van der Hoeven JJM, van der Wall E, van der Groep P, van Diest PJ, Comans EFI, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA, Molthoff CFM. Biologic Correlates of ^{18}Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography, 379
Bosl G, *see* Osman I
Bosl GJ, *see* Vuky J
Bosq J, *see* Aloulou S
Bosshart H. T Helper Cell Activation in B-Cell Lymphomas (correspondence), 2904
Bottet P, *see* Joly F
Bottini A, *see* Berruti A
Bottomley A, *see* Efficace F
Bouchardy C, Verkooijen HM, Fioretta G, Sappino AP, Vlastos G. Increased Risk of Malignant Mullerian Tumor of the Uterus Among Women With Breast Cancer Treated by Tamoxifen (correspondence), 4403
Boukovinas J, *see* Kosmidis P
Bouleuc C, *see* Louvet C
Bourgeon A, *see* Etienne M-C
Bourstyn E, *see* Rouzier R
Boutard P, *see* Patte C
Bouvier CV, *see* Brett BT
Bowling MK, *see* Carducci MA
Bowman LC, *see* Katzenstein HM
Boyd C, *see* Huang J
Boyd J, *see* Scheuer L
Boye N, *see* Sundstrøm S
Boyett JM, *see* Jennings MT
Brach del Prever A, *see* Fagioli F
Bradley TL, *see* Sweet KM
Bradof JE, *see* Greco FA
Brady C, *see* Lipton A
Brainard J, *see* Thomas J
Bramble J, *see* Oscier D
Bramwell V, *see* Winquist E
Brandberg Y, *see* Österborg A
Brandi M, *see* Vici P
Branson K, Chopra R, Kottaridis PD, McQuaker G, Parker A, Schey S, Chakraverty RK, Craddock C, Milligan DW, Pettengell R, Marsh JCW, Linch DC, Goldstone AH, Williams CD, Mackinnon S. Role of Nonmyeloablative Allogeneic Stem-Cell Transplantation After Failure of Autologous Transplantation in Patients With Lymphoproliferative Malignancies, 4022
Branstetter AD, *see* Stanton AL
Brauchli P, *see* Borner MM
Braun D, *see* Depierre A
Braun S, *see* Winer EP
Braun T, *see* Levine JE
see Yanik GA
Brawley O, *see* Sateren WB
Breast Cancer Linkage Consortium, *see* Lakhani SR
Bréchot J-M, *see* Depierre A
Brecht ML, *see* Sarna L
Bredeson CN, *see* Loberiza FR Jr
Breen N, *see* Sateren WB
Bremnes RM, *see* Sundstrøm S
Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, Bemis L, Gemmill RM, Drabkin HA, Franklin WA. High-Throughput Tissue Microarray Analysis Used to Evaluate Biology and Prognostic Significance of the E-Cadherin Pathway in Non-Small-Cell Lung Cancer, 2417
Brenckman WD Jr, *see* Rizvi NA
Brennan M, *see* Holen KD
Brennan MF, *see* Alektiar KM
see Hochwald SN
see Kattan MW
see Stojadinovic A
Brenner H, Hakulinen T. Up-to-Date Long-Term Survival Curves of Patients With Cancer by Period Analysis, 826
Brenner H, Hakulinen T. Very-Long-Term Survival Rates of Patients With Cancer (correspondence), 4405
Breslin S, *see* Horning SJ
Breslow NE, *see* Green DM
Breton J-L, *see* Depierre A
Brett BT, Smith SC, Bouvier CV, Michaeli D, Hochhauser D, Davidson BR, Kurzawinski TR, Watkinson AF, Van Someren N, Pounder RE, Caplin ME. Phase II Study of Anti-Gastrin-17 Antibodies, Raised to G17DT, in Advanced Pancreatic Cancer, 4225
Brettman L, *see* Rai KR
Brey K, *see* Schover LR
Brezinschek R, *see* Jäger G
Briassoulis E, *see* Bafaloukos D
Brice P, *see* Fermé C
Bridge JA, *see* Sorensen PHB
Bridges JE, *see* Kolomainen DF
Brierley JD, Catton PA, O'Sullivan B, Dancey JE, Dowling AJ, Irish JC, McGowan TS, Sturgeon JFG, Swallow CJ, Rodrigues GB, Panzarella T. Accuracy of Recorded Tumor, Node, and Metastasis Stage in a Comprehensive Cancer Center, 413

Brisson J, *see* Maunsell E
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis, 1248
Broadwater G, *see* Berry DA
see Guidi AJ
Brock C, *see* Bomanji JB
Brockbank JC, *see* Bennett CL
Brockmöller J, *see* Kaiser R
Broemeling L, *see* Ellerhorst JA
see Wang XS
Brook RH, *see* Malin JL
Brooks BJ, Bani JC, Fletcher CDM, Demetri GD. Challenges in Oncology; Case 4. Response of Metastatic Gastrointestinal Stromal Tumor Including CNS Involvement to Imatinib Mesylate (STI-571), 870
Broome CM, *see* Vaughn DJ
Brosteanu O, *see* Sieber M
Browman GP, *see* Rizzo JD
see Winer EP
Brown AE, *see* Timoney JP
Brown BW, *see* Horning SJ
Brown C, *see* Barakat RR
Brown J, *see* Czauderna P
Brown ML, *see* Warren JL
Bruckner H, *see* Lima CMSR
Bruckner JD, *see* Rubin BP
Bruera E, *see* Ripamonti C
see Strasser F
see Suarez-Almazor ME
see Sweeney C
Bruera E, Russell N, Sweeney C, Fisch M, Palmer JL. Place of Death and Its Predictors for Local Patients Registered at a Comprehensive Cancer Center, 2127
Brugger S, *see* Scheithauer W
Brugger W, *see* Viens P
Bruggers CS, *see* Gururangan S
see Jennings MT
Brugnara S, *see* Ridolfi R
Bruland OS, *see* Anderson PM
Brümmer J, *see* Laack E
see Thies A
Brun O, *see* Page E
Brundage M, *see* Pearcey R
Brune D, *see* Joly F
Bruner JM, *see* Jennings MT
Brunet R, *see* Louvet C
Brunetti IM, *see* Falcone A
Bruning P, *see* Biganzoli L
Brunner G, *see* Thies A
Bruzzi P, *see* Berruti A
Bryant J, *see* Fisher B
see Wickerham DL
Bryce DA, *see* Smith TJ
Buatti JM, Meeks SL, Ryken TC, Carlisle TL. Low-Grade Gliomas: Answering One Question in a Myriad of New Questions (editorial), 2223
Bucana C, *see* Herbst RS
Buchbarker D, *see* Ramanathan RK
Buchholz E, *see* Ardizzoni A
Buchholz TA, Tucker SL, Masullo L, Kuerer HM, Erwin J, Salas J, Frye D, Strom EA, McNeese MD, Perkins G, Katz A, Singletary SE, Hunt KK, Buzdar AU, Hortobagyi GN. Predictors of Local-Regional Recurrence After Neoadjuvant Chemotherapy and Mastectomy Without Radiation, 17
Buchser E, *see* Smith TJ
Buckley JD, *see* Woods WG
Buckman R, *see* Baile WF
Buda A, *see* Cantù MG
Budman DR, *see* Guidi AJ
Budzar A, *see* Bonneterre J
Bugat R, *see* Culine S
Buhler H, *see* Fuchs IB
Bukowski R, Ernstoff MS, Gore ME, Nemunaitis JJ, Amato R, Gupta SK, Tendler CL. Pegylated Interferon Alfa-2b Treatment for Patients With Solid Tumors: A Phase I/II Study, 3841
Bumma C, *see* Berruti A
Bundy BN, *see* Rose PG
Bunjes D, *see* Ringdén O
Bunn PA Jr. Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Who, What, When, Why?, 23s
Bunn PA Jr. Treatment of Advanced Non-Small-Cell Lung Cancer With Two-Drug Combinations (editorial), 3565
Bunnell CA, Winer EP. Lumping Versus Splitting: The Splitters Take This Round (editorial), 3576
Burchmore M, *see* Osoba D
see Vogel CL
Burgart LJ, *see* Lindor NM
Burgess C, *see* Damani MN
Burghouts J, *see* Ardizzoni A
Burke TW, *see* Levenback C
Burkes RL, *see* Leighl NB
Burkhardt JH, Litwin MS, Rose CM, Correa RJ, Sunshine JH, Hogan C, Hayman JA. Comparing the Costs of Radiation Therapy and Radical Prostatectomy for the Initial Treatment of Early-Stage Prostate Cancer, 2869
Burnett CB, *see* Liang W
Burns P, *see* El-Sayed S
Burris HA III, *see* Greco FA
Burstein HJ, *see* Chlebowski RT
see Winer EP
Burstein S, *see* Leung W
Burtles S, *see* Seymour LW
Burton G, *see* Osborne CK
Butow PN, *see* Gattellari M
Buyse M, *see* Di Leo A
Buzaglo K, *see* Cremin C
Buzaid AC, *see* Eton O

Buzdar A, *see* Osborne CK
Buzdar AU, *see* Bessell EM
Buzdar AU. Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy (correspondence), 876
Byrne P, *see* Bessell EM

C

Cabanillas F, *see* Rassidakis GZ
see Sarris AH
see Witzig TE
Cadoni G, *see* Piantelli M
Cagiannos I, *see* Graefen M
Cagiannos I, Graefen M, Karakiewicz PI, Ohori M, Eastham JA, Rabbani F, Fair W, Wheeler TM, Hammerer PG, Haese A, Erbersdobler A, Huland H, Scardino PT, Kattan MW. Analysis of Clinical Stage T2 Prostate Cancer: Do Current Subclassifications Represent an Improvement?, 2025
Cagnoni PJ, *see* Nieto Y
Caimcross JG, *see* Betensky RA
Cain AM, *see* Spunt SL
Cairo MS, *see* Lones MA
Calvert AH, *see* Biganzoli L
Calvert H, *see* Baselga J
see Hughes A
Calvert P, *see* Hughes A
Calvo F, *see* Bergeron A
Calzone K, *see* Shih HA
Camerini R, *see* Belli F
Cameron T, *see* Kehrer DFS
Camidge R, Price A. Radiation Recall Dermatitis May Represent the Koebner Phenomenon (correspondence), 4130
Camphausen K, *see* Coleman CN
Campos F, *see* Herbrecht R
Campos S, *see* Vasey PA
Cancer Research Campaign Phase I/II Clinical Trials Committee, *see* Seymour LW
Candolfi E, *see* Herbrecht R
Canellos GP, *see* Graefen M
Canellos GP. New Treatments for Advanced Hodgkin's Disease: An Uphill Fight Beginning Close to the Top (editorial), 607
Cangiano T, *see* Graefen M
Cannistra SA. Is There a "Best" Choice of Second-Line Agent in the Treatment of Recurrent, Potentially Platinum-Sensitive Ovarian Cancer? (editorial), 1158
Cantor SB, *see* Esnaola NF
Cantù MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, Dell'Anna T, Torri V, Colombo N. Randomized Controlled Trial of Single-Agent Paclitaxel Versus Cyclophosphamide, Doxorubicin, and Cisplatin in Patients With Recurrent Ovarian Cancer Who Responded to First-Line Platinum-Based Regimens, 1232
Cany L, Fitoussi O, Boiron JM, Marit G. Tumor Lysis Syndrome at the Beginning of Thalidomide Therapy for Multiple Myeloma (correspondence), 2212
Canzonieri V, *see* Pizzichetta MA
Capanna T, *see* DiPaola RS
Capdeville R, *see* Viens P
Capelli A, *see* Ferrandina G
Caplin ME, *see* Brett BT
Cappelletti V, *see* Daidone MG
Cardiovascular Thrombolytic to Open Occluded Lines-2 Investigators, *see* Deitcher SR
Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinibaldi V, Donehower R, Leahy TL, Carr RA, Isaacson JD, Janus TJ, Andre A, Hosmane BS, Padley RJ. Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and Pharmacokinetics, 2171
Carli M, *see* Ferrari A
Carlisle TL, *see* Buatti JM
Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, Skovsgaard T, Munier S, Martin C. Randomized Comparative Study of Tegafur/Uracil and Oral Leucovorin Versus Parenteral Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer, 3617
Carney DP, *see* McDermott RS
Carney W, *see* Lipton A
Carpano S, *see* Lopez M
Carr RA, *see* Carducci MA
Carrabba M, *see* Belli F
Carreras E, *see* Prieto JM
Carson D, *see* Liptay MJ
Carson K, *see* Kleinberg L
Carson L, *see* Markman M
Cartwright TH, Cohn A, Varkey JA, Chen Y-M, Szatrowski TP, Cox JV, Schulz JJ. Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic Cancer, 160
Casanova M, *see* Ferrari A
see Massimino M
see Spreafico F
Cascinelli N, *see* Belli F
Cascino T, *see* Shaw E
Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, Beretta GD, Ubiali E, Catalano G. Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial, 3478
Cassem NH, *see* Rauch PK
Castagna L, *see* Bertuzzi A
Castel T, *see* Mellado B
Castiglione F, *see* Berruti A
Castiglione-Gertsch M, *see* Borner MM
see Colleoni M

Castleberry RP, *see* Katzenstein HM
Castro M. Eniluracil's Need for a Targeted Approach: A Lesson in Drug Development (correspondence), 3750
Castro M. The Simpleton's Error in Drug Development (correspondence), 4606
Català E, *see* Smith TJ
Catalano G, *see* Cascinu S
Catalano P, *see* Berlin JD
see Hinton S
Catalano V, *see* Cascinu S
Cattelan A, *see* Belli F
Catton CN, *see* Davis AM
Catton PA, *see* Brierley JD
Cau TT, *see* Love RR
Cavazos CM, *see* Gururangan S
Cazin B, *see* Keating MJ
Cecchetto G, *see* Ferrari A
Cefalo G, *see* Massimino M
Cefalo GS, *see* Spreafico F
Cella D, *see* Heffernan N
see Rizzo JD
Cellerino R, *see* Porfiri E
see Scartozzi M
Cellini N, *see* Trodella L
Ceribelli A, *see* Scagliotti GV
Cervantes G, *see* O'Shaughnessy J
Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, Gargantini L, Granata S, Valentini M, Morra E. Prognostic Factors for Malignant Transformation in Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma, 1625
Cesario A, *see* Trodella L
Cha SS, *see* Sloan JA
Chabannon C, *see* Viens P
Chabot P, *see* Davis AM
Chada S, *see* Ellerhorst JA
Chakrabarti S. Critical Factors in Optimizing Graft-Versus-Leukemia Effect for Relapsed Leukemias (correspondence), 2756
Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ, Loeffler JS. Quantitatively Determined Survivin Expression Levels Are of Prognostic Value in Human Gliomas, 1063
Chakraverty RK, *see* Branson K
Chalian AA, *see* Machtay M
Chamberlain MC. Treatment of Intracranial Metastatic Esthesionneuroblastoma (correspondence), 357
Chambers GK, *see* Van Patten CL
Chamorey E, *see* Etienne M-C
Chan ATC, Teo PML, Ngan RK, Leung TW, Lau WH, Zee B, Leung SF, Cheung FY, Yeo W, Yiu HH, Yu KH, Chiu KW, Chan DT, Mok T, Yuen KT, Mo F, Lai M, Kwan WH, Choi P, Johnson PJ. Concurrent Chemotherapy-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: Progression-Free Survival Analysis of a Phase III Randomized Trial, 2038
Chan DT, *see* Chan ATC
Chan JL, Lee SW, Fraass BA, Normolle DP, Greenberg HS, Junck LR, Gebarski SS, Sandler HM. Survival and Failure Patterns of High-Grade Gliomas After Three-Dimensional Conformal Radiotherapy, 1635
Chan JL, Sandler HM, Fraass BA. In Reply to Drs Knisely and LaCombe (correspondence), 3359
Chan K-W, *see* Jennings MT
Chan S-H, *see* Cheng H-L
Chan WC, *see* Vose JM
see Weekes CD
Chang J, *see* Radford JA
Chao DH, *see* Zisman A
Chapchap P, *see* Czauderna P
Chapman PB, *see* Hwu W-J
see Wolchok JD
Chapman PB. Vaccinating Patients With Autologous Tumor (editorial), 4139
Charnsangavej C, *see* Herbst RS
see Pisters PWT
Chastang C, *see* Depierre A
Chau I, *see* Maisey N
Chaudri-Ross HA, *see* Mouridsen H
Chazal M, *see* Etienne M-C
Cheever MA, *see* Disis ML
Chemotherapy and Radiotherapy Expert Panel, American Society of Clinical Oncology, *see* Schuchter LM
Chen C-J, *see* Singer S
Chen J-D, *see* Chou Y-H
Chen LL, *see* Ahmad SA
Chen WY, Garber JE, Higham S, Schneider KA, Davis KB, Deffenbaugh AM, Frank TS, Gelman RS, Li FP. *BRCA1/2* Genetic Testing in the Community Setting, 4485
Chen Y-M, *see* Cartwright TH
Cheng H-L, Trink B, Tzai T-S, Liu H-S, Chan S-H, Ho C-L, Sidransky D, Chow N-H. Overexpression of *c-met* as a Prognostic Indicator for Transitional Cell Carcinoma of the Urinary Bladder: A Comparison With *p53* Nuclear Accumulation, 1544
Chervinsky DS, *see* Bepler G
Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, Beller U, Ben-Baruch G, Fishman A, Levavi H, Lubin F, Menczer J, Piura B, Struewing JP, Modan B, National Israeli Study of Ovarian Cancer. Effect of *BRCA* Mutations on the Length of Survival in Epithelial Ovarian Tumors, 463
Cheung FY, *see* Chan ATC
Cheung YB, *see* Tan SB
Chevalier V, *see* Curé H
Chevalier V, Curé H, Chollet P, Lévi F. In Reply (correspondence), 3938
Chevret S, *see* Depierre A
Chiang J-H, *see* Chou Y-H

Chiarion-Sileni V, *see* Ridolfi R
Chihara S, *see* Morita T
Childhood Cancer Survivor Study, *see* Emmons K
Childhood Oncology Group, *see* Sorensen PHB
Children's Cancer Group, *see* Nachman JB
Chilosi M, *see* Rassidakis GZ
Chim CS, Lam CCK, Nicholls JM, Ooi GC, Kwong YL. Unusual Hematologic Malignancies: Case 3. CNS Involvement in CD56-Positive Intestinal Gamma/Delta T-Cell Lymphoma, 3742
Chim CS, Wong WM, Nicholls J, Chung LP, Liang R. Extramedullary Sites of Involvement in Hematologic Malignancies: Case 3. Hemorrhagic Gastric Plasmacytoma as the Primary Presentation in Multiple Myeloma, 344
China C, *see* Rajq V
Chinchilli V, *see* Lipton A
Chiou H-J, *see* Chou Y-H
Chiou WL, Wu TC, Ma C, Jeong HY. Enhanced Oral Bioavailability of Docetaxel by Coadministration of Cyclosporine: Quantitation and Role of P-Glycoprotein (correspondence), 1951
Chipponi J, *see* Curé H
Chirikos TN, *see* Jacobsen PB
Chisesi T, *see* Federico M
Chiu KW, *see* Chan ATC
Chlebowski RT, *see* Winer EP
Chlebowski RT, Aiello E, McTiernan A. Weight Loss in Breast Cancer Patient Management, 1128
Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG III, Burstein HJ, Eisen A, Lipkus I, Pfister DG. American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition, 3328
Choi P, *see* Chan ATC
Chollet P, *see* Curé H
see Chevalier V
see Zelek L
Chong G, *see* Andermann A
Chong N, *see* Vallis KA
Chopra R, *see* Branson K
Chott A, *see* Jäger G
Chou Y-H, Chiou H-J, Tiu C-M, Chen J-D, Hung G-S, Chiang J-H. Some Unusual Complications of Malignancies: Case 1. Spontaneous Rupture of Hepatocellular Carcinoma Demonstrated by Contrast-Enhanced Sonography, 4108
Chouaki N, *see* Zelek L
Chow N-H, *see* Cheng H-L
Christakis J, *see* Dimopoulos MA
Christensen B, *see* Jatoi A
Christian MC, *see* Sateren WB
Chu P, *see* Schwarz RE
Chun H, *see* Mikulski SM
Chung JW, *see* Lee H-S
Chung LP, *see* Chim CS
Chung YFA, *see* Tan SB
Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Scadden DT, Ratner L, Pluda JM, Figg WD, Krown SE, Dezube BJ. Matrix Metalloproteinase Inhibitor COL-3 in the Treatment of AIDS-Related Kaposi's Sarcoma: A Phase I AIDS Malignancy Consortium Study, 153
Ciardella M, *see* DiPaola RS
Cirera E, *see* Prieto JM
Cisar L, *see* Hudes G
Clark G, *see* Singletary SE
Clark JI, *see* Albain KS
Clark JW, *see* Eder JP Jr
Clark MM, *see* Cox LS
Clarke EA, *see* Dores GM
Classen J, Dieckmann K-P. Radiotherapy of Carcinoma-In-Situ of the Testis (correspondence), 3559
Clavell LA, *see* LeClerc JM
see Lipshultz SE
Clavier J, *see* Depierre A
Clayman G, *see* Shin DM
Cleary KR, *see* Pisters PWT
see Vauthey J-N
Cleeland CS, *see* Esnaola NF
see Wang XS
Clegg L, *see* Harlan LC
Clerici M, *see* Scagliotti GV
Clifford JL, *see* Shin DM
Clinton S, *see* Nadella P
Clipp EC, *see* Ingram SS
Clohisy DR, *see* Nagarajan R
Coates AS, *see* Colleoni M
see Goldhirsch A
see Hersey P
Cobau CD, *see* Hobday TJ
Cobleigh MA, *see* Vogel CL
see Winer EP
Codrington H, Sutedja T, Golding R, van Mourik J, Risse E, Postmus PE. Unusual Pulmonary Lesions: Case 2. Endobronchial Carcinoid of the Lung, 2747
Coeffic D, *see* Page E
Coen JJ, Zietman AL, Thakral H, Shipley WU. Radical Radiation for Localized Prostate Cancer: Local Persistence of Disease Results in a Late Wave of Metastases, 3199
Coëtmeur D, *see* Depierre A
Coetzee G, Irvine R. Size of the Androgen Receptor CAG Repeat and Prostate Cancer: Does It Matter? (editorial), 3572
Cohen EEW, Vokes EE. Searching for a Standard (editorial), 359
Cohen GL, *see* Pecora AL
Cohen HJ, *see* Ingram SS
see LeClerc JM
Cohen L, *see* Baile WF
Cohen MZ, *see* Pentz RD

Cohn A, *see* Cartwright TH
Cohn SL, *see* Kletzel M
Coiffier B, *see* Gisselbrecht C
Cokgor I, *see* Reardon DA
Col N, *see* Chlebowski RT
Colan SD, *see* Lipshultz SE
Coldiron B, Dinehart S. Sentinel-Node Technique Will Change the Design of Clinical Trials in Malignant Melanoma (correspondence), 2208
Cole B, *see* Ahles TA
Cole BF, *see* Kilbridge KL
Coleman CN, Mitchell JB, Camphausen K. Tumor Hypoxia: Chicken, Egg, or a Piece of the Farm? (editorial), 610
Coleman R, *see* Biganzoli L
Coleman RE, *see* Reardon DA
Coleman RL, *see* Levenback C
Coliarakis N, *see* Antonadou D
Colin P, *see* Fermé C
Colleoni M, Goldhirsch A, Coates AS, Gelber RD, Gelber S, Castiglione-Gertsch M. In Reply (correspondence), 2211
Colleoni R, *see* Hochwald SN
Collini P, *see* Spreafico F
Collins CA, *see* Stanton AL
Collins RH Jr, *see* Levine JE
Collyar DE, *see* Chlebowski RT
Colombo A, *see* Benedetti-Panici P
Colombo N, *see* Cantù MG
Colomer D, *see* Mellado B
Colomer R, *see* Beltrán M
Colosimo C, *see* Massimino M
Colucci G, *see* Vici P
Colvin OM, *see* Quinn JA
Colwell B, *see* Rivera E
see Schilsky RL
Comans EFI, *see* Bos R
Come S, *see* Osborne CK
Compasso S, *see* Bertuzzi A
Compton LD, *see* Lima CMSR
Conklin HS, *see* Rivera E
Conlon K, *see* Holen KD
see Hochwald SN
Connor M, *see* Timoney JP
Connors JM, *see* Shenkier TN
Connors S, *see* Eder JP Jr
Conrad EU, *see* Rubin BP
Conte P, *see* Falcone A
Conti F, *see* Vici P
Cony-Makhoul P, *see* Mahon FX
Cooley TP, *see* Cianfrocca M
see Evans SR
Cooper MR, *see* Rai KR
Cooperative Family Registry for Colon Cancer Studies, *see* Lindor NM
Cooperative German-Austrian-Swiss Osteosarcoma Study Group, *see* Bielack SS
Cooperative Investigators of the Dutch Colorectal Cancer Group, *see* Marijnen CAM
Corbo GM, *see* Trodella L
Cordella L, *see* Cascinu S
Cordon-Cardo C, *see* Osman I
see Stojadinovic A
Corle D, *see* Shike M
Corless CL, *see* Heinrich MC
Cornetta K, *see* Levine JE
Cornu P, *see* Pignatti F
Correa RJ, *see* Burkhardt JH
Corry J, *see* Rischin D
Corsi M, *see* Belli F
Corstens FHM, *see* Langenhoff BS
see Ruers TJM
Cortes JE, *see* Giles FJ
Cortez A, *see* Barranger E
Costa DC, *see* Bomanji JB
Costa EB, *see* Costa L
Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC, Lipton A. Prospective Evaluation of the Peptide-Bound Collagen Type I Cross-Links N-Telopeptide and C-Telopeptide in Predicting Bone Metastases Status, 850
Costantino J, *see* Wickerham DL
Costanza M, *see* Berry DA
Costanzi JJ, *see* Mikulski SM
Cote K, *see* D'Amico AV
Cottler-Fox M, *see* Badros A
Cottu P, *see* Zelek L
Couanet D, *see* Lashford LS
Couch FJ, *see* Shih HA
Coudert B, *see* Curé H
Couëtte JE, *see* Joly F
Couillaud G, *see* Perel Y
Court W, *see* Order SE
Coutré S, *see* Keating MJ
Cova A, *see* Belli F
Coventry BJ, *see* Hersey P
Cowan RA, *see* Radford JA
Cox E, *see* Loesch D
Cox JV, *see* Cartwright TH
Cox LS, Patten CA, Ebbert JO, Drews AA, Croghan GA, Clark MM, Wolter TD, Decker PA, Hurt RD. Tobacco Use Outcomes Among Patients With Lung Cancer Treated for Nicotine Dependence, 3461
Coyle LA, *see* Mortuza FY
Coyne PJ, *see* Smith TJ
Craddock C, *see* Branson K
Craft P, *see* Shadbolt B
Cragg GM, *see* Schwartsmann G
Cramer L, *see* Modi S
Crane CH, *see* Esnaola NF
Crane CN, *see* Pisters PWT
Crane EA, *see* Herbst RS

Crawford ED. Intravesical Therapy for Superficial Cancer: Need for More Options (editorial), 3185
Crawford J, *see* Lawrence G
see Vokes EE
Cremieux P, *see* Gabrilove JL
Cremin C, Wong N, Buzaglo K, Paradis A-J, Foulkes W. Nonovarian Pelvic Cancers in *BRCA1/2* Mutation Carriers and the BRCAPRO Statistical Model (correspondence), 3936
Crews KR, Gandhi V, Srivastava DK, Razzouk BI, Tong X, Behm FG, Plunkett W, Raimondi SC, Pui C-H, Rubnitz JE, Stewart CF, Ribeiro RC. Interim Comparison of a Continuous Infusion Versus a Short Daily Infusion of Cytarabine Given in Combination With Cladribine for Pediatric Acute Myeloid Leukemia, 4217
Crinò L, *see* Scagliotti GV
Cripe L, *see* Witzig TE
Crist WM, *see* Baker KS
see Sorensen PHB
Cristofanilli M, *see* Esteva FJ
Critchfield GC, *see* Frank TS
Crivellari D, *see* Spazzapan S
Croghan GA, *see* Cox LS
Cropp GF, *see* Kuenen BC
Cross C, D'Amico A. In Reply (correspondence), 4129
Cross CK, Shultz D, Malkowicz SB, Huang WC, Whittington R, Tomaszewski JE, Renshaw AA, Richie JP, D'Amico AV. Impact of Race on Prostate-Specific Antigen Outcome After Radical Prostatectomy for Clinically Localized Adenocarcinoma of the Prostate, 2863
Crowley JJ, *see* Albain KS
Crowther D, *see* Radford JA
Cruciani G, *see* Ravaioli A
Crugnola M, *see* Cesana C
Crul M, de Klerk GJ, Swart M, van't Veer LJ, de Jong D, Boerrigter L, Palmer PA, Bol CJ, Tan H, de Gast GC, Beijnen JH, Schellens JHM. Phase I Clinical and Pharmacologic Study of Chronic Oral Administration of the Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer, 2726
Cude K, *see* Bennett CL
Cufer T, *see* Biganzoli L
Culine S, *see* Tepper JE
Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, Merrouche Y, Laplanche A, Fizazi K. Development and Validation of a Prognostic Model to Predict the Length of Survival in Patients With Carcinomas of an Unknown Primary Site, 4679
Cummings B, *see* Tepper JE
Cummings SR, *see* Chlebowski RT
Cunningham D, *see* Maisey N
see Ross P
Cunningham JM, *see* Lindor NM
Cupini S, *see* Falcone A
Curé H, *see* Chevalier V
Curé H, Chevalier V, Adenis A, Tubiana-Mathieu N, Niezgodzki G, Kwiatkowski F, Pezet D, Perpoint B, Coudert B, Focan C, Lévi F, Chipponi J, Chollet P. Phase II Trial of Chronomodulated Infusion of High-Dose Fluorouracil and *l*-Folinic Acid in Previously Untreated Patients With Metastatic Colorectal Cancer, 1175
Curigliano G, *see* De Pas T
Curley SA, *see* Esnaola NF
see Vauthey J-N
Curran D, *see* Pignatti F
Curran W, *see* Mehta MP
see Shaw E
Curtis RE, *see* Dores GM
Cutler C, Antin JH. In Reply (correspondence), 604
Cuzick J, *see* Jonat W
Cvitkovic E, *see* Louvet C
Czauderna P, Mackinlay G, Perilongo G, Brown J, Shafford E, Aronson D, Pritchard J, Chapchap P, Keeling J, Plaschkes J, Otte JB for the Liver Tumors Study Group of the International Society of Pediatric Oncology. Hepatocellular Carcinoma in Children: Results of the First Prospective Study of the International Society of Pediatric Oncology Group, 2798
Czuczman MS, *see* Witzig TE

D

Dagher R, *see* Schwartsmann G
Dagnelie PC, *see* Agteresch HJ
Dahle R, *see* Sundstrøm S
Daidone MG, Veneroni S, Cappelletti V, Radice P, Pierotti MA, Younes M. Estrogen Receptor-Beta Expression in Hereditary Breast Cancer (correspondence), 3752
Dakhil S, *see* Loesch D
Dakhil SR, *see* Jatoi A
Dal Lago D, *see* Repetto L
Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W, Rabbani F, Donat MS, Herr HW, Sogani P, DePalma D, Bajorin D. Phase I Trial of Intravesical Gemcitabine in Bacillus Calmette-Guérin-Refractory Transitional-Cell Carcinoma of the Bladder, 3193
Daliani D, *see* Pagliaro LC
see Papandreou CN
Dalle J-H, *see* Perel Y
Dalton V, *see* LeClerc JM
Dalton VK, *see* Lipshultz SE
Damani MN, Master V, Meng MV, Burgess C, Turek P, Oates RD. Postchemotherapy Ejaculatory Azoospermia: Fatherhood With Sperm From Testis Tissue With Intracytoplasmic Sperm Injection, 930
Damasio EE, *see* Federico M

D'Amico AV, *see* Cross CK
D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of Prostate Cancer-Specific Survival After Radiation Therapy for Patients With Clinically Localized Prostate Cancer, 4567
D'Amico AV. Predicting Prostate-Specific Antigen Recurrence Established: Now, Who Will Survive? (editorial), 3188
Damon L, *see* Linker C
Dan ME, *see* Vaishampayan U
Dancey J, *see* Freidlin B
Dancey JE, *see* Brierley JD
Danese S, *see* Berruti A
Danesi R, *see* Falcone A
D'Angelillo RM, *see* Trodella L
D'Angelo A, *see* Oliva EN
Daniell HW. Inhibition of Opioid Analgesia by Selective Serotonin Reuptake Inhibitors (correspondence), 2409
Danielsen HE, *see* Sudbø J
Danish RK, *see* Leung W
Dann EJ, Fineman R, Rowe JM. Tumor Lysis Syndrome After STI571 in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (correspondence), 354
Danoff-Burg S, *see* Stanton AL
Darai E, *see* Barranger E
Darrah D, *see* Mitchell MS
Daskalakis T, *see* Datta RV
Datta RV, Daskalakis T, Adler H, Lehman H. Unusual Presentations of Uncommon Tumors: Case 3. Giant Cell Plasmacytoma Presenting as an Intraperitoneal Mass, 2405
Daugaard G, *see* Petersen PM
Daugherty CK, Steensma DP. Overcoming Obstacles to Hospice Care: An Ethical Examination of Inertia and Inaction, 2752
Daugherty CK. The "Cure" for Cancer: Can the Media Report the Hope Without the Hype? (editorial), 3761
Daus H, *see* Trümper L
David J, *see* Vasey PA
Davidson BR, *see* Brett BT
Davidson N, *see* Douillard J-Y
Davidson NE, Levine M. Breast Cancer Consensus Meetings: Vive la Difference? (editorial), 1719
Davis AM, O'Sullivan B, Bell RS, Turcotte R, Catton CN, Wunder JS, Chabot P, Hammond A, Benk V, Isler M, Freeman C, Goddard K, Bezjak A, Kandel RA, Sadura A, Day A, James K, Tu D, Pater J, Zee B. Function and Health Status Outcomes in a Randomized Trial Comparing Preoperative and Postoperative Radiotherapy in Extremity Soft Tissue Sarcoma, 4472
Davis D, *see* Disis ML
Davis DW, *see* Herbst RS
Davis KB, *see* Chen WY
Davis MP, Dreicer R. Revisiting Truth and Consequences: What to Do When the Patient Doesn't Want to Know (correspondence), 4403
Davis P, *see* Bass AJ
see Rizzieri DA
Davis PC, *see* Nachman JB
Dawes M, *see* Lens MB
Day A, *see* Davis AM
de Bono JS, Stephenson J Jr, Baker SD, Hidalgo M, Patnaik A, Hammond LA, Weiss G, Goetz A, Siu L, Simmons C, Jolivet J, Rowinsky EK. Troxacitabine, an L-Stereoisomeric Nucleoside Analog, on a Five-Times-Daily Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies, 96
de Braud F, *see* De Pas T
de Bruijn P, *see* Kehrer DFS
De Conno F, *see* Galeazzi G
de Gast GC, *see* Crul M
de Gast GC, Vyth-Dreese FA, Nooijen W, van den Bogaard CJC, Sein J, Holtkamp MMJ, Linthorst GAM, Baars JW, Schornagel JH, Rodenhuis S. Reinfusion of Autologous Lymphocytes With Granulocyte-Macrophage Colony-Stimulating Factor Induces Rapid Recovery of CD4+ and CD8+ T Cells After High-Dose Chemotherapy for Metastatic Breast Cancer, 58
de Giacomi C, *see* Pizzichetta MA
de Graeff A, *see* Koedoot CG
de Gramont A, *see* Louvet C
de Haan RJ, *see* Koedoot CG
de Haes JC, *see* Jonat W
de Haes JCJM, *see* Koedoot CG
de Jong D, *see* Crul M
de Jonge MJA, *see* Kehrer DFS
see Mathiissen RHJ
de Jonge MJA, Punt CJA, Sparreboom A, Planting AST, Peters MEWJ, van de Schraaf J, Jackman A, Smith R, de Mulder PHM, Verweij J. Phase I and Pharmacologic Study of Oral ZD9331, A Novel Nonpolyglutamated Thymidylate Synthase Inhibitor, in Adult Patients With Solid Tumors, 1923
de Jongh F, *see* Sparreboom A
de Jongh FE, Verweij J, Sparreboom A. In Reply (correspondence), 1144
de Juan C, *see* González-Quevedo R
de Kernion J, *see* Graefen M
de Klerk GJ, *see* Crul M
de la Chapelle A. Microsatellite Instability Phenotype of Tumors: Genotyping or Immunohistochemistry? The Jury Is Still Out (editorial), 897
de Lemos M. Safety Issues of Soy Phytoestrogensin Breast Cancer Patients (correspondence), 3040
De Lena M, *see* Berruti A
De Lumley L, *see* Perel Y
De Maio E, *see* Perrone F
De Marinis F, *see* Scagliotti GV

De Matteis A, *see* Berruti A
de Matteis A, *see* Jonat W
de Moura MC, *see* Costa L
de Mulder PHM, *see* de Jonge MJA
De Pas T, Pastorino U, Spaggiari L, Curigliano G, de Braud F, Robertson C. Preoperative Chemotherapy in Non-Small-Cell Lung Cancer: Nothing New in N2 Disease (correspondence), 2603
De Stefano V, *see* Teofili L
de Tribolet N, *see* Stupp R
de Vries EGE, *see* Kehrer DFS
De Wolf-Peeters C, *see* Achten R
Deakin DP, *see* Radford JA
Dean A, Rogers TE, Diehl J, Dowell JE. Extramedullary Sites of Involvement in Hematologic Malignancies: Case 1. Multifocal Intracranial Involvement With Mantle-Cell Lymphoma, 340
DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination Chemotherapy and Radiotherapy for Primary Central Nervous System Lymphoma: Radiation Therapy Oncology Group Study 93-10, 4643
Deavers M, *see* Levenback C
Debruyne C, *see* Ardizzoni A
see Pignatti F
see Shepherd FA
DeCastro C, *see* Kornblith AB
DeCastro CM, *see* Bass AJ
see Rizzieri DA
see Silverman LR
Decker PA, *see* Cox LS
Decker V, *see* Northouse LL
Declerck L, *see* LeClerc JM
Deer T, *see* Smith TJ
DeFabiani E, *see* Berruti A
Deffenbaugh AM, *see* Chen WY
see Frank TS
Deitcher SR, Fesen MR, Kiproff PM, Hill PA, Li X, McCluskey ER, Semba CP, Cardiovascular Thrombolytic to Open Occluded Lines-2 Investigators. Safety and Efficacy of Alteplase for Restoring Function in Occluded Central Venous Catheters: Results of the Cardiovascular Thrombolytic to Open Occluded Lines Trial, 317
deKernion JB, *see* Zisman A
del Carmen Vela M, *see* Mellado B
Del Tacca M, *see* Falcone A
Delaney S, *see* Quinn JA
Delbrel X, *see* Mahon FX
Dell'Anna T, *see* Cantù MG
Delling G, *see* Bielack SS
Delmas PD, *see* Menssen HD
Delpassand ES, *see* Levenback C
Delpero J-R, *see* Etienne M-C
Delvecchio P, *see* El-Sayed S
Demakos EP, *see* Kornblith AB
see Silverman LR
Demers L, *see* Lipton A
Demers LM, *see* Costa L
Demetri GD, *see* Brooks BJ
see Singer S
DeMets DL, *see* Love RR
DeMichele A, Weber BL. Risk Management in *BRCA1* and *BRCA2* Mutation Carriers: Lessons Learned, Challenges Posed (editorial), 1164
Denman JP, Gilbar PJ, Abdi EA. Hypersensitivity Reaction (HSR) to Docetaxel After a Previous HSR to Paclitaxel (correspondence), 2760
dePalma D, *see* Dalbagni G
Depcik-Smith ND, *see* Orlowski RZ
Depee JK, *see* Ramanathan RK
Depierre A, Milleron B, Moro-Sibilot, Chevret S, Quoix E, Lebeau B, Braun D, Breton J-L, Lemarié E, Gouva S, Paillot N, Bréchot J-M, Janicot H, Lebas F-X, Terrioux P, Clavier J, Foucher P, Monchâtre M, Coëtmeur D, Level M-C, Leclerc P, Blanchon F, Rodier J-M, Thiberville L, Villeneuve A, Westeel V, Chastang C, French Thoracic Cooperative Group. Preoperative Chemotherapy Followed by Surgery Compared With Primary Surgery in Resectable Stage I (except T1N0), II, and IIIa Non-Small-Cell Lung Cancer, 247
Depierre A, Westeel V, Milleron B, Moro-Sibilot D, Quoix E, Braun D, Lebeau B. In Reply (correspondence), 2605
Depisch D, *see* Scheithauer W
Derigs H-G, *see* Kollmannsberger C
DeSantis M, *see* Jäger G
Deschênes L, *see* Maunsell E
Detmar SB, Muller MJ, Schornagel JH, Wever LDV, Aaronson NK. Role of Health-Related Quality of Life in Palliative Chemotherapy Treatment Decisions, 1056
Detterbeck F. Unusual Pulmonary Lesions: Endobronchial Carcinoid of the Lung (correspondence), 4269
Deutsch M, *see* Dourakis SP
Deutsch P, *see* DiPaola RS
Devergie A, *see* Bergeron A
Devidas M, *see* Goorin AM
Dezube BJ, *see* Cianfrocca M
Di Costanzo F, *see* Scagliotti GV
Di Lauro L, *see* Lopez M
Di Leo A, *see* Bleiberg H
Di Leo A, Buyse M. Equivalence Between Ovarian Suppression and Chemotherapy in the Adjuvant Treatment of Endocrine-Responsive Breast Cancer (correspondence), 1954
Di Leone L, *see* Schwartsmann G
Di Lorenzo G, *see* Perrone F
Di Maio M, *see* Perrone F
Di Mario A, *see* Teofili L
Di Paolo A, *see* Falcone A
Di Rocco C, *see* Massimino M
Di Russo A, *see* Galeazzi G

Diasio RB, *see* Adjei AA
Diasio RB. An Evolving Role for Oral Fluoropyrimidine Drugs (editorial), 894
Díaz-Rubio E, *see* González-Quevedo R
Dicks-Mireaux C, *see* Owens CM
Dieckmann K, *see* Timmermann B
Dieckmann K-P, *see* Classen J
Diehl J, *see* Dean A
Diehl V, *see* Josting A
see Sieber M
see Weihrauch MR
Dieras V, *see* Zelek L
Dietemann A, *see* Iamandi C
Dietrich D, *see* Borner MM
Dietrich P-Y, *see* Stupp R
DiFronzo LA, Gupta RK, Essner R, Foshag LJ, O'Day SJ, Wanek LA, Stern SL, Morton DL. Enhanced Humoral Immune Response Correlates With Improved Disease-Free and Overall Survival in American Joint Committee on Cancer Stage II Melanoma Patients Receiving Adjuvant Polyvalent Vaccine, 3242
DiGianni LM, Garber JE, Winer EP. Complementary and Alternative Medicine Use Among Women With Breast Cancer, 34s
Dignam JJ, *see* Fisher B
Diller L, *see* Emmons K
Diller L, Nancarrow CM, Shaffer K, Matulonis U, Mauch P, Neuberg D, Tarbell NJ, Litman H, Garber J. Breast Cancer Screening in Women Previously Treated for Hodgkin's Disease: A Prospective Cohort Study, 2085
Dillman RO. Radiolabeled Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoma, 3545
Dillon H, *see* Hersey P
Dimery I, *see* Osborne CK
Dimitrov BD, *see* Oliva EN
Dimopoulos M, *see* Kosmidis P
Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V, Karkantaris C, Mitsouli C, Gika D, Christakis J, Anagnostopoulos N. Treatment of Waldenström's Macroglobulinemia With Rituximab, 2327
Dinapoli R, *see* Shaw E
Dinehart S, *see* Coldiron B
Dingee C, *see* Kwan W
Dinh NV, *see* Love RR
Dinjens WNM, *see* van der Sijp JRM
Dionne J, *see* Bélanger K
DiPaola RS, Rinehart J, Nemunaitis J, Ebbinghaus S, Rubin E, Capanna T, Ciardella M, Doyle-Lindrud S, Goodwin S, Fontaine M, Adams N, Williams A, Schwartz M, Winchell G, Wickersham K, Deutsch P, Yao S-L. Characterization of a Novel Prostate-Specific Antigen-Activated Peptide-Doxorubicin Conjugate in Patients With Prostate Cancer, 1874
Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K. Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide-Based Vaccines, 2624
Dispenzieri A, *see* Anderson PM
see Rajkumar SV
Distefano MG, *see* Ferrandina G
DiTaranto S, *see* Womer RB
Dittrich Ch, *see* van Kesteren Ch
Diviné M, *see* Fermé C
Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian C, Hummer A, Venkatraman E, Spriggs DR. Retrospective Analysis of Carboplatin and Paclitaxel as Initial Second-Line Therapy for Recurrent Epithelial Ovarian Carcinoma: Application Toward a Dynamic Disease State Model of Ovarian Cancer, 1238
Djavan B, Remzi M, Zlotta A, Seitz C, Snow P, Marberger M. Novel Artificial Neural Network for Early Detection of Prostate Cancer, 921
Djulbegovic B, *see* Rizzo JD
Dmitrovsky E, *see* Freemantle SJ
Do K-A, *see* Vauthey J-N
Doelken G, *see* Sieber M
see Sucker C
Dogan A, *see* Bomanji JB
Dogliotti L, *see* Berruti A
see Sperone P
Döhner H, *see* Döhner K
see Viardot A
Döhner J, *see* Fröhling S
Döhner K, *see* Fröhling S
Döhner K, Tobis K, Ulrich R, Fröhling S, Benner A, Schlenk RF, Döhner H. Prognostic Significance of Partial Tandem Duplications of the MLL Gene in Adult Patients 16 to 60 Years Old With Acute Myeloid Leukemia and Normal Cytogenetics: A Study of the Acute Myeloid Leukemia Study Group Ulm, 3254
Dolan ME, *see* Quinn JA
Domingo-Domènech JM, *see* Mellado B
Donaldson SS, *see* Friedmann AM
Donaldson SS, Hudson MM, Lamborn KR, Link MP, Kun L, Billett AL, Marcus KC, Hurwitz CA, Young JA, Tarbell NJ, Weinstein HJ. VAMP and Low-Dose, Involved-Field Radiation for Children and Adolescents With Favorable, Early-Stage Hodgkin's Disease: Results of a Prospective Clinical Trial, 308
Donat MS, *see* Dalbagni G
Donehower R, *see* Carducci MA
Donnelly S, *see* Kirkwood JM
Doody D, *see* Harper-Wynne CL
Doran J, *see* Seymour LW
Dordal M, *see* Herbst RS
Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, van Leeuwen FE, Holowaty EJ, Andersson M, Wiklund T, Joen-

suu T, van't Veer MB, Stovall M, Gospodarowicz M, Travis LB. Second Malignant Neoplasms Among Long-Term Survivors of Hodgkin's Disease: A Population-Based Evaluation Over 25 Years, 3484
Dorey F, *see* Zisman A
Dorresteijn LDA, Kappelle AC, Boogerd W, Klokman WJ, Balm AJM, Keus RB, van Leeuwen FE, Bartelink H. Increased Risk of Ischemic Stroke After Radiotherapy on the Neck in Patients Younger Than 60 Years, 282
Dougherty J, *see* Modi S
Douglas PS, *see* Vallis KA
Douglass EC, *see* Katzenstein HM
Douglass H, *see* Khushalani NI
Douillard JY, *see* Louvet C
Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, Vincent MD, Lembersky BC, Thompson S, Maniero A, Benner SE. Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer, 3605
Dourakis SP, Sevastianos VA, Alexopoulou A, Deutsch M, Stavrianeas N. Treatment Side Effects: Case 2. Toxic, Epidermal, Necrolysis-Like Reaction Associated With Docetaxel Chemotherapy, 3030
Dowell JE, *see* Dean A
Dowling AJ, *see* Brierley JD
Downey RJ, *see* Martin J
Downing JR, *see* Rubnitz JE
Dowsett M, *see* Geisler J
see Harper-Wynne CL
see Lønning PE
Doyle ME, *see* Ingram SS
Doyle-Lindrud S, *see* DiPaola RS
Doz F, *see* Lashford LS
Drabkin HA, *see* Bremnes RM
Dreicer R, *see* Davis MP
see Thomas J
Dreisbach A, *see* Rozans M
Drews AA, *see* Cox LS
Drobyski WR, *see* Levine JE
Drolet M, *see* Maunsell E
Drouin P, *see* Pearcey R
Droz JP, *see* Bokemeyer C
see van Kesteren Ch
Druker BJ, *see* Heinrich MC
see Mauro MJ
Du M, *see* Gandhi V
Du XL, Osborne C, Goodwin JS. Population-Based Assessment of Hospitalization for Toxicity From Chemotherapy in Older Women With Breast Cancer, 4636
Duc NB, *see* Love RR
Duchateau L, *see* Biganzoli L
Duck ET, *see* Modi S
Ducreux M, *see* Raymond E
Dudas M, *see* Stojadinovic A
Dudek A, *see* Lima CMSR
Dudeney S, Lieberman IH, Reinhardt M-K, Hussein M. Kyphoplasty in the Treatment of Osteolytic Vertebral Compression Fractures as a Result of Multiple Myeloma, 2382
Duehmke E, *see* Sieber M
Duenas-Gonzalez A, Lopez-Graniel CM, Mota A, Mohar A. Neoadjuvant Chemotherapy Followed by Surgery in Locally Advanced Cervical Carcinoma (correspondence), 2908
Dufour P, *see* Herbrecht R
Dugan M, *see* Lashford LS
see Lipton A
Dulguerov P, *see* Allal AS
Dumez H, *see* van Kesteren Ch
Dunleavy K, *see* McDermott RS
Dunlop DJ, *see* Radford JA
Dunn RL, *see* Wei JT
Dunst J, *see* Rödel C
Dunst J, Reese T, Sutter T, Zühlke H, Hinke A, Kölling-Schlebusch K, Frings S. Phase I Trial Evaluating the Concurrent Combination of Radiotherapy and Capecitabine in Rectal Cancer, 3983
Durini E, *see* Vici P
Dusenbery KE, *see* Jennings MT
Duvic M, *see* Sarris AH
Dvorak HF. Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy, 4368
Dy GK, Adjei AA. Novel Targets for Lung Cancer Therapy: Part I, 2881
Dy GK, Adjei AA. Novel Targets for Lung Cancer Therapy: Part II, 3016
D'yachkova Y, *see* Weir L
Dyson NJ, *see* Chakravarti A
Dziadziuszko R, *see* Ardizzoni A

E

Eagan J, *see* Walshe LJ
Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC. Impact of Referral Patterns on the Use of Chemotherapy for Lung Cancer, 1786
Earle J, *see* Shaw E
Early Clinical Studies Group of the European Organization for Research and Treatment of Cancer, *see* van Kesteren Ch
Eary JF, *see* Rubin BP
East MJ, *see* Eton O
Eastham JA, *see* Cagiannos I
see Graefen M
Easton DF, *see* Lakhani SR
Ebbert JO, *see* Cox LS
Ebbinghaus S, *see* DiPaola RS

Eckardt J, *see* Lima CMSR
Economopoulos T, *see* Kosmidis P
Economou I, *see* Antonadou D
Eden L, *see* Schwartz GK
Eder JP Jr, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW. Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated Daily, 3772
Edge SB, *see* Singletary SE
see Winer EP
Edler D, Glimelius B, Hallström M, Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H. Thymidylate Synthase Expression in Colorectal Cancer: A Prognostic and Predictive Marker of Benefit From Adjuvant Fluorouracil-Based Chemotherapy, 1721
Edler L, *see* Laack E
Efficace F, Bottomley A. Do Quality-of-Life Randomized Clinical Trials Support Clinicians in Their Decision-Making? (correspondence), 4126
Eggermont AMM, *see* van der Sijp JRM
Eggert L, *see* Liang W
Eggleton SP, *see* Smith IC
Eguchi K, *see* Sobue T
Eiermann W, *see* Jonat W
Eifel PJ, Jhingran A, Bodurka DC, Levenback C, Thames H. Correlation of Smoking History and Other Patient Characteristics With Major Complications of Pelvic Radiation Therapy for Cervical Cancer, 3651
Einhorn L, *see* Bokemeyer C
Einhorn LH, *see* Hinton S
Einhorn LH, Levinson J, Li S, Lamar L, Kamin D, Mendelson D. American Society of Clinical Oncology 2001 Presidential Initiative: Impact of Regulatory Burdens on Quality Cancer Care, 4722
Eisen A, *see* Chlebowski RT
Eisen T. Thalidomide in Solid Malignancies (editorial), 2607
Eisen TG, *see* Nathan PD
Eisenberg P, *see* Douillard J-Y
Eisenberger MA, *see* Carducci MA
Eisenhauer E, *see* Freidlin B
Ekmekcioglu S, *see* Ellerhorst JA
El Ghazi EA, *see* Allal AS
El-Sayed S, Nabid A, Shelley W, Hay J, Balogh J, Gelinas M, MacKenzie R, Read N, Berthelet E, Lau H, Epstein J, Delvecchio P, Ganguly PK, Wong F, Burns P, Tu D, Pater J. Prophylaxis of Radiation-Associated Mucositis in Conventionally Treated Patients With Head and Neck Cancer: A Double-Blind, Phase III, Randomized, Controlled Trial Evaluating the Clinical Efficacy of an Antimicrobial Lozenge Using a Validated Mucositis Scoring System, 3956
Elfring GL, *see* Lima CMSR
Elias L, *see* Morrison VA
Ell PJ, *see* Bomanji JB
Elledge R, *see* Osborne CK
Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S, Grimm EA. Loss of MDA-7 Expression With Progression of Melanoma, 1069
Ellerton J, *see* Kornblith AB
see Silverman LR
Elliott PJ, *see* Orlowski RZ
Ellis GK, Livingston RB, Gralow JR, Green SJ, Thompson T. Dose-Dense Anthracycline-Based Chemotherapy for Node-Positive Breast Cancer, 3637
Ellis LM, *see* Herbst RS
see Herbst RS
see Vauthey J-N
Ellis M, *see* Osborne CK
Ellis N, *see* Scheuer L
Ellis PA, *see* Galani E
see Plunkett TA
Ellman M, *see* Hudes G
Elshaikh M, *see* Kupelian PA
Emanuel EJ, *see* Agrawal M
Emmanouilides C, *see* Witzig TE
Emmenegger U, Spaeth PJ, Neftel KA. Intravenous Immunoglobulin for Hemophagocytic Lymphohistiocytosis? (correspondence), 599
Emmons K, Li FP, Whitton J, Mertens AC, Hutchinson R, Diller L, Robison LL. Predictors of Smoking Initiation and Cessation Among Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor Study, 1608
Endres S, *see* Schwartz GK
Eng SL, *see* Timoney JP
Engel J, *see* Kerr J
Enger S, *see* Ursin G
Engert A, *see* Josting A
see Sieber M
Engle L, *see* Lipton A
Engler H, *see* Kuball J
Engstrom MC, *see* Wang XS
Enke C, *see* Weekes CD
Ennis M, *see* Goodwin PJ
Epelbaum R, *see* Biganzoli L
Epirubicin-Lonidamine Group, *see* Berruti A
Epoetin Alfa Study Group, *see* Littlewood TJ
Epoetin Beta Hematology Study Group, *see* Österborg A
Epstein J, *see* El-Sayed S
Erbersdobler A, *see* Cagiannos I
see Graefen M
Erdal S, *see* Nadella P
Erdman W, *see* Levenback C
Eremin O, *see* Smith IC
Eriksson B, *see* Hudes G
Erikstein B, *see* Howell A
Erland JB, *see* Greco FA
Erlichman C, *see* Adjei AA
Ernstoff MS, *see* Bukowski R

see Kirkwood JM
Erwin J, *see* Buchholz TA
Esmaeli B, *see* Esteva FJ
Esnaola NF, *see* Vauthey J-N
Esnaola NF, Cantor SB, Johnson ML, Mirza AN, Miller AR, Curley SA, Crane CH, Cleeland CS, Janjan NA, Skibber JM. Pain and Quality of Life After Treatment in Patients With Locally Recurrent Rectal Cancer, 4361
Esnaola NF, Lazarides SN, Mentzer SJ, Kuntz KM. Outcomes and Cost-Effectiveness of Alternative Staging Strategies for Non-Small-Cell Lung Cancer, 263
Espérou H, *see* Bergeron A
Esseesse I, *see* Ferrari AC
Esseltine D-L, *see* Orlowski RZ
Essennan LJ, *see* Sepucha KR
Essner R, *see* DiFronzo LA
see Hsueh EC
Estapé J, *see* Mellado B
Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2-Overexpressing Metastatic Breast Cancer, 1800
Estey EH, *see* Gandhi V
Etienne M-C, Chazal M, Laurent-Puig P, Magné N, Rosty C, Formento J-L, Francoual M, Formento P, Renée N, Chamorey E, Bourgeon A, Seitz J-F, Delpero J-R, Letoublon C, Pezet D, Milano G. Prognostic Value of Tumoral Thymidylate Synthase and p53 in Metastatic Colorectal Cancer Patients Receiving Fluorouracil-Based Chemotherapy: Phenotypic and Genotypic Analyses, 2832
Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS. Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized Trial, 2045
Ettinger LJ, *see* Jennings MT
Eucker J, *see* Sezer O
Euller-Ziegler L, *see* Menssen HD
European Organization for Research and Treatment of Cancer-Lung Cancer Group, *see* Ardizzoni A
European Organization for the Research and Treatment of Cancer Early Clinical Study Group, *see* Raymond E
Evangelista L, *see* Sarna L
Evans DB, *see* Pisters PWT
Evans SR, Krown SE, Testa MA, Cooley TP, Von Roenn JH. Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressive AIDS-Related Kaposi's Sarcoma: An AIDS Clinical Trials Group Clinical Study, 3236
Evans T, *see* Ramanathan RK
Evans WE, *see* Leung W
Exner GU, *see* Bielack SS
Extra J-M, *see* Rouzier R

F

Fabères C, *see* Mahon FX
Facon T, *see* Menssen HD
Fagioli F, Aglietta M, Tienghi A, Ferrari S, Brach del Prever A, Vassallo E, Palmero A, Biasin E, Bacci G, Picci P, Madon E. High-Dose Chemotherapy in the Treatment of Relapsed Osteosarcoma: An Italian Sarcoma Group Study, 2150
Failla G, *see* Scagliotti GV
Fair W, *see* Cagiannos I
Fairey R, *see* Shenkier TN
Faivre S, *see* Raymond E
Falcone A, Masi G, Allegrini G, Danesi R, Pfanner E, Brunetti IM, Di Paolo A, Cupini S, Del Tacca M, Conte P. Biweekly Chemotherapy With Oxaliplatin, Irinotecan, Infusional Fluorouracil, and Leucovorin: A Pilot Study in Patients With Metastatic Colorectal Cancer, 4006
Falcou M-C, *see* Rouzier R
Falk S, *see* Carmichael J
Fallowfield L, *see* Jenkins V
Familiari U, *see* Sperone P
Fan L, *see* Goh B-C
Fan S-T, *see* Poon RT-P
Fanale MA, Zeldenrust SR, Moynihan TJ. Some Unusual Complications of Malignancies: Case 2. Marantic Endocarditis in Advanced Cancer, 4111
Fargeot P, *see* Biganzoli L
Farrar WB, *see* Albain KS
Farris A, *see* Berruti A
Fassas A, *see* Badros A
Fata F, Mirza A, Bernath A. Skin Lesions in Melanoma and Kaposi's Sarcoma: Case 3. Familial Classic Mediterranean Kaposi's Sarcoma, 1415
Fay MP, *see* Warren JL
Fayers P, *see* Jordhøy MS
Federico M, Zinzani PL, Frassoldati A, Vinceti M, Modè A, Annino L, Chisesi T, Pagnucco G, Invernizzi R, Spriano M, Resegotti L, Bendandi M, Damasio EE, Italian Cooperative Group for the Study of Hairy Cell Leukemia. Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up, 638
Fehrenbacher L, *see* Vogel CL
Feiden W, *see* Samnick S
Feig BW, *see* Ahmad SA
Feld R, *see* Leighl NB
Ferguson W, *see* Goorin AM
Fermé C, Mounier N, Diviné M, Brice P, Stamatoullas A, Reman O, Voillat L, Jaubert J, Lederlin P, Colin P, Berger F, Salles G. Intensive Salvage Therapy With

High-Dose Chemotherapy for Patients With Advanced Hodgkin's Disease in Relapse or Failure After Initial Chemotherapy: Results of the Group d'Études des Lymphomes de l'Adulte H89 Trial, 467
Fernández C, *see* González-Quevedo R
Ferrandina G, Lauriola L, Distefano MG, Zannoni GF, Gessi M, Legge F, Maggiano N, Mancuso S, Capelli A, Scambia G, Ranelletti FO. Increased Cyclooxygenase-2 Expression Is Associated With Chemotherapy Resistance and Poor Survival in Cervical Cancer Patients, 973
Ferranti G, *see* Santini D
Ferrara JLM, *see* Yanik GA
Ferrari A, *see* Massimino M
see Spreafico F
Ferrari A, Bisogno G, Casanova M, Meazza C, Piva L, Cecchetto G, Zanetti I, Pilz T, Mattke A, Treuner J, Carli M. Paratesticular Rhabdomyosarcoma: Report From the Italian and German Cooperative Group, 449
Ferrari AC, Stone N, Stock R, Bednar M, Esseesse I, Singh H, Baldwin Y, Mandeli J. 13-*cis* Retinoic Acid and Complete Androgen Blockade in Advanced Hormone-Naive Prostate Cancer Patients: Report of a Phase II Randomized Study, 538
Ferrari S, *see* Fagioli F
Ferrari S, Mercuri M, Bacci G. Comment on "Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols" (correspondence), 2910
Ferreira CMM, *see* Kashani-Sabet M
Ferry D, *see* Ranson M
Ferry DR, *see* Seymour LW
Fesen MR, *see* Deitcher SR
Feun L, *see* Agarwala SS
Feusner JH, *see* Bhatia S
see Katzenstein HM
Feyereislova A, *see* Albanell J
see Baselga J
Fiebiger W, *see* Jäger G
see Scheithauer W
Fiere D, *see* Menssen HD
Figg WD, *see* Bennett CL
see Cianfrocca M
see Tan AR
Figlin RA, *see* Zisman A
Fillet G, *see* Gisselbrecht C
Fine HA. Primary Central Nervous System Lymphoma: Time to Ask the Question (editorial), 4615
Fine R, *see* Mikulski SM
Finegold MJ, *see* Katzenstein HM
Fineman R, *see* Dann EJ
Fink A, *see* Silliman RA
Fink H, *see* Kröger K
Fink L, *see* Kaushal V
Finkelstein DF, *see* Chakravarti A
Finkelstein DM, *see* Chakravarti A
Finn WG, *see* Mirza I
Fioretta G, *see* Bouchardy C
Fisch M, *see* Bruera E
see Strasser F
Fisher B, *see* DeAngelis LM
see Wickerham DL
Fisher B, Bryant J, Dignam JJ, Wickerham L, Mamounas EP, Fisher ER, Margolese RG, Nesbitt L, Paik S, Pisanksy TM, Wolmark N. Tamoxifen, Radiation Therapy, or Both for Prevention of Ipsilateral Breast Tumor Recurrence After Lumpectomy in Women With Invasive Breast Cancers of One Centimeter or Less, 4141
Fisher C, *see* Kolomainen DF
Fisher ER, *see* Fisher B
Fisher RI. Autologous Stem-Cell Transplantation as a Component of Initial Treatment for Poor-Risk Patients With Aggressive Non-Hodgkin's Lymphoma: Resolved Issues Versus Remaining Opportunity (editorial), 4411
Fishman A, *see* Chetrit A
Fishwick K, *see* Hughes A
Fitch TR, *see* Hobday TJ
see Jatoi A
Fitoussi O, *see* Cany L
Fitz CR, *see* Jennings MT
Fizazi K, *see* Culine S
Flaherty K, *see* Tao J
Flaherty L, *see* Kirkwood JM
Flaherty LE, *see* Rao UNM
see Sondak VK
see Sosman JA
Flamm AL, *see* Pentz RD
Flege S, *see* Bielack SS
Fleischauer AT, *see* Neugut AI
Fleisher M, *see* Shike M
Fleming D, *see* Morkas M
Flesch M, *see* Louvet C
Fletcher CDM, *see* Brooks BJ
see Singer S
Fletcher JA, *see* Singer S
Flinn IW, *see* Witzig TE
Floeter MK, *see* Grem JL
see Wilson RH
Flom KJ, *see* Press MF
Flonn K, *see* Press MF
Floriani I, *see* Cantù MG
Focan C, *see* Curé H
Fogelman I, *see* Jonat W
Fogler WE, *see* Eder JP Jr
Folkman J, *see* Eder JP Jr
Fong Y, *see* Heffernan N
Fonseca R, *see* Rajkumar SV
Fontaine M, *see* DiPaola RS
Fontana A, *see* Menssen HD

Fontanillas M, *see* Mellado B
Forastiere AA, *see* Glisson BS
see Shin DM
Ford J, *see* Mehta MP
Ford L, *see* Sateren WB
Formenti S, *see* Ursin G
Formento J-L, *see* Etienne M-C
Formento P, *see* Etienne M-C
Foroni L, *see* Mortuza FY
Foshag LJ, *see* DiFronzo LA
see Hsueh EC
Foskett M, *see* McNeish IA
Fossa SD, *see* Bokemeyer C
Fossati-Bellani F, *see* Massimino M
Fossati-Bettani F, *see* Spreafico F
Fossella FV, *see* Herbst RS
Foster T, *see* Bass AJ
see Rizzieri DA
Foucher P, *see* Depierre A
Foulkes W, *see* Andermann A
see Cremin C
Fountzilas G, *see* Bafaloukos D
see Kosmidis P
Fowble BL, *see* Freedman GM
Fraass BA, *see* Chan JL
François E, *see* Louvet C
Francoual M, *see* Etienne M-C
Frank TS, *see* Chen WY
Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC. Clinical Characteristics of Individuals With Germline Mutations in *BRCA1* and *BRCA2:* Analysis of 10,000 Individuals, 1480
Franke A, *see* Kaiser U
Franklin J, *see* Josting A
see Sieber M
Franklin WA, *see* Bremnes RM
Franzius C, Schuck A, Bielack SS. High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients With Osteosarcoma and Bone Metastases (correspondence), 1953
Frappaz D, *see* Lashford LS
see Patte C
Frassoldati A, *see* Federico M
Frassoni F, *see* Ringdén O
see Rocha V
Fratino L, *see* Repetto L
Freedman GM, Hanlon AL, Fowble BL, Anderson PR, Nicolaou N. Recursive Partitioning Identifies Patients at High and Low Risk for Ipsilateral Tumor Recurrence After Breast-Conserving Surgery and Radiation, 4015
Freeman C, *see* Davis AM
Freemantle SJ, Dmitrovsky E. Clinical Link Between *p53* and Angiogenesis in Lung Cancer (editorial), 883
Freezer LJ, *see* Toso JF
Freidlin B, Dancey J, Korn EL, Zee B, Eisenhauer E. Multinomial Phase II Trial Designs (correspondence), 599
French Society of Pediatric Hematology and Immunology, Group LAME, *see* Perel Y
French Study Group on Carcinomas of Unknown Primary, *see* Culine S
French Thoracic Cooperative Group, *see* Depierre A
Frenette G, *see* Glisson BS
Freschi A, *see* Ridolfi R
Freter CE, *see* Rai KR
Freund M, *see* Steiner M
Freytes CO, *see* Berry DA
Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs, 4713
Fric D, *see* Page E
Fridrik M, *see* Jakesz R
Friebert S, Kodish E. The Right to Decide, 4115
Friedberg J, *see* Ng AK
Friedman AH, *see* Quinn JA
see Reardon DA
Friedman DL, *see* Bhatia S
Friedman E, *see* Chetrit A
Friedman HS, *see* Gururangan S
see Quinn JA
see Reardon DA
Friedman M. Of What Value Is Uracil/Tegafur Plus Leucovorin to Colorectal Cancer Patients? (editorial), 3574
Friedmann AM, Hudson MM, Weinstein HJ, Donaldson SS, Kun L, Tarbell NJ, Link MP. Treatment of Unfavorable Childhood Hodgkin's Disease With VEPA and Low-Dose, Involved-Field Radiation, 3088
Frings S, *see* Dunst J
Fritsche HA, *see* Esteva FJ
Fritsche HA Jr, *see* Herbst RS
Fritz MA, *see* Kuball J
Fröhling S, *see* Döhner K
Fröhling S, Skelin S, Liebisch C, Scholl C, Schlenk RF, Döhner J, Döhner K for the Acute Myeloid Leukemia Study Group Ulm. Comparison of Cytogenetic and Molecular Cytogenetic Detection of Chromosome Abnormalities in 240 Consecutive Adult Patients With Acute Myeloid Leukemia, 2480
Frontini L, *see* Scagliotti GV
Fry WA, *see* Liptay MJ
Frye D, *see* Buchholz TA
see Rivera E
Fuchs IB, Loebbecke M, Buhler H, Stoltenburg-Didinger G, Heine B, Lichtenegger W, Schaller G. *HER2* in Brain Metastases: Issues of Concordance, Survival, and Treatment (correspondence), 4130
Fujieda K, *see* Aoyama H
Fujiwara Y, *see* Schwartsmann G

Fukuda H, *see* Takada M
Fukunaga H, *see* Noura S
Fukuoka M, *see* Takada M
Fuller RA, *see* Schwarz RE
Fumoleau P, *see* O'Shaughnessy J
see Raymond E
see van Kesteren Ch
Furman WL, Stewart CF, Kirstein M, Kepner JL, Bernstein ML, Kung F, Vietti TJ, Steuber CP, Becton DL, Baruchel S, Pratt C. Protracted Intermittent Schedule of Topotecan in Children With Refractory Acute Leukemia: A Pediatric Oncology Group Study, 1617
Furstenberg CT, *see* Ahles TA
Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, Hill RP. Tumor Hypoxia Has Independent Predictor Impact Only in Patients With Node-Negative Cervix Cancer, 680

G

Gabarre J, *see* Gisselbrecht C
Gabrielson E, *see* Bremnes RM
Gabrilove JL, Sarokhan B, Cremieux P. In Reply (correspondence), 3183
Gabrilove JL, Sarokhan B, Cremieux P. Statistical Explanations for a Community-Based Study of Once-Weekly Epoetin Alfa Therapy in Patients Receiving Chemotherapy (correspondence), 2757
Gajewski TF, *see* Rini BI
Gajjar A, *see* Athale UH
Galani E, *see* Steer CB
Galani E, Ellis PA, Harper PG. Small-Cell Lung Cancer, High Growth Rate, High Response Rate to Chemotherapy: Ideal for High-Dose Chemotherapy? (editorial), 3941
Galbraith SM, Rustin GJS, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, Thompson P, Hough D, Gumbrell L, Padhani AR. Effects of 5,6-Dimethylxanthenone-4-Acetic Acid on Human Tumor Microcirculation Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging, 3826
Gale RP, *see* Berry DA
Galeazzi G, Di Russo A, Boffi R, De Conno F. Unusual Presentations of Lung Cancer: Case 4. Palliative Radiotherapy in Eyelid Non-Hodgkin's Lymphoma, 4601
Galetta D, *see* Trodella L
Galizia E, *see* Scartozzi M
Gallinger S, *see* Lindor NM
Gallino G, *see* Belli F
Gallo C, *see* Perrone F
Galvin E, *see* Northouse LL
Gameiro P, *see* Mortuza FY
Gamelin E, *see* Louvet C
see Zelek L
Gammon G, *see* Hsueh EC
Gamucci T, *see* Biganzoli L
Gandara DR, *see* Albain KS
Gandemer V, *see* Perel Y
Gandhi V, *see* Crews KR
Gandhi V, Plunkett W, Du M, Ayres M, Estey EH. Prolonged Infusion of Gemcitabine: Clinical and Pharmacodynamic Studies During a Phase I Trial in Relapsed Acute Myelogenous Leukemia, 665
Gandini D, *see* Mortuza FY
Gandolo L, *see* Massimino M
Ganguly PK, *see* El-Sayed S
Gans S, *see* Ardizzoni A
Ganz PA, *see* Levine MN
see Pearson ML
see Silliman RA
Garber J, *see* Diller L
Garber JE, *see* Berry DA
see Chen WY
see DiGianni LM
Garcia-Carbonero R, *see* Eder JP Jr
Garcia-Manero G, *see* Giles FJ
Gargantini L, *see* Cesana C
Garrett E, *see* Baker SD
Garrison MA, Glanton C, Rasnke M, Smith ME, Ornstein DL. Challenging Cases and Diagnostic Dilemmas; Case 1. Tracheal Compression in Hodgkin's Disease, 3344
Gascón P, *see* Mellado B
Gascoyne RD, *see* Mirza I
see Shenkier TN
Gasparini M, *see* Spreafico F
Gastó C, *see* Prieto JM
Gatineau M, *see* Raymond E
Gattellari M, Voigt KJ, Butow PN, Tattersall MHN. When the Treatment Goal Is Not Cure: Are Cancer Patients Equipped to Make Informed Decisions?, 503
Gatti A, *see* Pizzichetta MA
see Spazzapan S
Gaulard P, *see* Mounier N
Gautam A, *see* Bepler G
Gebarski SS, *see* Chan JL
Gebbia N, *see* Vici P
Gebbia V, *see* Vici P
Geberth M, *see* Jonat W
Gebhardt MC, *see* Goorin AM
Gedlicka C, *see* Scheithauer W
Gedlicka C, Scheithauer W, Schüll B, Kornek GV. Effective Treatment of Oxaliplatin-Induced Cumulative Polyneuropathy With Alpha-Lipoic Acid (correspondence), 3359
Gee J, *see* Albanell J
Gehlsen KR, *see* Agarwala SS
Geisler J, *see* Lønning PE
Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE. Influence of Letrozole and Anastrozole on Total

Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over Study, 751
Geissler G, *see* Kletzel M
Gelber RD, *see* Colleoni M
see Earle CC
see Goldhirsch A
see LeClerc JM
see Lipshultz SE
Gelber S, *see* Colleoni M
Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, van Zomeren DM, Verweij J, Sparreboom A. Comparative Pharmacokinetics of Unbound Paclitaxel During 1- and 3-Hour Infusions, 574
Gelinas M, *see* El-Sayed S
Geller G, *see* Hensley ML
Gelman RS, *see* Chen WY
Gelmann EP. Molecular Biology of the Androgen Receptor, 3001
Gelmon KA, *see* Van Patten CL
Gemmill RM, *see* Bremnes RM
Genitori L, *see* Massimino M
Georgii A, *see* Sieber M
Georgoulias V, *see* Bafaloukos D
see Souglakos J
see Stathopoulou A
Gerber M, *see* Kleinberg L
Gerl A, *see* Bokemeyer C
see Kollmannsberger C
Gershenwald JE, *see* Ballo MT
Gerson SL. Clinical Relevance of *MGMT* in the Treatment of Cancer, 2388
Gertler SZ, *see* Osborne CK
Gertz MA, *see* Rajkumar SV
Gesk S, *see* Viardot A
Gessi M, *see* Ferrandina G
Geyer S, *see* Rajkumar SV
Gheewala P, *see* Narasimhan P
Ghossein RA, *see* Stojadinovic A
Giaccone G, *see* Ardizzoni A
see Kuenen B
see Shepherd FA
Giannarelli D, *see* Benedetti-Panici P
see Vici P
Gianni AM, *see* Rassidakis GZ
Gianni L, *see* Baselga J
Gianni W, *see* Repetto L
Giantris AL, *see* Lipshultz SE
Giardina G, *see* Berruti A
Giardini R, *see* Rassidakis GZ
Gika D, *see* Dimopoulos MA
Gilbar PJ, *see* Denman JP
Gilbert FJ, *see* Smith IC
Gilchrist GS, *see* Nachman JB
Giles F, *see* Baker SD
Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien SM, Thomas DA, Andreeff M, Bivins C, Jolivet J, Kantarjian HM. Phase II Study of Troxacitabine, a Novel Dioxolane Nucleoside Analog, in Patients With Refractory Leukemia, 656
Gill PG, *see* Hersey P
Gill VJ, *see* Toso JF
Gille J, *see* Spieth K
Gillon T, *see* Hudes G
Ginsberg L, *see* Shin DM
Ginsberg M, *see* Motzer RJ
Ginsberg RJ, *see* Martin J
see Minsky BD
Gioia F, *see* Repetto L
Giordani P, *see* Cascinu S
Giotta F, *see* Vici P
Giovanis P, *see* Ravaioli A
Giralt S, *see* Levine JE
Giralt SA, *see* Wang XS
Gisselbrecht C, *see* Mounier N
Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P, Coiffier B, Tilly H, Gabarre J, Guilmin G, Hermine O, Reyes F for the Groupe d'Etude des Lymphomes de l'Adulte. Shortened First-Line High-Dose Chemotherapy for Patients With Poor-Prognosis Aggressive Lymphoma, 2472
Gitlitz BJ, *see* Zisman A
Gitten R, *see* Socinski MA
Giwercman A, *see* Petersen PM
Glanton C, *see* Garrison MA
Glantz MJ, *see* Mehta MP
Glaspy J, *see* Agarwala SS
see Holmes FA
Glatstein E, *see* Machtay M
Glick HA, *see* Lee JH
Glick JH, *see* Goldhirsch A
see Goldhirsch A
Glimelius B, *see* Dores GM
see Edler D
Glisson BS, *see* Shin DM
Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA. Phase II Trial of Docetaxel and Cisplatin Combination Chemotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck, 1593
Gluckman E, *see* Bergeron A
see Ringdén O
see Rocha V
Gnant M, *see* Jakesz R
Gockerman JP, *see* Bass AJ
see Rizzieri DA
Goddard K, *see* Davis AM
Goepfert H, *see* Shin DM
Goessling W, McKee PH, Mayer RJ. Merkel Cell Carcinoma, 588
Goetz A, *see* de Bono JS
Gogas H, *see* Bafaloukos D
Goh B-C, Lee S-C, Wang L-Z, Fan L, Guo J-Y, Lamba J, Schuetz E, Lim R, Lim H-L, Ong A-B, Lee H-S. Explaining Interindividual Variability of Docetaxel

Pharmacokinetics and Pharmacodynamics in Asians Through Phenotyping and Genotyping Strategies, 3683
Gold S, *see* Woods WG
Goldberg RM, *see* Adjei AA
see Allegra CJ
see Hobday TJ
see Lindor NM
see Sloan JA
Goldberg RM, Sargent DJ, Morton RF, Mahoney MR, Krook JE, O'Connell MJ. Early Detection of Toxicity and Adjustment of Ongoing Clinical Trials: The History and Performance of the North Central Cancer Treatment Group's Real-Time Toxicity Monitoring Program, 4591
Goldberg S, *see* Pecora AL
Goldhirsch A, *see* Bomer MM
see Colleoni M
Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn H-J. In Reply (correspondence),880, 1956
Golding R, *see* Codrington H
Golding RP, *see* Kunst PWA
Goldman JM, *see* Raanani P
Goldstein LJ, *see* Winer EP
Goldstone A, *see* Mortuza FY
Goldstone AH, *see* Branson K
Golub TR, *see* Ramaswamy S
Gonen M, *see* Holen KD
see Wong RJ
González-Quevedo R, Iniesta P, Morán A, de Juan C, Sánchez-Pernaute A, Fernández C, Torres A, Díaz-Rubio E, Balibrea J-L, Benito M. Cooperative Role of Telomerase Activity and *p16* Expression in the Prognosis of Non-Small-Cell Lung Cancer, 254
Gonzalez R, *see* Agarwala SS
Goode MJ, *see* Rizzo JD
Goodin T, *see* Herbst RS
Goodwin JS, *see* Du XL
Goodwin PJ, *see* Leighl NB
Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N. Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study, 42
Goodwin S, *see* DiPaola RS
Gooley TA, *see* Disis ML
Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M, Siegal GP, Gebhardt MC, Schwartz CL, Link M, Grier HE. Phase II/III Trial of Etoposide and High-Dose Ifosfamide in Newly Diagnosed Metastatic Osteosarcoma: A Pediatric Oncology Group Trial, 426
Gordon LI, *see* Witzig TE
Gordon MS, *see* Rizzo JD
Gordon P, *see* Andermann A
Gore M, *see* Vasey PA
see Wheatley K
Gore ME, *see* Bukowski R
see Kolomainen DF
see Nathan PD
Gorzegno G, *see* Berruti A
see Sperone P
Gospodarowicz M, *see* Dores GM
see Warde P
Gospodarowicz M. Radiotherapy and Organ Preservation in Bladder Cancer: Are We Ignoring the Evidence? (editorial), 3048
Gouva S, *see* Depierre A
Gouveia-Oliveira A, *see* Costa L
Grabenbauer GG, *see* Rödel C
Grace MJ, *see* Kuball J
Graefen M, *see* Cagiannons I
Graefen M, Karakiewicz PI, Cagiannos I, Klein E, Kupelian PA, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, de Kernion J, Cangiano T, Schröder FH, Wildhagen MF, Scardino PT, Kattan MW. Validation Study of the Accuracy of a Postoperative Nomogram for Recurrence After Radical Prostatectomy for Localized Prostate Cancer, 951
Graefen M, Karakiewicz PI, Cagiannos I, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Klein E, Kupelian P, Skinner DG, Lieskovsky G, Bochner B, Huland H, Hammerer PG, Haese A, Erbersdobler A, Eastham JA, de Kernion J, Cangiano T, Schröder FH, Wildhagen MF, van der Kwast TH, Scardino PT, Kattan MW. International Validation of a Preoperative Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy, 3206
Graham M, *see* Rivera E
Grahek D, *see* Barranger E
Gralow J, *see* Winer EP
Gralow JR, *see* Ellis GK
Granata S, *see* Cesana C
Grann VR, *see* Hershman D
see Neugut AI
see Sundararajan V
Grann VR, Jacobson JS, Thomason D, Hershman D, Heitjan DF, Neugut AI. Effect of Prevention Strategies on Survival and Quality-Adjusted Survival of Women With *BRCA1/2* Mutations: An Updated Decision Analysis, 2520
Granone P, *see* Trodella L
Grasso Y, *see* Thomas J
Graus F, *see* Bessell EM
Gravenstein S, *see* Ramanathan RK
Gray B, *see* Kemeny MM
Gray JR, *see* Hainsworth JD
Gray JR. Prostate Cancer Risk Groups and Comparisons: Fruitless or Fruitful? (correspondence), 4129
Greco FA, *see* Hainsworth JD
Greco FA, Burris HA III, Litchy S, Barton JH, Bradof JE, Richards P, Scullin DC Jr, Erland JB, Morrissey LH, Hainsworth JD. Gemcitabine, Carboplatin, and Paclitaxel for Patients With Carcinoma of Un-

known Primary Site: A Minnie Pearl Cancer Research Network Study, 1651
Greco W, *see* Khushalani NI
Green DM, Peabody EM, Nan B, Peterson S, Kalapurakal JA, Breslow NE. Pregnancy Outcome After Treatment for Wilms Tumor: A Report From the National Wilms Tumor Study Group, 2506
Green DM. Use of Chest Computed Tomography for Staging and Treatment of Wilms' Tumor in Children (editorial), 2763
Green MR, *see* Lima CMSR
see Vokes EE
Green S, Liu P-Y, O'Sullivan J. Factorial Design Considerations, 3424
Green SJ, *see* Ellis GK
Greenberg ER, *see* Ahles TA
Greenberg HS, *see* Chan JL
Greenberg MJ, *see* Machtay M
Greene FL, *see* Singletary SE
Greenwald P. Cancer Prevention Clinical Trials, 14s
Greggi S, *see* Benedetti-Panici P
Gregurich MA, *see* Loesch D
Greil R, *see* Sieber M
Greiner T, *see* Weekes CD
Greipp PR, *see* Rajkumar SV
Grem JL, *see* Leonard GD
see Wilson RH
Grem JL. In Reply (correspondence), 3562
Grenier J-F, *see* Klasa RJ
Gribben JG, *see* Howard OM
Gridelli C, *see* Scagliotti GV
Grier HE, *see* Goorin AM
Griffin M, *see* Hughes A
Griffiths PD, *see* Lashford LS
Grigoraki V, *see* Dimopoulos MA
Grillo-López AJ, *see* Witzig TE
Grimm EA, *see* Ellerhorst JA
Groeger JS, *see* Timoney JP
Groen HJ, *see* Kehrer DFS
Groene WS, *see* Pecora AL
Grondin SC, *see* Liptay MJ
Groome PA, *see* Huang J
Gross P, *see* Pecora AL
Grossbard M, *see* Howard OM
Grosshans E, *see* Iamandi C
Grossman SA, *see* Kleinberg L
Group LAME of the French Society of Pediatric Hematology and Immunology, *see* Perel Y
Groupe d'Etude des Lymphomes de l'Adulte, *see* Gisselbrecht C
Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WKA, Levin VA. Phase II Trial of Temozolomide Plus the Matrix Metalloproteinase Inhibitor, Marimastat, in Recurrent and Progressive Glioblastoma Multiforme, 1383
Gruetzner KU, *see* Heiss MM
Grundeis M, *see* Kaiser U
Grütter R, *see* Kröger K
Grygiel JJ, *see* Graefen M
Gu C-D, *see* Osaki T
Guadagnoli E, *see* Keating NL
see Silliman RA
Gualano G, *see* Trodella L
Gudbjartsson DF, *see* Berry DA
Guerciolini R, *see* Orlowski RZ
Guerra LT, *see* Esteva FJ
Guévin R, *see* Klasa RJ
Guida M, *see* Ridolfi R
Guidi AJ, Berry DA, Broadwater G, Helmchen B, Bleiweiss IJ, Budman DR, Henderson IC, Norton L, Hayes DF. Association of Angiogenesis and Disease Outcome in Node-Positive Breast Cancer Patients Treated With Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil: A Cancer and Leukemia Group B Correlative Science Study From Protocols 8541/8869, 732
Guilmin G, *see* Gisselbrecht C
Gumbrell L, *see* Galbraith SM
Gumpper KL, *see* Frank TS
Gunderson LL, *see* Tepper JE
Gunnarsson PO, *see* Hudes G
Guo J-Y, *see* Goh B-C
Gupta M, *see* Thomas J
Gupta RK, *see* DiFronzo LA
see Radford JA
Gupta SK, *see* Bukowski R
Gururangan S, *see* Quinn JA
Gururangan S, Cavazos CM, Ashley D, Herndon JE II, Bruggers CS, Moghrabi A, Scarcella DL, Watral M, Tourt-Uhlig S, Reardon D, Friedman HS. Phase II Study of Carboplatin in Children With Progressive Low-Grade Gliomas, 2951
Gurwitz J, *see* Silliman RA
Gutheil J, *see* Agarwala SS
Gutheil JC, *see* Vaughn DJ
see Vogel CL
Gutierrez L, *see* Mellado B
Gutierrez M, Pautier P, Lhommé C. Replacement of Carboplatin by Oxaliplatin May Be One Solution for Patients Treated for Ovarian Carcinoma Who Are Hypersensitive to Carboplatin (correspondence), 353

H

Haas JE, *see* Katzenstein HM
Haas N, *see* Hudes G
Habermann TM, *see* Ansell SM
Haenggeli C-A, *see* Allal AS
Haese A, *see* Cagiannos I; Graefen M
Haglund MM, *see* Quinn JA
Hahl M, *see* Morkas M
Haider K, *see* Jakesz R

Hainsworth J, *see* Lima CMSR
Hainsworth JD, *see* Greco FA
Hainsworth JD, Gray JR, Morrissey LH, Kalman LA, Hon JK, Greco FA. Long-Term Follow-Up of Patients Treated With Paclitaxel/Carboplatin-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Sequential Phase II Trials of the Minnie Pearl Cancer Research Network, 2937
Hainsworth JD, Litchy S, Burris HA III, Scullin DC Jr, Corso SW, Yardley DA, Morrissey L, Greco FA. Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin's Lymphoma, 4261
Haioun C, *see* Mounier N
Hakama M, *see* Mäkinen T
Hakama M. Screening for Lung Cancer (correspondence), 3931
Hakulinen T, *see* Brenner H
Halabi S, *see* Small EJ
Hall J, *see* Markman M
Hall JM, *see* Bichakjian CK
Haller DG, *see* Berlin JD
Hallström M, *see* Edler D
Halpern S, *see* Mitchell MS
Haluska FG, *see* Kilbridge KL
Haluska FJ, *see* Kirkwood JM
Halyard MY, *see* Loprinzi CL
Hamilton A. Ethical Issues Surrounding the Conduct of Off-Shore Clinical Research (correspondence), 3934
Hamilton M, *see* Kehrer DFS
Hamilton-Nelson KL, *see* Sofer M
Hammel P, *see* Louvet C
Hammerer PG, *see* Cagiannos I
see Graefen M
Hammett E, *see* Bass AJ
Hammond A, *see* Davis AM
Hammond LA, *see* de Bono JS
see Ranson M
Hanaoka N, *see* Shoji T
Hancock B, *see* Wheatley K
Hancock ML, *see* Leung W
Hanlon AL, *see* Freedman GM
Hannisdal E, *see* Sundstrøm S
Hanselmann S, *see* Borner MM
Hansen SW, *see* Petersen PM
Hanson J, *see* Suarez-Almazor ME
Hanson LJ, *see* Adjei AA
Harbeck N, Kates RE, Schmitt M. Clinical Relevance of Invasion Factors Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type I for Individualized Therapy Decisions in Primary Breast Cancer Is Greatest When Used in Combination, 1000
Harlan LC, *see* Potosky AL
Harlan LC, Abrams J, Warren JL, Clegg L, Stevens J, Ballard-Barbash R. Adjuvant Therapy for Breast Cancer: Practice Patterns of Community Physicians, 1809
Harper P, *see* Douillard J-Y
see Marx GM
see Ross P
Harper PG, *see* Galani E
see Steer CB
Harper-Wynne CL, Sacks NPM, Shenton K, MacNeill FA, Sauven P, Laidlaw IJ, Rayter Z, Miall S, Howes A, Salter J, Hills MJ, Lowe FM, A'Hern R, Nasiri N, Doody D, Iqbal J, Dowsett M. Comparison of the Systemic and Intratumoral Effects of Tamoxifen and the Aromatase Inhibitor Vorozole in Postmenopausal Patients With Primary Breast Cancer, 1026
Harrington A, *see* Maisey N
Harris A, *see* Baselga J
Harris JM, *see* Abramson N
Harris LN, *see* Vogel CL
Harris MB, *see* Goorin AM
Hars V, *see* Small EJ
Hartley-Asp B, *see* Hudes G
Hartmann JT, *see* Bokemeyer C
Hartmann LC, *see* Anderson PM
Hartwick W, *see* Goodwin PJ
Harvey HA, *see* Lipton A
Hasenclever D, *see* Sieber M
Hassoun H, *see* Oo TH
Hatlevoll R, *see* Sundstrøm S
Hauger M, *see* Nadella P
Hausmaninger H, *see* Jakesz R
Haut PR, *see* Kletzel M
Havemann K, *see* Kaiser U
Havighurst TC, *see* Love RR
Hawkins MJ, *see* Rizvi NA
Haworth L, *see* Toso JF
Hay J, *see* El-Sayed S
Hayakawa K, *see* Sekine I
Hayashi Y, *see* Yamamoto K
Hayes DF, *see* Guidi AJ
see Singletary SE
see Stearns V
Hayman JA, *see* Burkhardt JH
see Lee JH
Hayman S, *see* Rajkumar SV
Haynes B, *see* Geisler J
Head DR, *see* Biankin AV
Headlee D, *see* Tan AR
Heaney ML, *see* Timoney JP
Hedenus M, *see* Österborg A
Hedley D, *see* Fyles A
Heffernan N, Cella D, Webster K, Odom L, Martone M, Passik S, Bookbinder M, Fong Y, Jarnagin W, Blumgart L. Measuring Health-Related Quality of Life in Patients With Hepatobiliary Cancers: The Functional Assessment of Cancer Therapy-Hepatobiliary Questionnaire, 2229
Heidecke C-D, *see* Sucker C

Heideman RL, *see* Athale UH
Heider U, *see* Sezer O
Heine B, *see* Fuchs IB
Heinrich MC, *see* Mauro MJ
Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies, 1692
Heinz J, *see* Josting A
Heiss MM, Simon EH, Beyer BCM, Gruetzner KU, Tarabichi A, Babic R, Schildberg FW, Allgayer H. Minimal Residual Disease in Gastric Cancer: Evidence of an Independent Prognostic Relevance of Urokinase Receptor Expression by Disseminated Tumor Cells in the Bone Marrow, 2005
Heisterkamp SH, *see* Koedoot CG
Heitjan DF, *see* Hershman D
see Grann VR
see Neugut AI
Hellenic Cooperative Oncology Group, *see* Kosmidis P
Hellman R, *see* Shaw E
Hellstrand K, *see* Agarwala SS
Hellwig D, *see* Samnick S
Helmchen B, *see* Guidi AJ
Helmke K, *see* Bielack SS
Henderson CI. A Rose Is No Longer a Rose (editorial), 3365
Henderson IC, *see* Berry DA
see Guidi AJ
Hennan TS, *see* Vijayalaxmi
Henningsson A, *see* Friberg LE
Henry-Amar M, *see* Joly F
Henshall SM, *see* Biankin AV
see Graefen M
Hensley M, *see* Barakat RR
see Scheuer L
Hensley ML, *see* Dizon DS
see Schuchter LM
Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR. Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial, 2824
Hérait P, *see* Keating MJ
Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, Campos F, Villard O, Liu K-L, Natarajan-Amé S, Lutz P, Dufour P, Bergerat J-P, Candolfi E. *Aspergillus* Galactomannan Detection in the Diagnosis of Invasive Aspergillosis in Cancer Patients, 1989
Herbst RS, *see* Albanell J
see Pentz RD
Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL. Phase I Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors, 3792
Herbst RS, Madden TL, Tran HT, Blumenschein GR Jr, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA Jr, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK. Safety and Pharmacokinetic Effects of TNP-470, an Angiogenesis Inhibitor, Combined With Paclitaxel in Patients With Solid Tumors: Evidence for Activity in Non-Small-Cell Lung Cancer, 4440
Herbst RS, Maddox A-M, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non-Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial, 3815
Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim H-W, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL. Development of Biologic Markers of Response and Assessment of Antiangiogenic Activity in a Clinical Trial of Human Recombinant Endostatin, 3804
Herling M, *see* Rassidakis GZ
Herman T, *see* Kleinberg L
Herman TS, *see* Vijayalaxmi
Hermine O, *see* Gisselbrecht C
Herndon JE II, *see* Gururangan S
see Kornblith AB
see Quinn JA
see Reardon DA
see Vokes EE
Héron JF, *see* Joly F
Herr HW, *see* Dalbagni G
see Rabbani F
Herrmann R, *see* Borner MM
see Sieber M
Herrmann Z, *see* Menssen HD
Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar RW, McLeod R, Gill PG, Coventry BJ, McMullen A, Dillon H, Simes RJ. Adjuvant Immunotherapy of Patients With High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial, 4181
Hersh E, *see* Agarwala SS
Hershman D, *see* Grann VR
see Sundararajan V
Hershman D, Sundararajan V, Jacobson JS, Heitjan DF, Neugut AI, Grann VR. Outcomes of Tamoxifen Chemoprevention for Breast Cancer in Very High-Risk Women: A Cost-Effectiveness Analysis, 9
Hershock D, *see* Machtay M
Herzog P, *see* Nachman JB
Hess KR, *see* Groves MD
see Herbst RS
Hesslewood S, *see* Seymour LW

Heston WD, *see* Thomas J
Hewitt M, Rowland JH. Mental Health Service Use Among Adult Cancer Survivors: Analyses of the National Health Interview Survey, 4581
Heys SD, *see* Smith IC
Hiatt M-A, *see* Roche K
Hibi S, *see* Imashuku S
Hickish T, *see* Maisey N
see Ross P
Hidalgo M, *see* de Bono JS
Hiddemann W, *see* Wendtner C-M
Hien NN, *see* Love RR
Higashigawa M, *see* Yamamoto K
Higginson IJ, Costantini M. Communication in End-of-Life Cancer Care: A Comparison of Team Assessments in Three European Countries, 3674
Higham S, *see* Chen WY
Hill DA, *see* Spunt SL
Hill LR, *see* Holmes FA
Hill M, *see* Maisey N
Hill PA, *see* Deitcher SR
Hill RP, *see* Fyles A
Hiller EH, *see* Berry DA
Hillner BE, *see* Berenson JR
see Love RR
Hills MJ, *see* Harper-Wynne CL
Hilsenbeck SG, *see* Berry DA
Himelstein B. In Reply (correspondence), 1953
Hinerman RW, *see* Mendenhall WM
Hines JD, *see* Morrison VA
Hinke A, *see* Dunst J
Hinkelbein W, *see* Hoecht S
Hinterleitner T, *see* Jäger G
Hinton L, *see* Herbst RS
Hinton S, Catalano P, Einhorn LH, Loehrer PJ Sr, Kuzel T, Vaughn D, Wilding G. Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors (E9897): A Trial of the Eastern Cooperative Oncology Group, 1859
Hirsch FR, *see* Bremnes RM
Hirsh V, *see* Shepherd FA
Hirsh-Yechezkel G, *see* Chetrit A
Hislop TG, *see* Van Patten CL
Hitti IF, *see* Narasimhan P
Ho AD, *see* Viardot A
Ho C-L, *see* Cheng H-L
Hobday TJ, Kugler JW, Mahoney MR, Sargent DJ, Sloan JA, Fitch TR, Krook JE, O'Connell MJ, Mailliard JA, Tirona MT, Tschetter LK, Cobau CD, Goldberg RM. Efficacy and Quality-of-Life Data Are Related in a Phase II Trial of Oral Chemotherapy in Previously Untreated Patients With Metastatic Colorectal Carcinoma, 4574
Hobson R, *see* Lashford LS
Hochhauser D, *see* Brett BT
Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, Klimstra DS. Prognostic Factors in Pancreatic Endocrine Neoplasms: An Analysis of 136 Cases With a Proposal for Low-Grade and Intermediate-Grade Groups, 2633
Hodges C, *see* Eton O
Hodges E, *see* Oscier D
Hoecht S, Rosenthal P, Sancar D, Behrens S, Hinkelbein W, Hoeller U. Implantable Cardiac Defibrillators May Be Damaged by Radiation Therapy (correspondence), 2212
Hoekman K, *see* Kuenen BC
Hoekstra OS, *see* Bos R
Hoeller U, *see* Hoecht S
Hoff PM, *see* Douillard J-Y
Hoffbrand AV, *see* Mortuza FY
Hoffman B, *see* Goodwin PJ
Höfler G, *see* Jäger G
Hogan C, *see* Burkhardt JH
Högel J, *see* Viardot A
Hohenberg G, *see* Ortmann E
Hohenberger P, *see* Stein U
Holden L, *see* McNeish IA
Holen KD, Klimstra DS, Hummer A, Gonen M, Conlon K, Brennan M, Saltz LB. Clinical Characteristics and Outcomes From an Institutional Series of Acinar Cell Carcinoma of the Pancreas and Related Tumors, 4673
Holland JC, *see* Kornblith AB
see Silverman LR
Holland JF, *see* Kornblith AB
see Silverman LR
Hollis DR, *see* Tepper JE
Holmes C, *see* Sarna L
Holmes E, *see* Jennings MT
Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC. Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer, 727
Holmes HE, *see* Levine JE
Holowaty E, *see* Vallis KA
Holowaty EJ, *see* Dores GM
Holtkamp MMJ, *see* de Gast GC
Hölzel D, *see* Kerr J
Hon C, Au WY, Ma ESK, Kwok AKH, Lie AKW, Liang RHS. Unusual Sites of Involvement in Non-Hodgkin's Lymphoma; Case 1. Isolated Orbit Relapse After Allogeneic Bone Marrow Transplantation for Malignant Lymphoma, 4394
Hon JK, *see* Hainsworth JD
Honegger H, *see* Borner MM
Hong WK, *see* Herbst RS
see Rizvi NA
see Shin DM
Hood N, *see* Goodwin PJ

Hoogerbrugge N, *see* van Roosmalen MS
Hook HC, *see* Biankin AV
Hoos A, *see* Rosenberg R
see Stojadinovic A
Hoppe RT, *see* Horning SJ
Hopper J, *see* Lindor NM
Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical Trial, 630
Horowitz M, *see* Levine JE
Horowitz MM, *see* Berry DA
see Loberiza FR Jr
Hortobagyi GN, *see* Buchholz TA
see Esteva FJ
see Rivera E
Hortobagyi GN. Can We Cure Limited Metastatic Breast Cancer? (editorial), 620
Horwich A, *see* Bokemeyer C
see Warde P
Hoshida Y, *see* Nakatsuka S
Hoskins P, *see* Shenkier TN
Hoskins WJ, *see* Barakat RR
Hosmane BS, *see* Carducci MA
Hossfeld DK, *see* Kaiser U
see Laack E
Hough D, *see* Galbraith SM
Houghton AN, *see* Hwu W-J
House A, *see* Stark D
Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, Shipp MA. Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival, 1288
Howell A, Robertson JFR, Albano JQ, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C. Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine Treatment, 3396
Howell SB, *see* Alberts DS
Howes A, *see* Harper-Wynne CL
Hrubisko M, *see* Menssen HD
Hsi ED, *see* Mirza I
Hsueh EC, Essner R, Foshag LJ, Ollila DW, Gammon G, O'Day SJ, Boasberg PD, Stern SL, Ye X, Morton DL. Prolonged Survival After Complete Resection of Disseminated Melanoma and Active Immunotherapy With a Therapeutic Cancer Vaccine, 4561
Huang J, Boyd C, Tyldesley S, Zhang-Salomons J, Groome PA, Mackillop WJ. Time Spent in Hospital in the Last Six Months of Life in Patients Who Died of Cancer in Ontario, 1584
Huang WC, *see* Cross CK
Huber C, *see* Kuball J
Hubers D, *see* Yanik GA
Hudes G. Boosting Bioavailability of Topotecan: What Do We Gain? (editorial), 2918
Hudes G, Haas N, Yeslow G, Gillon T, Gunnarsson PO, Ellman M, Nordle O, Eriksson B, Miller L, Cisar L, Kopreski M, Viaro D, Hartley-Asp B. Phase I Clinical and Pharmacologic Trial of Intravenous Estramustine Phosphate, 1115
Hudis C, *see* Modi S
see Seidman A
see Seidman AD
see Van Poznak C
see Winer EP
Hudson MM. Pediatric Hodgkin's Therapy: Time for a Paradigm Shift (editorial), 3755
Hudson MM, *see* Donaldson SS
see Friedmann AM
see Leung W
Hugh TB, *see* Biankin AV
Hughes A, Calvert P, Azzabi A, Plummer R, Johnson R, Rusthoven J, Griffin M, Fishwick K, Boddy AV, Verrill M, Calvert H. Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma, 3533
Hughes C, *see* Schwartz MD
Hughes KS, *see* Berry DA
Hughes LL, *see* Singletary SE
Hughes P, *see* Rischin D
Huisman H, *see* Kuenen BC
Huland H, *see* Cagiannos I
see Graefen M
Hulick M, *see* Frank TS
Hummer A, *see* Dizon DS
see Holen KD
Hung G-S, *see* Chou Y-H
Hunt KK, *see* Ahmad SA
see Buchholz TA
Huong DT, *see* Love RR
Hurt RD, *see* Cox LS
Hurwitz C, *see* LeClerc JM
Hurwitz CA, *see* Donaldson SS
see Lipshultz SE
Hurwitz H, *see* Rizzieri DA
Hussain M, *see* Vaishampayan U
see Vaughn DJ
Hussein M, *see* Dudeney S
Hutcheon AW, *see* Smith IC
Hutchins B, *see* Kuball J
Hutchinson R, *see* Emmons K
Hutchinson RJ, *see* Nachman JB
see Yanik GA
Hutter RVP, *see* Singletary SE
Hwang Y-T, *see* Liang W
Hwu P, *see* Toso JF
Hwu W-J, Krown SE, Panageas KS, Menell JH, Chapman PB, Livingston PO, Williams LJ, Quinn CJ,

Houghton AN. Temozolomide Plus Thalidomide in Patients With Advanced Melanoma: Results of a Dose-Finding Trial, 2610
Hyland A, *see* Bepler G

I

Iacobelli S, *see* Piantelli M
Iamandi C, Dietemann A, Grosshans E, Pauli G, Quoix E. Unusual Presentations of Lung Cancer: Case 3. Paraneoplasic Digital Necrosis in a Patient With Small-Cell Lung Cancer, 4600
Ibrahim J, *see* Kirkwood JM
see Rao UNM
Iezzi M, *see* Piantelli M
Ikeda J, *see* Aoyama H
see Aoyama H
Ikeda M, *see* Noura S
Ikenaga M, *see* Noura S
Ilson D, *see* Schwartz GK
Ilson DH. Epirubicin, Cisplatin, and Fluorouracil in Gastric and Esophageal Cancer: A Step Ahead? (editorial), 1962
Imashuku S, Teramura T, Ishii E, Kinugawa N, Kato M, Sako M, Kuriyama K, Hibi S. In Reply (correspondence), 600
Imeson J, *see* Owens CM
Implantable Drug Delivery Systems Study Group, *see* Smith TJ
Indelicato RA, *see* Portenoy RK
Indelicato RA, Portenoy RK. Opioid Rotation in the Management of Refractory Cancer Pain, 348
Ingle JN, *see* Winer EP
Ingram SS, Seo PH, Martell RE, Clipp EC, Doyle ME, Montana GS, Cohen HJ. Comprehensive Assessment of the Elderly Cancer Patient: The Feasibility of Self-Report Methodology, 770
Iniesta P, *see* González-Quevedo R
International Breast Cancer Study Group, *see* Colleoni M
International Society of Pediatric Oncology, Liver Tumors Study Group, *see* Czauderna P
Invernizzi R, *see* Federico M
Inwards D, *see* Vose JM
Iosava G, *see* Österborg A
Iqbal J, *see* Harper-Wynne CL
Iriondo A, *see* Rocha V
Irish JC, *see* Brierley JD
Ironside J, *see* Lashford LS
Irvine R, *see* Coetzee G
Isaacs C, *see* Schwartz MD
Isaacson JD, *see* Carducci MA
Ishii E, *see* Imashuku S
Ishikawa S, *see* Shoji T
Ishizuka N, *see* Sekine I
Isler M, *see* Davis AM
Issels RD, *see* Wendtner C-M
Isu K, *see* Tsuchiya H
Italian Cooperative Group for the Study of Hairy Cell Leukemia, *see* Federico M
Italian Lung Cancer Project, *see* Scagliotti GV
Italian Melanoma Intergroup, *see* Ridolfi R
Ito E, *see* Yamamoto K
Iturria N, *see* Rajkumar SV
Itzhaki M, *see* Keating MJ
Iuchi K, *see* Nakatsuka S
Iversen ES Jr, *see* Berry DA
Ives N, *see* Wheatley K
Iveson T, *see* Maisey N
see Ross P
Ivnik R, *see* Shaw E
Iwashyna TJ, Lamont EB. Effectiveness of Adjuvant Fluorouracil in Clinical Practice: A Population-Based Cohort Study of Elderly Patients With Stage III Colon Cancer, 3992
Izawa JI, Madsen LT, Scott SS, Tran J-P, McGuire EJ, von Eschenbach AC, Pisters LL. Salvage Cryotherapy for Recurrent Prostate Cancer After Radiotherapy: Variables Affecting Patient Outcome, 2664

J

Jackman A, *see* de Jonge MJA
Jackson J, *see* Kwan W
Jacob JH, *see* Louvet C
Jacobs G, *see* Trümper L
Jacobs H, *see* Rizvi NA
Jacobs SA, *see* Ramanathan RK
Jacobsen PB, Meade CD, Stein KD, Chirikos TN, Small BJ, Ruckdeschel JC. Efficacy and Costs of Two Forms of Stress Management Training for Cancer Patients Undergoing Chemotherapy, 2851
Jacobson JS, *see* Grann VR
see Hershman D
see Neugut AI
see Sundararajan V
Jacobson R, *see* Rizzieri DA
Jacquemier J, *see* Lakhani SR
Jacques C, *see* Raymond E
Jaeckle KA, *see* Groves MD
Jäger G, Neumeister P, Brezinschek R, Hinterleitner T, Fiebiger W, Penz M, Neumann HJ, Mlineritsch B, DeSantis M, Quehenberger F, Chott A, Beham-Schmid C, Höfler G, Linkesch W, Raderer M. Treatment of Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue Type With Cladribine: A Phase II Study, 3872
Jager GJ, *see* Langenhoff BS
see Ruers TJM
Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T, Seifert M, Haider K, Mlineritsch B, Steindorfer P, Kwasny W, Fridrik M, Steger G, Wette V, Samonigg H. Randomized Adjuvant Trial

of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5, 4621
Jakob C, *see* Sezer O
Jakobsen A, *see* Edler D
Jakowatz JG, *see* Sondak VK
Jakubowski AA, *see* Rizzo JD
Jamal N, *see* Kiss TL
James K, *see* Davis AM
James RD, *see* Radford JA
Jameson M, *see* Galbraith SM
Janicek MJ, *see* Eder JP Jr
see Howard OM
Janicot H, *see* Depierre A
Janjan NA, *see* Esnaola NF
see Pisters PWT
Jankowska P, *see* Bomanji JB
Jansson A, Sun X-F. *Bax* Expression Decreases Significantly From Primary Tumor to Metastasis in Colorectal Cancer, 811
Janus TJ, *see* Carducci MA
Janvier M, *see* Viens P
Janzer R, *see* Stupp R
Japan Clinical Oncology Group, *see* Takada M
Jaques DP, *see* Stojadinovic A
Jargens H, *see* Bielack SS
Jarnagin W, *see* Heffernan N
Jasiewicz Y, *see* Laack E
Jaspan T, *see* Lashford LS
Jass JR, *see* Lindor NM
Jatoi A, Loprinzi C, Windschitl H. In Reply (correspondence), 2913
Jatoi A, Loprinzi CL. Adenosine Triphosphate: Does It Help Cancer Patients "Get Bigger and Stronger"? (editorial), 362
Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B. Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study, 567
Jaubert J, *see* Fermé C
Jeffrey J, *see* Pearcey R
Jeha S, *see* Schover LR
Jelinek DF, *see* Ansell SM
Jenkins V, Fallowfield L. Can Communication Skills Training Alter Physicians' Beliefs and Behavior in Clinics?, 765
Jenney MEM, *see* Bhatia S
Jennings MT, Sposto R, Boyett JM, Vezina LG, Holmes E, Berger MS, Bruggers CS, Bruner JM, Chan K-W, Dusenbery KE, Ettinger LJ, Fitz CR, Lafond D, Mandelbaum DE, Massey V, McGuire W, McNeely L, Moulton T, Pollack IF, Shen V. Preradiation Chemotherapy in Primary High-Risk Brainstem Tumors: Phase II Study CCG-9941 of the Children's Cancer Group, 3431
Jeong HY, *see* Chiou WL
Jett JR. Screening for Lung Cancer: No Longer a Taboo Subject (editorial), 1959
Jewell RC, *see* Kruijtzer CMF
Jhingran A, *see* Eifel PJ
Joensuu T, *see* Dores GM
Johannessen AC, *see* Sudbø J
Johnson BA, *see* Wang XS
Johnson DH. "The Guard Dies, It Does Not Surrender!" Progress in the Management of Small-Cell Lung Cancer? (editorial), 4618
Johnson KA, *see* Potosky AL
Johnson M, *see* Levine JE
Johnson ME, *see* Bennett CL
Johnson ML, *see* Esnaola NF
Johnson PJ, *see* Chan ATC
Johnson R, *see* Hughes A
Johnson TM, *see* Bichakjian CK
Johnston D, *see* Pearcey R
Johnston P, *see* Allegra CJ
Johnston PG, *see* Edler D
Johnston S, *see* Vasey PA
Jolivet J, *see* Bélanger K
see de Bono JS
see Giles FJ
Joly F, Héron JF, Kalusinski L, Bottet P, Brune D, Allouache N, Macé-Lesec'h J, Couëtte JE, Pény J, Henry-Amar M. Quality of Life in Long-Term Survivors of Testicular Cancer: A Population-Based Case-Control Study, 73
Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B. Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in Premenopausal Patients With Node-Positive Breast Cancer: The Zoladex Early Breast Cancer Research Association Study, 4628
Jones C, *see* Shaw E
Jones H, *see* Machtay M
Jones RB, *see* Nieto Y
Jones S, *see* O'Shaughnessy J
Jones SE, *see* Holmes FA
see Osborne CK
Jones V, *see* Mitchell MS
Jordhøy MS, Kaasa S, Loge JH, Fayers P. In Reply (correspondence), 1704
Jordon VC, Marrow M. Chemoprevention of Breast Cancer: A Model for Change (editorial), 1
Joshi U, *see* Bos R
Josting A, *see* Sieber M
Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, Rudolph C, Diehl V, Engert A. New Prognostic

Score Based on Treatment Outcome of Patients With Relapsed Hodgkin's Lymphona Registered in the Database of the German Hodgkin's Lymphona Study Group, 221
Jouvet A, *see* Lashford LS
Jovanovic BD, *see* Bennett CL
Joyce R, *see* Witzig TE
Julyan PJ, *see* Seymour LW
Junck LR, *see* Chan JL
Jürchott K, *see* Stein U
Jürgens H, *see* Bielack SS
Juusela H, *see* Mäkinen T

K

Kaasa S, *see* Jordhøy MS
see Sundstrøm S
Kadin ME, *see* Lones MA
see Nachman JB
Kahn KA, *see* Malin JL
Kahn KL, *see* Pearson ML
Kahn MJ, *see* Rozans M
Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay P-B, Possinger K, Roots I, Brockmöller J. Patient-Tailored Antiemetic Treatment With 5-Hydroxytryptamine Type 3 Receptor Antagonists According to Cytochrome P-450 2D6 Genotypes, 2805
Kaiser U, Uebelacker I, Abel U, Birkmann J, Trümper L, Schmalenberg H, Karakas T, Metzner B, Hossfeld DK, Bischoff HG, Franke A, Reiser M, Müller P, Mantovani L, Grundeis M, Rothmann F, von Seydewitz C-U, Mesters RM, Steinhauer EU, Krahl D, Schumacher K, Kneba M, Baudis M, Schmitz N, Pfab R, Köppler H, Parwaresch R, Pfreundschuh M, Havemann K. Randomized Study to Evaluate the Use of High-Dose Therapy as Part of Primary Treatment for "Aggressive" Lymphoma, 4413
Kakinuma R, *see* Sobue T
Kakolyris S, *see* Souglakos J
see Stathopoulou A
Kalapurakal JA, *see* Green DM
see Kletzel M
Kalbakis K, *see* Souglakos J
Kalemkerian GP, *see* Reddy P
see Sirachainan E
Kalman LA, *see* Hainsworth JD
Kalofonos C, *see* Bafaloukos D
Kalophonos C, *see* Kosmidis P
Kalusinski L, *see* Joly F
Kamada T, Tsujii H, Tsuji H, Yanagi T, Mizoe J, Miyamoto T, Kato H, Yamada S, Morita S, Yoshikawa K, Kandatsu S, Tateishi A. Efficacy and Safety of Carbon Ion Radiotherapy in Bone and Soft Tissue Sarcomas, 4466
Kamin D, *see* Einhorn LH
Kan-Mitchell J, *see* Mitchell MS
Kanazawa Y, *see* Tsuchiya H
Kandatsu S, *see* Kamada T
Kandel RA, *see* Davis AM
Kane RL, *see* Bhatia S
Kaneko M, *see* Sobue T
Kang Y-K, *see* Lee Jung-Hee
Kanis JA, *see* Powles T
Kantarjian HM, *see* Giles FJ
Kantarjian HM. Treatment of Myelodysplastic Syndrome: Questions Raised by the Azacitidine Experience (editorial), 2415
Kanz L, *see* Bokemeyer C
see Kollmannsberger C
Kanzer B, *see* Narasimhan P
Kapiteijn E, *see* Marijnen CAM
see Nagtegaal ID
Kaplan R, *see* Quinn JA
see Sateren WB
Kaplan RS, *see* Potosky AL
Kappelle AC, *see* Dorresteijn LDA
Karabelis A, *see* Bafaloukos D
Karageorgis P, *see* Antonadou D
Karakas T, *see* Kaiser U
Karakiewicz PI, *see* Cagiannos I
see Graefen M
Karapetis C, *see* Price T
Kardinal CG, *see* Jatoi A
Kardos G, *see* Kunst PWA
Karim ABMF, *see* Pignatti F
Karkantaris C, *see* Dimopoulos MA
Karlan, BY, *see* Liede A
Karlsson MO, *see* Friberg LE
see Mathijssen RHJ
see Xie R
Karnad AB. House Calls by Oncologists: A Home-Visit Primer, 3745
Karnicka-Mlodkowska H, *see* Ardizzoni A
Karrison T, Ratain M. Troxacitabine in Patients With Refractory Leukemia (correspondence), 3356
Kashani-Sabet M, Sagebiel RW, Ferreira CMM, Nosrati M, Miller JR III. Tumor Vascularity in the Prognostic Assessment of Primary Cutaneous Melanoma, 1826
Kashiwamura M, *see* Aoyama H
Katakura H, *see* Shoji T
Kates RE, *see* Harbeck N
Kato H, *see* Kamada T
Kato M, *see* Imashuku S
Kattan M. Statistical Prediction Models, Artificial Neural Networks, and the Sophism "I Am a Patient, Not a Statistic" (editorial), 885
Kattan MW, *see* Cagiannos I
see Graefen M
see Shariat SF
see Smaletz O
Kattan MW, Leung DHY, Brennan MF. Postoperative Nomogram for 12-Year Sarcoma-Specific Death, 791

Katz A, *see* Buchholz TA
Katzenstein HM, *see* Kletzel M
Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Liu-Mares W, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Newman K, Finegold MJ, Haas JE, Sensel MG, Castleberry RP, Bowman LC. Hepatocellular Carcinoma in Children and Adolescents: Results From the Pediatric Oncology Group and the Children's Cancer Group Intergroup Study, 2789
Katzenstein HM, London WB, Douglass EC, Reynolds M, Plaschkes J, Finegold MJ, Bowman LC. Treatment of Unresectable and Metastatic Hepatoblastoma: A Pediatric Oncology Group Phase II Study, 3438
Kauff N, *see* Scheuer L
Kauff ND, *see* Scheuer L
Kaufmann M, *see* Jonat W
Kaufmann R, *see* Spieth K
Kaushal V, Kohli M, Zangari M, Fink L, Mehta P. Endothelial Dysfunction in Antiangiogenesis-Associated Thrombosis (correspondence), 3042
Kawahara M, *see* Takada M
Kawano Y, *see* Shoji T
Kaye SB, *see* Baselga J
see Kolomainen DF
see Vasey PA
Keating MJ, Cazin B, Coutré S, Birhiray R, Kovacsovics T, Langer W, Leber B, Maughan T, Rai K, Tjønnfjord G, Bekradda M, Itzhaki M, Hérait P. Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed, 205
Keating NL, Guadagnoli E, Landrum MB, Borbas C, Weeks JC. Treatment Decision Making in Early-Stage Breast Cancer: Should Surgeons Match Patients' Desired Level of Involvement?, 1473
Kedde MA, *see* Kuenen BC
Keefe D, *see* Seidman A
see Timoney JP
Keeling J, *see* Czauderna P
Kehrer DFS, Bos AM, Verweij J, Groen HJ, Loos WJ, Sparreboom A, de Jonge MJA, Hamilton M, Cameron T, de Vries EGE. Phase I and Pharmacologic Study of Liposomal Lurtotecan, NX 211: Urinary Excretion Predicts Hematologic Toxicity, 1222
Kehrer DFS, Mathijssen RHJ, Verweij J, de Bruijn P, Sparreboom A. Modulation of Irinotecan Metabolism by Ketoconazole, 3122
Keilholz U, *see* Kruijtzer CMF
Keith G, *see* Mohr S
Kelly B, *see* Scheuer L
Kelly WK, *see* Smaletz O
Kelsen D, *see* Schwartz GK
Kelsen DP, *see* Minsky BD
Kemeny MM, Adak S, Gray B, Macdonald JS, Smith T, Lipsitz S, Sigurdson ER, O'Dwyer PJ, Benson AB III. Combined-Modality Treatment for Resectable Metastatic Colorectal Carcinoma to the Liver: Surgical Resection of Hepatic Metastases in Combination With Continuous Infusion of Chemotherapy—An Intergroup Study, 1499
Kempf RA, *see* Sondak VK
see Sosman JA
Kempf-Bielack B, *see* Bielack SS
Kench JG, *see* Biankin AV
Keogan MT, *see* Eder JP Jr
Kepner JL, *see* Furman WL
Kerkhofs LGM, *see* Agteresch HJ
Kerr DJ, *see* Seymour LW
Kerr J, Engel J, Hölzel D. Colostomies May Influence Patient Quality of Life More Than Poor Sphincter Function (correspondence), 3930
Kersemaekers A-M, *see* Mayer F
Kersemaekers A-MF, Mayer F, Molier M, van Weeren PC, Oosterhuis JW, Bokemeyer C, Looijenga LHJ. Role of P53 and MDM2 in Treatment Response of Human Germ Cell Tumors, 1551
Kershaw T, *see* Northouse LL
Kessinger A, *see* Vose JM
Kessler C, *see* Rizvi NA
Keus RB, *see* Dorresteijn LDA
Kha NN, *see* Love RR
Khang HX, *see* Love RR
Khayat D, *see* Marx GM
see Steer CB
Khayat D, Bernard-Marty C, Meric J-B, Rixe O. Biochemotherapy for Advanced Melanoma: Maybe It Is Real (editorial), 2411
Khouri I. In Reply (correspondence), 1427
Khuri FR, *see* Herbst RS
see Glisson BS
see Shin DM
Khushalani NI, Leichman CG, Proulx G, Nava H, Bodnar L, Klippenstein D, Litwin A, Smith J, Nava E, Pendyala L, Smith P, Greco W, Berdzik J, Douglass H, Leichman L. Oxaliplatin in Combination With Protracted-Infusion Fluorouracil and Radiation: Report of a Clinical Trial for Patients With Esophageal Cancer, 2844
Kiamouris C, *see* Dimopoulos MA
Kieback DG, *see* Baselga J
Kiely M, *see* Stark D
Kies MS, *see* Socinski MA
Kilbridge KL, Cole BF, Kirkwood JM, Haluska FG, Atkins MA, Ruckdeschel JC, Sock DE, Nease RF Jr, Weeks JC. Quality-of-Life-Adjusted Survival Analysis of High-Dose Adjuvant Interferon Alfa-2b for High-Risk Melanoma Patients Using Intergroup Clinical Trial Data, 1311
Kildal W, *see* Sudbø J
Kim CY, *see* Lee H-S
Kim H, *see* Ramanathan RK
Kim H-W, *see* Herbst RS
Kim J, *see* Shariat SF
Kim J-C, *see* Lee Jung-Hee

Kim J-H, *see* Lee Jung-Hee
Kim KBS, *see* Ballo MT
Kim KM, *see* Lee H-S
Kim S, *see* Bennett CL
Kim S-H, *see* Lee Jung-Hee
Kim T-W, *see* Lee Jung-Hee
Kim W-K, *see* Lee Jung-Hee
Kim Y-C, *see* Bepler G
Kinchla N, *see* Eder JP Jr
Kindler HL, *see* Schilsky RL
King DM, *see* Kolomainen DF
King K, *see* Sarris AH
Kinugawa N, *see* Imashuku S
Kiproff PM, *see* Deitcher SR
Kirchner H, *see* Sieber M
Kirk SB, *see* Stanton AL
Kirkbride P, *see* Vallis KA
Kirkwood JM, *see* Agarwala SS
see Kilbridge KL
see Rao UNM
Kirkwood JM, Agarwala SS, Ibrahim J, Manola J, Sondak VK, Ernstoff MS, Ross MK. In Reply (correspondence), 2209
Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, Donnelly S, Stover L. Mechanisms and Management of Toxicities Associated With High-Dose Interferon Alfa-2b Therapy, 3703
Kirkwood JM, Ibrahim J, Sondak VK, Ernstoff MS, Flaherty L, Haluska FJ. Use and Abuse of Statistics in Evidence-based Medicine (correspondence), 4123
Kirn DH, *see* Vasey PA
Kirsch C-M, *see* Samnick S
Kirstein M, *see* Furman WL
Kirvan M, *see* Eder JP Jr
Kiss TL, Abdolell M, Jamal N, Minden MD, Lipton JH, Messner HA. Long-Term Medical Outcomes and Quality-of-Life Assessment of Patients With Chronic Myeloid Leukemia Followed at Least 10 Years After Allogeneic Bone Marrow Transplantation, 2334
Kittas C, *see* Rassidakis GZ
Kjeldsberg CR, *see* Lones MA
Klang M, *see* Timoney JP
Klasa R, *see* Shenkier TN
Klasa RJ, Meyer RM, Shustik C, Sawka CA, Smith A, Guévin R, Maksymiuk A, Rubinger M, Samosh M, Laplante S, Grenier J-F. Randomized Phase III Study of Fludarabine Phosphate Versus Cyclophosphamide, Vincristine, and Prednisone in Patients With Recurrent Low-Grade Non-Hodgkin's Lymphoma Previously Treated With an Alkylating Agent or Alkylator-Containing Regimen, 4649
Kleeberg UR, *see* Howell A
Klein E, *see* Graefen M
Klein EA, *see* Kupelian PA
see Thomas J
Klein JP, *see* Berry DA
Klein P, *see* Allegra CJ
Kleinberg L, Grossman SA, Carson K, Lesser G, O'Neill A, Pearlman J, Phillips P, Herman T, Gerber M. Survival of Patients With Newly Diagnosed Glioblastoma Multiforme Treated With RSR13 and Radiotherapy: Results of a Phase II New Approaches to Brain Tumor Therapy CNS Consortium Safety and Efficacy Study, 3149
Klersy C, *see* Cesana C
Kletzel M, Katzenstein HM, Haut PR, Yu AL, Morgan E, Reynolds M, Geissler G, Marymount MH, Liu D, Kalapurakal JA, Shore RM, Bardo DME, Schmoldt J, Rademaker AW, Cohn SL. Treatment of High-Risk Neuroblastoma With Triple-Tandem High-Dose Therapy and Stem-Cell Rescue: Results of the Chicago Pilot II Study, 2284
Klijanienko J, *see* Rouzier R
Klima K-M, *see* Sucker C
Klimo P, *see* Shenkier TN
Klimstra DS, *see* Hochwald SN
see Holen KD
Klippenstein D, *see* Khushalani NI
Klokman WJ, *see* Dorresteijn LDA
Kneba M, *see* Kaiser U
Knisely J. Conformal Radiotherapy for High-Grade Gliomas: How Much Is Too Much? (correspondence), 3357
Knop C, *see* Liptay MJ
Knutson KL, *see* Disis ML
Kobayashi T, *see* Sobue T
Kobrinsky N, *see* Woods WG
Koc H, *see* Ringdén O
Koch M, *see* Laroia ST
Koch P, *see* Josting A
see Sieber M
Koch T, *see* Sieber M
Kodish E, *see* Friebert S
Koduri J, Baumann MA. Cisplatin and Dacarbazine With or Without Subcutaneous Interleukin-2 and Interferon Alfa-2b in Advanced Melanoma Patients (correspondence), 3560
Koedoot CG, de Haes JCJM, Heisterkamp SH, Bakker PJM, de Graeff A, de Haan RJ. Palliative Chemotherapy or Watchful Waiting? A Vignettes Study Among Oncologists, 3658
Köhler D, *see* Trümper L
Kohli M, *see* Kaushal V
Köhne C-H, *see* Steiner M
Koivistoinen A, *see* Auvinen MI
Kolitz JE, *see* Morrison VA
Kölling-Schlebusch K, *see* Dunst J
Kollmannsberger C, Rick O, Derigs H-G, Schleucher N, Schöffski P, Beyer J, Schoch R, Sayer HG, Gerl A, Kuczyk M, Spott C, Kanz L, Bokemeyer C. Activity of Oxaliplatin in Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group, 2031
Kolomainen DF, Larkin JMG, Badran M, A'Hern RP, King

DM, Fisher C, Bridges JA, Blake PR, Barton DPJ, Shepherd JH, Kaye SB, Gore ME. Epithelial Ovarian Cancer Metastasizing to the Brain: A Late Manifestation of the Disease With an Increasing Incidence, 982
Komaki R, *see* Minsky BD
Koo J, *see* Goodwin PJ
Koppang HS, *see* Sudbø J
Köppler H, *see* Kaiser U
Kopreski M, *see* Hudes G
Korn EL, *see* Freidlin B
Kornblith AB, *see* Silverman LR
Kornblith AB, Herndon JE II, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA, Holland JC. Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study, 2441
Kornek GV, *see* Gedlicka C
see Scheithauer W
Korst RJ, *see* Martin J
Kortmann R-D, *see* Timmermann B
Koslowsky TC, *see* Weihrauch MR
Kosmidis P, *see* Bafaloukos D
Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J, Fountzilas G, Skarlos D, Economopoulos T, Tsavdaridis D, Papakostas P, Bacoyiannis C, Dimopoulos M. Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non-Small-Cell Lung Cancer: A Phase III Randomized Trial, 3578
Kotsakis A, *see* Stathopoulou A
Kottaridis PD, *see* Branson K
Kotz R, *see* Bielack SS
Kourousis C, *see* Souglakos J
see Stathopoulou A
Kovacsovics T, *see* Keating MJ
Krahl D, *see* Kaiser U
Krailo MD, *see* Katzenstein HM
Kraljevic SO, *see* Stupp R
Kramar A, *see* Culine S
Kranenbarg EK, *see* Marijnen CAM
Kraus D, *see* Osman I
Kraus DH, *see* Wong RJ
Kraut E, *see* Nadella P
Kretschmer L, Neumann C. Sentinel-Node Technique Will Change the Design of Clinical Trials in Malignant Melanoma (correspondence), 2208
Kris M, *see* Ranson M
Kris MG, *see* Martin J
Kristal AR. Diet and Trend in Prostate-Specific Antigen: Inferences for Prostate Cancer Risk (editorial), 3570
Kröger K, Grütter R, Rudofsky G, Fink H, Niebel W. Follow-Up After Port-a-Cath-Induced Thrombosis (correspondence), 2605
Krook JE, *see* Goldberg RM
see Hobday TJ
see Jatoi A
Krown SE, *see* Evans SR
see Cianfrocca M
see Hwu W-J
Kruijtzer CMF, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, Schellens JHM. Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918, 2943
Kruijtzer CMF, Schellens JHM, Mezger J, Scheulen ME, Keilholz U, Beijnen JH, Rosing H, Mathôt RAA, Marcus S, van Tinteren H, Baas P. Phase II and Pharmacologic Study of Weekly Oral Paclitaxel Plus Cyclosporine in Patients With Advanced Non-Small-Cell Lung Cancer, 4508
Krych M, *see* Wendtner C-M
Krzakowski M, *see* Shepherd FA
Kuball J, Wen SF, Leissner J, Atkins D, Meinhardt P, Quijano E, Engler H, Hutchins B, Maneval DC, Grace MJ, Fritz MA, Störkel S, Thüroff JW, Huber C, Schuler M. Successful Adenovirus-Mediated Wild-Type *p53* Gene Transfer in Patients With Bladder Cancer by Intravesical Vector Instillation, 957
Kubista E, *see* Jakesz R
Kuczyk M, *see* Kollmannsberger C
Kuenen B, Giaccone G. In Reply (correspondence), 3042
Kuenen BC, Rosen L, Smit EF, Parson MRN, Levi M, Ruijter R, Huisman H, Kedde MA, Noordhuis P, van der Vijgh WJF, Peters GJ, Cropp GF, Scigalla P, Hoekman K, Pinedo HM, Giaccone G. Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors, 1657
Kuerer HM, *see* Buchholz TA
Kufe DW, *see* Eder JP Jr
Kugler C, *see* Laack E
Kugler JW, *see* Allegra CJ
see Berlin JD
see Hobday TJ
Kühl J, *see* Timmermann B
Kühn R, *see* Rödel C
Kuhn-Regnier F, *see* Weihrauch MR
Kun L, *see* Donaldson SS
see Friedmann AM
Kung F, *see* Furman WL
Kunst PWA, Sutedja G, Golding RP, Risse E, Kardos G, Postmus PE. Unusual Pulmonary Lesions; Case 1. A Juvenile Bronchopulmonary Fibrosarcoma, 2745
Kuntz KM, *see* Esnaola NF
Kuo S-H, *see* Yuan A
Kupelian P, *see* Graefen M
Kupelian PA, *see* Graefen M
see Thomas J

Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Comparison of the Efficacy of Local Therapies for Localized Prostate Cancer in the Prostate-Specific Antigen Era: A Large Single-Institution Experience With Radical Prostatectomy and External-Beam Radiotherapy, 3376
Kuperstein G, *see* Liede A
Kurie JM, *see* Rizvi NA
Kuriyama K, *see* Imashuku S
Kurzawinski TR, *see* Brett BT
Kusumoto M, *see* Sobue T
Kutok JL, Aster JC. Molecular Biology of Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma, 3691
Kuttesch JF, *see* Athale UH
Kuzel T, *see* Hinton S
Kwan W, Jackson J, Weir LM, Dingee C, McGregor G, Olivotto IA. Chronic Arm Morbidity After Curative Breast Cancer Treatment: Prevalence and Impact on Quality of Life, 4242
Kwan WH, *see* Chan ATC
Kwasny W, *see* Jakesz R
Kwiatkowski F, *see* Curé H
Kwok AKH, *see* Hon C
Kwong R, *see* Leighl NB
Kwong YL, *see* Chim CS
Kyle RA, *see* Berenson JR
see Rajkumar SV

L

Laack E, Nikbakht H, Peters A, Kugler C, Jasiewicz Y, Edler L, Brümmer J, Schumacher U, Hossfeld DK. Expression of CEACAM1 in Adenocarcinoma of the Lung: A Factor of Independent Prognostic Significance, 4279
Labianca R, *see* Cascinu S
see Ridolfi R
Labopin M, *see* Ringdén O
see Rocha V
LaCombe MA. Radiotherapy Dose Escalation in High-Grade Gliomas (correspondence), 3358
Lacy MQ, *see* Rajkumar SV
Lafond D, *see* Jennings MT
Lai M, *see* Chan ATC
Laidlaw IJ, *see* Harper-Wynne CL
Lakhani SR, van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF for the Breast Cancer Linkage Consortium. The Pathology of Familial Breast Cancer: Predictive Value of Immunohistochemical Markers Estrogen Receptor, Progesterone Receptor, HER-2, and p53 in Patients With Mutations in *BRCA1* and *BRCA2*, 2310
Lam CCK, *see* Chim CS
Lamagnere J-P, *see* Perel Y
Lamaj E, *see* Belli F
Lamar L, *see* Einhorn LH
Lamb DJ, *see* Shariat SF
Lamba J, *see* Goh B-C
Lamborn KR, *see* Donaldson SS
Lammertsma AA, *see* Bos R
Lamont A, *see* Shepherd FA
Lamont EB, *see* Iwashyna TJ
Landman-Parker J, *see* Perel Y
Landoni F, *see* Benedetti-Panici P
Landrum MB, *see* Keating NL
see Silliman RA
Lang F, *see* Scheithauer W
Lange BJ, *see* Ruers TJM
see Woods WG
Langenhoff BS, Oyen WJG, Jager GJ, Strijk SP, Wobbes Th, Corstens FHM, Ruers TJM. Efficacy of Fluorine-18-Deoxyglucose Positron Emission Tomography in Detecting Tumor Recurrence After Local Ablative Therapy for Liver Metastases: A Prospective Study, 4453
Langer AS, *see* Winer EP
Langer W, *see* Keating MJ
Lanza E, *see* Shike M
Laplanche A, *see* Culine S
see Patte C
Laplante S, *see* Klasa RJ
Larkin JMG, *see* Kolomainen DF
Larocca LM, *see* Teofili L
Laroia ST, Potti A, Rabbani M, Mehdi SA, Koch M. Unusual Pulmonary Lesions; Case 3. Pulmonary Vein Leiomyosarcoma Presenting as a Left Atrial Mass, 2749
Larson RA, *see* Kornblith AB
see Morrison VA
see Silverman LR
Larson SM, *see* Wong RJ
Lash TL, *see* Silliman RA
Lashford LS, Thiesse P, Jouvet A, Jaspan T, Couanet D, Griffiths PD, Doz F, Ironside J, Robson K, Hobson R, Dugan M, Pearson ADJ, Vassal G, Frappaz D. Temozolomide in Malignant Gliomas of Childhood: A United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study, 4684
Lathan B, *see* Sieber M
Latkany L, *see* Shike M
Lau C, *see* Poon RT-P
Lau H, *see* El-Sayed S
Lau WH, *see* Chan ATC
Laughlin MJ, *see* Rizzieri DA
Laurent-Puig P, *see* Etienne M-C
Lauriola L, *see* Ferrandina G
see Piantelli M
Lauwers GY, *see* Vauthey J-N
Lawlor P, *see* Watanabe S
Lawrence G, Crawford J, Shennan F. Evaluating Neoadju-

vant Chemotherapy in Breast Cancer (correspondence), 2905
Lazarides SN, *see* Esnaola NF
Lazarovici D, *see* Zisman A
Lazarus HM, *see* Berry DA
Lazzari I, *see* Belli F
Leahy TL, *see* Carducci MA
Lebas F-X, *see* Depierre A
Lebeau B, *see* Depierre A
Leber B, *see* Keating MJ
Leblanc T, *see* Perel Y
LeClerc JM, Billett AL, Gelber RD, Dalton V, Tarbell N, Lipton JM, Barr R, Clavell LA, Asselin B, Hurwitz C, Schorin M, Lipshultz SE, Declerck L, Silverman LB, Cohen HJ, Sallan SE. Treatment of Childhood Acute Lymphoblastic Leukemia: Results of Dana-Farber ALL Consortium Protocol 87-01, 237
Leclerc P, *see* Depierre A
Lederlin P, *see* Fermé C
see Gisselbrecht C
Lee H-S, *see* Goh B-C
Lee H-S, Kim KM, Yoon J-H, Lee T-R, Suh KS, Lee KU, Chung JW, Park JH, Kim CY. Therapeutic Efficacy of Transcatheter Arterial Chemoembolization as Compared With Hepatic Resection in Hepatocellular Carcinoma Patients With Compensated Liver Function in a Hepatitis B Virus-Endemic Area: A Prospective Cohort Study, 4459
Lee J, *see* Socinski MA
Lee J-H, *see* Socinski MA
Lee J-S, *see* Lee Jung-Hee
Lee JE, *see* Ballo MT
see Pisters PWT
Lee Je-Hwan, *see* Lee Jung-Hee
Lee JH, Glick HA, Hayman JA, Solin LJ. Decision-Analytic Model and Cost-Effectiveness Evaluation of Postmastectomy Radiation Therapy in High-Risk Premenopausal Breast Cancer Patients, 2713
Lee JJ, *see* Eton O
see Shin DM
Lee JS, *see* Rizvi NA
Lee Jung-Hee, Lee Je-Hwan, Ahn J-H, Bahng H, Kim T-W, Kang Y-K, Lee K-H, Kim J-C, Yu C-S, Kim J-H, Ahn S-D, Kim W-K, Kim S-H, Lee J-S. Randomized Trial of Postoperative Adjuvant Therapy in Stage II and III Rectal Cancer to Define the Optimal Sequence of Chemotherapy and Radiotherapy: A Preliminary Report, 1751
Lee JY, *see* Cianfrocca M
Lee K-H, *see* Lee Jung-Hee
Lee KU, *see* Lee H-S
Lee S-C, *see* Biankin AV
see Goh B-C
Lee SJ, *see* Loberiza FR Jr
see Rizzo JD
Lee SM, *see* Bomanji JB
Lee SW, *see* Chan JL
Lee T-R, *see* Lee H-S
Lee WR. Quality of Life After Prostate Cancer Treatment (correspondence), 3038
Lee Y-C, *see* Yuan A
Leer JWH, *see* Marijnen CAM
Legault S, *see* Powles T
Legge F, *see* Ferrandina G
Leggett BA, *see* Lindor NM
Legha SS, *see* Eton O
Legrand C, *see* Ardizzoni A
Lehky T, *see* Grem JL
see Wilson RH
Lehman H, *see* Datta RV
Lehman MJ, *see* Orlowski RZ
Lehmann W, *see* Allal AS
Leibel SA, *see* Zelefsky MJ
Leibenhaut M, *see* Mehta MP
Leichman CG, *see* Khushalani NI
Leichman L, *see* Khushalani NI
Leighl NB, Shepherd FA, Goodwin PJ. In Reply (correspondence), 3751
Leighl NB, Shepherd FA, Kwong R, Burkes RL, Feld R, Goodwin PJ. Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non-Small-Cell Lung Cancer, 1344
Leikauf GD, *see* Mohr S
Leis J, *see* Levine JE
Leissner J, *see* Kuball J
Leitzel K, *see* Lipton A
Lemarié E, *see* Depierre A
Lembersky BC, *see* Douillard J-Y
Lenauer A, *see* Scheithauer W
Lens MB, Dawes M. In Reply (correspondence),4121, 4123
Lens MB, Dawes M. Interferon Alfa Therapy for Malignant Melanoma: A Systematic Review of Randomized Controlled Trials, 1818
Lenzi R, *see* Baile WF
see Pisters PWT
Leonard GD, Zhuang SH, Grem JL. Epirubicin, Cisplatin, and Protracted Venous-Infusion Fluorouracil in Advanced Esophagogastric Cancer (correspondence), 4124
Leonard R, *see* O'Shaughnessy J
Leone DM, *see* Timoney JP
Leone G, *see* Teofili L
Leontovich O, *see* Lindor NM
Leopold KA, *see* Vokes EE
Lepage E, *see* Gisselbrecht C
Lerman C, *see* Berry DA
see Schwartz MD
Lersch C, *see* Schmelz R
Lertora JJL, *see* Rozans M
Lesimple T, *see* Culine S
Lesser G, *see* Kleinberg L
Lester E, *see* Lima CMSR
Letoublon C, *see* Etienne M-C

Letscher-Bru V, *see* Herbrecht R
Leung D, *see* Alektiar KM
Leung DHY, *see* Kattan MW
see Stojadinovic A
Leung SF, *see* Chan ATC
Leung TW, *see* Chan ATC
Leung W, Rose SR, Zhou Y, Hancock ML, Burstein S, Schriock EA, Lustig R, Danish RK, Evans WE, Hudson MM, Pui C-H. Outcome of Growth Hormone Replacement Therapy in Survivors of Childhood Acute Lymphoblastic Leukemia, 2959
Levavi H, *see* Chetrit A
Level M-C, *see* Depierre A
Levenback C, *see* Eifel PJ
Levenback C, Coleman RL, Burke TW, Lin WM, Erdman W, Deavers M, Delpassand ES. Lymphatic Mapping and Sentinel Node Identification in Patients With Cervix Cancer Undergoing Radical Hysterectomy and Pelvic Lymphadenectomy, 688
Levenback C, Coleman RL. In Reply (correspondence), 2603
Leverger G, *see* Perel Y
Lévi F, *see* Chevalier V
see Curé H
Levi M, *see* Kuenen BC
Levin HS, *see* Thomas J
Levin J, *see* Rivera E
see Schilsky RL
Levin VA, *see* Groves MD
Levin W, *see* Fyles A
Levine JE, *see* Yanik GA
Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R, Drobyski WR, Barrett AJ, Porter DL, Giralt S, Leis J, Holmes HE, Johnson M, Horowitz M, Collins RH Jr. Prospective Trial of Chemotherapy and Donor Leukocyte Infusions for Relapse of Advanced Myeloid Malignancies After Allogeneic Stem-Cell Transplantation, 405
Levine JE, Collins RH Jr. In Reply (correspondence), 2756
Levine M, *see* Davidson NE
Levine MN, Ganz PA. Beyond the Development of Quality-of-Life Instruments: Where Do We Go From Here? (editorial), 2215
Levine MN, Ganz PA. In Reply (correspondence), 4127
Levinson J, *see* Einhorn LH
Levitt G, *see* Owens CM
Levitt R, *see* Allegra CJ
Levoir D, *see* Louvet C
Lewis JJ, *see* Belli F
see Stojadinovic A
Leyvraz S, *see* Stupp R
Lhommé C, *see* Gutierrez M
Li FP, *see* Chen WY
see Emmons K
Li KH, *see* Au WY
Li S, *see* Einhorn LH
Li X, *see* Deitcher SR
Liang BC, *see* Holmes FA
Liang R, *see* Au WY
see Chim CS
Liang RHS, *see* Hon C
Liang W, Burnett CB, Rowland JH, Meropol NJ, Eggert L, Hwang Y-T, Silliman RA, Weeks JC, Mandelblatt JS. Communication Between Physicians and Older Women With Localized Breast Cancer: Implications for Treatment and Patient Satisfaction, 1008
Lichinitser MR, *see* Menssen HD
Lichtenegger W, *see* Fuchs IB
Lichtin A, *see* Schover LR
Lichtin AE, *see* Rizzo JD
Lie AKW, *see* Hon C
Lieberman IH, *see* Dudeney S
Liebisch C, *see* Fröhling S
Liebmann PM, *see* Wölfler A
Liede A, Karlan BY, Baldwin RL, Platt LD, Kuperstein G, Narod SA. Cancer Incidence in a Population of Jewish Women at Risk of Ovarian Cancer, 1570
Lieskovsky G, *see* Graefen M
Lim F, *see* Ramanathan RK
Lim H-L, *see* Goh B-C
Lim JF, *see* Sorensen PHB
Lim R, *see* Goh B-C
Lima CMSR, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR. Irinotecan Plus Gemcitabine Induces Both Radiographic and CA 19-9 Tumor Marker Responses in Patients With Previously Untreated Advanced Pancreatic Cancer, 1182
Lin DT, *see* Wong RJ
Lin PP, *see* Ahmad SA
Lin WM, *see* Levenback C
Linch DC, *see* Branson K
Lindner LH, *see* Wendtner C-M
Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, Walsh-Vockley C, Petersen GM, Walsh MD, Leggett BA, Young JP, Barker MA, Jass JR, Hopper J, Gallinger S, Bapat B, Redston M, Thibodeau SN, Cooperative Family Registry for Colon Cancer Studies. Immunohistochemistry Versus Microsatellite Instability Testing in Phenotyping Colorectal Tumors, 1043
Lingenfelter B, *see* Frank TS
Link M, *see* Goorin AM
Link MP, *see* Baker KS
see Donaldson SS
see Friedmann AM
Linker C, Damon L, Ries C, Navarro W. Intensified and Shortened Cyclical Chemotherapy for Adult Acute Lymphoblastic Leukemia, 2464
Linkesch W, *see* Jäger G
see Wölfler A
Linthorst GAM, *see* de Gast GC
Lioure B, *see* Herbrecht R
Lipkus I, *see* Chlebowski RT

Lippman SM, *see* Shin DM
Lipshultz LI, *see* Schover LR
Lipshultz SE, *see* LeClerc JM
Lipshultz SE, Giantris AL, Lipsitz SR, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE, Colan SD. Doxorubicin Administration by Continuous Infusion Is Not Cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol, 1677
Lipshultz SE, Lipsitz SR, Sallan SE, Simbre VC II, Shaikh SL, Mone SM, Gelber RD, Colan SD. Long-Term Enalapril Therapy for Left Ventricular Dysfunction in Doxorubicin-Treated Survivors of Childhood Cancer, 4517
Lipsitz S, *see* Kemeny MM
Lipsitz SR, *see* Lipshultz SE
Liptay MJ, Grondin SC, Fry WA, Pozdol C, Carson D, Knop C, Masters GA, Perlman RM, Watkin W. Intraoperative Sentinel Lymph Node Mapping in Non-Small-Cell Lung Cancer Improves Detection of Micrometastases, 1984
Lipton A, *see* Berenson JR
see Costa L
Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carney W, Allard J. Elevated Serum HER-2/*neu* Level Predicts Decreased Response to Hormone Therapy in Metastatic Breast Cancer, 1467
Lipton A, Ali SM, Leitzel K, Engle L, Chinchilli V. In Reply (correspondence), 3357
Lipton A, Ali SM, Leitzel K. In Reply (correspondence), 4606
Lipton JH, *see* Kiss TL
Lipton JM, *see* LeClerc JM
Lisboa B, *see* Jonat W
Lister TA, *see* Radford JA
Litchy S, *see* Greco FA
Litman H, *see* Diller L
Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B, Epoetin Alfa Study Group. In Reply (correspondence), 602
Litwin A, *see* Khushalani NI
Litwin MS, *see* Burkhardt JH
see Wei JT
Liu D, *see* Bennett CL
see Kletzel M
see Seiter K
see Shin DM
Liu H-S, *see* Cheng H-L
Liu K-L, *see* Herbrecht R
Liu-Mares W, *see* Katzenstein HM
Liu P-Y, *see* Green S
see Sondak VK
see Sosman JA
Liver Tumors Study Group of the International Society of Pediatric Oncology, *see* Czauderna P
Livingston PO, *see* Hwu W-J
Livingston RB, *see* Albain KS
see Ellis GK
Lledo G, *see* Louvet C
Lo Re G, *see* Ridolfi R
Lobchuk MM, Degner LF. Symptom Experiences: Perceptual Accuracy Between Advanced-Stage Cancer Patients and Family Caregivers in the Home Care Setting, 3495
Lobe TE, *see* Baker KS
Loberiza FR Jr, Rizzo JD, Bredeson CN, Antin JH, Horowitz MM, Weeks JC, Lee SJ. Association of Depressive Syndrome and Early Deaths Among Patients After Stem-Cell Transplantation for Malignant Diseases, 2118
Locker PK, *see* Lima CMSR
Lodge MA, *see* Galbraith SM
Loebbecke M, *see* Fuchs IB
Loeffler JS, *see* Chakravarti A
Loeffler M, *see* Sieber M
Loehrer PJ Jr, *see* Von Roenn JH
Loehrer PJ Sr, *see* Hinton S
Loesch D, Robert N, Asmar L, Gregurich MA, O'Rourke M, Dakhil S, Cox E. Phase II Multicenter Trial of a Weekly Paclitaxel and Carboplatin Regimen in Patients With Advanced Breast Cancer, 3857
Loffredo M, *see* D'Amico AV
Lofts F, *see* Ross P
Loge JH, *see* Jordhøy MS
Logothetis CJ, *see* Pagliaro LC
see Papandreou CN
see Siefker-Radtke AO
Logothetis CJ. Challenge of Locally Persistent Prostate Cancer: An Unresolved Clinical Dilemma (editorial), 3187
Loh K, *see* Vose JM
Lohrisch C, *see* Biganzoli L
Lombardi AV, *see* Perrone F
Lombardi D, *see* Spazzapan S
Lombardo C, *see* Belli F
London WB, *see* Katzenstein HM
Lones MA, Perkins SL, Sposto R, Tedeschi N, Kadin ME, Kjeldsberg CR, Wilson JF, Zwick DL, Cairo MS. Non-Hodgkin's Lymphoma Arising in Bone in Children and Adolescents Is Associated With an Excellent Outcome: A Children's Cancer Group Report, 2293
Lønning PE, *see* Geisler J
Lønning PE, Geisler J, Dowsett M. In Reply (correspondence), 3040
Looijenga LHJ, *see* Kersemaekers A-MF
see Mayer F
Loos WJ, *see* Kehrer DFS
see Mathijssen RHJ
Lopez M, *see* Vici P
Lopez M, Vici P, Di Lauro L, Carpano S. Increasing Single

Epirubicin Doses in Advanced Soft Tissue Sarcomas, 1329
Lopez-Graniel CM, *see* Duenas-Gonzalez A
López-Guillermo A, *see* Bessell EM
Loprinzi CL, *see* Jatoi A
see Sloan JA
Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, Halyard MY, Pruthi S, Novotny PJ, Rummans TA. Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes, 157
Lorence RM, *see* Pecora AL
Lorenz G, *see* Sucker C
Loretelli C, *see* Scartozzi M
Lortholary A, *see* Culine S
LoRusso P, *see* Albanell J
LoRusso PM, *see* Herbst RS
Lorusso V, *see* Berruti A
Lotan R, *see* Shin DM
Loughran T, *see* Seiter K
Louie O, *see* Hochwald SN
Louis DN, *see* Betensky RA
Louvet C, André T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E, Flesch M, Cvitkovic E, de Gramont A. Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II Study, 1512
Louvet C, André T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, François E, Jacob JH, Levoir D, Taamma A, Rougier P, Cvitkovic E, de Gramont A. Phase II Study of Oxaliplatin, Fluorouracil, and Folinic Acid Administered According to the FOLFOX6 Regimen in Locally Advanced or Metastatic Gastric Cancer Patients, 4543
Love RR, Duc NB, Allred DC, Binh NC, Dinh NV, Kha NN, Thuan TV, Mohsin SK, Roanh LD, Khang HX, Tran TL, Quy TT, Thuy NV, Thé PN, Cau TT, Tung ND, Huong DT, Quang LM, Hien NN, Thuong L, Shen T, Xin Y, Zhang Q, Havighurst TC, Yang YF, Hillner BE, DeMets DL. Oophorectomy and Tamoxifen Adjuvant Therapy in Premenopausal Vietnamese and Chinese Women With Operable Breast Cancer, 2559
Love RR. In Reply (correspondence), 3934
Love RR. Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer (correspondence),879, 1955
Lovegren M, *see* Hensley ML
Lowe FM, *see* Harper-Wynne CL
Lubin F, *see* Chetrit A
Lucarelli CD, *see* Timoney JP
Lucie NP, *see* Radford JA
Luh K-T, *see* Yuan A
Lui W-Y, *see* O'Shaughnessy J
Luke M, *see* Abramson N
Lukka H, *see* Pearcey R
Luksch R, *see* Massimino M
see Spreafico F
Luongo M, *see* Teofili L
Lust JA, *see* Rajkumar SV
Lustig R, *see* Leung W
Lutz P, *see* Herbrecht R
Lux ML, *see* Singer S
Lyckholm L, *see* Neff P
Lynch CF, *see* Dores GM
see Potosky AL
Lynch HT, *see* Berry DA
Lynch JC, *see* Sorensen PHB
see Vose JM
see Weekes CD

M

Ma C, *see* Chiou WL
Ma ESK, *see* Hon C
Maas H, *see* Friberg LE
Maat APWM, *see* van der Sijp JRM
Määttänen L, *see* Mäkinen T
Mabuchi O, *see* Yamamoto K
Macdonald JS, *see* Kemeny MM
see Tepper JE
Macdonald JS. Vive La Difference: Sex and Fluorouracil Toxicity (editorial), 1439
MacDonald S, *see* Toso JF
Macé-Lesec'h J, *see* Joly F
Machin D, *see* Tan SB
Machtay M, Glatstein E. Reply 1 (correspondence), 1428
Machtay M, Rosenthal DI, Hershock D, Jones H, Williamson S, Greenberg MJ, Weinstein GS, Aviles VM, Chalian AA, Weber RS. Organ Preservation Therapy Using Induction Plus Concurrent Chemoradiation for Advanced Resectable Oropharyngeal Carcinoma: A University of Pennsylvania Phase II Trial, 3964
Machtay M. The Early Rad Catches the Tumor? (editorial), 3045
Macis G, *see* Trodella L
MacKenzie R, *see* El-Sayed S
Mackenzie S, *see* Zelek L
Mackillop WJ, *see* Huang J
Mackinlay G, *see* Czauderna P
Mackinnon S, *see* Branson K
see Peggs KS
MacLean G, *see* Pearcey R
Maclean M, *see* Bélanger K
MacNamara E, *see* Andermann A
MacNeill FA, *see* Harper-Wynne CL
Macpherson N, *see* Mirza I
Madarnas Y, *see* Goodwin PJ
Madden T, *see* Herbst RS
Madden TL, *see* Herbst RS
Maddox A-M, *see* Herbst RS
Madon E, *see* Fagioli F

Madsen LT, *see* Izawa JI
Maeder P, *see* Stupp R
Maggiano N, *see* Ferrandina G
Magné N, *see* Etienne M-C
Magnusson I, *see* Edler D
Magri MD, *see* Spazzapan S
Maher MM, *see* McDermott RS
Mahon FX, Delbrel X, Cony-Makhoul P, Fabères C, Boiron JM, Barthe C, Bilhou-Nabéra C, Pigneux A, Marit G, Reiffers J. Follow-Up of Complete Cytogenetic Remission in Patients With Chronic Myeloid Leukemia After Cessation of Interferon Alfa, 214
Mahoney MR, *see* Allegra CJ
see Goldberg RM
see Hobday TJ
Maibach R, *see* Bernhard J
Maillard I, *see* Stupp R
Mailliard JA, *see* Hobday TJ
see Jatoi A
see Loprinzi CL
Main D, *see* Schwartz MD
Maio M, *see* Belli F
Maione P, *see* Perrone F
Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T, Iveson T, O'Brien M, Tebbutt N, Harrington A, Hill M. Multicenter Randomized Phase III Trial Comparing Protracted Venous Infusion (PVI) Fluorouracil (5-FU) With PVI 5-FU Plus Mitomycin in Inoperable Pancreatic Cancer, 3130
Maki R, *see* Hensley ML
Mäkinen T, Tammela TLJ, Stenman U-H, Määttänen L, Rannikko S, Aro J, Juusela H, Hakama M, Auvinen A. Family History and Prostate Cancer Screening With Prostate-Specific Antigen, 2658
Maksymiuk A, *see* Klasa RJ
Malak SF, *see* Walshe LJ
Malamos N, *see* Stathopoulou A
Malamos NA, *see* Stathopoulos GP
Malik AA, *see* Moazzam N
Malin JL, Schuster MA, Kahn KA, Brook RH. Quality of Breast Cancer Care: What Do We Know?, 4381
Malin JR, *see* Pearson ML
Malingré MM, Beijnen JH, Schellens JHM. In Reply (correspondence), 1952
Malkin MG, *see* Timoney JP
Malkowicz SB, *see* Cross CK
Malogolowkin MH, *see* Katzenstein HM
Maltoni M, *see* Tassinari D
Mamounas EP, *see* Fisher B
see Winer EP
Manchul L, *see* Fyles A
Mancuso S, *see* Ferrandina G
Mandelbaum DE, *see* Jennings MT
Mandelblatt JS, *see* Liang W
Mandeli J, *see* Ferrari AC
Manegold C, *see* Ardizzoni A
Maneval DC, *see* Kuball J
Mangioni C, *see* Benedetti-Panici P
Maniero A, *see* Douillard J-Y
Mannel RS, *see* Bloss JD
Männistö E, *see* Powles T
Manola J, *see* Kirkwood JM
Mansfield PF, *see* Ballo MT
Mantovani L, *see* Kaiser U
Mao J, *see* Toso JF
Marangolo M, *see* Ravaioli A
see Scagliotti GV
Maraninchi D, *see* Viens P
Marberger M, *see* Djavan B
Marchianó A, *see* Belli F
Marcus KC, *see* Donaldson SS
see Ng AK
Marcus S, *see* Kruijtzer CMF
Margaritora S, *see* Trodella L
Margolese RG, *see* Fisher B
Mariani T, *see* Motzer RJ
Marijnen CAM, Kapiteijn E, van de Velde CJH, Martijn H, Steup WH, Wiggers T, Kranenbarg EK, Leer JWH, Cooperative Investigators of the Dutch Colorectal Cancer Group, Acute Side Effects and Complications After Short-Term Preoperative Radiotherapy Combined With Total Mesorectal Excision in Primary Rectal Cancer: Report of a Multicenter Randomized Trial, 817
Marincola FM, *see* Toso JF
Marit G, *see* Cany L
see Mahon FX
Markman M, *see* Alberts DS
see Barakat RR
see Bloss JD
Markman M, Hall J, Spitz D, Weiner S, Carson L, Van Le L, Baker M. Phase II Trial of Weekly Single-Agent Paclitaxel in Platinum/Paclitaxel-Refractory Ovarian Cancer, 2365
Markman M. Safety Issues in Using Complementary and Alternative Medicine, 39s
Markowitz AB, *see* Vaughn DJ
Marks AR, *see* Abramson N
Marrow M, *see* Jordon VC
Marsh JCW, *see* Branson K
Marshall D, *see* Stojadinovic A
Marshall E, *see* Small EJ
Marshall JL, *see* Pecora AL
see Rizvi NA
Martell RE, *see* Ingram SS
Martenson J, *see* Minsky BD
Martenson JA, *see* Tepper JE
Martijn H, *see* Marijnen CAM
Martin C, *see* Carmichael J
Martin J, Ginsberg RJ, Venkatraman S, Bains MS, Downey RJ, Korst RJ, Kris MG, Rusch VW. Long-Term Results of Combined-Modality Therapy in Resectable Non-Small-Cell Lung Cancer, 1989

Martini M, *see* Teofili L
Martino B, *see* Oliva EN
Martino R, *see* Levine JE
Martins H, *see* Shepherd FA
Martone M, *see* Heffernan N
Marty M, *see* Zelek L
Marx GM, *see* Steer CB
Marx GM, Steer CB, Harper P, Pavlakis N, Rixe O, Khayat D. Unexpected Serious Toxicity With Chemotherapy and Antiangiogenic Combinations: Time to Take Stock! (editorial), 1446
Marymount MH, *see* Kletzel M
Masaki KH, *see* Rajq V
Mascaro JM, *see* Albanell J
Masi G, *see* Falcone A
Maslak P, *see* Schwartz GK
Massey V, *see* Jennings MT
Massimino M, *see* Spreafico F
Massimino M, Spreafico F, Cefalo G, Riccardi R, Tesoro-Tess JD, Gandolo L, Riva D, Ruggiero A, Valentini L, Mazza E, Genitori L, Di Rocco C, Navarria P, Casanova M, Ferrari A, Luksch R, Terenziani M, Balestrini MR, Colosimo C, Fossati-Bellani F. High Response Rate to Cisplatin/Etoposide Regimen in Childhood Low-Grade Glioma, 4209
Master V, *see* Damani MN
Masters GA, *see* Liptay MJ
Masuda N, *see* Noura S
Masullo L, *see* Buchholz TA
Matano E, *see* Scagliotti GV
Mathijssen RHJ, *see* Kehrer DFS
see Xie R
Mathijssen RHJ, Loos WJ, Sparreboom A, Verweij J, Karlsson MO. In Reply (correspondence), 4609
Mathijssen RHJ, Verweij J, de Jonge MJA, Nooter K, Stoter G, Sparreboom A. Impact of Body-Size Measures on Irinotecan Clearance: Alternative Dosing Recommendations, 81
Mathôt RAA, *see* Kruijtzer CMF
see van Kesteren Ch
Matsui E, *see* Sobue T
Matsumoto T, *see* Noura S
Matsuura N, *see* Noura S
Matthay KK, *see* Yanik GA
Matthes S, *see* Nieto Y
Mattke A, *see* Ferrari A
Matulonis U, *see* Diller L
Mauch P, *see* Diller L
Mauch PM, *see* Ng AK
Maughan T, *see* Keating MJ
Maunsell E, Drolet M, Brisson J, Robert J, Deschênes L. Dietary Change After Breast Cancer: Extent, Predictors, and Relation With Psychological Distress, 1017
Maurer HM, *see* Sorensen PHB
Mauriac L, *see* Howell A
see O'Shaughnessy J
Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: A Paradigm of New Agents for Cancer Therapeutics, 325
Mavroudis D, *see* Souglakos J
see Stathopoulou A
Mavroukakis S, *see* Toso JF
May JT, *see* Osborne CK
May M, *see* Josting A
Mayer F, *see* Kersemaekers A-MF
Mayer F, Kersemaekers A-M, Oosterhuis JW, Bokemeyer C, Looijenga LHJ. In Reply (correspondence), 3928
Mayer RJ, *see* Goessling W
see Tepper JE
Mazumdar M, *see* Dalbagni G
see Motzer RJ
see Vuky J
Mazza E, *see* Massimino M
McCabe M, *see* Sateren WB
McCachren S, *see* Mikulski SM
McCarthy PL Jr, *see* Berry DA
McCarthy WH, *see* Hersey P
McCloskey E, *see* Powles T
McCluskey ER, *see* Deitcher SR
McConkey DJ, *see* Herbst RS
McDermott RS, Maher MM, Dunleavy K, O'Keane CJ, Stack JP, Carney DP. Unusual Presentations of Lymphoma; Case 2. Non-Hodgkin's Lymphoma Presenting as Liver Disease, 1943
McGowan TS, *see* Brierley JD
McGregor G, *see* Kwan W
McGuffog L, *see* Lakhani SR
McGuigan K, *see* Pearson ML
McGuire EJ, *see* Izawa JI
McGuire W, *see* Jennings MT
McGuirt C, *see* Rivera E
McGuirt PV, *see* Schilsky RL
McIntyre LM, *see* Bepler G
McKee PH, *see* Goessling W
McLaughlin P, *see* Rassidakis GZ
see Sarris AH
McLaughlin PW, *see* Sanda MG
see Wei JT
McLendon RE, *see* Quinn JA
see Reardon DA
McLeod HL. Genetic Strategies to Individualize Supportive Care (editorial), 2765
McLeod R, *see* Hersey P
McMillan A, *see* Smaletz O
McMullen A, *see* Hersey P
McNeely L, *see* Jennings MT
McNeese MD, *see* Buchholz TA
McNeish IA, Strickland S, Holden L, Rustin GJS, Foskett M, Seckl MJ, Newlands ES. Low-Risk Persistent Gestational Trophoblastic Disease: Outcome After Initial Treatment With Low-Dose Methotrexate and Folinic Acid From 1992 to 2000, 1838
McQuaker G, *see* Branson K

McSweeney PA, *see* Nieto Y
McTiernan A, *see* Chlebowski RT
Meade CD, *see* Jacobsen PB
Meadows AT, *see* Vaughn DJ
Meazza C, *see* Ferrari A
Mechinaud F, *see* Patte C
Mechtersheimer G, *see* Viardot A
Medeiros LJ, *see* Rassidakis GZ
see Sarris AH
Meeks SL, *see* Buatti JM
Mehdi SA, *see* Laroia ST
see Moazzam N
Mehta J, Singhal S. Chronic Graft-Versus-Host Disease After Allogeneic Peripheral-Blood Stem-Cell Transplantation: A Little Methotrexate Goes a Long Way (correspondence), 603
Mehta MP, Shapiro WR, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA, Schultz CJ, Roa WH, Leibenhaut M, Ford J, Curran W, Phan S, Smith JA, Miller RA, Renschler MF. Lead-In Phase to Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation for Patients With Brain Metastases: Centralized Assessment of Magnetic Resonance Imaging, Neurocognitive, and Neurologic End Points, 3445
Mehta P, *see* Kaushal V
Meinhardt P, *see* Kuball J
Meisner C, *see* Timmermann B
Melanoma Group, *see* Mellado B
Melillo G, *see* Tan AR
Mellado B, del Carmen Vela M, Colomer D, Gutierrez L, Castel T, Quintó L, Fontanillas M, Reguart N, Domingo-Domènech JM, Montagut C, Estapé J, Gascón P. Tyrosinase mRNA in Blood of Patients With Melanoma Treated With Adjuvant Interferon, 4032
Mellon S, *see* Northouse LL
Menczer J, *see* Chetrit A
Mendelsohn J. Targeting the Epidermal Growth Factor Receptor for Cancer Therapy, 1s
Mendelson D, *see* Einhorn LH
Mendenhall WM, Morris CG, Stringer SP, Amdur RJ, Hinerman RW, Villaret DB, Robbins KT. Voice Rehabilitation After Total Laryngectomy and Postoperative Radiation Therapy, 2500
Mendoza TR, *see* Wang XS
Menell JH, *see* Hwu W-J
Meng MV, *see* Damani MN
Menges M, *see* Trümper L
Menssen HD, Sakalová A, Fontana A, Herrmann Z, Boewer C, Facon T, Lichinitser MR, Singer CRJ, Euller-Ziegler L, Wetterwald M, Fiere D, Hrubisko M, Thiel E, Delmas PD for the Myeloma Ibandronate Study Group. Effects of Long-Term Intravenous Ibandronate Therapy on Skeletal-Related Events, Survival, and Bone Resorption Markers in Patients With Advanced Multiple Myeloma, 2353
Mentzer SJ, *see* Esnaola NF
Menzel C, *see* Jakesz R
Merchant TE, *see* Spunt SL
Mercier RJ, *see* Rai KR
Mercuri M, *see* Ferrari S
Méresse V, *see* Viens P
Meric J-B, *see* Khayat D
Meropol NJ, *see* Liang W
see Pecora AL
see Rothenberg ML
see Schuchter LM
Merrouche Y, *see* Culine S
Mertens AC, *see* Emmons K
Mesina O, *see* Rassidakis GZ
see Sarris AH
Messinger D, *see* Österborg A
Messmann R, *see* Tan AR
Messner HA, *see* Kiss TL
Mesters RM, *see* Kaiser U
Metayer C, *see* Dores GM
Metzner B, *see* Kaiser U
Meuli R, *see* Stupp R
Meyer L, Zuberbier T, Worm M, Oettle H, Riess H. Hypersensitivity Reactions to Oxaliplatin: Cross-Reactivity to Carboplatin and the Introduction of a Desensitization Schedule (correspondence), 1146
Meyer M, *see* Rödel C
Meyer RM, *see* Klasa RJ
Meyer W, *see* Athale UH
Meyer WH, *see* Baker KS
Meyers CA, *see* Herbst RS
see Mehta MP
Meyers P. Prognostic Factors for Sarcomas: Hard and Soft (editorial), 627
Meyskens F, *see* Agarwala SS
Meza L, *see* Holmes FA
Mezger J, *see* Kruijtzer CMF
Miall S, *see* Harper-Wynne CL
Miaskowski C. In Reply (correspondence), 2908
Michaeli D, *see* Brett BT
Michel G, *see* Perel Y
Michon J, *see* Patte C
Mielke S, *see* Gelderblom H
Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H, Mittelman A, Panella T, Puccio C, Fine R, Shogen K. Phase II Trial of a Single Weekly Intravenous Dose of Ranpirnase in Patients With Unresectable Malignant Mesothelioma, 274
Milano G, *see* Etienne M-C
Miles D, *see* O'Shaughnessy J
Miller AA, *see* Vokes EE
Miller AR, *see* Esnaola NF
Miller CB, *see* Giles FJ
see Rizzo JD
Miller ID, *see* Smith IC
Miller JR III, *see* Kashani-Sabet M
Miller L, *see* Hudes G
Miller LL, *see* Lima CMSR

Miller RA, *see* Mehta MP
Miller V, *see* Ranson M
Miller W, *see* Lima CMSR
Milleron B, *see* Depierre A
Milligan DW, *see* Branson K
Millikan RE, *see* Pagliaro LC
see Siefker-Radtke AO
Milosevic M, *see* Fyles A
Minden MD, *see* Kiss TL
Minsky BD. In Reply (correspondence), 3931
Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy, 1167
Minsky BD. Sphincter Preservation for Rectal Cancer: Fact or Fiction? (editorial), 1971
Miralbell R, *see* Stupp R
Mirimanoff RO, *see* Stupp R
Mirza A, *see* Fata F
Mirza AN, *see* Esnaola NF
Mirza I, Macpherson N, Paproski S, Gascoyne RD, Yang B, Finn WG, Hsi ED. Primary Cutaneous Follicular Lymphoma: An Assessment of Clinical, Histopathologic, Immunophenotypic, and Molecular Features, 647
Mirza N, *see* Vauthey J-N
Mirza S, *see* Rubin BP
Misset J-L, *see* Zelek L
Mitchell BS, *see* Orlowski RZ
see Rai KR
Mitchell JB, *see* Coleman CN
Mitchell M, *see* Agarwala SS
Mitchell MS, Darrah D, Yeung D, Halpern S, Wallace A, Voland J, Jones V, Kan-Mitchell J. Phase I Trial of Adoptive Immunotherapy With Cytolytic T Lymphocytes Immunized Against a Tyrosinase Epitope, 1075
Mitchell MS. In Reply (correspondence), 3176
Mitchell T, *see* Ahles TA
Mitra N, *see* Neugut AI
Mitsouli C, *see* Dimopoulos MA
Mittelman A, *see* Mikulski SM
Miyahara R, *see* Shoji T
Miyake Y, *see* Noura S
Miyamoto T, *see* Kamada T
Miyasaka K, *see* Aoyama H
Mizoe J, *see* Kamada T
Mlineritsch B, *see* Jäger G
see Jakesz R
Mo F, *see* Chan ATC
Moazzam N, Malik AA, Mehdi SA, Potti A. Treatment Side Effects; Case 3. Fluorouracil-Induced Exacerbation of Systemic Lupus Erythematosus, 3032
Modan B, *see* Chetrit A
Modè A, *see* Federico M
Modi S, Panageas KS, Duck ET, Bach A, Weinstock N, Dougherty J, Cramer L, Hudis C, Norton L, Seidman A. Prospective Exploratory Analysis of the Association Between Tumor Response, Quality of Life, and Expenditures Among Patients Receiving Paclitaxel Monotherapy for Refractory Metastatic Breast Cancer, 3665
Moghrabi A, *see* Athale UH
see Gururangan S
see Lipshultz SE
Mohar A, *see* Duenas-Gonzalez A
Mohr S, Leikauf GD, Keith G, Rihn BH. Microarrays as Cancer Keys: An Array of Possibilities, 3165
Mohsin SK, *see* Love RR
Moiseyenko V, *see* O'Shaughnessy J
Mok T, *see* Chan ATC
Mok TSK, Zee B. Adequate Lymph Node Staging Is Fundamental to Comparative Study on Resectable Non-Small-Cell Lung Cancer (correspondence), 2604
Moldawer N, *see* Zisman A
Molier M, *see* Kersemaekers A-MF
Molina T, *see* Gisselbrecht C
Moll I, *see* Thies A
Möller P, *see* Viardot A
Molostova V, *see* Österborg A
Molthoff CFM, *see* Bos R
Monchâtre M, *see* Depierre A
Monden M, *see* Noura S
Mone SM, *see* Lipshultz SE
Monfardini S, *see* Repetto L
Monk P, *see* Nadella P
Montagut C, *see* Mellado B
Montana GS, *see* Ingram SS
Montgomery JS, *see* Bennett CL
Montie JE, *see* Wei JT
Montserrat E, *see* Bessell EM
Montz FJ, *see* Bristow RE
Mood D, *see* Northouse LL
Moore DF Jr, *see* Siefker-Radtke AO
Moore JO, *see* Bass AJ
see Rizzieri DA
Moore M, *see* Bélanger K
see Holmes FA
see Socinski MA
Mor V, *see* Silliman RA
Morán A, *see* González-Quevedo R
Morant R, *see* Borner MM
Moreira IM, *see* Mortuza FY
Morey AL, *see* Biankin AV
Morgan E, *see* Kletzel M
Mori K, *see* Sekine I
Moringlane JR, *see* Samnick S
Morita S, *see* Kamada T
see Wong JH
Morita T, Akechi T, Sugawara Y, Chihara S, Uchitomi Y. Practices and Attitudes of Japanese Oncologists

and Palliative Care Physicians Concerning Terminal Sedation: A Nationwide Survey, 758
Morita T, Shima Y, Adachi I. Attitudes of Japanese Physicians Toward Terminal Dehydration: A Nationwide Survey, 4699
Moriyama N, *see* Sobue T
Morkas M, Fleming D, Hahl M. Challenges in Oncology; Case 2. Radiation Recall Associated With Docetaxel, 867
Moro G, *see* Berruti A
Moro-Sibilot D, *see* Depierre A
Morra E, *see* Cesana C
Morris C, *see* Badros A
see Howell A
see Osborne CK
see Ranson M
Morris CG, *see* Mendenhall WM
Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shepherd L, Larson RA, Schiffer CA. Therapy-Related Myeloid Leukemias Are Observed in Patients With Chronic Lymphocytic Leukemia After Treatment With Fludarabine and Chlorambucil: Results of an Intergroup Study, Cancer and Leukemia Group B 9011, 3878
Morrissey LH, *see* Greco FA
see Hainsworth JD
Morrow M, *see* Singletary SE
Morton DL, *see* DiFronzo LA
see Hsueh EC
Morton KE, *see* Toso JF
Morton RF, *see* Goldberg RM
Mortuza FY, Papaioannou M, Moreira IM, Coyle LA, Gameiro P, Gandini D, Prentice HG, Goldstone A, Hoffbrand AV, Foroni L. Minimal Residual Disease Tests Provide an Independent Predictor of Clinical Outcome in Adult Acute Lymphoblastic Leukemia, 1094
Moschel RC, *see* Quinn JA
Moser C, *see* Trümper L
Mota A, *see* Duenas-Gonzalez A
Motosue AM, *see* Spunt SL
Mott LA, *see* Ahles TA
Motzer RJ, *see* Vuky J
Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment Outcome and Survival Associated With Metastatic Renal Cell Carcinoma of Non-Clear-Cell Histology, 2376
Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma, 289
Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, Bacik J, Mazumdar M. Phase II Trial of Thalidomide for Patients With Advanced Renal Cell Carcinoma, 302
Moulton T, *see* Jennings MT
Mounier N, *see* Fermé C
Mounier N, Simon D, Haioun C, Gaulard P, Gisselbrecht C. Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas (correspondence), 1426
Mouridsen H, Chaudri-Ross HA. In Reply (correspondence), 877
Moynihan TJ, *see* Fanale MA
Mross K, *see* Gelderblom H
Mueller J, *see* Rosenberg R
Muggia F, *see* Alberts DS
Muggia FM, Blessing JA, Sorosky J, Reid GC. Phase II Trial of the Pegylated Liposomal Doxorubicin in Previously Treated Metastatic Endometrial Cancer: A Gynecologic Oncology Group Study, 2360
Mullan BP, *see* Anderson PM
Mullani NA, *see* Herbst RS
Muller MJ, *see* Detmar SB
Müller P, *see* Kaiser U
Muller RJ, *see* Timoney JP
Müller S, *see* Borner MM
Multani P, *see* Witzig TE
Multani PS, *see* Witzig TE
Mundy GR. Bisphosphonates and Tumor Burden (editorial), 3191
Munier S, *see* Carmichael J
Munker R, *see* Sieber M
Murace R, *see* Santini D
Murgo AJ, *see* Tan AR
Muriel AC, *see* Rauch PK
Murphy BA, *see* Glisson BS
see Motzer RJ
Murphy M, *see* Osoba D
see Seidman A
see Vogel CL
Murray JL, *see* Esteva FJ
Murray PL, *see* Ranson M
Musi M. Lack of Adherence With the Analgesic Regimen: The Cancer Patients' Perspective on a Two-Sided Problem (correspondence), 2907
Mutchnick S, *see* Sepucha KR
Myeloma Ibandronate Study Group, *see* Menssen HD
Myers J, *see* Shin DM
Mylonakis N, *see* Kosmidis P

N

Nabholtz J-M, *see* Bonneterre J
Nabid A, *see* El-Sayed S
Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J, Kadin ME, Pattengale P, Davis PC, Hutchinson RJ, White K. Randomized Comparison of Low-Dose Involved-Field Radiotherapy and No Radiotherapy for Children With Hodgkin's Disease Who Achieve a Complete Response to Chemotherapy, 3765
Nadali G-P, *see* Rassidakis GZ
Nadella P, Shapiro V, Otterson GA, Hauger M, Erdal S,

Kraut E, Clinton S, Shah M, Stanek M, Monk P, Villalona-Calero MA. Pharmacobiologically Based Scheduling of Capecitabine and Docetaxel Results in Antitumor Activity in Resistant Human Malignancies, 2616
Nagai K, *see* Sobue T
Nagarajan R, Neglia JP, Clohisy DR, Robison LL. Limb Salvage and Amputation in Survivors of Pediatric Lower-Extremity Bone Tumors: What Are the Long-Term Implications?, 4493
Nagorney DM, *see* Vauthey J-N
Nagtegaal ID, van de Velde CJH, van der Worp E, Kapiteijn E, Quirke P, van Krieken JHJM. Macroscopic Evaluation of Rectal Cancer Resection Specimen: Clinical Significance of the Pathologist in Quality Control, 1729
Nair S, *see* Sloan JA
Nakagawa T, *see* Shoji T
Nakano G, *see* Rajq V
Nakatsuka S, Yao M, Hoshida Y, Yamamoto S, Iuchi K, Aozasa K. Pyothorax-Associated Lymphoma: A Review of 106 Cases, 4255
Nalin CM, *see* Lipton A
Namer M, *see* Jonat W
Nan B, *see* Green DM
Nancarrow CM, *see* Diller L
Nanni O, *see* Ridolfi R
Narasimhan P, Hitti IF, Gheewala P, Pulakhandam U, Kanzer B. Unusual Presentations of Lymphoma; Case 3. Splenic Hematoma Associated With Non-Hodgkin's Lymphoma, 1946
Naredi P, *see* Agarwala SS
Narod SA, *see* Liede A
Nasiri N, *see* Harper-Wynne CL
Natarajan-Amé S, *see* Herbrecht R
Nathan D, *see* Bennett CL
Nathan PD, Gore ME, Eisen TG. Unexpected Toxicity of Combination Thalidomide and Interferon Alfa-2a Treatment in Metastatic Renal Cell Carcinoma (correspondence), 1429
Nathanson KL, *see* Shih HA
National Israeli Study of Ovarian Cancer, *see* Chetrit A
National Surgical Adjuvant Breast and Bowel Project, *see* Fisher B
Natoli C, *see* Piantelli M
Nava E, *see* Khushalani NI
Nava H, *see* Khushalani NI
Navarria P, *see* Massimino M
Navarro W, *see* Linker C
Nawaz S, *see* Nieto Y
Nease RF Jr, *see* Kilbridge KL
Nebraska Lymphoma Study Group, *see* Weekes CD
Neeleman N, *see* Ruers TJM
Neff P, Lyckholm L, Smith T. Truth or Consequences: What to Do When the Patient Doesn't Want to Know, 3035
Neftel KA, *see* Emmenegger U
Neglia JP, *see* Nagarajan R
Nekarda H, *see* Rosenberg R
Nelken B, *see* Patte C
see Perel Y
Nelson D, *see* Shaw E
see Silverman LR
Nelson JB, *see* Carducci MA
Nemunaitis J, *see* Bukowski R
see DiPaola RS
Nesbitt L, *see* Fisher B
Ness E, *see* Rizvi NA
Neuberg D, *see* Diller L
Neuberg DS, *see* Howard OM
Neudorf S, *see* Woods WG
Neugut AI, *see* Grann VR
see Hershman D
see Sundararajan V
Neugut AI, Fleischauer AT, Sundararajan J, Mitra N, Heitjan DF, Jacobson JS, Grann VR. Use of Adjuvant Chemotherapy and Radiation Therapy for Rectal Cancer Among the Elderly: A Population-Based Study, 2643
Neugut AI, Grann VR. Referral to Medical Oncologists: Are There Barriers at the Gate? (editorial), 1716
Neumann C, *see* Kretschmer L
Neumann HJ, *see* Jäger G
Neumann PJ, *see* Earle CC
Neumann TA, *see* Holmes FA
Neumeister P, *see* Jäger G
Nevalainen J, *see* Powles T
Nevantaus A, *see* Powles T
Newlands ES, *see* McNeish IA
Newman C, *see* Suarez-Almazor ME
see Viens P
Newman DJ, *see* Schwartsmann G
Newman K, *see* Katzenstein HM
Newman RA, *see* Herbst RS
Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, Tarbell NJ, Friedberg J, Canellos GP, Mauch PM. Long-Term Survival and Competing Causes of Death in Patients With Early-Stage Hodgkin's Disease Treated at Age 50 or Younger, 2101
Ng IO-L, *see* Poon RT-P
Ngan RK, *see* Chan ATC
Nguyen C, *see* Shariat SF
Nguyen L, *see* Friberg LE
Nguyen TV, Trinh GN. Clinical Evaluation of Once-Weekly and Three-Times-Weekly Dosings of Epoetin Alfa in Chemotherapy Patients: Problems of Study Design and Interpretation (correspondence), 878
Nicholls J, *see* Chim CS
Nicholls JM, *see* Chim CS
Nichols C, *see* Vose JM
Nichols CR, *see* Bokemeyer C
Nichols D, *see* Shaw E
Nicholson RI, *see* Albanell J

Nicolaides C, *see* Kosmidis P
Nicolaou N, *see* Freedman GM
Nicolini M, *see* Ravaioli A
Nicolson M, *see* Ross P
Niebel W, *see* Kröger K
Nieder C. Treatment of Newly Diagnosed Glioblastoma Multiforme (correspondence), 3179
Niedzwiecki D, *see* Tepper JE
Nieto Y, Nawaz S, Jones RB, Shpall EJ, Cagnoni PJ, McSweeney PA, Barón A, Razook C, Matthes S, Bearman SI. Prognostic Model for Relapse After High-Dose Chemotherapy With Autologous Stem-Cell Transplantation for Stage IV Oligometastatic Breast Cancer, 707
Niezgodzki G, *see* Curé H
Nikbakht H, *see* Laack E
Nishiwaki Y, *see* Sekine I
see Takada M
Nishiyama H, *see* Sobue T
Nissan A, *see* Stojadinovic A
Nitschke R. The Art of Oncology: When the Tumor Is Not the Target—The Power of Silence (correspondence), 1952
Nobile F, *see* Oliva EN
Noda K, *see* Takada M
Noll E, *see* Chakravarti A
Nomdedeu B, *see* Bessell EM
Nooijen W, *see* de Gast GC
Noordhuis P, *see* Kuenen BC
Nooter K, *see* Mathijssen RHJ
Nordle O, *see* Hudes G
Nordlinger B, Rougier P. Liver Metastases From Colorectal Cancer: The Turning Point (editorial), 1442
Norman A, *see* Maisey N
see Ross P
Normolle DP, *see* Chan JL
Northouse LL, Mood D, Kershaw T, Schafenacker A, Mellon S, Walker J, Galvin E, Decker V. Quality of Life of Women With Recurrent Breast Cancer and Their Family Members, 4050
Nortier JWR, *see* Littlewood TJ
Nortilli R, *see* Ridolfi R
Norton L, *see* Berry DA
see Guidi AJ
see Modi S
see Scheuer L
see Van Poznak C
Norwegian Lung Cancer Study Group, *see* Sundstrøm S
Norwood TH, *see* Rubin BP
Nosari AM, *see* Cesana C
Nosrati M, *see* Kashani-Sabet M
Nottage M, Siu LL. Principles of Clinical Trial Design, 42s
Noura S, Yamamoto H, Ohnishi T, Masuda N, Matsumoto T, Takayama O, Fukunaga H, Miyake Y, Ikenaga M, Ikeda M, Sekimoto M, Matsuura N, Monden M. Comparative Detection of Lymph Node Micrometastases of Stage II Colorectal Cancer by Reverse Transcriptase Polymerase Chain Reaction and Immunohistochemistry, 4232
Novick SC, *see* Orlowski RZ
Novotny PJ, *see* Jatoi A
see Loprinzi CL
see Sloan JA
Novotny WF, *see* Vogel CL
Noyes RD, *see* Sondak VK
Nozza A, *see* Bertuzzi A
Nuzzo F, *see* Berruti A
Nyquist L, *see* Wei JT

O

Oates RD, *see* Damani MN
Oberhuber G, *see* Birner P
Oberlin O. When Quality of Life Is the Major Challenge (editorial), 3051
Oberling F, *see* Viens P
O'Brien M, *see* Maisey N
O'Brien MER, *see* Waters JS
O'Brien SM, *see* Giles FJ
Ochs J, *see* Herbst RS
see Ranson M
O'Connell M, *see* Tepper JE
O'Connell MJ, *see* Allegra CJ
see Goldberg RM
see Hobday TJ
see Sloan JA
O'Connor OA, *see* Orlowski RZ
O'Day SJ, *see* Agarwala SS
see DiFronzo LA
see Hsueh EC
Odchimar-Reissig R, *see* Kornblith AB
see Silverman LR
Odom L, *see* Heffernan N
O'Dwyer M, *see* Mauro MJ
O'Dwyer PJ, *see* Kemeny MM
see Stevenson JP
Oettle H, *see* Meyer L
O'Fallon J, *see* Shaw E
Offit K, *see* Scheuer L
Ogino T, *see* Sekine I
Ogston KN, *see* Smith IC
Ohmatsu H, *see* Sobue T
Ohnishi T, *see* Noura S
Ohori M, *see* Cagiannos I
Ohta S, *see* Yamamoto K
Okawara G, *see* Minsky BD
O'Keane CJ, *see* McDermott RS
Olejnik T, *see* Witzig TE
Oliva EN, D'Angelo A, Martino B, Nobile F, Dimitrov BD, Perna A. More Concern About Transfusion Requirement When Evaluating Quality of Life in Anemic Patients (correspondence), 3182
Oliver RTD, Shamash J, Berney DM. p53 and MDM2 in

Germ Cell Cancer Treatment Response (correspondence), 3928
Oliver T, *see* Warde P
Oliverio G, *see* Ravaioli A
Olivotto IA, *see* Kwan W
see Van Patten CL
see Weir L
Ollila DW, *see* Hsueh EC
O'Neil JD, *see* Pecora AL
O'Neill A, *see* Kleinberg L
O'Neill B, *see* Shaw E
O'Neill V, *see* Vasey PA
Oneschuk D, *see* Watanabe S
Ong A-B, *see* Goh B-C
Oo TH, Aish LS, Hassoun H. Unusual Presentations of Lymphoma; Case 1. Sea-Blue Histiocytes in Non-Hodgkin's Lymphoma, 1942
Ooi CGC, *see* Au WY
Ooi GC, *see* Chim CS
Oosterhuis JW, *see* Kersemaekers A-MF
see Mayer F
Oprea C, *see* Herbrecht R
Order SE, Court W. When the Mirror Doesn't Reflect It at All (correspondence), 1144
O'Reilly E, *see* Schwartz GK
O'Reilly MS, *see* Herbst RS
O'Reilly SE, *see* Shenkier TN
Orel SG, *see* Tillman GF
Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine D-L, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL. Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies, 4420
Ornstein DL, *see* Garrison MA
O'Rourke M, *see* Loesch D
Ortega JA, *see* Katzenstein HM
Ortmann E, Hohenberg G. In Reply (correspondence), 4130
Ortmann E, Hohenberg G. Treatment Side Effects; Case 1. Radiation Recall Phenomenon After Administration of Capecitabine, 3029
Osaki T, Oyama T, Gu C-D, Yamashita T, So T, Takenoyama M, Sugio K, Yasumoto K. Prognostic Impact of Micrometastatic Tumor Cells in the Lymph Nodes and Bone Marrow of Patients With Completely Resected Stage I Non-Small-Cell Lung Cancer, 2930
Osborne C, *see* Du XL
Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A. Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American Trial, 3386
Oscier D, Bramble J, Hodges E, Wright D. Regression of Mucosa-Associated Lymphoid Tissue Lymphoma of the Bladder After Antibiotic Therapy (correspondence), 882
O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub J-P, Cervantes G, Fumoleau P, Jones S, Lui W-Y, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R. Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results, 2812
O'Shaughnessy JA, *see* Holmes FA
Osin PP, *see* Lakhani SR
Osman I, Sherman E, Singh B, Venkatraman E, Zelefsky M, Bosl G, Scher H, Shah J, Shaha A, Kraus D, Cordon-Cardo C, Pfister DG. Alteration of p53 Pathway in Squamous Cell Carcinoma of the Head and Neck: Impact on Treatment Outcome in Patients Treated With Larynx Preservation Intent, 2980
Osoba D, Slamon DJ, Burchmore M, Murphy M. Effects on Quality of Life of Combined Trastuzumab and Chemotherapy in Women With Metastatic Breast Cancer, 3106
Österborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, Messinger D for the Epoetin Beta Hematology Study Group. Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Erythropoietin, Epoetin Beta, in Hematologic Malignancies, 2486
Ostermann-Kraljevic S, *see* Stupp R
O'Sullivan B, *see* Brierley JD
see Davis AM
O'Sullivan J, *see* Green S
Otake Y, *see* Shoji T
Ott G, *see* Viardot A
Ottaiano A, *see* Perrone F
Otte JB, *see* Czauderna P
Otterson GA, *see* Nadella P
Ottestad L, *see* Powles T
Owen RG. Extramedullary Sites of Involvement in Hematologic Malignancies; Case 2. Lymphocyte Morphology in Splenic Marginal Zone Lymphoma, 342
Owens CM, Veys PA, Pritchard J, Levitt G, Imeson J, Dicks-Mireaux C. Role of Chest Computed Tomography at Diagnosis in the Management of Wilms' Tumor: A Study by the United Kingdom Children's Cancer Study Group, 2768
Oyama T, *see* Osaki T
Oyen WJG, *see* Langenhoff BS
see Ruers TJM
Oza A, *see* Carmichael J
Ozols RF. Recurrent Ovarian Cancer: Evidence-Based Treatment (editorial), 1161
Ozyilkan O, *see* Saglam S

P

Padhani AR, *see* Galbraith SM
Padilla G, *see* Sarna L
Padley RJ, *see* Carducci MA
Padre N, *see* Witzig TE
Paganini-Hill A, *see* Ursin G
Page DL, *see* Singletary SE
Page E, Assouline D, Brun O, Coeffic D, Fric D, Winckel P. Cardiac Dysfunction in Clinical Trials of Trastuzumab (correspondence), 4119
Pagliaro LC, Millikan RE, Tu S-M, Williams D, Daliani D, Papandreou CN, Logothetis CJ. Cisplatin, Gemcitabine, and Ifosfamide As Weekly Therapy: A Feasibility and Phase II Study of Salvage Treatment for Advanced Transitional-Cell Carcinoma, 2965
Pagnucco G, *see* Federico M
Paik S, *see* Fisher B
Paillot N, *see* Depierre A
Pajak TF, *see* Minsky BD
Pajunen M, *see* Powles T
Palchak D, *see* Small EJ
Palmer JL, *see* Bruera E
see Sweeney C
Palmer M, *see* Jonat W
Palmer PA, *see* Crul M
Palmero A, *see* Fagioli F
Panageas KS, *see* Modi S
Panageas KS, *see* Hwu W-J
see Van Poznak C
Panasci LC. HER-2/*neu* Serum Levels Vis-à-Vis Hormonal Response in Metastatic Breast Cancer (correspondence), 3357
Panella T, *see* Mikulski SM
Pangalis GA, *see* Rassidakis GZ
Pantuck AJ, *see* Zisman A
Panzarella T, *see* Brierley JD
see Warde P
Panzini I, *see* Ravaioli A
see Tassinari D
Papadopoulos NE, *see* Ballo MT
see Eton O
Papadopoulos T, *see* Rödel C
Papaioannou M, *see* Mortuza FY
Papakostas P, *see* Kosmidis P
Papandreou CN, *see* Pagliaro LC
Papandreou CN, Daliani DD, Thall PF, Tu S-M, Wang X, Reyes A, Troncoso P, Logothetis CJ. Results of a Phase II Study With Doxorubicin, Etoposide, and Cisplatin in Patients With Fully Characterized Small-Cell Carcinoma of the Prostate, 3072
Papies A, *see* Kaiser R
Pappo AS, *see* Spunt SL
Paproski S, *see* Mirza I
Paradis A-J, *see* Cremin C
Paraskevaidis M, *see* Antonadou D
Park J, *see* Press MF
Park JH, *see* Lee H-S
Park MS, *see* Sosman JA
Parker A, *see* Branson K
Parker LM, *see* Osborne CK
Parker PA, *see* Baile WF
Parkinson DR, *see* Schwartsmann G
Parma G, *see* Cantù MG
Parmiani G, *see* Belli F
Parmigiani G, *see* Berry DA
Parnes H, *see* Berry DA
Parodi S, *see* Repetto L
Parr AL, *see* Allegra CJ
Parra HS, *see* Bertuzzi A
Parson MRN, *see* Kuenen BC
Parwaresch R, *see* Kaiser U
Pasquini E, *see* Ravaioli A
Passik S, *see* Heffernan N
Pastorino U, *see* De Pas T
Patchell RA, *see* Mehta MP
Patel SG, *see* Wong RJ
Patel SR, *see* Ahmad SA
Pater J, *see* Davis AM
see El-Sayed S
see Roche K
Paterson S, *see* Powles T
Patnaik A, *see* de Bono JS
Paton V, *see* Seidman A
Patte C, Laplanche A, Bertozzi AI, Baruchel A, Frappaz D, Schmitt C, Mechinaud F, Nelken B, Boutard P, Michon J. Granulocyte Colony-Stimulating Factor in Induction Treatment of Children With Non-Hodgkin's Lymphoma: A Randomized Study of the French Society of Pediatric Oncology, 441
Patten CA, *see* Cox LS
Pattengale P, *see* Nachman JB
Paul EM, *see* Kruijtzer CMF
Paul N, *see* Roche K
Pauli G, *see* Iamandi C
Paulino AC. Induction Chemotherapy and Involved-Field Radiotherapy for Intracranial Germinoma, 2911
Paulus U, *see* Sieber M
Pautier P, *see* Gutierrez M
Pavlakis N, *see* Marx GM
Payne N, *see* Bass AJ
Payne S, *see* Smith IC
Pazdur R, *see* Schilsky RL
see Schwartsmann G
Peabody EM, *see* Green DM
Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, MacLean G, Souhami L, Stuart G, Tu D. Phase III Trial Comparing Radical Radiotherapy With and Without Cisplatin Chemotherapy in Patients With Advanced Squamous Cell Cancer of the Cervix, 966
Pearlman J, *see* Kleinberg L
Pearson ADJ, *see* Lashford LS
Pearson ML, Ganz PA, McGuigan K, Malin JR, Adams J,

Kahn KL. The Case Identification Challenge in Measuring Quality of Cancer Care, 4353
Pecora A, *see* Berry DA
Pecora AL, Rizvi N, Cohen GL, Meropol NJ, Sterman D, Marshall JL, Goldberg S, Gross P, O'Neil JD, Groene WS, Roberts MS, Rabin H, Bamat MK, Lorence RM. Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers, 2251
Pegg AE, *see* Quinn JA
Peggs KS, Mackinnon S, Yong K. Reduced Intensity Conditioning and Allogeneic Stem-Cell Transplantation: Determining Its Role in Multiple Myeloma (correspondence), 4268
Pegram CN, *see* Reardon DA
Peltomäki P, *see* Percesepe A
Pendyala L, *see* Khushalani NI
Penn Cancer Center Clinical Trials Group, *see* Machtay M
Pensabene M, *see* Perrone F
Pentz RD, Flamm AL, Sugarman J, Cohen MZ, Ayers GD, Herbst RS, Abbruzzese JL. Study of the Media's Potential Influence on Prospective Research Participants' Understanding of and Motivations for Participation in a High-Profile Phase I Trial, 3785
Pény J, *see* Joly F
Penz M, *see* Jäger G
Penza SL, *see* Levine JE
Percesepe A, Ponz de Leon M, Peltomäki P. In Reply (correspondence), 1706
Perel Y, Auvrignon A, Leblanc T, Vannier J-P, Michel G, Nelken B, Gandemer V, Schmitt C, Lamagnere J-P, De Lumley L, Bader-Meunier B, Couillaud G, Schaison G, Landman-Parker J, Thuret I, Dalle J-H, Baruchel A, Leverger G for the Group LAME of the French Society of Pediatric Hematology and Immunology. Impact of Addition of Maintenance Therapy to Intensive Induction and Consolidation Chemotherapy for Childhood Acute Myeloblastic Leukemia: Results of a Prospective Randomized Trial, LAME 89/91, 2774
Perez EA, *see* Loprinzi CL
Perez EA. In Reply (correspondence), 4405
Pergantas N, *see* Stathopoulos GP
Perilongo G, *see* Czauderna P
Perkins G, *see* Buchholz TA
Perkins P, *see* Schwartz GK
Perkins SL, *see* Lones MA
Perlman RM, *see* Liptay MJ
Perna A, *see* Oliva EN
Perotti J, *see* Winer EP
Perpoint B, *see* Curé H
Perraki M, *see* Stathopoulou A
Perrone F, De Maio E, Maione P, Di Maio M, Ottaiano A, Pensabene M, Di Lorenzo G, Lombardi AV, Gallo C. Survey of Modalities of Toxicity Assessment and Reporting in Noncomparative Prospective Studies of Chemotherapy in Breast Cancer, 52
Perry MC, *see* Berry DA
see Vokes EE
Peshkin BN, *see* Berry DA
see Schwartz MD
Pestalozzi BC, *see* Borner MM
Pestalozzi BC. Looking at the Dying Patient: The Ferdinand Hodler Paintings of Valentine Godé-Darel, 1948
Pestalozzi BC. Oxaliplatin: Bimonthly, Biweekly, or Semimonthly? (correspondence), 2758
Peterman A, *see* Socinski MA
Peters A, *see* Laack E
Peters GJ, *see* Kuenen BC
Peters L, *see* Rischin D
Peters LJ, *see* Rischin D
Peters MEWJ, *see* de Jonge MJA
Petersen GM, *see* Lindor NM
Petersen JH, *see* Petersen PM
Petersen PM, Giwercman A, Daugaard G, Rørth M, Petersen JH, Skakkebæk NE, Hansen SW, von der Maase H. Effect of Graded Testicular Doses of Radiotherapy in Patients Treated for Carcinoma-In-Situ in the Testis, 1537
Peterson BL, *see* Morrison VA
see Silverman LR
Peterson N, *see* Wang XS
Peterson P, *see* Groves MD
Peterson S, *see* Green DM
Petit J, *see* Bessell EM
Petros W, *see* Rizvi NA
Petros WP, *see* Rizzieri DA
Petrylak D, *see* Small EJ
Pettengell R, *see* Branson K
Pezet D, *see* Curé H
see Etienne M-C
Pezzella G, *see* Vici P
Pfab R, *see* Kaiser U
Pfanner E, *see* Falcone A
Pfister DG, *see* Chlebowski RT
see Osman I
see Wong RJ
Pfistner B, *see* Sieber M
Pfreundschuh M, *see* Kaiser U
see Sieber M
see Trümper L
Phan A, *see* Sarris AH
Phan S, *see* Mehta MP
Phillips E, *see* Eder JP Jr
Phillips P, *see* Kleinberg L
Piantelli M, Iacobelli S, Almadori G, Iezzi M, Tinari N, Natoli C, Cadoni G, Lauriola L, Ranelletti FO. Lack of Expression of Galectin-3 Is Associated With a Poor Outcome in Node-Negative Patients With Laryngeal Squamous-Cell Carcinoma, 3850
Pica A, *see* Stupp R
Piccart MJ, *see* Biganzoli L
Picci P, *see* Fagioli F
Pien CS, *see* Orlowski RZ

Piepkorn M, *see* Disis ML
Pierotti MA, *see* Daidone MG
Pierri MK, *see* Seidman A
see Seidman AD
Pietsch T, *see* Timmermann B
Piga A, *see* Porfiri E
see Scartozzi M
Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Áfra D, Cornu P, Bolla M, Vecht C, Karim ABMF. Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma, 2076
Pigneux A, *see* Mahon FX
Pike MC, *see* Ursin G
Pilla L, *see* Belli F
Pilz T, *see* Ferrari A
Pinedo HM, *see* Kuenen BC
Pintilie M, *see* Fyles A
see Vallis KA
Pippen J, *see* Osborne CK
Piris A, *see* Belli F
Pisanksy TM, *see* Fisher B
Pisansky TM, *see* Minsky BD
Pisconti S, *see* Vici P
Pisters LL, *see* Izawa JI
Pisters PWT, *see* Ahmad SA
Pisters PWT, Wolff RA, Janjan NA, Cleary KR, Charnsangavej C, Crane CN, Lenzi R, Vauthey JN, Lee JE, Abbruzzese JL, Evans DB. Preoperative Paclitaxel and Concurrent Rapid-Fractionation Radiation for Resectable Pancreatic Adenocarcinoma: Toxicities, Histologic Response Rates, and Event-Free Outcome, 2537
Pitot HC, *see* Adjei AA
Pitterle DM, *see* Bepler G
Piura B, *see* Chetrit A
Piva L, *see* Ferrari A
Pizzichetta MA, Canzonieri V, Gatti A, de Giacomi C, Trevisan G, Veronesi A, Soyer HP. Skin Lesions in Melanoma and Kaposi's Sarcoma; Case 2. Dermoscopic Features of Metastases From Cutaneous Melanoma Mimicking Benign Nevi and Primary Melanoma, 1412
Pizzolato G, *see* Stupp R
Pizzolo G, *see* Rassidakis GZ
Plager C, *see* Eton O
Planting AST, *see* de Jonge MJA
Plaschkes J, *see* Czauderna P
see Katzenstein HM
Platt LD, *see* Liede A
Platzer E, *see* Viens P
Pluda J, *see* Herbst RS
see Quinn JA
Pluda JM, *see* Cianfrocca M
Plummer R, *see* Hughes A
Plunkett TA, Ellis PA. CEACAM1: A Marker With a Difference or More of the Same? (editorial), 4273
Plunkett W, *see* Crews KR
see Gandhi V
Pohlman BL, *see* Witzig TE
Polastri D, *see* Spreafico F
Pollack IF, *see* Jennings MT
Pollock RE, *see* Ahmad SA
Polyp Prevention Trial Study Group, *see* Shike M
Pont J, *see* Bokemeyer C
Ponz de Leon M, *see* Percesepe A
Pool GE, *see* Smith TJ
Poon MA, *see* Sloan JA
Poon RT-P, Ng IO-L, Lau C, Yu W-C, Yang Z-F, Fan S-T, Wong J. Tumor Microvessel Density as a Predictor of Recurrence After Resection of Hepatocellular Carcinoma: A Prospective Study, 1775
Poor C, *see* Howard OM
Popiela T, *see* Carmichael J
Poplin EA, *see* Rothenberg ML
Porchet F, *see* Stupp R
Porfiri E, *see* Scartozzi M
Porfiri E, Scartozzi M, Piga A, Cellerino R. In Reply (correspondence), 3178
Portenoy RK, *see* Indelicato RA
Portenoy RK, Indelicato RA. In Reply to Daniell and Watanabe et al (correspondence), 2409
Porter DL, *see* Levine JE
Possinger K, *see* Kaiser R
see Sezer O
Postmus PE, *see* Ardizzoni A
see Codrington H
see Kunst PWA
Postmus PE, Sutedja T. In Reply (correspondence), 4269
Potosky AL, *see* Warren JL
Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age, Sex, and Racial Differences in the Use of Standard Adjuvant Therapy for Colorectal Cancer, 1192
Potter DM, *see* Ramanathan RK
Potti A, *see* Laroia ST
see Moazzam N
Pouillard P, *see* Viens P
Pounder RE, *see* Brett BT
Powell BL, *see* Kornblith AB
see Silverman LR
Powles R, *see* Rocha V
Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Männistö E, Suovuori A, Atula S, Nevalainen J, Pylkkänen L. Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast Cancer, 3219
Powles TJ, *see* Winer EP
Poyner R, *see* Seymour LW
Poynor EA, *see* Dizon DS
Pozdol C, *see* Liptay MJ
Pratt C, *see* Athale UH
see Furman WL
Pratt CB, *see* Spunt SL

Prentice HG, *see* Mortuza FY
Press M, *see* Vogel CL
Press MF, Bernstein L, Flonn K, Slamon D. In Reply (correspondence), 4607
Press MF, Slamon DJ, Flom KJ, Park J, Zhou J-Y, Bernstein L. Evaluation of HER-2/*neu* Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens, 3095
Price A, *see* Camidge R
Price DK, *see* Bennett CL
Price T, *see* Ross P
Price T, Karapetis C. Chronomodulated Chemotherapy in Advanced Colorectal Carcinoma (correspondence), 3937
Prieto JM, Blanch J, Atala J, Carreras E, Rovira M, Cirera E, Gastó C. Psychiatric Morbidity and Impact on Hospital Length of Stay Among Hematologic Cancer Patients Receiving Stem-Cell Transplantation, 1907
Prieto VG, *see* Ballo MT
see Ellerhorst JA
Prior JC, *see* Van Patten CL
Pritchard J, *see* Czauderna P
see Owens CM
Pritchard KI, *see* Goodwin PH
see Winer EP
Pritchard KI. Adjuvant Therapy for Premenopausal Women With Breast Cancer: Is It Time for Another Paradigm Shift? (editorial), 4611
Proper J, *see* Eder JP Jr
Prosnitz LR. Reducing Treatment-Related Morbidity and Mortality in Early-Stage Hodgkin's Disease and Why the Recent Southwest Oncology Group Trial Is Not the Way to Go (editorial), 2225
Proulx G, *see* Khushalani NI
Provenzale JM, *see* Quinn JA
see Reardon DA
Pruss DR, *see* Frank TS
Pruthi S, *see* Loprinzi CL
Puccio C, *see* Mikulski SM
Puchalski TA, *see* Eder JP Jr
Puduvalli VK, *see* Groves MD
see Herbst RS
Pui C-H, *see* Crews KR
see Leung W
see Rubnitz JE
Pukkala E, *see* Dores GM
Pulakhandam U, *see* Narasimhan P
Pundaleeka S, *see* Jatoi A
Pungolino E, *see* Cesana C
Punt C, *see* van Kesteren Ch
Punt CJA, *see* de Jonge MJA
Pusztai L, *see* Esteva FJ
Pylkkänen L, *see* Powles T

Q

Quagliuolo V, *see* Bertuzzi A
Qualman SJ, *see* Baker KS
see Sorensen PHB
Quang LM, *see* Love RR
Quehenberger F, *see* Jäger G
Queirolo P, *see* Belli F
Quella SK, *see* Loprinzi CL
Quesnel B, *see* Gisselbrecht C
Quijano E, *see* Kuball J
Quinn CJ, *see* Hwu W-J
Quinn DI, *see* Graefen M
Quinn JA, *see* Reardon DA
Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon JE II, Bigner DD, Friedman HS. Phase II Trial of Carmustine Plus O^6-Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant Glioma, 2277
Quinn JJ, *see* Katzenstein HM
Quinn M, *see* Grem JL
Quinn MG, *see* Wilson RH
Quintó L, *see* Mellado B
Quirke P, *see* Nagtegaal ID
Quoix E, *see* Depierre A
see Iamandi C
Quy TT, *see* Love RR

R

Raanani P, Goldman JM, Ben-Bassat I. Challenges in Oncology; Case 3. Depigmentation in a Chronic Myeloid Leukemia Patient Treated With STI-571, 869
Rabbani F, *see* Cagiannos I
see Dalbagnni G
Rabbani F, Herr HW, Almahmeed T, Russo P. Temporal Change in Risk of Metachronous Contralateral Renal Cell Carcinoma: Influence of Tumor Characteristics and Demographic Factors, 2370
Rabbani M, *see* Laroia ST
Rabin H, *see* Pecora AL
Rademaker AW, *see* Kletzel M
Rader JS, *see* Bloss JD
Raderer M, *see* Jäger G
see Scheithauer W
Radford JA, Rohatiner AZS, Ryder WDJ, Deakin DP, Barbui T, Lucie NP, Rossi A, Dunlop DJ, Cowan RA, Wilkinson PM, Gupta RK, James RD, Shamash J, Chang J, Crowther D, Lister TA. ChlVPP/EVA Hybrid Versus the Weekly VAPEC-B Regimen for Previously Untreated Hodgkin's Disease, 2988
Radice P, *see* Daidone MG

Radstone D, *see* Carmichael J
Raffin L, *see* Toffoli G
Ragnhammar P, *see* Edler D
Rago R, *see* Small EJ
Rai K, *see* Keating MJ
Rai KR, *see* Morrison VA
Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Santábarbara P, Wacker B, Brettman L. Alemtuzumab in Previously Treated Chronic Lymphocytic Leukemia Patients Who Also Had Received Fludarabine, 3891
Raimondi SC, *see* Crews KR
see Rubnitz JE
Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE. Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma, 4319
Rajq V, China C, Masaki KH, Nakano G. Unusual Presentations of Uncommon Tumors; Case 1. Benign Metastasizing Pleomorphic Adenoma, 2400
Rakowski W, *see* Silliman RA
Ramanathan RK, Potter DM, Belani CP, Jacobs SA, Gravenstein S, Lim F, Kim H, Savona S, Evans T, Buchbarker D, Simon MB, Depee JK, Trump DL. Randomized Trial of Influenza Vaccine With Granulocyte-Macrophage Colony-Stimulating Factor or Placebo in Cancer Patients, 4313
Ramaswamy S, Golub TR. DNA Microarrays in Clinical Oncology, 1932
Ramella S, *see* Trodella L
Rämö JO, *see* Auvinen MI
Ranelletti FO, *see* Ferrandina G
see Piantelli M
Raney RB, *see* Baker KS
Rannikko S, *see* Mäkinen T
Ranson M, *see* Baselga J
Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PL, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky EK. ZD1839, a Selective Oral Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial, 2240
Rao BN, *see* Spunt SL
Rao UNM, Ibrahim J, Flaherty LE, Richards J, Kirkwood JM. Implications of Microscopic Satellites of the Primary and Extracapsular Lymph Node Spread in Patients With High-Risk Melanoma: Pathologic Corollary of Eastern Cooperative Oncology Group Trial E1690, 2053
Rapoport B, *see* Littlewood TJ
Rarick MU, *see* Rizzo JD
Rashid A, *see* Herbst RS
see Vauthey J-N
Rasnke M, *see* Garrison MA
Raspagliesi F, *see* Benedetti-Panici P
Rassidakis GZ, *see* Sarris AH
Rassidakis GZ, Medeiros LJ, Viviani S, Bonfante V, Nadali G-P, Vassilakopoulos TP, Mesina O, Herling M, Angelopoulou MK, Giardini R, Chilosi M, Kittas C, McLaughlin P, Rodriguez MA, Romaguera J, Bonadonna G, Gianni AM, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH. CD20 Expression in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin's Disease: Associations With Presenting Features and Clinical Outcome, 1278
Ratain M, *see* Karrison T
see Rosner GL
see Schellens JHM
see Schilsky RL
see Schwartsmann G
see Small EJ
Ratain MJ. Dear Doctor: We Really Are Not Sure What Dose of Capecitabine You Should Prescribe for Your Patient (editorial), 1434
Ratain MJ. Irinotecan Dosing: Does the CPT in CPT-11 Stand for "Can't Predict Toxicity"? (editorial), 7
Ratner L, *see* Cianfrocca M
Rattner B, *see* Eder JP Jr
Rauch PK, Muriel AC, Cassem NH. Parents With Cancer: Who's Looking After the Children?, 4399
Rauck RL, *see* Smith TJ
Ravaioli A, *see* Tassinari D
Ravaioli A, Marangolo M, Pasquini E, Rossi A, Amadori D, Cruciani G, Tassinari D, Oliverio G, Giovanis P, Turci D, Zumaglini F, Nicolini M, Panzini I. Bolus Fluorouracil and Leucovorin With Oxaliplatin as First-Line Treatment in Metastatic Colorectal Cancer, 2545
Ravic M, *see* Raymond E
see van Kesteren Ch
Raymond E, *see* Baselga J
see van Kesteren Ch
Raymond E, Boige V, Faivre S, Sanderink G-J, Rixe O, Vernillet L, Jacques C, Gatineau M, Ducreux M, Armand JP. Dosage Adjustment and Pharmacokinetic Profile of Irinotecan in Cancer Patients With Hepatic Dysfunction, 4303
Raymond E, ten Bokkel Huinink WW, Taäieb J, Beijnen JH, Faivre S, Wanders J, Ravic M, Fumoleau P, Armand JP, Schellens JHM. Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl Sulfonamide Cell-Cycle Inhibitor, Administered as a One-Hour Infusion Every Three Weeks in Patients With Advanced Cancer, 3508
Rayson D. Sweet Time Unafflicted, 4603
Rayter Z, *see* Harper-Wynne CL
Razook C, *see* Nieto Y
Razzouk BI, *see* Crews KR
see Rubnitz JE
Re D, *see* Weihrauch MR
Read N, *see* El-Sayed S
Reardon D, *see* Gururangan S

Reardon D, Bigner DD. Reply 2 (correspondence), 3181
Reardon DA, *see* Quinn JA
Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE II, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao X-G, Zalutsky MR, Bigner DD. Phase II Trial of Murine ^{131}I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas, 1389
Rebbeck TR, *see* Shih HA
Recht A, *see* Singletary SE
see Vicini FA
Reddy CA, *see* Kupelian PA
see Thomas J
Reddy P, Kalemkerian GP. Unusual Presentations of Lung Cancer: Case 1. Diabetes Insipidus as the Initial Manifestation of Non-Small-Cell Lung Cancer, 4597
Redman BG, *see* Sondak VK
Redston M, *see* Lindor NM
Reese T, *see* Dunst J
Regalado LV, *see* Reardon DA
Regan DH, *see* Rizzo JD
Regan K, *see* Smaletz O
Regimbeau J-M, *see* Vauthey J-N
Regli L, *see* Stupp R
Reguart N, *see* Mellado B
Reid GC, *see* Muggia FM
Reid JE, *see* Frank TS
Reid JM, *see* Adjei AA
Reiffers J, *see* Mahon FX
see Rocha V
Reinhard J-O, *see* Trümper L
Reinhardt M-K, *see* Dudeney S
Reiser M, *see* Kaiser U
Reiter RJ, *see* Vijayalaxmi
Reith A, *see* Sudbø J
Reman O, *see* Fermé C
Remzi M, *see* Djavan B
Renée N, *see* Etienne M-C
Renschler MF, *see* Mehta MP
Renshaw AA, *see* Cross CK
see D'Amico AV
Repetto L, Fratino L, Audisio RA, Venturino A, Gianni W, Vercelli M, Parodi S, Dal Lago D, Gioia F, Monfardini S, Aapro MS, Serraino D, Zagonel V. Comprehensive Geriatric Assessment Adds Information to Eastern Cooperative Oncology Group Performance Status in Elderly Cancer Patients: An Italian Group for Geriatric Oncology Study, 494
Reppa D, *see* Stathopoulou A
Resegotti L, *see* Federico M
Restifo NP, *see* Toso JF
Reuter V, *see* Motzer RJ
see Vuky J
Revzin M, *see* Barakat RR
Reyes A, *see* Papandreou CN
Reyes F, *see* Gisselbrecht C
Reynolds M, *see* Katzenstein HM
see Kletzel M
Reynolds R. Comparative Efficacy of Dronabinol and Megestrol Acetate (correspondence), 2912
Ribaud P, *see* Bergeron A
Ribeiro RC, *see* Crews KR
see Rubnitz JE
Ribrag V, *see* Aloulou S
Riccardi R, *see* Massimino M
Ricci S, *see* Scagliotti GV
Rich JN, *see* Quinn JA
see Reardon DA
Richards J, *see* Rao UNM
Richards P, *see* Greco FA
Richie JP, *see* Cross CK
Rick O, *see* Kollmannsberger C
Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, Lo Re G, Nortilli R, Brugnara S, Vitali P, Nanni O. Cisplatin, Dacarbazine With or Without Subcutaneous Interleukin-2, and Interferon Alfa-2b in Advanced Melanoma Outpatients: Results From an Italian Multicenter Phase III Randomized Clinical Trial, 1600
Ridolfi R, Nanni O. In Reply (correspondence), 3560
Riedel E, *see* Shike M
Ries C, *see* Linker C
Riess H, *see* Meyer L
Rietveld T, *see* Agteresch HJ
Rifas-Shiman S, *see* Schrag D
Riftin R, *see* Vose JM
Rigatos SK, *see* Stathopoulos GP
Rihn BH, *see* Mohr S
Riley GF, *see* Warren JL
Rinaldi M, *see* Scagliotti GV
Rinehart J, *see* DiPaola RS
Ring SE, *see* Eton O
Ringdén O, *see* Rocha V
Ringdén O, Labopin M, Bacigalupo A, Arcese W, Schaefer UW, Willemze R, Koc H, Bunjes D, Gluckman E, Rocha V, Schattenberg A, Frassoni F. Transplantation of Peripheral Blood Stem Cells as Compared With Bone Marrow From HLA-Identical Siblings in Adult Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia, 4655
Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ. Allogeneic Stem-Cell Transplantation of Renal Cell Cancer After Nonmyeloablative Chemotherapy: Feasibility, Engraftment, and Clinical Results, 2017
Rinn K, *see* Disis ML
Ripamonti C, Sweeney C, Bruera E. Use of Trade Names of Drugs and the Scientific Content of Medical Congresses (correspondence), 1707

Risberg B, *see* Sudbø J
Rischin D, *see* Albanell J
see Baselga J
Rischin D, Corry J, Smith J, Stewart J, Hughes P, Peters L. Excellent Disease Control and Survival in Patients With Advanced Nasopharyngeal Cancer Treated With Chemoradiation, 1845
Rischin D, Peters LJ. The Local-Regionally Advanced Nasopharyngeal Carcinoma Jigsaw Puzzle: Where Does the Chemotherapy Piece Fit? (editorial), 1968
Risse E, *see* Codrington H
see Kunst PWA
Risse J, *see* Spieth K
Ristow KM, *see* Ansell SM
Riva D, *see* Massimino M
Rivera E, Sutton L, Colwell B, Graham M, Frye D, Somerville M, Conklin HS, McGuirt C, Levin J, Hortobagyi GN. Multicenter Phase II Study of a 28-Day Regimen of Orally Administered Eniluracil and Fluorouracil in the Treatment of Patients With Anthracycline- and Taxane-Resistant Advanced Breast Cancer, 987
Rivoltini L, *see* Belli F
Rixe O, *see* Khayat D
see Marx GM
see Raymond E
Rizvi N, *see* Pecora AL
Rizvi NA, Marshall JL, Ness E, Hawkins MJ, Kessler C, Jacobs H, Brenckman WD Jr, Lee JS, Petros W, Hong WK, Kurie JM. Initial Clinical Trial of Oral TAC-101, a Novel Retinoic Acid Receptor-Alpha Selective Retinoid, in Patients With Advanced Cancer, 3522
Rizzieri DA, *see* Bass AJ
Rizzieri DA, Bass AJ, Rosner GL, Gockerman JP, DeCastro CM, Petros WP, Adams DJ, Laughlin MJ, Davis P, Foster T, Jacobson R, Hurwitz H, Moore JO. Phase I Evaluation of Prolonged-Infusion Gemcitabine With Mitoxantrone for Relapsed of Refractory Acute Leukemia, 674
Rizzo JD, *see* Loberiza FR Jr
Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS. Use of Epoetin in Patients With Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of Hematology, 4083
Roa WH, *see* Mehta MP
Roach J, *see* Herbst RS
Roanh LD, *see* Love RR
Robbins KT, *see* Mendenhall WM
Robert J, *see* Maunsell E
Robert N, *see* Loesch D
Roberts MS, *see* Pecora AL
Robertson C, *see* De Pas T
Robertson J, *see* Bonneterre J
Robertson JFR, *see* Howell A
Robison LL, *see* Bhatia S
see Emmons K
see Nagarajan R
Robson K, *see* Lashford LS
Robson M, *see* Scheuer L
Robson ME, *see* Scheuer L
Rocha V, *see* Ringdén O
Rocha V, Labopin M, Gluckman E, Powles R, Arcese W, Bacigalupo A, Reiffers J, Iriondo A, Ringdén O, Ruutu T, Frassoni F. Relevance of Bone Marrow Cell Dose on Allogeneic Transplantation Outcomes for Patients With Acute Myeloid Leukemia in First Complete Remission: Results of a European Survey, 4324
Roché H, *see* van Kesteren Ch
Roche K, Paul N, Smuck B, Whitehead M, Zee B, Pater J, Hiatt M-A, Walker H. Factors Affecting Workload of Cancer Clinical Trials: Results of a Multicenter Study of the National Cancer Institute of Canada Clinical Trials Group, 545
Rock CL, Demark-Wahnefried W. Nutrition and Survival After the Diagnosis of Breast Cancer: A Review of the Evidence, 3302
Rockwood TH, *see* Bhatia S
Rödel C, Grabenbauer GG, Kühn R, Papadopoulos T, Dunst J, Meyer M, Schrott KM, Sauer R. Combined-Modality Treatment and Selective Organ Preservation in Invasive Bladder Cancer: Long-Term Results, 3061
Rodenhuis S, *see* de Gast GC
Rodier J-M, *see* Depierre A
Rodrigues GB, *see* Brierley JD
Rodriguez MA, *see* Rassidakis GZ
Rodriguez-Bigas MA. Pathologic Evaluation of Total Mesorectal Excision: Big Brother is Watching (editorial), 1714
Rodriguez-Hanley A, *see* Stanton AL
Rogers T, *see* Carducci MA
Rogers TE, *see* Dean A
Rohatiner AZS, *see* Radford JA
Rojo F, *see* Albanell J
see Baselga J
see Herbst RS
Romaguera J, *see* Rassidakis GZ
see Sarris AH
Romanini A, *see* Ridolfi R
Romeike BFM, *see* Samnick S
Rönnholm R, *see* Auvinen MI
Roodman GD. In Reply (correspondence), 354
Roots I, *see* Kaiser R
Rørth M, *see* Petersen PM
Rosati S, *see* Scartozzi M
Rose CM, *see* Burkhardt JH
Rose PG, Bundy BN. Chemoradiation for Locally Advanced Cervical Cancer: Does It Help? (editorial), 891

Rose SR, *see* Leung W
Rosen L, *see* Kuenen BC
Rosenberg R, Hoos A, Mueller J, Baier P, Stricker D, Werner M, Nekarda H, Siewart J-R. Prognostic Significance of Cytokeratin-20 Reverse Transcriptase Polymerase Chain Reaction in Lymph Nodes of Node-Negative Colorectal Cancer Patients, 1049
Rosenberg SA, *see* Horning SJ
see Toso JF
Rosenqvist K, *see* Powles T
Rosenthal DI, *see* Machtay M
Rosenthal P, *see* Hoecht S
Rosenthal SA, *see* Minsky BD
Rosing H, *see* Kruijtzer CMF
Rosner G, *see* Small EJ
Rosner GL, *see* Bass AJ
see Rizzieri DA
Rosner GL, Stadler W, Ratain MJ. Randomized Discontinuation Design: Application to Cytostatic Antineoplastic Agents, 4478
Ross MI, *see* Ballo MT
Ross MK, *see* Kirkwood JM
Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A. Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer, 1996
Ross PJ, Cunningham D. In Reply (correspondence), 4125
Ross RK, *see* Ursin G
Rossi A, *see* Radford JA
see Ravaioli A
Rossi R, *see* Cantù MG
Rosty C, *see* Etienne M-C
Roth AD, *see* Borner MM
Rothenberg ML, *see* Alberts DS
see Herbst RS
Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. In Reply (correspondence), 1145
Rothmann F, *see* Kaiser U
Rougier P, *see* Louvet C
see Nordlinger B
Rousselot Ph, *see* Bergeron A
Rouzier R, Extra J-M, Klijanienko J, Falcou M-C, Asselain B, Vincent-Salomon A, Vielh P, Bourstyn E. Incidence and Prognostic Significance of Complete Axillary Downstaging After Primary Chemotherapy in Breast Cancer Patients With T1 to T3 Tumors and Cytologically Proven Axillary Metastatic Lymph Nodes, 1304
Rovira M, *see* Prieto JM
Rowe JM, *see* Dann EJ
Rowinsky EK, *see* de Bono JS
see Ranson M
see Tolcher AW
Rowland JH, *see* Hewitt M
see Liang W
Rowlings P, *see* Berry DA
Rozans M, Dreisbach A, Lertora JJL, Kahn MJ. Palliative Uses of Methylphenidate in Patients With Mantle-Cell Lymphoma, 335
Rubin BP, *see* Singer S
Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, Bruckner JD. Molecular Targeting of Platelet-Derived Growth Factor B by Imatinib Mesylate in a Patient With Metastatic Dermatofibrosarcoma Protuberans, 3586
Rubin E, *see* DiPaola RS
Rubin EH, *see* Herbst RS
Rubin J, *see* Adjei AA
Rubin S, *see* Shepherd FA
Rubinger M, *see* Klasa RJ
Rubinstein W, *see* Berry DA
Rubinstein WS, *see* Berry DA
Rubnitz JE, *see* Crews KR
Rubnitz JE, Raimondi SC, Tong X, Srivastava DK, Razzouk BI, Shurtleff SA, Downing JR, Pui C-H, Ribeiro RC, Behm FG. Favorable Impact of the t(9;11) in Childhood Acute Myeloid Leukemia, 2302
Ruckdeschel JC, *see* Jacobsen PB
see Kilbridge KL
Rudek MA, *see* Cianfrocca M
Rudofsky G, *see* Kröger K
Rudolph C, *see* Josting A
Rueffer U, *see* Sieber M
Ruers TJM, *see* Langenhoff BS
Ruers TJM, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, Corstens FHM, Oyen WJG. Value of Positron Emission Tomography With [F-18]Fluorodeoxyglucose in Patients With Colorectal Liver Metastases: A Prospective Study
Ruggiero A, *see* Massimino M
Ruijter R, *see* Kuenen BC
Rummans TA, *see* Loprinzi CL
Runowiez CD, *see* Wickerham DL
Ruohtula T, *see* Auvinen MI
Rusch VW, *see* Martin J
Russell N, *see* Bruera E
Russo P, *see* Dalbagni G
see Motzer RJ
see Rabbani F
Rusthoven J, *see* Hughes A
Rustin GJS, *see* Galbraith SM
see McNeish IA
Ruutu T, *see* Rocha V
Ruymann FB, *see* Baker KS
Ryan DP, *see* Eder JP Jr
Ryder WDJ, *see* Radford JA
Ryken TC, *see* Buatti JM

S

Sabbatini P, *see* Barakat RR
see Dizon DS
see Hensley ML
Sackmann M, *see* Trümper L
Sacks NPM, *see* Harper-Wynne CL
Sadura A, *see* Davis AM
see Shepherd FA
Sagebiel RW, *see* Kashani-Sabet M
Saghatchian M, *see* Culine S
Saglam S, Yetis B, Ozyilkan O, Akçali Z. Cost-Effectiveness of Chemotherapy in Non-Small-Cell Lung Cancer (correspondence), 3750
Said JW, *see* Zisman A
Saijo N, *see* Schwartsmann G
see Sekine I
see Takada M
Saito M, *see* Sekine I
Sakalová A, *see* Menssen HD
Sako M, *see* Imashuku S
Salas J, *see* Buchholz TA
Saleh MN, *see* Witzig TE
Saletti P, *see* Borner MM
Sallan SE, *see* LeClerc JM
see Lipshultz SE
Salles G, *see* Fermé C
Salminen JT, *see* Auvinen MI
Salo JA, *see* Auvinen MI
Salter J, *see* Harper-Wynne CL
Saltz L, *see* Schrag D
see Schwartz GK
Saltz LB, *see* Hoen KD
see Timoney JP
Salzer-Kuntschik M, *see* Bielack SS
Samantas E, *see* Bafaloukos D
see Kosmidis P
Samnick S, Bader JB, Hellwig D, Moringlane JR, Alexander C, Romeike BFM, Feiden W, Kirsch C-M. Clinical Value of Iodine-123-Alpha-Methyl-L-Tyrosine Single-Photon Emission Tomography in the Differential Diagnosis of Recurrent Brain Tumor in Patients Pretreated for Glioma at Follow-Up, 396
Samonigg H, *see* Jakesz R
Samonis G, *see* Souglakos J
Samosh M, *see* Klasa RJ
Samowitz WS, Slattery ML. Missense Mismatch Repair Gene Alterations, Microsatellite Instability, and Hereditary Nonpolyposis Colorectal Cancer (correspondence), 3178
Sampson JH, *see* Quinn JA
see Reardon DA
Samson Y, *see* Lipshultz SE
Samuels B, *see* Sarris AH
Sancar D, *see* Hoecht S
Sánchez-Pernaute A, *see* González-Quevedo R
Sanda MG, *see* Wei JT
Sanda MG, McLaughlin PW. In Reply (correspondence), 3038
Sanderink G-J, *see* Raymond E
Sanders J, *see* Woods WG
Sandler HM, *see* Chan JL
see Wei JT
Sandmaier B, *see* Appelbaum FR
Santábarbara P, *see* Rai KR
Santantonio C, *see* Belli F
Santini D, Tonini G, Vincenzi B, Murace R, Ferranti G, Baldi A. Skin Lesions in Melanoma and Kaposi's Sarcoma; Case 1. Detection of Circulating Malignant Cells by RT-PCR in a Case of Cutaneous Melanoma in Complete Regression, 1411
Santoro A, *see* Bertuzzi A
Sappino AP, *see* Bouchardy C
Sargent DJ, *see* Allegra CJ
see Goldberg RM
see Hobday TJ
see Lindor NM
see Sloan JA
Sarkar TK, *see* Smith IC
Sarna L, Padilla G, Holmes C, Tashkin D, Brecht ML, Evangelista L. Quality of Life of Long-Term Survivors of Non-Small-Cell Lung Cancer, 2920
Sarobba MG, *see* Berruti A
Sarokhan B, *see* Gabrilove JL
Sarris AH, *see* Rassidakis GZ
Sarris AH, Phan A, Duvic M, Romaguera J, McLaughlin P, Mesina O, King K, Medeiros LJ, Rassidakis GZ, Samuels B, Cabanillas F. Trimetrexate in Relapsed T-Cell Lymphoma With Skin Involvement, 2876
Sarris G, *see* Antonadou D
Sartor F, *see* Toffoli G
Sartor O, *see* Bennett CL
Sartori S, *see* Tassinari D
Satagopan J, *see* Scheuer L
Sateren WB, Trimble EL, Abrams J, Brawley O, Breen N, Ford L, McCabe M, Kaplan R, Smith M, Ungerleider R, Christian MC. How Sociodemographics, Presence of Oncology Specialists, and Hospital Cancer Programs Affect Accrual to Cancer Treatment Trials, 2109
Sauer R, *see* Rödel C
Sauerbrei W, *see* Jonat W
Sauleda S, *see* Albanell J
Sausville EA, *see* Tan AR
Sauven P, *see* Harper-Wynne CL
Savarese D, *see* Lima CMSR
Saville W, *see* Lima CMSR
Savin M, *see* Holmes FA
Savona S, *see* Ramanathan RK
Sawamura Y, *see* Aoyama H
Sawka CA, *see* Klasa RJ
Sawyers CL. Imatinib GIST Keeps Finding New Indications: Successful Treatment of Dermatofibrosarcoma Pro-

tuberans by Targeted Inhibition of the Platelet-Derived Growth Factor Receptor (editorial), 3568
Sayer HG, *see* Kollmannsberger C
Saykin AJ, *see* Ahles TA
Scadden DT, *see* Cianfrocca M
Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Costanzo F, Frontini L, Tonato M. Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non-Small-Cell Lung Cancer, 4285
Scambia G, *see* Ferrandina G
Scappaticci FA. Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies, 3906
Scarcella DL, *see* Gururangan S
Scardino PT, *see* Cagiannos I
see Graefen M
Scartozzi M, *see* Porfiri E
Scartozzi M, Bianchi F, Rosati S, Galizia E, Antolini A, Loretelli C, Piga A, Bearzi I, Cellerino R, Porfiri E. Mutations of *hMLH1* and *hMSH2* in Patients With Suspected Hereditary Nonpolyposis Colorectal Cancer: Correlation With Microsatellite Instability and Abnormalities of Mismatch Repair Protein Expression, 1203
Schaefer UW, *see* Ringdén O
Schafenacker A, *see* Northouse LL
Schaison G, *see* Perel Y
Schalk K-P, *see* Sieber M
Schaller G, *see* Fuchs IB
Schaller J, *see* Costa L
Schapira L. An Existential Oncologist, 2407
Schattenberg A, *see* Ringdén O
Schatzkin A, *see* Shike M
Schauenstein K, *see* Wölfler A
Scheinberg D, *see* Von Roenn JH
Scheithauer B, *see* Shaw E
Scheithauer W, *see* Gedlicka C
Scheithauer W, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Gedlicka C, Schüll B, Brugger S, Schneeweiss B, Lang F, Lenauer A, Depisch D. Randomized Multicenter Phase II Trial of Oxaliplatin Plus Irinotecan Versus Raltitrexed as First-Line Treatment in Advanced Colorectal Cancer, 165
Schelenz C, *see* Kaiser R
Schell MJ, *see* Socinski MA
Schellens JHM, *see* Crul M
see Kruijtzer CMF
see Malingré MM
see Raymond E
see van Kesteren Ch
Schellens JHM, Ratain MJ. Endostatin: Are the 2 Years Up Yet? (editorial), 3758
Scher H, *see* Osman I
Scher HI, *see* Smaletz O
Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J, Ellis N, Hensley M, Boyd J, Borgen P, Norton L, Offit K. Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in *BRCA* Mutation Carriers, 1260
Scheuer L, Kauff ND, Robson ME, Offit K. In Reply (correspondence), 3753
Scheulen ME, *see* Kruijtzer CMF
Schey S, *see* Branson K
Schiffer CA, *see* Kornblith AB
see Morrison VA
see Silverman LR
Schiffman K, *see* Disis ML
Schildberg FW, *see* Heiss MM
Schilsky RL, Bertucci D, Vogelzang NJ, Kindler HL, Ratain MJ. Dose-Escalating Study of Capecitabine Plus Gemcitabine Combination Therapy in Patients With Advanced Cancer, 582
Schilsky RL, Levin J, West WH, Wong A, Colwell B, Thirlwell MP, Ansari RH, Bell WN, White RL, Yates BB, McGuirt PV, Pazdur R. Randomized, Open-Label, Phase III Study of a 28-Day Oral Regimen of Eniluracil Plus Fluorouracil Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Therapy in Patients With Metastatic/Advanced Colorectal Cancer, 1519
Schläfke M, *see* Stein U
Schlegelberger B, *see* Viardot A
Schlenk RF, *see* Döhner K
see Fröhling S
Schlesselman JJ, *see* Sofer M
Schleucher N, *see* Kollmannsberger C
Schmalenberg H, *see* Kaiser U
Schmelz R, Lersch C. Acute Oxaliplatin-Induced Peripheral-Nerve Hyperexcitability (correspondence), 3561
Schmitt C, *see* Patte C
see Perel Y
Schmitt M, *see* Harbeck N
Schmitz N, *see* Kaiser U
Schmoldt J, *see* Kletzel M
Schmoll H-J, *see* Bokemeyer C
Schnall MD, *see* Tillman GF
Schneeweiss B, *see* Scheithauer W
Schneider KA, *see* Chen WY
Schnipper L, *see* Eder JP Jr
Schoch R, *see* Kollmannsberger C
Schöder H, *see* Wong RJ
Schöffski P, *see* Kollmannsberger C
Schold SC, *see* DeAngelis LM
Scholl C, *see* Fröhling S
Scholl T, *see* Frank TS
Schorin M, *see* LeClerc JM
Schorin MA, *see* Lipshultz SE
Schornagel JH, *see* de Gast GC
see Detmar SB
Schot M, *see* Kruijtzer CMF
Schover LR, Brey K, Lichtin A, Lipschultz LI, Jeha S.

Oncologists' Attitudes and Practices Regarding Banking Sperm Before Cancer Treatment, 1890
Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB. Adjuvant Chemotherapy Use for Medicare Beneficiaries With Stage II Colon Cancer, 3999
Schriock EA, *see* Leung W
Schröder FH, *see* Graefen M
Schrott KM, *see* Rödel C
Schuchter LM, Hensley ML, Meropol NJ, Winer EP for the American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel. 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology, 2895
Schuck A, *see* Franzius C
Schuetz E, *see* Goh B-C
Schuetze SM, *see* Rubin BP
Schuff-Werner P, *see* Steiner M
Schuler M, *see* Kuball J
Schuler U. Cautious Arguments in Favor of Body Surface Area-Based Dosing (correspondence), 4270
Schüll B, *see* Gedlicka C
see Scheithauer W
Schultz CJ, *see* DeAngelis LM
see Mehta MP
Schultz D, *see* D'Amico AV
Schultz DJ, *see* Tillman GF
Schulz JJ, *see* Cartwright TH
Schulze H-J, *see* Thies A
Schumacher K, *see* Kaiser U
Schumacher M, *see* Jonat W
Schumacher U, *see* Laack E
see Thies A
Schussler N, *see* Warren JL
Schuster MA, *see* Malin JL
Schwartsmann G, Ratain MJ, Cragg GM, Wong JE, Saijo N, Parkinson DR, Fujiwara Y, Pazdur R, Newman DJ, Dagher R, Di Leone L. Anticancer Drug Discovery and Development Throughout the World, 47s
Schwartz CL, *see* Goorin AM
Schwartz GK, O'Reilly E, Ilson D, Saltz L, Sharma S, Tong W, Maslak P, Stoltz M, Eden L, Perkins P, Endres S, Barazzoul J, Spriggs D, Kelsen D. Phase I Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination With Paclitaxel in Patients With Advanced Solid Tumors, 2157
Schwartz JL, *see* Bichakjian CK
Schwartz M, *see* DiPaola RS
Schwartz MD, Peshkin BN, Hughes C, Main D, Isaacs C, Lerman C. Impact of *BRCA1/BRCA2* Mutation Testing on Psychologic Distress in a Clinic-Based Sample, 514
Schwartzentruber DJ, *see* Toso JF
Schwarz RE, Fuller RA, Chu P. Unusual Presentations of Uncommon Tumors; Case 2. Gastric Carcinoid Metastatic to the Liver, 2403
Scigalla P, *see* Kuenen BC
Scita G, *see* Belli F
Scott SS, *see* Izawa JI
Scuderi C, *see* Spazzapan S
Scullin DC Jr, *see* Greco FA
Seabrooke LF, *see* Herbst RS
Seal S, *see* Shih HA
Seckl MJ, *see* McNeish IA
See H-J, *see* Goldhirsch A
Seiden MV, *see* Vasey PA
Seidenfeld J, *see* Rizzo JD
Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashbby M, Murphy M, Stewart SJ, Keefe D. Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience, 1215
see also Modi S
Seidman A, Pierri MK, Hudis C. In Reply (correspondence), 4119
Seidman A, *see* Modi S
see Van Poznak C
Seiferheld W, *see* DeAngelis LM
Seifert M, *see* Jakesz R
Sein J, *see* de Gast GC
Seipp C, *see* Toso JF
Seiter K, Liu D, Loughran T, Siddiqui A, Baskind P, Ahmed T. Phase I Study of Temozolomide in Relapsed/Refractory Acute Leukemia, 3249
Seitz C, *see* Djavan B
Seitz J-F, *see* Etienne M-C
Sek A, *see* Trümper L
Sekimoto M, *see* Noura S
Sekine I, Nishiwaki Y, Ogino T, Yokoyama A, Saito M, Mori K, Tsukiyama I, Tsuchiya S, Hayakawa K, Yoshimura K, Ishizuka N, Saijo N. Phase II Study of Twice-Daily High-Dose Thoracic Radiotherapy Alternating With Cisplatin and Vindesine for Unresectable Stage III Non-Small-Cell Lung Cancer: Japan Clinical Oncology Group Study 9306, 797
Selby P, *see* Stark D
Semba CP, *see* Deitcher SR
Semenza GL, *see* Bos R
Senderowicz AM, *see* Tan AR
Senn H-J, *see* Goldhirsch A
Sensel MG, *see* Katzenstein HM
Seo PH, *see* Ingram SS
Sepkowitz KA, *see* Walshe LJ
Sepucha KR, Belkora JK, Mutchnick S, Essennan LJ. Consultation Planning to Help Breast Cancer Patients Prepare for Medical Consultations: Effect on Communication and Satisfaction for Patients and Physicians, 2695
Serraino D, *see* Repetto L
Sertoli MR, *see* Belli F
Sessa C, *see* Bernhard J
Sevastianos VA, *see* Dourakis SP
Seymour, MT. Oxaliplatin: Bimonthly, Biweekly, or Semimonthly? No, Fortnightly!, 3753

Seymour L, *see* Bélanger K
see Shepherd FA
Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, Doran J, Young AM, Burtles S, Kerr DJ. Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin, 1668
Seymour M, *see* Maisey N
see Ross P
Seymour MT, *see* Scheuer L
Sezer O, *see* Kaiser R
Sezer O, Heider U, Jakob C, Eucker J, Possinger K. Human Bone Marrow Myeloma Cells Express RANKL (correspondence), 353
Shadbolt B, Barresi J, Craft P. Self-Rated Health as a Predictor of Survival Among Patients With Advanced Cancer, 2514
Shaffer K, *see* Diller L
Shafford E, *see* Czauderna P
Shafman TD, *see* Reardon DA
Shah J, *see* Osman I
Shah JP, *see* Wong RJ
Shah M, *see* Nadella P
Shaha A, *see* Osman I
Shaikh SL, *see* Lipshultz SE
Shak S, *see* Seidman A
see Vogel CL
Shamash J, *see* Oliver RTD
see Radford JA
Shapiro B, *see* Yanik GA
Shapiro V, *see* Nadella P
Shapiro WR, *see* Mehta MP
Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, Wheeler TM, Slawin KM. Association of Preoperative Plasma Levels of Insulin-Like Growth Factor I and Insulin-Like Growth Factor Binding Proteins-2 and -3 With Prostate Cancer Invasion, Progression, and Metastasis, 833
Sharma S, *see* Schwartz GK
Sharp G, *see* Vose JM
Shaw E, Arusell R, Scheithauer B, O'Fallon J, O'Neill B, Dinapoli R, Nelson D, Earle J, Jones C, Cascino T, Nichols D, Ivnik R, Hellman R, Curran W, Abrams R. Prospective Randomized Trial of Low- Versus High-Dose Radiation Therapy in Adults With Supratentorial Low-Grade Glioma: Initial Report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study, 2267
Shea TC, *see* Orlowski RZ
Sheinfeld J, *see* Dalbagni G
see Vuky J
Shek TW, *see* Au WY
Shelley W, *see* El-Sayed S
Shen T, *see* Love RR
Shen V, *see* Jennings MT
Shenkier TN, Voss N, Fairey R, Gascoyne RD, Hoskins P, Klasa R, Klimo P, O'Reilly SE, Sutcliffe S, Connors JM. Brief Chemotherapy and Involved-Region Irradiation for Limited-Stage Diffuse Large-Cell Lymphoma: An 18-Year Experience From the British Columbia Cancer Agency, 197
Shennan F, *see* Lawrence G
Shenton K, *see* Harper-Wynne CL
Shepherd FA, *see* Leighl NB
Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Sadura A, Zee B. Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Marimastat After Response to First-Line Chemotherapy in Patients With Small-Cell Lung Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer, 4434
Shepherd JH, *see* Kolomainen DF
Shepherd L, *see* Morrison VA
Sherman E, *see* Osman I
Sherry RM, *see* Toso JF
Shih HA, Couch FJ, Nathanson KL, Blackwood MA, Rebbeck TR, Armstrong KA, Calzone K, Stopfer J, Seal S, Stratton MR, Weber BL. *BRCA1* and *BRCA2* Mutation Frequency in Women Evaluated in a Breast Cancer Risk Evaluation Clinic, 994
Shike M, Latkany L, Riedel E, Fleisher M, Schatzkin A, Lanza E, Corle D, Begg CB. Lack of Effect of a Low-Fat, High-Fruit, -Vegetable, and -Fiber Diet on Serum Prostate-Specific Antigen of Men Without Prostate Cancer: Results From a Randomized Trial, 3592
Shima Y, *see* Morita T
Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK, Lippman SM. Phase II and Biologic Study of Interferon Alfa, Retinoic Acid, and Cisplatin in Advanced Squamous Skin Cancer, 364
Shipe-Spotloe J, *see* Kirkwood JM
Shipley WU, *see* Coen JJ
Shipp MA, *see* Howard OM
Shirato H, *see* Aoyama H
Shogan J, *see* Holmes FA
Shogen K, *see* Mikulski SM
Shoji T, Tanaka F, Takata T, Yanagihara K, Otake Y, Hanaoka N, Miyahara R, Nakagawa T, Kawano Y, Ishikawa S, Katakura H, Wada H. Clinical Significance of p21 Expression in Non-Small-Cell Lung Cancer, 3865
Shore RM, *see* Kletzel M
Shpall EJ, *see* Nieto Y
Shulkin BL, *see* Yanik GA
Shulman LN, *see* Eder JP Jr
see Vasey PA
Shultz D, *see* Cross CK
Shurtleff SA, *see* Rubnitz JE

Shustik C, *see* Klasa RJ
Siddiqui A, *see* Seiter K
Siddiqui N, *see* Vasey PA
Siderov J. Pharmacokinetics of Irinotecan and Its Metabolites (correspondence), 4609
Sidor C, *see* Eder JP Jr
Sidranksy D, *see* Cheng H-L
Sieber M, Tesch H, Pfistner B, Rueffer U, Lathan B, Brosteanu O, Paulus U, Koch T, Pfreundschuh M, Loeffler M, Engert A, Josting A, Wolf J, Hasenclever D, Franklin J, Duehmke E, Georgii A, Schalk K-P, Kirchner H, Doelken G, Munker R, Koch P, Herrmann R, Greil R, Anselmo AP, Diehl V. Rapidly Alternating COPP/ABV/IMEP Is Not Superior to Conventional Alternating COPP/ABVD in Combination With Extended-Field Radiotherapy in Intermediate-Stage Hodgkin's Lymphoma: Final Results of the German Hodgkin's Lymphoma Study Group Trial HD5, 476
Siebert R, *see* Viardot A
Siedek M, *see* Weihrauch MR
Siefker-Radtke AO, Millikan RE, Tu S-M, Moore DF Jr, Smith TL, Williams D, Logothetis CJ. Phase III Trial of Fluorouracil, Interferon Alfa-2b, and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Metastatic or Unresectable Urothelial Cancer, 1361
Siegal GP, *see* Goorin AM
Siegel E, *see* Badros A
Siewart J-R, *see* Rosenberg R
Sigurdson ER, *see* Kemeny MM
Sihvo EIT, *see* Auvinen MI
Siivola P, *see* Auvinen MI
Silberfarb PM, *see* Ahles TA
Sillar RW, *see* Hersey P
Silliman RA, *see* Liang W
Silliman RA, Guadagnoli E, Rakowski W, Landrum MB, Lash TL, Wolf R, Fink A, Ganz PA, Gurwitz J, Borbas C, Mor V. Adjuvant Tamoxifen Prescription in Women 65 Years and Older With Primary Breast Cancer, 2680
Silver B, *see* Ng AK
Silverman LB, *see* LeClerc JM
Silverman LR, *see* Kornblith AB
Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF. Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B, 2429
Simbre VC II, *see* Lipshultz SE
Simes RJ, *see* Hersey P
Simmons C, *see* de Bono JS
Simon D, *see* Mounier N
Simon EH, *see* Heiss MM
Simon MB, *see* Ramanathan RK
Simone JV. Understanding Cancer Centers (editorial), 4503
Singer CRJ, *see* Menssen HD
Singer S, Rubin BP, Lux ML, Chen C-J, Demetri GD, Fletcher CDM, Fletcher JA. Prognostic Value of *KIT* Mutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal Tumors, 3898
Singh B, *see* Osman I
Singh H, *see* Ferrari AC
Singhal S, *see* Mehta J
Singletary SE, *see* Buchholz TA
Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RVP, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Green FL. Revision of the American Joint Committee on Cancer Staging System for Breast Cancer, 3628
Sinibaldi V, *see* Carducci MA
Sirachainan E, Kalemkerian GP. Unusual Presentations of Lung Cancer: Case 2. Adrenal Insufficiency as the Initial Manifestation of Non-Small-Cell Lung Cancer, 4598
Siracusano L, *see* Bertuzzi A
Sisson JC, *see* Yanik GA
Siu L, *see* Bélanger K
see de Bono JS
Siu LL, *see* Nottage M
Sivesind D, *see* Strasser F
Skakkebæk NE, *see* Petersen PM
Skalla K, *see* Ahles TA
Skarlos D, *see* Bafaloukos D
see Kosmidis P
Skelin S, *see* Fröhling S
Skibber JM, *see* Esnaola NF
Skibowski E, *see* Weihrauch MR
Skillings JR, *see* Douillard J-Y
Skinner DG, *see* Graefen M
Skovlund E, *see* Sundstrøm S
Skovsgaard T, *see* Carmichael J
Slamon DJ, *see* Osoba D
see Press MF
see Vogel CL
Slattery ML, *see* Samowitz WS
Slawin KM, *see* Shariat SF
Sleddens HFBM, *see* van der Sijp JRM
Sloan J. Asking the Obvious Questions Regarding Patient Burden (editorial), 4
Sloan JA, *see* Adjei AA
see Hobday TJ
see Jatoi A
see Loprinzi CL
Sloan JA, Goldberg RM, Sargent DJ, Vargas-Chanes D, Nair S, Cha SS, Novotny PJ, Poon MA, O'Connell MJ, Loprinzi CL. Women Experience Greater Toxicity With Fluorouracil-Based Chemotherapy for Colorectal Cancer, 1491

Slosman DO, *see* Allal AS
Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, Kelly WK, Kattan MW. Nomogram for Overall Survival of Patients With Progressive Metastatic Prostate Cancer After Castration, 3972
Small BJ, *see* Jacobsen PB
Small EJ, *see* Herbst RS
see Smaletz O
Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Randomized Study of Three Different Doses of Suramin Administered With a Fixed Dosing Schedule in Patients With Advanced Prostate Cancer: Results of Intergroup 0159, Cancer and Leukemia Group B 9480, 3369
Small TN, *see* Timoney JP
Smaniotto D, *see* Benedetti-Panici P
Smelko B, *see* Kirkwood JM
Smit EF, *see* Kuenen BC
Smith A, *see* Barakat RR
see Klasa RJ
see Stark D
Smith DA, *see* Adjei AA
Smith I, *see* Powles T
Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN. Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel, 1456
Smith J, *see* Khushalani NI
see Rischin D
Smith JA, *see* Mehta MP
Smith M, *see* Sateren WB
Smith ME, *see* Garrison MA
Smith P, *see* Khushalani NI
Smith R, *see* de Jonge MJA
Smith SC, *see* Brett BT
Smith T, *see* Kemeny MM
see Neff P
Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, Buchser E, Català E, Bryce DA, Coyne PJ, Pool GE. Randomized Clinical Trial of an Implantable Drug Delivery System Compared With Comprehensive Medical Management for Refractory Cancer Pain: Impact on Pain, Drug-Related Toxicity, and Survival, 4040
Smith TL, *see* Esteva FJ
see Siefker-Radtke AO
Smithson WA, *see* Anderson PM
Smuck B, *see* Roche K
Smylie M, *see* Shepherd FA
Sneige N, *see* Esteva FJ
Snow P, *see* Djavan B
So T, *see* Osaki T
Sobue T, Moriyama N, Kaneko M, Kusumoto M, Kobayashi T, Tsuchiya R, Kakinuma R, Ohmatsu H, Nagai K, Nishiyama H, Matsui E, Eguchi K. Screening for Lung Cancer With Low-Dose Helical Computed Tomography: Anti-Lung Cancer Association Project, 911
Socié G, *see* Bergeron A
Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, Unger P, Lee J, Lee J-H, Tynan M, Moore M, Kies MS. Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non-Small-Cell Lung Cancer, 1335
Sock DE, *see* Kilbridge KL
Sofer M, Hamilton-Nelson KL, Schlesselman JJ, Soloway MS. Risk of Positive Margins and Biochemical Recurrence in Relation to Nerve-Sparing Radical Prostatectomy, 1853
Soft Tissue Sarcoma Committee, Representing the Childhood Oncology Group, *see* Sorensen PHB
Sogani P, *see* Dalbagni G
Soignet S, *see* Barakat RR
Soignet SL, *see* Orlowski RZ
Solin LJ, *see* Lee JH
see Tillman GF
Soloway MS, *see* Sofer M
Somerville M, *see* Rivera E
Sondak VK, *see* Kirkwood JM
see Sosman JA
Sondak VK, Liu P-Y, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, Thompson JA, Weiss GR, Redman BG, Jakowatz JG, Noyes RD, Flaherty LE. Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Overall Results of a Randomized Trial of the Southwest Oncology Group, 2058
Soo-Hoo W, *see* Womer RB
Sood AK, *see* Bloss JD
Sorensen PHB, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG for the Soft Tissue Sarcoma Committee, Representing the Childhood Oncology Group. *PAX3-FKHR* and *PAX7-FKHR* Gene Fusions Are Prognostic Indicators in Alveolar Rhabdomyosarcoma: A Report From the Children's Oncology Group, 2672
Sorio R, *see* Toffoli G
Sorosky J, *see* Muggia FM
Soslow R, *see* Barakat RR
Sosman JA, *see* Sondak VK
Sosman JA, Unger JM, Liu P-Y, Flaherty LE, Park MS, Kempf RA, Thompson JA, Terasaki PI, Sondak VK. Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Impact of HLA Class I Antigen Expression on Outcome, 2067
Souglakos J, Mavroudis D, Kakolyris S, Kourousis C, Vard-

akis N, Androutakis N, Agelaki S, Kalbakis K, Tsetis D, Athanasiadis N, Samonis G, Georgoulias V. Triplet Combination With Irinotecan Plus Oxaliplatin Plus Continuous-Infusion Fluorouracil and Leucovorin as First-Line Treatment in Metastatic Colorectal Cancer: A Multicenter Phase II Trial, 2651
Souhami L, *see* Pearcey R
Soulières D, *see* Bélanger K
Southwest Oncology Group, *see* Sosman JA
Soyer HP, *see* Pizzichetta MA
Spaeth PJ, *see* Emmenegger U
Spaggiari L, *see* De Pas T
Spalding S, *see* Yanik GA
Sparreboom A, *see* de Jongh FE
see Gelderblom H
see Kehrer DFS
see Mathijssen RHJ
see Xie R
Sparreboom A, de Jongh F, Verweij J. In Reply (correspondence), 4270
Spazzapan S, Crivellari D, Lombardi D, Scuderi C, Magri MD, Veronesi A, Gatti A. Nail Toxicity Related to Weekly Taxanes: An Important Issue Requiring a Change in Common Toxicity Criteria Grading?, 4404
Specht L, *see* Warde P
Speers C, *see* Weir L
Sperone P, Gorzegno G, Berruti A, Familiari U, Dogliotti L. Reversible Pancytopenia Caused by Oral Letrozole Assumption in a Patient With Recurrent Breast Cancer (correspondence), 3747
Speyer J. Cardiac Dysfunction in the Trastuzumab Clinical Experience (editorial), 1156
Spielmann M, *see* Zelek L
Spieth K, Risse J, Kaufmann R, Gille J. Challenging Cases and Diagnostic Dilemmas; Case 3. Positron Emission Tomography Scan Mimicking Lymph Node Metastases in a High-Risk Melanoma Patient, 3349
Spitz D, *see* Markman M
Spitzer G, *see* Berry DA
Sposto R, *see* Jennings MT
see Lones MA
see Nachman JB
Spott C, *see* Kollmannsberger C
Spreafico F, *see* Massimino M
Spreafico F, Massimino M, Luksch R, Casanova M, Cefalo GS, Collini P, Ferrari A, Polastri D, Terenziani M, Gasparini M, Fossati-Bettani F. Intensive, Very Short-Term Chemotherapy for Advanced Burkitt's Lymphoma in Children, 2783
Spriano M, *see* Federico M
Spriggs D, *see* Barakat RR
see Schwartz GK
Spriggs DR, *see* Dizon DS
see Hensley ML
Spunt SL, Hill DA, Motosue AM, Billups CA, Cain AM, Rao BN, Pratt CB, Merchant TE, Pappo AS. Clinical Features and Outcome of Initially Unresected Nonmetastatic Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma, 3225
Srivastava DK, *see* Crews KR
see Rubnitz JE
Srivastava P, *see* Belli F
Staats PS, *see* Smith TJ
Stack JP, *see* McDermott RS
Stadler W, *see* Rosner GL
Stadler WM, *see* Rini BI
Stadtmauer E, *see* Berry DA
see Rai KR
Stahl S, *see* Orlowski RZ
Stalmeier PFM, *see* van Roosmalen MS
Stamatoullas A, *see* Fermé C
Stanek M, *see* Nadella P
Stanton AL, Danoff-Burg S, Sworowski LA, Collins CA, Branstetter AD, Rodriguez-Hanley A, Kirk SB, Austenfeld JL. Randomized, Controlled Trial of Written Emotional Expression and Benefit Finding in Breast Cancer Patients, 4160
Stark D, Kiely M, Smith A, Velikova G, House A, Selby P. Anxiety Disorders in Cancer Patients: Their Nature, Associations, and Relation to Quality of Life, 3137
Stathopoulos GP, Rigatos SK, Pergantas N, Tsavdarides D, Athanasiadis I, Malamos NA, Stathopoulos JG. Phase II Trial of Biweekly Administration of Vinorelbine and Gemcitabine in Pretreated Advanced Breast Cancer, 37
Stathopoulos JG, *see* Stathopoulos GP
Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis C, Apostolaki S, Malamos N, Kakolyris S, Kotsakis A, Xenidis N, Reppa D, Georgoulias V. Molecular Detection of Cytokeratin-19-Positive Cells in the Peripheral Blood of Patients With Operable Breast Cancer: Evaluation of Their Prognostic Significance, 3404
Stavrianeas N, *see* Dourakis SP
Stea B, *see* Thomas R
Stearns LJ, *see* Smith TJ
Stearns V, Hayes DF. Cooling Off Hot Flashes (editorial), 1436
Steensma DP, *see* Daugherty CK
Steensma DP. Why Me?, 873
Steer CB, *see* Marx GM
Steer CB, Marx GM, Galani E, Harper PG, Khayat D. Quality of Life: It's Never Too Late (editorial), 2915
Steger G, *see* Jakesz R
Stein KD, *see* Jacobsen PB
Stein U, Jürchott K, Schläfke M, Hohenberger P. Expression of Multidrug Resistance Genes *MVP, MDR1,* and *MRP1* Determined Sequentially Before, During, and After Hyperthermic Isolated Limb Perfusion of Soft Tissue Sarcoma and Melanoma Patients, 3282
Steinberg M, *see* Bonneterre J

Steindorfer P, *see* Jakesz R
Steinemann S, *see* Wong JH
Steiner M, Schuff-Werner P, Freund M, Köhne C-H. Combined Chemotherapy Trials Require Combined Pharmacogenetic Approaches (correspondence), 1425
Steinhauer EU, *see* Kaiser U
Stella PJ, *see* Loprinzi CL
Stenman U-H, *see* Mäkinen T
Stephenson J Jr, *see* de Bono JS
Sterman D, *see* Pecora AL
Stern SL, *see* DiFronzo LA
see Hsueh EC
Steuber CP, *see* Furman WL
Steup WH, *see* Marijnen CAM
Stevens J, *see* Harlan LC
Stevenson JP, Whitehead AS, O'Dwyer PJ. In Reply (correspondence), 1425
Stewart A, *see* Jonat W
Stewart C, *see* Athale UH
Stewart CF, *see* Crews KR
see Furman WL
Stewart J, *see* Rischin D
Stewart SJ, *see* Seidman A
see Vogel CL
Stinchcombe TE, *see* Orlowski RZ
Stirling JJ, *see* Galbraith SM
Stock F, *see* Toso JF
Stock R, *see* Ferrari AC
Stockschlaeder M, *see* Sucker C
Stojadinovic A, Ghossein RA, Hoos A, Nissan A, Marshall D, Dudas M, Cordon-Cardo C, Jaques DP, Brennan MF. Adrenocortical Carcinoma: Clinical, Morphologic, and Molecular Characterization, 941
Stojadinovic A, Leung DHY, Allen P, Lewis JJ, Jaques DP, Brennan MF. Primary Adult Soft Tissue Sarcoma: Time-Dependent Influence of Prognostic Variables, 4344
Stokes PK, *see* Abramson N
Stoltenburg-Didinger G, *see* Fuchs IB
Stoltz M, *see* Schwartz GK
Stone N, *see* Ferrari AC
Stone RM, *see* Silverman LR
Stopfer J, *see* Shih HA
Störkel S, *see* Kuball J
Storm H, *see* Dores GM
Stoter G, *see* Mathijssen RHJ
Stovall M, *see* Dores GM
Stover L, *see* Kirkwood JM
Strasser F, Fisch M, Bodurka DC, Sivesind D, Bruera E. E-Motions: Email for Written Emotional Expression, 3352
Stratton MR, *see* Shih HA
Strauss GM. In Reply (correspondence), 3931
Strauss GM. The Mayo Lung Cohort: A Regression Analysis Focusing on Lung Cancer Incidence and Mortality, 1973
Stricker D, *see* Rosenberg R
Stricker PD, *see* Graefen M
Strickland S, *see* McNeish IA
Strijk S, *see* Ruers TJM
Strijk SP, *see* Langenhoff BS
Stringer SP, *see* Mendenhall WM
Strom EA, *see* Ballo MT; Buchholz TA
Struewing JP, *see* Chetrit A
Stuart G, *see* Pearcey R
Stupp R, *see* Borner MM
Stupp R, Dietrich P-Y, Kraljevic SO, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO, Leyvraz S. Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide, 1375
Stupp R, Ostermann-Kraljevic S, Dietrich P-Y, Mirimanoff RO. Reply 1, to Nieder and Beauchesne (correspondence), 3181
Sturgeon JFG, *see* Brierley JD
Suarez-Almazor ME, Newman C, Hanson J, Bruera E. Attitudes of Terminally Ill Cancer Patients About Euthanasia and Assisted Suicide: Predominance of Psychosocial Determinants and Beliefs Over Symptom Distress and Subsequent Survival, 2134
Sucker C, Klima K-M, Doelken G, Heidecke C-D, Lorenz G, Stockschlaeder M. Unusual Sites of Involvement in Non-Hodgkin's Lymphoma; Case 3. Intussusception as a Rare Complication of Mantle-Cell Lymphoma, 4397
Sudbø A, *see* Sudbø J
Sudbø J, Kildal W, Johannessen AC, Koppang HS, Sudbø A, Danielsen HE, Risberg B, Reith A. Gross Genomic Aberrations in Precancers: Clinical Implications of a Long-Term Follow-Up Study in Oral Erythroplakias, 456
Sugarman J, *see* Pentz RD
Sugawara Y, *see* Morita T
Sugio K, *see* Osaki T
Sugita T, *see* Tsuchiya H
Sugiura T, *see* Takada M
Suh KS, *see* Lee H-S
Sun X-F, *see* Jansson A
Sundararajan J, *see* Neugut AI
Sundararajan V, *see* Hershman D
Sundararajan V, Hershman D, Grann VR, Jacobson JS, Neugut AI. Variations in the Use of Chemotherapy for Elderly Patients With Advanced Ovarian Cancer: A Population-Based Study, 173
Sunshine JH, *see* Burkhardt JH
Suovuori A, *see* Powles T
Supko JG, *see* Eder JP Jr
Sutcliffe S, *see* Shenkier TN
Sutedja G, *see* Kunst PWA
Sutedja T, *see* Codrington H

see Postmus PE
Sutherland RL, *see* Biankin AV
see Graefen M
Sutter T, *see* Dunst J
Sutton L, *see* Rivera E
Swain SM, *see* Tan AR
Swaisland H, *see* Baselga J
see Herbst RS
Swallow CJ, *see* Brierley JD
Swart M, *see* Crul M
Sweeney C, *see* Bruera E
see Ripamonti C
Sweeney C, Beattie-Palmer L, Palmer JL, Bruera E. In Reply (correspondence), 882
Sweet KM, Bradley TL, Westman JA. Identification and Referral of Families at High Risk for Cancer Susceptibility, 528
Swiss Group for Clinical Cancer Research, *see* Bernhard J
Sworowski LA, *see* Stanton AL
Syed R, *see* Bomanji JB
Sylvester R, *see* Pignatti F
Szakolczai I, *see* Jonat W
Szatrowski TP, *see* Cartwright TH
Sznol M, *see* Toso JF

T

Taamma A, *see* Louvet C
Tai BC, *see* Tan SB
Taäieb J, *see* Raymond E
Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, Nishiwaki Y, Watanabe K, Noda K, Tamura T, Fukuda H, Saijo N. Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104, 3054
Takata T, *see* Shoji T
Takayama O, *see* Noura S
Takenoyama M, *see* Osaki T
Takimoto CH, *see* Tolcher AW
Tammela TLJ, *see* Mäkinen T
Tamura T, *see* Takada M
Tan AR, Headlee D, Messmann R, Sausville EA, Arbuck SG, Murgo AJ, Melillo G, Zhai S, Figg WD, Swain SM, Senderowicz AM. Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms, 4074
Tan H, *see* Crul M
Tan JE, *see* Tillman GF
Tan L, *see* Van Poznak C
Tan SB, Machin D, Cheung YB, Chung YFA, Tai BC, Machin D. Following a Trial That Stopped Early: What Next for Adjuvant Hepatic Intra-Arterial Iodine-131 Lipiodol in Resectable Hepatocellular Carcinoma? (correspondence), 1709
Tanaka F, *see* Shoji T
Tanimura M, *see* Yamamoto K
Tao J, Flaherty K, Bagg A. Unusual Hematologic Malignancies; Case 1. Hematologic Malignancy Presenting With Diarrhea and Bony Lesions: Systemic Mastocytosis, 3737
Tarabichi A, *see* Heiss MM
Tarbell N, *see* LeClerc JM
Tarbell NJ, *see* Diller L
see Donaldson SS
see Friedmann AM
see Ng AK
Tarhini A, *see* Kirkwood JM
Tarumi Y, *see* Watanabe S
Tashkin D, *see* Sarna L
Tassinari D, *see* Ravaioli A
Tassinari D, Panzini I, Ravaioli A, Maltoni M, Sartori S. Quality of Life at the End of Life: How Is the Solution Far Away? (correspondence), 1704
Tateishi A, *see* Kamada T
Tattersall MHN, *see* Gattellari M
Taub RN, *see* Mikulski SM
Tauchi-Nishi P, *see* Wong JH
Tavtigian SV, *see* Frank TS
Taylor NJ, *see* Galbraith SM
Tazi A, *see* Bergeron A
Tebbutt N, *see* Maisey N
Tedeschi N, *see* Lones MA
Templeton E, *see* Van Patten CL
ten Bokkel Huinink WW, *see* Kruijtzer CMF
see Raymond E
ten Tije AJ, *see* Gelderblom H
Tendler CL, *see* Bukowski R
Teo PML, *see* Chan ATC
Teofili L, Martini M, Luongo M, Di Mario A, Leone G, De Stefano V, Larocca LM. Overexpression of the Polycythemia Rubra Vera-1 Gene in Essential Thrombocythemia, 4249
Tepper JE, O'Connell M, Niedzwiecki D, Hollis DR, Benson AB III, Cummings B, Gunderson LL, Macdonald JS, Martenson JA, Mayer RJ. Adjuvant Therapy in Rectal Cancer: Analysis of Stage, Sex, and Local Control—Final Report of Intergroup 0114, 1744
Teramura T, *see* Imashuku S
Terasaki PI, *see* Sosman JA
Terenziani M, *see* Massimino M
see Spreafico F
Terrioux P, *see* Depierre A
Tesch H, *see* Sieber M
Tesoro-Tess JD, *see* Massimino M
Testa MA, *see* Evans SR
Testori A, *see* Belli F
Thakral H, *see* Coen JJ
Thall PF, *see* Papandreou CN
Thames H, *see* Eifel PJ

Thé PN, *see* Love RR
Therasse P, *see* Pignatti F
Theriault RL, *see* Singletary SE
Thiberville L, *see* Depierre A
Thibodeau SN, *see* Lindor NM
Thiel E, *see* Menssen HD
Thies A, Moll I, Berger J, Wagener C, Brümmer J, Schulze H-J, Brunner G, Schumacher U. CEACAM1 Expression in Cutaneous Malignant Melanoma Predicts the Development of Metastatic Disease, 2530
Thiesse P, *see* Lashford LS
Thiffault I, *see* Andermann A
Thirlwell MP, *see* Schilsky RL
Thomas CR Jr, *see* Vijayalaxmi
Thomas DA, *see* Giles FJ
Thomas J, Gupta M, Grasso Y, Reddy CA, Heston WD, Zippe C, Dreicer R, Kupelian PA, Brainard J, Levin HS, Klein EA. Preoperative Combined Nested Reverse Transcriptase Polymerase Chain Reaction for Prostate-Specific Antigen and Prostate-Specific Membrane Antigen Does Not Correlate With Pathologic Stage or Biochemical Failure in Patients With Localized Prostate Cancer Undergoing Radical Prostatectomy, 3213
Thomas JP, *see* Berlin JD
Thomas R, *see* Grem JL
Thomas R, Stea B. Radiation Recall Dermatitis From High-Dose Interferon Alfa-2b (correspondence), 355
Thomas RR, *see* Wilson RH
Thomason D, *see* Grann VR
Thompson JA, *see* Sondak VK
see Sosman JA
Thompson JF, *see* Hersey P
Thompson P, *see* Galbraith SM
Thompson S, *see* Douillard J-Y
Thompson T, *see* Ellis GK
Thomson J, *see* Nachman JB
Thor A, *see* Singletary SE
Throuvalas N, *see* Antonadou D
Thuan TV, *see* Love RR
Thuong L, *see* Love RR
Thuret I, *see* Perel Y
Thürlimann B, *see* Bernhard J
see Bonneterre J
Thüroff JW, *see* Kuball J
Thuy NV, *see* Love RR
Tickoo SK, *see* Vuky J
Tidy A, *see* Powles T
Tienghi A, *see* Fagioli F
Tigaud JM, *see* Louvet C
Tillman GF, Orel SG, Schnall MD, Schultz DJ, Tan JE, Solin LJ. Effect of Breast Magnetic Resonance Imaging on the Clinical Management of Women With Early-Stage Breast Carcinoma, 3413
Tilly H, *see* Gisselbrecht C
Timmerman RD. Adjuvant Radiation for Stage IIB Soft Tissue Sarcoma of the Externality (correspondence), 3929
Timmermann B, Kortmann R-D, Kühl J, Meisner C, Dieckmann K, Pietsch T, Bamberg M. Role of Radiotherapy in the Treatment of Supratentorial Primitive Neuroectodermal Tumors in Childhood: Results of the Prospective German Brain Tumor Trials HIT 88/89 and 91, 842
Timoney JP, Malkin MG, Leone DM, Groeger JS, Heaney ML, Keefe DL, Klang M, Lucarelli CD, Muller RJ, Eng SL, Connor M, Small TN, Brown AE, Saltz LB. Safe and Cost Effective Use of Alteplase for the Clearance of Occluded Central Venous Access Devices, 1918
Tinari N, *see* Piantelli M
Tirabosco R, *see* Sorensen PHB
Tirona MT, *see* Allegra CJ
see Hobday TJ
Tiu C-M, *see* Chou Y-H
Tjan-Heijnen VCG, *see* Ardizzoni A
Tjønnfjord G, *see* Keating MJ
Tobis K, *see* Döhner K
Toffoli G, Sorio R, Sartor F, Raffin L, Veronesi A, Boiocchi M. Carboplatin and Topotecan Combination and Myelosuppression (correspondence), 3558
Tolcher AW, Takimoto CH, Rowinsky EK. The Multifunctional, Multi-Institutional, and Sometimes Even Global Phase I Study: A Better Life for Phase I Evaluations or Just "Living Large"? (editorial), 4276
Tom P, *see* Wong JH
Tomacruz RS, *see* Bristow RE
Tomaszewski JE, *see* Cross CK
Tomita K, *see* Tsuchiya H
Tonato M, *see* Scagliotti GV
Tong W, *see* Dalbagni G
see Hensley ML
see Schwartz GK
Tong X, *see* Crews KR
see Rubnitz JE
Tonini G, *see* Santini D
Topalian SL, *see* Toso JF
Torres A, *see* González-Quevedo R
Torri V, *see* Cantù MG
Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA. Phase I Study of the Intravenous Administration of Attenuated *Salmonella typhimurium* to Patients With Metastatic Melanoma, 142
Tourt-Uhlig S, *see* Gururangan S
see Quinn JA
Tracy E, *see* Womer RB
Tragni G, *see* Belli F
Tran HT, *see* Herbst RS

Tran J-P, *see* Izawa JI
Tran TL, *see* Love RR
Travis LB, *see* Dores GM
Tremblay P-B, *see* Kaiser R
Treuner J, *see* Ferrari A
Trevisan G, *see* Pizzichetta MA
Triche TJ, *see* Sorensen PHB
Tricot G, *see* Badros A
Trimble EL, *see* Bristow RE
see Sateren WB
Trinh GN, *see* Nguyen TV
Trink B, *see* Cheng H-L
Tripathy D, *see* Vogel CL
Trodella L, Granone P, Valente S, Turriziani A, Macis G, Corbo GM, Margaritora S, Cesario A, D'Angelillo RM, Gualano G, Ramella S, Galetta D, Cellini N. Phase I Trial of Weekly Gemcitabine and Concurrent Radiotherapy in Patients With Inoperable Non-Small-Cell Lung Cancer, 804
Troncoso P, *see* Papandreou CN
Trudeau ME, *see* Goodwin PJ
Trump DL, *see* Ramanathan RK
Trümper L, *see* Kaiser U
Trümper L, Menges M, Daus H, Köhler D, Reinhard J-O, Sackmann M, Moser C, Sek A, Jacobs G, Zeitz M, Pfreundschuh M. Low Sensitivity of the *ki-ras* Polymerase Chain Reaction for Diagnosing Pancreatic Cancer From Pancreatic Juice and Bile: A Multicenter Prospective Trial, 4331
Tsavdarides D, *see* Stathopoulos GP
see Kosmidis P
Tschetter LK, *see* Hobday TJ
Tseng C-C, *see* Ursin G
Tseng JE, *see* Herbst RS
Tsetis D, *see* Souglakos J
Tsuchiya H, Kanazawa Y, Abdel-Wanis ME, Asada N, Abe S, Isu K, Sugita T, Tomita K. Effect of Timing of Pulmonary Metastases Identification on Prognosis of Patients With Osteosarcoma: The Japanese Musculoskeletal Oncology Group Study, 3470
Tsuchiya R, *see* Sobue T
Tsuchiya S, *see* Sekine I
Tsujii H, *see* Kamada T
Tsukiyama I, *see* Sekine I
Tu D, *see* Davis AM
see El-Sayed S
see Pearcey R
Tu S-M, *see* Pagliaro LC
see Papandreou CN
see Siefker-Radtke AO
Tubiana-Hulin M, *see* Zelek L
Tubiana-Mathieu N, *see* Curé H
Tucker SL, *see* Buchholz TA
Tullo A, *see* Ranson M
Tung ND, *see* Love RR
Turci D, *see* Ravaioli A
Turcotte R, *see* Davis AM
Turek P, *see* Damani MN
Turrisi AT III, *see* Albain KS
Turriziani A, *see* Trodella L
Tuthill RJ, *see* Sondak VK
Twelves C, *see* Biganzoli L
see O'Shaughnessy J
Tyldesley S, *see* Huang J
Tynan M, *see* Socinski MA
Tzai T-S, *see* Cheng H-L

U

Ubiali E, *see* Cascinu S
Uchitomi Y, *see* Morita T
Uebelacker I, *see* Kaiser U
Ulrich-Pur H, *see* Scheithauer W
Ulrich R, *see* Döhner K
Unger JM, *see* Sondak VK
see Sosman JA
Unger P, *see* Socinski MA
Ungerleider R, *see* Sateren WB
Urba WJ, Alvord WG. Are All Hypotheses Generated Before Data Analysis Prospective? (editorial), 1431
Ursin G, Tseng C-C, Paganini-Hill A, Enger S, Wan PC, Formenti S, Pike MC, Ross RK. Does Menopausal Hormone Replacement Therapy Interact With Known Factors to Increase Risk of Breast Cancer?, 699
Uzan S, *see* Barranger E

V

Vaishampayan U, Dan ME, Hussain M. Unusual Hematologic Malignancies; Case 2. Mediastinal Germ Cell Tumor, Malignant Histiocytosis, and Acute Leukemia, 3739
Valente S, *see* Trodella L
Valentini L, *see* Massimino M
Valentini M, *see* Cesana C
Valerio MR, *see* Vici P
Valero V, *see* Esteva FJ
Valle J, *see* Ross P
Vallières E. Adjuvant Radiation Therapy After Complete Resection of Non-Small-Cell Lung Cancer (correspondence), 1427
Vallis KA, Pintilie M, Chong N, Holowaty E, Douglas PS, Kirkbride P, Wielgosz A. Assessment of Coronary Heart Disease Morbidity and Mortality After Radiation Therapy for Early Breast Cancer, 1036
Van Cutsem E, *see* Rothenberg ML
van Daal WAJ, *see* van Roosmalen MS
van de Schraaf J, *see* de Jonge MJA
van de Velde CJH, *see* Marijnen CAM
see Nagtegaal ID
see van der Hage JA

van de Vijver MJ, *see* Lakhani SR
van den Bent M, *see* Pignatti F
van den Berg JWO, *see* Agteresch HJ
van den Bogaard CJC, *see* de Gast GC
Van der Auwera P, *see* Viens P
van der Groep P, *see* Bos R
van der Hage JA, van de Velde CJH. In Reply (correspondence), 2906
van der Hage JA, van de Velde CJH. Perioperative Chemotherapy in Patients With Node-Negative Postmenopausal Breast Cancer (correspondence), 2210
van der Hoeven JJM, *see* Bos R
van der Kwast TH, *see* Graefen M
van der Sijp JRM, van Meerbeeck JPAM, Maat APWM, Zondervan PE, Sleddens HFBM, van Geel AN, Eggermont AMM, Dinjens WNM. Determination of the Molecular Relationship Between Multiple Tumors Within One Patient Is of Clinical Importance, 1105
van der Vijgh WJF, *see* Kuenen BC
van der Wall E, *see* Bos R
van der Worp E, *see* Nagtegaal ID
van Diest PJ, *see* Bos R
van Geel AN, *see* van der Sijp JRM
Van Hazel G, *see* O'Shaughnessy J
van Kesteren Ch, Mathôt RAA, Raymond E, Armand JP, Dittrich Ch, Dumez H, Roché H, Droz JP, Punt C, Ravic M, Wanders J, Beijnen JH, Fumoleau P, Schellens JHM. Population Pharmacokinetics of the Novel Anticancer Agent E7070 During Phase I Studies: Model Building and Validation, 4065
van Krieken JHJM, *see* Nagtegaal ID
Van Le L, *see* Markman M
van Leeuwen FE, *see* Dores GM
see Dorresteijn LDA
van Meerbeeck JP, *see* Ardizzoni A
see van der Sijp JRM
van Mourik J, *see* Codrington H
Van Patten CL, Gelmon KA, Olivotto IA. In Reply (correspondence), 3041
Van Patten CL, Olivotto IA, Chambers GK, Gelmon KA, Hislop TG, Templeton E, Wattie A, Prior JC. Effect of Soy Phytoestrogens on Hot Flashes in Postmenopausal Women With Breast Cancer: A Randomized, Controlled Clinical Trial, 1449
Van Poznak C, Tan L, Panageas KS, Arroyo CD, Hudis C, Norton L, Seidman AD. Assessment of Molecular Markers of Clinical Sensitivity to Single-Agent Taxane Therapy for Metastatic Breast Cancer, 2319
Van Rhee F, *see* Badros A
van Roosmalen MS, Verhoef LCG, Stalmeier PFM, Hoogerbrugge N, van Daal WAJ. Decision Analysis of Prophylactic Surgery or Screening for *BRCA1* Mutation Carriers: A More Prominent Role for Oophorectomy, 2092
Van Someren N, *see* Brett BT
van Tinteren H, *see* Kruijtzer CMF
van Weeren PC, *see* Kersemaekers A-MF
van Zomeren DM, *see* Gelderblom H
Vandenberg T, *see* Winquist E
Vanel D, *see* Aloulou S
Vannetzel J-M, *see* Zelek L
Vannier J-P, *see* Perel Y
van't Veer LJ, *see* Crul M
van't Veer MB, *see* Dores GM
Vanuytsel L, *see* Achten R
Vardakis N, *see* Souglakos J
Vargas-Chanes, *see* Sloan JA
Varkey JA, *see* Cartwright TH
Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, Kirn DH, O'Neill V, Siddiqui N, Seiden MV, Kaye SB. Phase I Trial of Intraperitoneal Injection of the *E1B*-55-kd-Gene-Deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients With Recurrent/Refractory Epithelial Ovarian Cancer, 1562
Vassal G, *see* Lashford LS
Vassallo E, *see* Fagioli F
Vassilakopoulos TP, *see* Rassidakis GZ
Vaughn D, *see* Hinton S
Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer, 937
Vaughn DJ, Meadows AT. Cancer Survivorship Research: The Best Is Yet to Come (editorial), 888
Vauthey J-N, Lauwers GY, Esnaola NF, Do K-A, Belghiti J, Mirza N, Curley SA, Ellis LM, Regimbeau J-M, Rashid A, Cleary KR, Nagorney DM. Simplified Staging for Hepatocellular Carcinoma, 1527
Vauthey JN, *see* Pisters PWT
Vecht C, *see* Pignatti F
Velikova G, *see* Stark D
Veneroni S, *see* Daidone MG
Venkatraman E, *see* Barakat RR
see Dizon DS
see Hensley ML
see Osman I
Venkatraman ES, *see* Martin J
Venook AP, *see* Bergsland EK
Venturino A, *see* Repetto L
Verbel DA, *see* Smaletz O
Vercammen E, *see* Littlewood TJ
Vercelli M, *see* Repetto L
Verger E, *see* Bessell EM
Vergote I, *see* Howell A
Verhoef G, *see* Achten R
Verhoef LCG, *see* van Roosmalen MS
Verkooijen HM, *see* Bouchardy C
Verma S, *see* O'Shaughnessy J
Vernillet L, *see* Raymond E
Veronesi A, *see* Pizzichetta MA
see Spazzapan S
see Toffoli G

Verrill M, *see* Hughes A
Verweij J, *see* de Jonge MJA
see de Jongh FE
see Gelderblom H
see Kehrer DFS
see Mathijssen RHJ
see Sparreboom A
see Xie R
Veve R, *see* Bremnes RM
Veys PA, *see* Owens CM
Vezina LG, *see* Jennings MT
Viardot A, Möller P, Högel J, Werner K, Mechtersheimer G, Ho AD, Ott G, Barth TFE, Siebert R, Gesk S, Schlegelberger B, Döhner H, Bentz M. Clinicopathologic Correlations of Genomic Gains and Losses in Follicular Lymphoma, 4523
Viaro D, *see* Hudes G
Vici P, *see* Lopez M
Vici P, Colucci G, Gebbia V, Amodio A, Giotta F, Belli F, Conti F, Gebbia N, Pezzella G, Valerio MR, Brandi M, Pisconti S, Durini E, Giannarelli D, Lopez M. First-Line Treatment With Epirubicin and Vinorelbine in Metastatic Breast Cancer, 2689
Vicini FA, Recht A. Age at Diagnosis and Outcome for Women With Ductal Carcinoma-In-Situ of the Breast: A Critical Review of the Literature, 2736
Vielh P, *see* Rouzier R
Viens P, Chabannon C, Pouillard P, Janvier M, Brugger W, Blay JY, Oberling F, Capdeville R, Newman C, Méresse V, Xu ZX, Platzer E, Van der Auwera P, Maraninchi D. Randomized, Controlled, Dose-Range Study of Ro 25-8315 Given Before and After a High-Dose Combination Chemotherapy Regimen in Patients With Metastatic or Recurrent Breast Cancer Patients, 24
Vietti TJ, *see* Furman WL
Vigander T, *see* Sundstrøm S
Vijayalaxmi, Thomas CR Jr, Reiter RJ, Hennan TS. Melatonin: From Basic Research to Cancer Treatment Clinics, 2575
Vijayalaxmi, Thomas CR Jr, Reiter RJ, Herman TS. In Reply (correspondence), 4128
Vilela G, *see* Bergeron A
Villá S, *see* Bessell EM
Villalona-Calero MA, *see* Nadella P
Villard O, *see* Herbrecht R
Villaret DB, *see* Mendenhall WM
Villeneuve A, *see* Depierre A
Vilsvik J, *see* Sundstrøm S
Vincent MD, *see* Douillard J-Y
Vincent-Salomon A, *see* Rouzier R
Vincenzi B, *see* Santini D
Vinceti M, *see* Federico M
Viniou NA, *see* Dimopoulos MA
Vitali P, *see* Ridolfi R
Viviani S, *see* Rassidakis GZ
Vlachonikolis I, *see* Stathopoulou A
Vlastos G, *see* Bouchardy C
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of *HER2*-Overexpressing Metastatic Breast Cancer, 719
Vogel VG. Why Do We Still Use Hormone Replacement Therapy? Why Don't We Use It More? (editorial), 616
Vogel VG III, *see* Chlebowski RT
Vogelzang NJ, *see* Mikulski SM
see Rini BI
see Schilsky RL
see Small EJ
Voigt KJ, *see* Gattellari M
Voillat L, *see* Fermé C
Voiss W, *see* Weihrauch MR
Vokes EE, *see* Cohen EEW
Vokes EE, Herndon JE II, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR. Randomized Phase II Study of Cisplatin With Gemcitabine or Paclitaxel or Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Stage IIIB Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B Study 9431, 4191
Voland J, *see* Mitchell MS
von der Maase H, *see* Petersen PM
see Warde P
von Eschenbach AC, *see* Izawa JI
von Euler M, *see* Bonneterre J
von Gunten CF. Discussing Hospice Care, 1419
Von Roenn JH, *see* Evans SR
Von Roenn JH, Scheinberg D, Loehrer PJ Sr. Role of Symptom Control and Palliative Care Abstract Presentations (correspondence), 880
von Seydewitz C-U, *see* Kaiser U
Vose JM, *see* Weekes CD
Vose JM, Sharp G, Chan WC, Nichols C, Loh K, Inwards D, Riftin R, Bierman PJ, Lynch JC, Weisenburger DD, Kessinger A, Armitage JO. Autologous Transplantation for Aggressive Non-Hodgkin's Lymphoma: Results of a Randomized Trial Evaluating Graft Source and Minimal Residual Disease, 2344
Voss N, *see* Shenkier TN
Vukelja S, *see* Holmes FA
see O'Shaughnessy J
Vuky J, *see* Motzer RJ
Vuky J, Tickoo SK, Sheinfeld J, Bacik J, Amsterdam A, Mazumdar M, Reuter V, Bajorin DF, Bosl GJ, Motzer RJ. Salvage Chemotherapy for Patients With Advanced Pure Seminoma, 297
Vyth-Dreese FA, *see* de Gast GC

W

Wacker B, *see* Rai KR
Wada H, *see* Shoji T
Wadler S, *see* Rothenberg ML
Wagener C, *see* Thies A
Wainman N, *see* Bélanger K
Walker H, *see* Roche K
Walker J, *see* Northouse LL
Walker LG, *see* Smith IC
Wallace A, *see* Mitchell MS
Waller J, *see* Herbrecht R
Walsh MD, *see* Lindor NM
Walsh-Vockley C, *see* Lindor NM
Walshe LJ, Malak SF, Eagan J, Sepkowitz KA. Complication Rates Among Cancer Patients With Peripherally Inserted Central Catheters, 3276
Wan PC, *see* Ursin G
Wanders J, *see* Raymond E
see van Kesteren Ch
Wanek LA, *see* DiFronzo LA
Wang L-Z, *see* Goh B-C
Wang M, *see* Sundstrøm S
Wang TS, *see* Bichakjian CK
Wang X, *see* Ahmad SA
see Papandreou CN
Wang XS, Giralt SA, Mendoza TR, Engstrom MC, Johnson BA, Peterson N, Broemeling LD, Cleeland CS. Clinical Factors Associated With Cancer-Related Fatigue in Patients Being Treated for Leukemia and Non-Hodgkin's Lymphoma, 1319
Ward BE, *see* Frank TS
Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, von der Maase H. Prognostic Factors for Relapse in Stage I Seminoma Managed by Surveillance: A Pooled Analysis, 4448
Warren JL, *see* Takada M
Warren JL, Brown ML, Fay MP, Schussler N, Potosky AL, Riley GF. Costs of Treatment for Elderly Women With Early-Stage Breast Cancer in Fee-For-Service Settings, 307
Watanabe K, *see* Takada M
Watanabe S, Tarumi Y, Oneschuk D, Lawlor P. Opioid Rotation to Methadone: Proceed With Caution (correspondence), 2409
Waters JS, O'Brien MER, Ashley S. Management of Anemia in Patients Receiving Chemotherapy (correspondence), 601
Watkin W, *see* Liptay MJ
Watkinson AF, *see* Brett BT
Watral M, *see* Gururangan S
Watson P, *see* Berry DA
Wattie A, *see* Van Patten CL
Weaver DL, *see* Singletary SE
Weber BL, *see* DeMichele A
see Shih HA
Weber KL, *see* Ahmad SA
Weber RS, *see* Machtay M
Webster A, *see* Bonneterre J
see Howell A
see Osborne CK
Webster K, *see* Heffernan N
Weekes CD, Vose JM, Lynch JC, Weisenburger DD, Bierman PJ, Greiner T, Bociek G, Enke C, Bast M, Chan WC, Armitage JO, Nebraska Lymphoma Study Group. Hodgkin's Disease in the Elderly: Improved Treatment Outcome With a Doxorubicin-Containing Regimen, 1087
Weeks JC, *see* Earle CC
see Keating NL
see Kilbridge KL
see Liang W
see Loberiza FR Jr
Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS, Nyquist L, Sanda MG. Comprehensive Comparison of Health-Related Quality of Life After Contemporary Therapies for Localized Prostate Cancer, 557
Weihrauch MR, Skibowski E, Koslowsky TC, Voiss W, Re D, Kuhn-Regnier F, Bannwarth C, Siedek M, Diehl V, Bohlen H. Immunomagnetic Enrichment and Detection of Micrometastases in Colorectal Cancer: Correlation With Established Clinical Parameters, 4338
Weiner S, *see* Markman M
Weinstein GS, *see* Machtay M
Weinstein HJ, *see* Donaldson SS
see Friedmann AM
Weinstein MC, *see* Earle CC
Weinstock N, *see* Modi S
Weir L, Speers C, D'yachkova Y, Olivotto IA. Prognostic Significance of the Number of Axillary Lymph Nodes Removed in Patients With Node-Negative Breast Cancer, 1793
Weir LM, *see* Kwan W
Weisenburger DD, *see* Vose JM
see Weekes CD
Weiss G, *see* de Bono JS
Weiss GR, *see* Sondak VK
Weitzner MA, *see* Mehta MP
Weller E, *see* Ng AK
Wen SF, *see* Kuball J
Wendtner C-M, Abdel-Rahman S, Krych M, Baumert J, Lindner LH, Baur A, Hiddemann W, Issels RD. Response to Neoadjuvant Chemotherapy Combined With Regional Hyperthermia Predicts Long-Term Survival for Adult Patients With Retroperitoneal and Visceral High-Risk Soft Tissue Sarcoma, 3156
Werner K, *see* Viardot A
Werner M, *see* Bielack SS
see Rosenberg R
Wernli M, *see* Borner MM
West WH, *see* Schilsky RL

Westeel V, *see* Depierre A
Westman JA, *see* Sweet KM
Wette V, *see* Jakesz R
Wetterwald M, *see* Menssen HD
Wettstein PJ, *see* Ansell SM
Wever LDV, *see* Detmar SB
Wharam MD, *see* Baker KS
Wheatley K, Ives N, Hancock B, Gore M. Need for a Quantitative Meta-Analysis of Trials of Adjuvant Interferon in Melanoma (correspondence), 4120
Whedon MB, *see* Ahles TA
Wheeler TM, *see* Cagiannos I
see Shariat SF
Whelan T. A Trial of Two Questions (editorials), 4135
Whelan TJ, *see* Winer EP
White CA, *see* Witzig TE
White D, *see* Toso JF
White K, *see* Nachman JB
White RL, *see* Schilsky RL
Whitehead AS, *see* Stevenson JP
Whitehead M, *see* Roche K
Whitman E, *see* Agarwala SS
Whittington R, *see* Cross CK
Whitton J, *see* Emmons K
Wickerham DL, Fisher B, Wolmark N, Bryant J, Costantino J, Bernstein L, Runowiez CD. Association of Tamoxifen and Uterine Sarcoma (correspondence), 2758
Wickerham L, *see* Fisher B
Wickersham K, *see* DiPaola RS
Wieand HS, *see* Singletary SE
Wieder J, *see* Zisman A
Wielgosz A, *see* Vallis KA
Wiggers T, *see* Marijnen CAM
Wiklund T, *see* Dores GM
Wikstrand CJ, *see* Reardon DA
Wildhagen MF, *see* Graefen M
Wilding G, *see* Hinton S; Small EJ
Wilkinson PM, *see* Radford JA
Willemze R, *see* Ringdén O
Willett CG. Radiation Dose Escalation in Combined-Modality Therapy for Esophageal Cancer (editorial), 1151
Williams A, *see* DiPaola RS
Williams CD, *see* Branson K
Williams D, *see* Pagliaro LC
see Siefker-Radtke AO
Williams LJ, *see* Hwu W-J
Williamson S, *see* Machtay M
Wilson JF, *see* Lones MA
Wilson JHP, *see* Agteresch HJ
Wilson R, *see* Grem JL
Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute Oxaliplatin-Induced Peripheral Nerve Hyperexcitability, 1767
Winchell G, *see* DiPaola RS
Winckel P, *see* Page E
Windschitl H, *see* Jatoi A
Winer EP, *see* Bunnell CA
see Chlebowski RT
see DiGianni LM
see Schuchter LM
Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor-Positive Breast Cancer: Status Report 2002, 3317
Winkelmann W, *see* Bielack SS
Winkler K, *see* Bielack SS
Winquist E, Bramwell V, Vandenberg T. Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer: Methodologic Issues (correspondence), 3748
Wiseman GA, *see* Anderson PM
see Ansell SM
see Witzig TE
Witzig TE, *see* Ansell SM
see Raikumar SV
Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA. Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma, 3262
Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA. Randomized Controlled Trial of Yttrium-90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma, 2453
Wiznitzer I, *see* Holmes FA
Wobbes Th, *see* Langenhoff BS
see Ruers TJM
Wolchok JD, Chapman PB. Phase I Trial of Adoptive Immunotherapy With Cytolytic T Lymphocytes Immunized Against a Tyrosinase Epitope (correspondence), 3176
Wold LE, *see* Allegra CJ
Wolden S, *see* Wong RJ
Wolden SL, *see* Nachman JB
Wolf J, *see* Sieber M
Wolf R, *see* Silliman RA
Wolff RA, *see* Pisters PWT
Wölfler A, Abuja PM, Linkesch W, Schauenstein K, Liebmann PM. Questionable Benefit of Melatonin for Antioxidant Pharmacologic Therapy (correspondence), 4127
Wolmark N, *see* Fisher B

see Wickerham DL
Wolter TD, *see* Cox LS
Womer RB, *see* Baker KS
Womer RB, Tracy E, Soo-Hoo W, Bickert B, DiTaranto S, Barnsteiner JH. Multidisciplinary Systems Approach to Chemotherapy Safety: Rebuilding Processes and Holding the Gains, 4705
Wong A, *see* Schilsky RL
Wong F, *see* El-Sayed S
Wong J, *see* Poon RT-P
Wong JE, *see* Schwartsmann G
Wong JH, Steinemann S, Tom P, Morita S, Tauchi-Nishi P. Volume of Lymphatic Metastases Does Not Independently Influence Prognosis in Colorectal Cancer, 1506
Wong N, *see* Andermann A
see Cremin C
Wong RJ, Lin DT, Schöder H, Patel SG, Gonen M, Wolden S, Pfister DG, Shah JP, Larson SM, Kraus DH. Diagnostic and Prognostic Value of [^{18}F]Fluorodeoxyglucose Positron Emission Tomography for Recurrent Head and Neck Squamous Cell Carcinoma, 4199
Wong TZ, *see* Reardon DA
Wong WM, *see* Chim CS
Wood D, *see* Agarwala SS
Woods WG. Substitute "Prostate Cancer" for "Neuroblastoma"? (editorial), 1154
Woods WG, Barnard DR, Alonzo TA, Buckley JD, Kobrinsky N, Arthur DC, Sanders J, Neudorf S, Gold S, Lange BJ. Prospective Study of 90 Children Requiring Treatment for Juvenile Myelomonocytic Leukemia or Myelodysplastic Syndrome: A Report From the Children's Cancer Group, 434
Woolf SH, *see* Rizzo JD
Working Group for the Bone and Soft Tissue Sarcomas, *see* Kamada T
Worm M, *see* Meyer L
Wright D, *see* Oscier D
Wu TC, *see* Chiou WL
Wunder JS, *see* Davis AM

X

Xenidis N, *see* Stathopoulou A
Xie R, Mathijssen RHJ, Sparreboom A, Verweij J, Karlsson MO. Clinical Pharmacokinetics of Irinotecan and Its Metabolites: A Population Analysis, 3293
Xin Y, *see* Love RR
Xu ZX, *see* Viens P

Y

Yamada S, *see* Kamada T
Yamamoto H, *see* Noura S
Yamamoto K, Ohta S, Ito E, Hayashi Y, Asami T, Mabuchi O, Higashigawa M, Tanimura M. Marginal Decrease in Mortality and Marked Increase in Incidence as a Result of Neuroblastoma Screening at 6 Months of Age: Cohort Study in Seven Prefectures in Japan, 1209
Yamamoto S, *see* Nakatsuka S
Yamashita T, *see* Osaki T
Yanagi T, *see* Kamada T
Yanagihara K, *see* Shoji T
Yang B, *see* Mirza I
Yang JC, *see* Toso JF
Yang P-C, *see* Yuan A
Yang YF, *see* Love RR
Yang Z-F, *see* Poon RT-P
Yanik GA, Levine JE, Matthay KK, Sisson JC, Shulkin BL, Shapiro B, Hubers D, Spalding S, Braun T, Ferrara JLM, Hutchinson RJ. Pilot Study of Iodine-131-Metaiodobenzylguanidine in Combination With Myeloablative Chemotherapy and Autologous Stem-Cell Support for the Treatment of Neuroblastoma, 2142
Yao M, *see* Nakatsuka S
Yao S-L, *see* DiPaola RS
Yasko AW, *see* Ahmad SA
Yasumoto K, *see* Osaki T
Yates BB, *see* Schilsky RL
Yates S, *see* Socinski MA
Ye X, *see* Hsueh EC
Yee GC, *see* Berenson JR
Yekell S, *see* Ellerhorst JA
Yeo W, *see* Chan ATC
Yeslow G, *see* Hudes G
Yetis B, *see* Saglam S
Yeung D, *see* Mitchell MS
Yiu HH, *see* Chan ATC
Yokota S, *see* Takada M
Yokoyama A, *see* Sekine I
see Takada M
Yong K, *see* Peggs KS
Yoon J-H, *see* Lee H-S
Yoshikawa K, *see* Kamada T
Yoshimura K, *see* Sekine I
Younes M, *see* Daidone MG
Young AM, *see* Seymour LW
Young JA, *see* Donaldson SS
Young JP, *see* Lindor NM
Yu AL, *see* Kletzel M
Yu C-J, *see* Yuan A
Yu C-S, *see* Lee Jung-Hee
Yu KH, *see* Chan ATC
Yu R, *see* Motzer RJ
Yu W-C, *see* Poon RT-P
Yuan A, Yu C-J, Luh K-T, Kuo S-H, Lee Y-C, Yang P-C. Aberrant *p53* Expression Correlates With Expression of Vascular Endothelial Growth Factor mRNA

and Interleukin-8 mRNA and Neoangiogenesis in Non-Small-Cell Lung Cancer, 900
Yuen KT, *see* Chan ATC
Yung WKA, *see* Groves MD
Yunus F, *see* Lima CMSR

Z

Zagars GK, *see* Ahmad SA
see Ballo MT
Zagonel V, *see* Repetto L
Zalutsky MR, *see* Reardon DA
Zanetti I, *see* Ferrari A
Zangari M, *see* Badros A
see Kaushal V
Zannoni GF, *see* Ferrandina G
Zee B, *see* Chan ATC
see Davis AM
see Freidlin B
see Mok TSK
see Roche K
see Shepherd FA
Zee S, *see* Hochwald SN
Zeitz M, *see* Trümper L
Zeldenrust SR, *see* Fanale MA
Zelefsky MJ, *see* Alektiar KM
see Osman I
Zelefsky MJ, Leibel SA. Comparing Contemporary Surgery to External-Beam Radiotherapy for Clinically Localized Prostate Cancer (editorial), 3363
Zelek L, Cottu P, Tubiana-Hulin M, Vannetzel J-M, Chollet P, Misset J-L, Chouaki N, Marty M, Gamelin E, Culine S, Dieras V, Mackenzie S, Spielmann M. Phase II Study of Oxaliplatin and Fluorouracil in Taxane- and Anthracycline-Pretreated Breast Cancer Patients, 2551
Zervas C, *see* Dimopoulos MA
Zhai S, *see* Tan AR
Zhan F, *see* Eton O
Zhang Q, *see* Love RR
Zhang-Salomons J, *see* Huang J
Zhao X-G, *see* Reardon DA
Zhou J-Y, *see* Press MF
Zhou Y, *see* Leung W
Zhuang SH, *see* Leonard GD
Zietman AL, *see* Coen JJ
Zilembo N, *see* Bajetta E
Zimmerman T, *see* Rini BI
Zinzani PL, *see* Federico M
Zippe C, *see* Kupelian PA
see Thomas J
Zisman A, Pantuck AJ, Dorey F, Chao DH, Gitlitz BJ, Moldawer N, Lazarovici D, deKernion JB, Figlin RA, Belldegrun AS. Mathematical Model to Predict Individual Survival for Patients With Renal Cell Carcinoma, 1368
Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS. Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell Carcinoma, 4553
Zlotta A, *see* Djavan B
Zola P, *see* Benedetti-Panici P
Zoladex Early Breast Cancer Research Association Trialists' Group, *see* Jonat W
Zomas A, *see* Dimopoulos MA
Zondervan PE, *see* van der Sijp JRM
Zoubek A, *see* Bielack SS
Zuberbier T, *see* Meyer L
Zühlke H, *see* Dunst J
Zumaglini F, *see* Ravaioli A
Zwick DL, *see* Lones MA

SUBJECT INDEX

A

Acinar cell carcinoma, of pancreas, 4673-4678
ACS. *See* American Cancer Society
Acute leukemias, 3739-3742
  lymphoblastic. *See* Acute lymphoblastic leukemia
  myeloblastic, of childhood, maintenance therapy in, 2774-2782
  myelogenous, relapsed, prolonged infusion gemcitabine in (phase I trial), 665-673
  myeloid. *See* Acute myeloid leukemia of childhood.
  relapsed/refractory
    gemcitabine and irinotecan for (phase I trial), 2995-3000
    prolonged infusion gemcitabine in
      with mitoxantrone (phase I trial), 665-673, 674-679
      myelogenous leukemia (phase I trial), 665-673
    temozolomide in (phase I trial), 3249-3253
    topotecan schedule in children with, 1617-1624
    troxacitabine in, 656-664 (phase II trial), 3356-3357 (correspondence)
Acute lymphoblastic leukemia
  allogeneic peripheral blood stem cells *vs.* bone marrow for, 4655-4664
  childhood
    growth hormone replacement therapy outcomes in, 2959-2964
    treatment results (Dana-Farber Institute), 237-246
  continuous doxorubicin infusion in, 1677-1682
  cyclical chemotherapy for, 2464-2471
  minimal residual disease tests in, 1094-1104
  tumor lysis syndrome after STI571 in, 354-355 (correspondence)
Acute myeloblastic leukemia, childhood, maintenance therapy in, 2774-2782
Acute myelogenous leukemia, relapsed, prolonged infusion gemcitabine in (phase I trial), 665-673
Acute myeloid leukemia
  allogeneic peripheral blood stem cells *vs.* bone marrow for, 4655-4664
  childhood
    cytarabine and cladribine in, 4217-4224
    t(9;11) impact in, 2302-2309
  genomic aberrations in, detection methods compared, 2480-2485
  MLL gene partial tandem duplication in, 3254-3261
  outcomes after BMT in, 4324-4330
  therapy-related, in chronic lymphocytic leukemia patients, 3878-3884
Adenocarcinoma
  Barrett's, lymphangiogenesis in, 2971-2979
  of lung, CEACAM1 expression in, 4273-4275 (editorial), 4279-4284
  mesorectal, excision of, 1714-1715 (editorial), 1729-1734
  pancreatic
    ductal, 4531-4542
    gemcitabine and oxaliplatin for (phase II trial), 1512-1518
    paclitaxel and radiotherapy for, 2537-2544
  prostatic, impact of race on PSA outcome after radical prostatectomy for, 2863-2868, 4129-4130 (correspondence)
  refractory, antrasentan for, 2171-2180
Adenoma, benign metastasizing pleomorphic, 2400-2403
Adenosine triphosphate, for cancer patients, 362-263 (editorial)
  nutritional status and, 371-378
Adherence, to analgesic regimen, patients' perspective on, 2907-2908 (correspondence)
Adjuvant chemotherapy. *See also* Neoadjuvant chemotherapy
  for colon cancer
    stage II, in Medicare beneficiaries, 3999-4005
    stage III, in elderly patients, 3992-3998
  for colorectal cancer, TS expression and, 1721-1728
  in premenopausal breast cancer patients, goserelin or tamoxifen/goserelin *vs.*, 4611-4614 (editorial), 4621-4627, 4628-4635
  in rectal cancer
    stage, sex, and local control analysis, 1744-1750
    stage II and III, 1751-1758
Adjuvant radiotherapy
  for anal-rectal melanoma, 4549-4552
  in rectal cancer, stage II and III, 1751-1758
  for soft tissue sarcoma of extremity, 1643-1650, 3929-3930 (correspondence)
Adjuvant therapy. *See also* Adjuvant chemotherapy; Adjuvant radiotherapy
  for breast cancer
    community physicians' practice patterns, 1809-1817
    hormone-receptor-positive (ASCO status report 2002), 3317-3327
    international research highlights on, 1954-1957 (correspondence)
    in older women, 2680-2688
    in premenopausal women, 2559-2566, 3934-3936 (correspondence), 4611-4614 (editorial), 4621-4627, 4628-4635
  for colorectal cancer, demographic differences in, 1192-1202
  for melanoma, 1818-1825, 4120-4124 (correspondence)
    quality-of-life–adjusted survival analysis of IFNα2b, 1311-1318
    tyrosinase mRNA in patients' blood after, 4032-4039
    vaccine, 2058-2066, 2067-2075, 4181-4190
  for rectal cancer in elderly, 2643-2650

Adolescents
early-stage Hodgkin's disease in, VAMP and low-dose radiation for, 3081-3087
hepatocellular carcinoma in, 2789-2797
Adoptive immunotherapy, in melanoma, 1075-1086, 3176-3177 (correspondence), 3184 (errata)
Adrenal insufficiency, as initial NSCLC manifestations, 4598-4600
Adrenocortical carcinoma, phenotyping of, 941-950
Advanced cancers/malignancies. *See also* Refractory cancers; *specific cancers*
capecitabine plus gemcitabine in (phase I trial), 582-587
E7070 pharmacokinetics in (phase I trial), 3508-3521
emotional expression by patients with, 3352-3355
flavopiridol for, daily 1-hour infusion of (phase I trial), 4074-4082
marantic endocarditis in, 4111-4114
pancreatic, gemcitabine with 5-FU *vs.* gemcitabine alone in, 3270-3275
R115777 in, chronic oral administration of (phase I trial), 2726-2735
self-rated health predicting survival in, 2514-1519
symptom experiences in home care setting, patient and caregiver perceptions of, 3495-3507
TAC-101 in, safety, toxicity, and pharmacokinetics of, 3522-3532
Age
adjuvant therapy for colorectal cancer and, 1192-1202
and stroke risk after radiotherapy on neck, 282-288
AIDS patients, Kaposi's sarcoma in
COL-3 for (phase I trial), 153-159
oral etoposide for (phase II trial), 3236-3241
AJCC (American Joint Committee on Cancer), breast cancer staging system update from, 3628-3636
Alemtuzumab, in chronic lymphocytic leukemia, 3891-3897
ALL. *See* Acute lymphoblastic leukemia
Allogeneic stem-cell transplantation. *See* Stem-cell transplantation, allogeneic
Alpha-lipoic acid, for oxaliplatin-induced cumulative polyneuropathy, 3359-3361 (correspondence)
Alteplase, for occluded venous catheters, safety and efficacy of, 317-324, 1918-1922
Alternative medicine. *See* Complementary/alternative medicine
American Cancer Society
cancer prevention clinical trials (ACS Award Lecture), 14*s*-22*s*
safety issues in use of complementary and alternative medicine (ASCO/American Cancer Society Symposium), 39*s*-41*s*
American Joint Committee on Cancer, breast cancer staging system update from, 3628-3636
American Society of Clinical Oncology
on adjuvant aromatase inhibitor therapy (status report 2002), 3317-3327
breast cancer risk reduction (update 2002), 3328-3343
guidelines from
bisphosphonates in multiple myeloma, 3719-3736
evidence-based, epoetin use in cancer patients, 4083-4107
use of chemotherapy and radiotherapy protectants (2002 update), 2895-2903
regulatory burdens on quality cancer care (Presidential Initiative 2001), 4722-4726
safety issues in use of complementary and alternative medicine (ASCO/American Cancer Society Symposium), 47s-59s
worldwide anticancer drug discovery and development (2002 ASCO International Symposium), 47s-59s
American Society of Hematology, evidence-based guidelines for epoetin use in cancer patients from, 4083-4107
AML. *See* Acute myeloid leukemia
Amputation, in survivors of pediatric lower-extremity bone tumors, 4493-4501
Anal-rectal melanoma, sphincter-sparing therapy for, 4549-4552
Analgesic regimen, adherence to, patients' perspective on, 2907-2908 (correspondence)
Anaplastic large-cell lymphoma
isolated meningeal, 4395-4397
kinase-positive, molecular biology of, 3691-3702
Anastrozole
fulvestrant *vs.*, in postmenopausal women with advanced breast cancer, 3386-3395, 3396-3403
influence on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients, 751-757, 3039-3040 (correspondence)
tamoxifen *vs.*, in advanced breast cancer, 3748-3750 (correspondence)
Androgen blockade, isotretinoin and, in prostate cancer, 538-544
Androgen receptor, molecular biology of, 3001-3015
Anemic patients
epoetin beta and, 2486-2494
transfusion requirements in, 3182-3184 (correspondence)
Angiogenesis
in Barrett's epithelium, 2971-2979
cancer therapy based on, mechanisms and future directions for, 3906-3927
inhibitors of. *See* rh-Endostatin
and node-positive breast cancer outcome (CALB 8541 study), 732-742
and *p53* link, in lung cancer, 883-884 (editorial)
VEGF-A and, 4368-4380
Anorexia, cancer-associated, 567-573, 2912-2913 (correspondence)
Anthracycline-based chemotherapy, for node-positive breast cancer, 3637-3643
Antiangiogenic therapy
chemotherapy with, toxicity of (editorial), 1446-1447
thrombosis associated with, 1657-1667, 3042-3043 (correspondence)

Antibiotic therapy
bladder MALT lymphoma regression after, 882 (correspondence)
prophylactic lozenge, for radiation mucositis (phase III trial), 3956-3963
Antibodies
anti-gastrin-17, in pancreatic cancer (phase II trial), 4225-4231
monoclonal
^{131}I-labeled 81C6 in newly diagnosed malignant gliomas (phase II trial), 1389-1397
anti-CD20, radiolabeled, for B-cell lymphoma, 3545-3557
Anticancer drugs. *See* Chemotherapeutics; *individual agents*
development of. *See* Drug development
Anticancer vaccines. *See* Immunotherapy, for melanoma; Vaccine/Vaccination, for melanoma
Antiemetics
patient-tailored treatment with, 2805-2811
patients' assessment of, 4-6 (editorial), 65-72
Antineoplastic drugs, cytostatic, discontinuation design applied to, 4478-4484
Antrasentan, for refractory adenocarcinomas, 2171-2180
Anxiety disorders, in cancer patients, 3137-3148
Ara-C. *See* Cytarabine
Arm morbidity, chronic, after breast cancer treatment, 4242-4248
Aromatase inhibitor therapy, for breast cancer, 876-878 (correspondence)
in hormone-receptor-positive breast cancer (ASCO status report 2002), 3317-3327
in metastatic breast cancer, 3365-3368 (editorial)
risk reduction with (ASCO update 2002), 3328-3343
total body, letrozole and anastrozole influence in postmenopausal patients, 751-757, 3039-3040 (correspondence)
Artificial hydration, in terminally-ill patients, 4699-4704
Artificial neural networks
for prostate cancer detection, 921-929
and statistical prediction models, 885-887 (editorial)
ASCO. *See* American Society of Clinical Oncology
Aspergillosis, invasive, 1898-1906
Assisted suicide, views in terminally-ill patients, 2134-2141
ATP. *See* Adenosine triphosphate
Atrial mass, pulmonary vein leiomyosarcoma presenting as, 2749-2751
Autologous stem-cell transplantation. *See* Stem-cell transplantation, autologous
Award lectures
cancer prevention clinical trials (American Cancer Society Award Lecture), 14*s*-22*s*
targeting epidermal growth factor receptor for cancer therapy (David A. Karnofsky Award Lecture), 1*s*-13*s*
Aza C (azacytidine) therapy, in myelodysplastic syndrome
impact on quality of life, 2441-2452
vs. supportive care, 2415-2416 (editorial), 2429-2440
Azoospermia, postchemotherapy ejaculatory, management of, 930-936

B

B-cell lymphoma
MALT type, cladribine therapy in (phase II trial), 3872-3877
radiolabeled anti-CD20 monoclonal antibodies for, 3545-3557
T-cell/histiocyte–rich large, 1269-1277
Barrett's adenocarcinoma, lymphangiogenesis in, 2971-2979
Barrett's epithelium, angiogenesis in, 2971-2979
Bax expression, in colorectal cancer, 811-816
BCNU. *See* Carmustine
Beliefs, physician communication skills training altering, 765-769
O^6-Benzylguanine, carmustine plus, for malignant glioma (phase II trial), 2277-2283
Best supportive care, docetaxel *vs.*, as second-line therapy of advanced NSCLC, 1344-1352, 3750-3751 (correspondence)
Bioavailability, of topotecan, 2918-2919 (editorial), 2943-2950
Biochemotherapy
for advanced melanoma, 2411-2414 (editorial)
for metastatic melanoma (phase III trials), 1600-1607, 2045-2052, 3560-3561 (correspondence)
Bisphosphonates
in multiple myeloma, ASCO use guidelines, 3719-3736
and tumor burden (editorial), 3191-3192
Bladder, MALT lymphoma of, regression after antibiotic therapy, 882 (correspondence)
Bladder cancer, 3191-3192. *See also* Urothelial tract, advanced cancer of
adenovirus-mediated *p53* gene transfer in, 957-965
c-met expression in, 1544-1550
intravesical therapy for, 3185-3186 (editorial)
with gemcitabine (phase I trial), 3193-3198
radiotherapy and organ preservation in, 3048-3050 (editorial), 3061-3071
Bleomycin, in CIB regimen for squamous cell carcinoma of cervix, 1832-1837
BMT. *See* Bone marrow transplantation
Body-surface area
and cisplatin clearance, 1144 (correspondence), 4270-4271 (correspondence)
and irinotecan clearance, 81-87
Bone
non-Hodgkin's lymphoma of, outcome in children, 2293-2301
resorption of, effects of long-term ibandronate therapy on, 2353-2359
sarcoma of, carbon ion radiotherapy in, 4466-4471
Bone marrow
micrometastases in, resected NSCLC and, 2930-2936

RANKL expression in, 353-354 (correspndence)
Bone marrow transplantation. *See also* Stem-cell transplantation
acute and chronic GVHD after, meta-analysis of, 603-606 (correspondence)
for acute lymphoblastic leukemia, 4655-4664
for acute myeloid leukemia
outcomes in, 4324-4330
vs. allogenic peripheral blood stem cells, 4655-4664
long-term data on CML patients after, 2334-2343
for malignant lymphoma, isolated orbit relapse after, 4394-4395
Bone metastases
N-/C-telopeptide cross-links in, 850-856
skeletal irradiation with high-dose ^{153}Sm-EDTMP in, 189-196, 1953-1954 (correspondence)
Bone tumors, lower-extremity, limb salvage and amputation in pediatric survivors of, 4493-4501
Bony lesions, hematologic malignancy presenting with, 3737-3739
Brain metastases
HER2 in, 4130-4133 (correspondence)
motexafin gadolinium for, 3445-3453
from ovarian cancer, 982-986
temozolomide and concurrent radiotherapy in (phase II trial), 3644-3650
Brain tumors, recurrent, in pretreated glioma patients, diagnosis of, 396-404
Brainstem tumors, high-risk pediatric, preradiation chemotherapy in (phase II trial), 3431-3437
BRCA1/*BRCA2* genes
BRCAPRO validity and, 2701-2712, 3936-3937 (correspondence)
and epithelial ovarian cancer survival, 463-466
germline mutations in, clinical characteristics of individuals with, 1480-1490
mutation carriers
decision analysis in, 2092-2100, 2420-2529
frequency in high-risk evaluation clinic, 994-999
immunohistochemistry in, 2310-2318, 3752-3753 (correspondence)
outcome in, 1260-1268
psychologic impact of testing in, 514-520
risk management in, 1164-1166 (editorial)
BRCA1/*BRCA2* genetic testing
in community setting, 4485-4492
psychologic impact of, 514-520
BRCAPRO statistical model, and genetic testing, 2701-2712, 3936-3937 (correspondence)
Breast cancer
^{18}FDG uptake in, biology of, 379-387
adjuvant therapy for
aromatase inhibitors in (ASCO status report 2002), 3317-3327
combined endocrine treatment and chemotherapy, 4611-4614 (editorial), 4621-4627, 4628-4635
community physicians' practice patterns, 1809-1817
international research highlights on, 1954-1957 (correspondence)
in older women, 2680-2688
oophorectomy and tamoxifen, 2559-2566, 3934-3936 (correspondence)
advanced
anastrozole *vs.* tamoxifen in, 3748-3750 (correspondence)
anthracycline- and taxane-resistant, eniluracil and 5-FU for (phase II trial), 987-993, 3750 (correspondence)
anthracycline-pretreated, combination chemotherapy for
phase II trial, 2551-2558
phase III trial results, 2812-2823
chemotherapy in (phase III trial), 4150-4159
fulvestrant *vs.* anastrozole in, 3386-3395, 3396-3403
letrozole therapy for, *vs.* tamoxifen, in postmenopausal women, 876-878 (correspondence)
pretreated, biweekly vinorelbine and gemcitabine for (phase II trial), 37-41
taxane pretreated, combination chemotherapy for (phase II trial), 2551-2558
weekly paclitaxel and carboplatin in (phase II trial), 3857-3864
AJCC staging system update in, 3576-3577 (editorial)
aromatase inhibitors for. *See* Aromatase inhibitor therapy; *individual agents*
axillary lymph node eradication in, 1304-1310
node-negative patients, 1793-1799
breast conservation in. *See* Breast-conserving therapy
chemotherapy for
assessing and reporting toxicity of, 52-57
high-dose, with Ro 25–8315, 24-36
pegfilgrastim as adjunct to, 727-731
preoperative, 2905-2907 (correspondence)
chronic arm morbidity after treatment of, 4242-4248
complementary and alternative medicine use in (discussion), 34*s*-38*s*
consultation planning in, 2695-2700
diagnosis of, nutrition and survival after, 3302-3316, 3939 (errata)
dietary change after, 1017-1025
early-stage
effect of MRI on clinical management of, 3413-3423
in elderly, treatment costs for, 307-316
insulin in, 42-51
patients' involvement in treatment decision making, 1473-1479
in elderly women
adjuvant tamoxifen therapy for, 2680-2688
treatment costs for, 307-316
familial, immunohistochemistry of, 2310-2318, 3752-3753 (correspondence)
HER-2/*neu* gene amplification and overexpression in, assay methods compared, 3095-3105, 4607-4608 (correspondence)
high-risk evaluation clinic for, *BRCA1*/*BRCA2* genes mutation frequency in, 994-999

hormone-receptor-positive, adjuvant aromatase inhibitor therapy in (ASCO status report 2002), 3317-3327
international consensus meetings on, 1719-1720 (editorial), 1954-1957 (correspondence)
mastectomy for. *See* Mastectomy
metastatic. *See* Metastatic breast cancer
neoadjuvant docetaxel in, 1456-1466
node-negative, postmenopausal, endocrine-related predictive factors in, 2210-2212 (correspondence)
node-positive. *See* Node-positive breast cancer
operable
and breast conservation. *See* Breast-conserving therapy
chemotherapy prior to, 2905-2907 (correspondence)
CK-19$^+$ cells in peripheral blood of patients with, 3404-3412
clodronate trial in, 3219-3224
uPA/PAI-1 in, clinical relevance of, 1000-1007
in postmenopausal women. *See* Postmenopausal women, breast cancer in
in premenopausal women, adjuvant therapy for, 2559-2566, 3934-3936 (correspondence)
combined endocrine treatment and chemotherapy, 4611-4614 (editorial), 4621-4627
oophorectomy and tamoxifen, 2559-2566, 3934-3936 (correspondence)
prevention of
chemoprevention. *See* Tamoxifen
hypercoagulability and, 4133-4134 (correspondence)
primary
adjuvant therapy for, international research highlights on, 1954-1957 (correspondence)
clodronate trial in, 3219-3224
quality of care in, 4381-4393
radiotherapy for, cardiac disease morbidity and mortality after, 1036-1042
recurrent. *See* Recurrent breast cancer
risk of
estrogen-raloxifene interaction and, 1430 (erratum)
reduction in, pharmacologic interventions for (ASCO update 2002), 3328-3343
screening for
in *BRCA1* mutation carriers, 2092-2100
in women with previous Hodgkin's disease, 2085-2091
survivors of. *See* Breast cancer survivors
susceptibility genes, BRCAPRO validity and, 2701-2712, 3936-3937 (correspondence)
tamoxifen for. *See* Tamoxifen
treatment options in
International Consensus Panel meeting highlights, 879-880 (correspondence)
physician communication with older women about, 1008-1016
weight loss in management of, 1128-1143
Breast cancer patients
early-stage, involvement in treatment decision making, 1473-1479
high-risk, tamoxifen for, cost-effectiveness analysis, 1-3 (editorial), 9-16
quality of care in, 4381-4393
written emotional expression and benefit finding in, 4160-4168
Breast cancer survivors, neuropsychologic impact of chemotherapy in, 485-493
Breast-conserving therapy. *See also* Lumpectomy
breast irradiation after, clinical trials evaluating (editorial), 4135-4138
ipsilateral breast tumor recurrence after, 4015-4021
Breast tumor, ipsilateral recurrence of, 4015-4021
preventive strategies, 4141-4149
Bronchopulmonary fibrosarcoma, juvenile, 2745-2746
BSA. *See* Body-surface area
Burkitt's lymphoma, advanced, in children, 2783-2788

C

c-met expression, in transitional cell carcinoma of urinary bladder, 1544-1550
CAM. *See* Complementary/alternative medicine
Campath-1H, in pretreated T-cell prolymphocytic leukemia, 205-213
Cancer
angiogenesis in. *See* Angiogenesis
anorexia in, dronabinol therapy for, 567-573, 2912-2913 (correspondence)
comprehensive geriatric assessment in, 494-502
developing viruses to treat, 2220-2222 (editorial)
microarrays and, 3165-3175
survivors of. *See* Childhood cancer survivors; Survivors
susceptibility to, identification of high-risk families with, 528-537
Cancer care
accuracy of recorded TNM stage in, 413-419
palliative, quality of life in, 1704-1705 (correspondence)
quality of
in breast cancer patients, 4381-4393
case identification challenge in, 4353-4360
regulatory burdens of (ASCO Presidential Initiative 2001), 4722-4726
Cancer centers, types of (editorial), 4503-4507
Cancer drugs. *See* Chemotherapeutics; *individual chemotherapeutic agents*
Cancer patients. *See also specific forms of cancer*
adenosine triphosphate for, 362-263 (editorial)
and nutritional status, 371-378
adherence to analgesic regimen by, perspective on, 2907-2908 (correspondence)
anxiety disorders in, 3137-3148
catheter-associated complications in, 3276-3281
chemotherapy in
effects of epoetin alfa on quality of life in
nonplatinum therapy, 601-603 (correspondence)
once-weekly dosing, 3182-3184 (correspondence)

once-weekly *vs.* three-times-weekly dosing, 878 (correspondence), 2757-2758 (correspondence)
stress management training for, 2851-2862
with hepatic dysfunction, irinotecan in, 4303-4312
hospitalization during last six months of life, 1584-1592
influenza vaccine with GM-CSF or placebo in, 4313-4318
informed decision making among, 503-513
invasive aspergillosis in, 1898-1906
long-term survival analysis of, 826-832, 4405-4409 (correspondence)
methylphenidate use in, 335-339
with pain. *See* Palliative therapy
parents as, child care and, 4399-4402
quality of life in. *See* Quality of life
self-rated health predicting survival in, 2514-1519
terminally-ill. *See* End-of-life care; Terminally-ill patient
unanswerable questions from, 873-875
Cancer prevention, clinical trials (American Cancer Society Award Lecture), 14*s*-22*s*
Cancer research. *See* Research
Cancer survivors. *See* Survivors
Cancer therapy. *See also specific therapies*
angiogenesis-based, mechanisms and future directions for, 3906-3927
with melatonin, potential usefulness of, 2575-2601, 4127-4129 (correspondence)
MGMT gene in, clinical relevance of, 2388-2399
sperm banking prior to
oncologists' attitudes toward, 1890-1897
patients' attitudes toward, 1880-1889
STI571 paradigm, 325-334. *See also* Imatinib mesylate
targeting epidermal growth factor receptor for (David A. Karnofsky Award Lecture), 1*s*-13*s*
Capecitabine
and docetaxel
in resistant malignancy, scheduling of, 2616-2623
survival in advanced breast cancer with (phase III trial), 2812-2823
dosing recommendations in renal impairment (editorial), 1434-1435
and gemcitabine, in advanced cancer (phase I trial), 582-587
oral, in advanced or metastatic pancreatic cancer (phase II trial), 160-164
and oxaliplatin, in advanced or metastatic colorectal cancer (phase II trial), 1759-1766
radiation recall phenomenon after administration of, 3029-3030, 4130 (correspondence)
in rectal cancer, radiotherapy concurrent with (phase I trial), 3983-3991
Carbon ion radiotherapy, in bone and soft tissue sarcomas, 4466-4471
Carboplatin
in combination chemotherapy for advanced NSCLC (phase III trial), 3578-3585
with gemcitabine/paclitaxel, for carcinoma of unknown primary site, 1651-1656
hypersensitivity to, oxaliplatin replacement for, 353 (correspondence)
with paclitaxel
as second-line therapy for recurrent epithelial ovarian cancer, 1238-1247
weekly, in advanced breast cancer (phase II trial), 3857-3864
and pemetrexed activity, in malignant mesothelioma (phase I trial), 3533-3544
for progressive pediatric low-grade gliomas (phase II trial), 2951-2958
with topotecan, in pediatric solid tumors (phase I trial), 88-95, 3558 (correspondence)
Carcinoembryonic antigen, as target for anticancer vaccines, 2197-2207
Carcinoid
endobronchial, of lung, 2747-2748, 4269-4270 (correspondence)
gastric, metastatic to liver, 2403-2404
Carcinoma. *See individual conditions and tumors*
Carcinoma-in-situ, testicular, radiotherapy for, 1537-1543, 3559-3560 (correspondence)
Carcinoma of unknown primary site
combination chemotherapy for, 1651-1656
prognostic model to predict survival length in, 4679-4683
Cardiac disease, after radiotherapy for breast cancer, 1036-1042
Cardiac dysfunction, trastuzumab and, 1156-1157 (editorial), 1215-1221, 4119-4120 (correspondence)
Caregivers
and oncologist house calls, 3745-3746
and physician communication, 1952-1953 (correspondence)
symptom experiences in home care setting, 3495-3507
Carmustine, plus O^6-benzylguanine, for malignant glioma (phase II trial), 2277-2283
Case identification challenge, in measuring cancer care quality, 4353-4360
Castration, nomogram for prostate cancer survival after, 3972-3982
Catheters
occluded central venous, alteplase for, 317-324, 1918-1922
peripherally inserted central, complications associated with, 3276-3281
CD4+ T cells
immune response to B-cell non-Hodgkin's lymphoma, 2904-2905 (correspondence)
recovery induced by lymphocyte reinfusion in metastatic breast cancer, 58-64
CD8+ T cells, recovery induced by lymphocyte reinfusion in metastatic breast cancer, 58-64
CD20 expression, in classical Hodgkin's disease, 1278-1287
CEACAM1 expression
in lung cancer, 4273-4275 (editorial), 4279-4284
in metastatic melanoma, 2530-2536

Central nervous system
involvement in intestinal gamma/delta T-cell lymphoma, 3742-3744
and metastatic gastrointestinal stromal tumor response to imatinib mesylate, 870-872, 1430 (erratum)
primary lymphoma of, 4615-4617 (editorial)
combined chemotherapy/radiotherapy for, 4643-4648
effect of radiotherapy on outcome in, 231-236
Central venous catheters
occluded, alteplase for, 317-324, 1918-1922
peripherally-inserted, complications associated with, 3276-3281
Cerebral glioma, low-grade, prognostic factors in, 2076-2084
Cervical cancer
COX-2 prognostic role in, 973-981
locally advanced
chemoradiation for, 891-893 (editorial)
neoadjuvant chemotherapy plus radical surgery *vs.* exclusive radiotherapy for, 179-188, 2908-2910 (correspondence)
lymphatic mapping and sentinel node identification in, 688-693, 2602-2603 (correspondence)
node-negative, tumor hypoxia in, 680-687
pelvic radiotherapy complications, smoking history associated with, 3651-3657
squamous cell
advanced, radiotherapy with/without cisplatin for (phase III trial), 966-972
CIB chemotherapy regimen for, 1832-1837
locally advanced, neoadjuvant chemotherapy plus radical surgery *vs.* exclusive radiotherapy for, 179-188, 2908-2910 (correspondence)
tumor hypoxia in, 610-615 (editorial), 680-687
Chemoembolization, transcatheter arterial, *vs.* hepatic resection in hepatocellular carcinoma, 4459-4465
Chemoprevention, for breast cancer. *See* Tamoxifen
Chemoradiotherapy
for advanced head and neck cancer, 1405-1410
for advanced nasopharyngeal cancer, disease control and survival in, 1845-1852
for cervical cancer, locally advanced, 891-893 (editorial)
for primary CNS lymphoma, 4643-4648
sequential, for limited-stage small-cell lung cancer (phase III trial), 3045-3047 (editorial), 3054-3060
for stage IIIB NSCLC, 3454-3460
following induction chemotherapy, 4191-4198
Chemotherapeutics. *See also individual agents*
irinotecan/ketoconazole interaction, 3122-3129
Chemotherapy. *See also* Adjuvant chemotherapy; Neoadjuvant chemotherapy; *specific regimens and agents*
for advanced breast cancer. *See* Breast cancer, advanced
for advanced NSCLC. *See* Non–small-cell lung cancer, advanced
for advanced ovarian cancer, variations in elderly, 173-178
and antiangiogenic combinations, toxicity of (editorial), 1446-1447
benefit from, patient *vs.* physician perceptions about, 4603-4604
for breast cancer. *See* Breast cancer, chemotherapy for
chronomodulated, in advanced colorectal cancer, 1175-1181 (phase II trial), 3937-3939 (correspondence)
consolidation, in childhood AML, 2774-2782
cyclical, for adult acute ALL, 2464-2471
duration of, in advanced NSCLC (phase III trial), 1335-1343
effects on quality of life in metastatic breast cancer, 3106-3113
endocrine treatment *vs.*, in premenopausal breast cancer patients, 4611-4614 (editorial), 4621-4627
for esophagogastric cancer, 1962-1964 (editorial)
high-dose. *See* High-dose chemotherapy
intensive short-term, in pediatric advanced Burkitt's lymphoma, 2783-2788
intraperitoneal, for ovarian cancer, follow-up results in, 694-698
and local-regionally advanced nasopharyngeal cancer, 1968-1970 (editorial)
for lung cancer, impact of referral patterns on use of, 1786-1792
for metastatic colorectal cancer. *See* Metastatic colorectal cancer
for myeloid relapse after allogeneic stem-cell transplantation, 405-412, 2756-2757 (correspondence)
myelosuppression induced by, model of, 4713-4721
neuropsychologic impact of, in breast cancer survivors, 485-493
for non-Hodgkin's lymphoma, after yttriun-90-labeled ibritumomab tiuxetan radioimmunotherapy, 3885-3890
nonplatinum, epoetin alfa in patients receiving, 601-603 (correspondence)
palliative
health-related quality of life and, 1056-1062
vs. watchful waiting, oncologists' preferences, 3658-3664, 4409 (erratum)
perioperative, for postmenopausal node-negative breast cancer, 2210-2212 (correspondence)
preoperative
in breast cancer, 2905-2907 (correspondence)
vs. primary surgery in resectable NSCLC, 247-253, 2603-2604 (correspondence)
preradiation, in pediatric high-risk brainstem tumors (phase II trial), 3431-3437
with radiation. *See* Chemoradiotherapy
resistance to, and COX-2 prognostic role in cervical cancer, 973-981
safety of, multidisciplinary approach to, 4705-4712
salvage, for advanced pure seminoma, 297-301
Stanford V regimen, for Hodgkin's disease, 630-637
stress management training for patients undergoing, 2851-2862
toxicity of
and antiangiogenic combinations (editorial), 1446-1447

in breast cancer, assessing and reporting, 52-57, 4636-4642
Chemotherapy protectants, ASCO guidelines on use of (2002 update), 2895-2903
Childhood cancer survivors
left ventricular dysfunction in, long-term enalapril therapy for, 4517-4522
limb salvage and amputation in, 4493-4501
quality of life measurement tool for, 4692-4698
smoking initiation and cessation among, 1608-1616
Children
acute leukemias in
lymphoblastic. *See* Acute lymphoblastic leukemia, childhood
myeloblastic. *See* Acute myeloblastic leukemia, childhood
myeloid. *See* Acute myeloid leukemia, childhood
advanced Burkitt's lymphoma in, 2783-2788
bronchopulmonary fibrosarcoma in, 2745-2746
cancer centers for (editorial), 4503-4507
gliomas in
low-grade
cisplatin/etoposide regimen for, 4209-4216
progressive, carboplatin for (phase II trial), 2951-2958
malignant, temozolomide in, 4684-4691
hepatocellular carcinoma in, 2789-2797, 2798-2804
Hodgkin's disease in. *See* Hodgkin's disease, in children and adolescents
juvenile myelomonocytic leukemia or myelodysplastic syndrome in, treatment results, 434-440
metastatic osteosarcoma in, etoposide and ifosfamide for (phase II/III trial), 426-433
neuroblastoma in, screening for, 1154-1155 (editorial)
incidence and mortality results, 1209-1214
non-Hodgkin's lymphoma in
of bone, outcome of, 2293-2301
G-CSF induction therapy in, 441-448
nonrhabdomyosarcoma soft tissue sarcoma in, 3225-3235
parents with cancer caring for, 4399-4402
preradiation chemotherapy in high-risk brainstem tumors (phase II trial), 3431-3437
refractory acute leukemia in, topotecan schedule for, 1617-1624
rhabdomyosarcoma outcomes in, by race, 4428-4433
solid tumors in, combined topotecan/carboplatin for (phase I trial), 88-95, 3558 (correspondence)
supratentorial PNET in, radiotherapy of, 842-849
unresectable and metastatic hepatoblastoma in, treatment of (phase II trial), 3438-3444
Wilms' tumor in, chest CT for staging of, 2763-2764 (editorial), 2768-2773
Chlorambucil, myeloid leukemia associated with, in CLL patients, 3878-3884
ChlVPP/EVA hybrid chemotherapy, *vs.* VAPEC-B regimen for Hodgkin's disease, 2980-2987
CHOD/BVAM chemotherapy, for CNS lymphoma, radiotherapy and, 231-236
CHOP chemotherapy, for mantle-cell lymphoma, 1288-1294
Chromosome abnormalities
in AML, detection methods compared, 2480-2485
on chromosome segment 11p15.5 in NSCLC, 1353-1360
Chronic leukemias
lymphocytic
alemtuzumab in, 3891-3897
therapy-related myeloid leukemias in, 3878-3884
myelogenous, STI571 therapeutic paradigm in, 325-334
myeloid
cytogenetic remission in, IFNa cessation and, 214-220
depigmentation in, following STI571 therapy, 869-870, 1430 (erratum)
long-term data after BMT, 2334-2343
myelomonocytic, juvenile, treatment protocol results in, 434-440
Cisplatin
in advanced cutaneous squamous cell cancer (phase II trial), 364-370
in chemoradiotherapy
for limited-stage small-cell lung cancer (phase III trial), 3045-3047 (editorial), 3054-3060
for pathologic stage IIIB NSCLC, 3454-3460
in CIB regimen for squamous cell carcinoma of cervix, 1832-1837
clearance of, body-surface area and, 1144 (correspondence), 4270-4271 (correspondence)
with docetaxel, for squamous cell carcinoma of head and neck (phase II trial), 1593-1599
with doxorubicin and etoposide, for small-cell prostate carcinoma (phase II trial), 3072-3080
with epirubicin, in advanced breast cancer (phase III trial), 4150-4159
for esophagogastric cancer, 1962-1964 (editorial), 1996-2004, 4124-4126 (correspondence)
with etoposide
and doxorubicin, for small-cell prostate carcinoma (phase II trial), 3072-3080
response rate in childhood low-grade glioma, 4209-4216
vs. CEV chemotherapy regimen, in small-cell lung cancer (phase III trial), 4665-4672
radiotherapy with/without, for advanced squamous cell cervical cancer (phase III trial), 966-972
in salvage chemotherapy for advanced transitional-cell carcinoma (phase II trial), 2965-2970
for solid tumors, dose-finding and pharmacokinetic study of, 1657-1667, 3042-3043 (correspondence)
CK-19$^+$ cells, in operable breast cancer, prognostic significance of, 3404-3412
Cladribine, and cytarabine, in childhood AML, 4217-4224
Clinical cancer research. *See* Research
Clinical practices, communication skills training for physicians and, 765-769
Clinical trials. *See also* Research; *specific* Phase *entries*

accrual in, 2109-2117
cancer prevention (American Cancer Society Award Lecture), 14*s*-22*s*
design of
factorial, considerations in, 3424-3430
principles of, 42*s*-46*s*
randomized discontinuation, cytostatic antineoplastic drugs and, 4478-4484
in malignant melanoma, sentinel-node techniques in, 2208-2210 (correspondence)
molecular heterogeneity influencing, 2495-2499, 4606-4607 (correspondence)
off-shore, ethical issues and, 3934-3936 (correspondence)
premature conclusion of, ethical issues associated with, 1709 (correspondence)
supporting clinician decision-making, 4126-4127 (correspondence)
workload of, factors affecting, 545-556
CLL. *See* Chronic leukemias, lymphocytic
Clodronate, in primary operable breast cancer, 3219-3224
CML. *See* Chronic leukemias, myelogenous; Chronic leukemias, myeloid
CNS lymphoma. *See* Central nervous system, primary lymphoma of
COL-3, for AIDS-related Kaposi's sarcoma (phase I trial), 153-159
Colon cancer. *See also* Colorectal cancer
advanced, adjuvant chemotherapy for
in elderly patients, 3992-3998
in Medicare beneficiaries, 3999-4005
thymidylate synthase levels in, prognostic and predictive values of, 1711-1713 (editorial), 1735-1743
Colony-stimulating factors. *See individual factors*
Colorectal cancer. *See also* Colon cancer; Rectal cancer
adjuvant therapy for, demographic differences in, 1192-1202
advanced
capecitabine and oxaliplatin for (phase II trial), 1759-1766
oral *vs.* intravenous first-line therapy for (phase III trial), 1519-1526
oxaliplatin neurotoxicity in, 3478-3483
oxaliplatin plus irinotecan *vs.* raltitrexed in (phase II trial), 165-172
Bax expression in, primary tumor *vs.* metastatic disease, 811-816
hereditary nonpolyposis. *See* Hereditary nonpolyposis colorectal cancer
liver metastases from, 1442-1445 (editorial)
FDG–PET scan in, 388-395
surgical resection of, 1499-1505
metastatic. *See* Metastatic colorectal cancer
micrometastases in, immunomagnetic enrichment and detection of, 4338-4343
node-negative, CK-20 RT-PCR in lymph nodes of patients with, 1049-1055
thymidylate synthase levels in, prognostic and predictive values of, 1711-1713 (editorial), 1721-1728
uracil/tegafur plus leucovorin in, 3574-3575 (editorial), 3605-3616 (phase III), 3617-3627
Colorectal tumors, phenotyping of, immunohistochemistry *vs.* microsatellite instability, 1043-1048
Colostomy, *vs.* sphincter preservation for rectal cancer, 1971-1972 (editorial), 3930-3931 (correspondence)
Combination therapy
dose escalation in advanced cancer (phase I trial), 582-587
for esophageal cancer (phase III trial), 1167-1174
dose escalation in, 1151-1153 (editorial)
in Hodgkin's lymphoma, 476-484
for newly diagnosed myeloma, 4319-4323
Combined chemotherapy regimens. *See also individual agents*
in advanced NSCLC, 3565-3567 (editorial), 3578-3585 (phase III trial)
for anthracycline-pretreated breast cancer
advanced cancer (phase III trial), 2812-2823
metastatic cancer (phase II trial), 2551-2558
in breast cancer
advanced, with capecitabine/docetaxel (phase III trial), 2812-2823
metastatic, for taxane and/or anthracycline (phase II trial), 2551-2558
for carcinoma of unknown primary site, 1651-1656
in Hodgkin's lymphoma, 476-484
for metastatic colorectal cancer, in combined drug therapy, 2545-2550
for small-cell prostate carcinoma (phase II trial), 3072-3080
for solid tumors, dose-finding and pharmacokinetic study of, 1657-1667, 3042-3043 (correspondence)
for squamous cell carcinoma of head and neck (phase II trial), 1593-1599
for taxane pretreated metastatic breast cancer (phase II trial), 2551-2558
Communication
in end-of-life cancer care, European team assessments of, 3674-3682
physician training in, altering beliefs and behavior in clinics, 765-769
silence as, 1952-1953 (correspondence)
Community physicians, practice patterns in adjuvant therapy for breast cancer, 1809-1817
Community setting
BRCA1/2 genetic testing in, 4485-4492
cancer centers in (editorial), 4503-4507
Complementary/alternative medicine
safety considerations in (ASCO/American Cancer Society Symposium), 39*s*-41*s*
use among breast cancer patients (discussion), 34*s*-38*s*
Compression fractures, myelomatous, kyphoplasty for, 2382-2387

Computed tomography
of chest, staging of pediatric Wilms' tumor by, 2763-2764 (editorial), 2768-2773
low-dose helical, lung cancer screening with, 911-920
Conditioning regimens, nonmyeloablative, in high-risk multiple myeloma patients, 1295-1303, 4268-4269 (correspondence)
Consolidation chemotherapy, in childhood AML, 2774-2782
Consultation planning, and patient-physician communication, 2695-2700
Cost
of early-stage breast cancer treatments in elderly, 307-316
radiotherapy *vs.* radical prostatectomy, in early-stage prostate cancer, 2869-2875
of stress management training for patients undergoing chemotherapy, 2851-2862
Cost-effectiveness
of alternative staging strategies for NSCLC, 263-273
of docetaxel *vs.* best supportive care, as second-line therapy of advanced NSCLC, 1344-1352, 3750-3751 (correspondence)
of postmastectomy radiotherapy, 2713-2725
COX-2, prognostic role in cervical cancer, 973-981
CPT-11. *See* Irinotecan
CSFs. *See individual factors*
Cutaneous lymphoma, primary follicular, 647-655
Cutaneous melanoma, primary, tumor vascularity in, 1826-1831
Cutaneous squamous cell carcinoma, 359-361 (editorial)
advanced, translational study of (phase II trial), 364-370
Cyclooxygenase-2, prognostic role in cervical cancer, 973-981
Cyclophosphamide
in CEV chemotherapy regimen, etoposide/cisplatin *vs.*, in small-cell lung cancer (phase III trial), 4665-4672
in CMF chemotherapy regimen, goserelin *vs.*, in premenopausal breast cancer patients, 4628-4635
tamoxifen and, 4611-4614 (editorial), 4621-4627
in CVP chemotherapy regimen, fludarabine *vs.*, for low-grade non-Hodgkin's lymphoma (phase III trial), 4649-4654
Cyclosporine
and oral bioavailability of docetaxel, 1951-1952 (correspondence)
paclitaxel and, in advanced non–small-cell lung cancer (phase II trial), 4508-4516
Cytarabine, and cladribine, in childhood AML, 4217-4224
Cytochrome p-450 2D6 genotypes, patient-tailored antiemetic treatment and, 2805-2811
Cytokeratin-19-positive cells, in operable breast cancer, 3404-3412
Cytokeratin-20 reverse transcriptase-PCR, in lymph nodes of node-negative colorectal cancer patients, 1049-1055
Cytokine therapy. *See* Interferon therapy; Interleukins
Cytolytic T lymphocytes, toxicity against a single melanoma epitope, 1075-1086, 3176-3177 (correspondence), 3184 (errata)
Cytoreductive surgery, for advanced ovarian cancer, 1248-1259
Cytostatic antineoplastic drugs, discontinuation design applied to, 4478-4484
Cytotoxics, patients' assessment of, 4-6 (editorial), 65-72

D

David A. Karnofsky Award Lecture, 1*s*-13*s*
DCIS. *See* Ductal carcinoma-in-situ
Death
in hospital *vs.* at home, 2127-2133
from intercurrent disease, postoperative radiotherapy for NSCLC and, 1427-1429 (correspondence)
sarcoma-specific, risk factor analysis, 791-796
Decision analysis
for *BRCA1/BRCA2* mutation carriers, 2092-2100, 2420-2529
for postmastectomy radiotherapy, 2713-2725
Decision making. *See also* Treatment decisions
among cancer patients, 503-513
by clinicians, clinical trials supporting, 4126-4127 (correspondence)
Dehydration, terminal, Japanese physicians' attitudes toward, 4699-4704
Demographics, in adjuvant therapy for colorectal cancer, 1192-1202
Depigmentation, in chronic myeloid leukemia patient, 869-870, 1430 (erratum)
Depression, after hematopoietic stem-cell transplantation for malignant disorders, 2118-2126
Dermatitis, radiation recall. *See* Radiation recall phenomenon
Dermatofibrosarcoma protuberans, metastatic, treatment of, 3568-3569 (editorial), 3586-3591
Dexamethasone, thalidomide plus, for myeloma, 4319-4323
Diabetes insipidus, as initial NSCLC manifestation, 4597-4598
Diarrhea, hematologic malignancy presenting with, 3737-3739
Diet, effect on PSA, 3570-3571 (editorial), 3592-3598
Dietary change, after breast cancer, 1017-1025
Digits, paraneoplastic necrotic, in small-cell lung cancer, 4600-4601
5,6-Dimethylxanthenone-4-acetic acid, effect on tumor microcirculation (phase I trial), 3826-3840
Disease control, in advanced nasopharyngeal cancer, 1845-1852
DLI (donor leukocyte infusion), for myeloid relapse after allogeneic stem-cell transplantation, 405-412, 2756-2757 (correspondence)
DMXAA (5,6-dimethylxanthenone-4-acetic acid), effect on tumor microcirculation (phase I trial), 3826-3840
DNA microassays, in clinical oncology, 1932-1941
Docetaxel
best supportive care *vs.*, as second-line therapy of ad-

vanced NSCLC, 1344-1352, 3750-3751 (correspondence)
with capecitabine
in resistant malignancy, scheduling of, 2616-2623
survival in advanced breast cancer with (phase III trial), 2812-2823
with cisplatin, for squamous cell carcinoma of head and neck (phase II trial), 1593-1599
with gemcitabine, in unresectable leiomyosarcoma (phase II trial), 2824-2831
hypersensitivity reaction to, 2760-2761 (correspondence)
neoadjuvant, in breast cancer, 1456-1466
oral bioavailability of, cyclosporine and, 1951-1952 (correspondence)
pharmacokinetics and pharmacodynamics of, interindividual variability in Asians, 3683-3690
radiation recall associated with, 867-869
with temozolomide, in advanced melanoma (phase II trial), 420-425
toxic, epidermal, necrolysis-like reaction associated with, 3030-3032
with trastuzumab, for metastatic breast cancer (phase II trial), 1800-1808
Donor leukocyte infusion, for myeloid relapse after allogeneic stem-cell transplantation, 405-412, 2756-2757 (correspondence)
Dose/dosing
anthracycline-based chemotherapy for node-positive breast cancer, 3637-3643
bone marrow cell, impact on BMT outcomes in AML, 4324-4330
cisplatin, body-surface area and, 1144 (correspondence), 4270-4271 (correspondence)
combination chemotherapy for solid tumors, 1657-1667, 3042-3043 (correspondence)
for ET-743 (abstract), 3563 (erratum)
irinotecan, 7-8 (editorial)
in cancer patients with hepatic dysfunction, 4303-4312
oxaliplatin, 2758 (correspondence), 3753 (correspondence)
suramin, in advanced prostate cancer, 3369-3375
temozolomide plus thalidomide, in advanced melanoma, 2610-2615, 3361 (erratum)
Dose escalation
in combination therapy, for advanced cancer, 582-587
in radiotherapy, for esophageal cancer, 1151-1153 (editorial)
Doxorubicin
continuous infusion in acute lymphoblastic leukemia, 1677-1682
with etoposide and cisplatin, for small-cell prostate carcinoma (phase II trial), 3072-3080
for Hodgkin's disease in elderly, treatment outcome in, 1087-1093
with paclitaxel *vs.* doxorubicin/cyclophosphamide in metastatic breast cancer, 3114-3121
pegylated liposomal. *See* Pegylated liposomal doxorubicin
polymer-bound, hepatic targeting evaluation of (phase I trial), 1668-1676
DPC4/Smad4 expression, in pancreatic ductal adenocarcinoma, 4531-4542
Dronabinol, for cancer-associated anorexia, 567-573, 2912-2913 (correspondence)
Drug delivery system, implantable, for refractory cancer pain, 4040-4049
Drug development. *See also* Chemotherapeutics; *individual agents*
molecular heterogeneity influencing, 2495-2499, 4606-4607 (correspondence)
worldwide, report on (ASCO 2002 International Symposium), 47*s*-59*s*
Drug names, trade *vs.* generic forms, use of, 1707-1708 (correspondence)
Ductal adenocarcinoma, pancreatic, 4531-4542
Ductal carcinoma-in-situ, age at diagnosis and outcome for women with, 2736-2744
Dying patient. *See* Terminally-ill patient
care of. *See* End-of-life care

E

E-cadherin pathway, prognostic value in NSCLC, 2417-2428
E7070, pharmacokinetics of, 4065-4073 (phase I trials)
in advanced cancer (phase I trial), 3508-3521
EBV. *See* Epstein-Barr virus
ECF chemotherapy regimen, for esophagogastric cancer, 1962-1964 (editorial), 1996-2004, 4124-4126 (correspondence)
EGF receptor. *See* Epidermal growth factor receptor
Ejaculatory azoospermia, postchemotherapy, management of, 930-936
Elderly
assessment of
comprehensive cancer assessment, 494-502
self-report methodology, 770-775
breast cancer in
adjuvant tamoxifen therapy for, 2680-2688
early-stage, treatment costs for, 307-316
colon cancer in, adjuvant 5-FU for, 3992-3998
Hodgkin's disease in, treatment outcome for, 1087-1093
ovarian cancer in, chemotherapy variations and, 173-178
quality of iife in, 2915-2917 (editorial)
rectal cancer in, adjuvant chemotherapy and radiation therapy for, 2643-2650
Email, for patient-physician communication, 3352-3355
Emotional expression, written, and benefit finding in breast cancer patients, 4160-4168
Enalapril therapy, long-term, for left ventricular dysfunction in childhood cancer survivors, 4517-4522
End-of-life care
communication in
caregiver-physician, 1952-1953 (correspondence)
European team assessments of, 3674-3682

death in hospital *vs.* at home, 2127-2133
emotional expression and, 3352-3355
hospice care, 1419-1424
and hospitalization of cancer patients, 1584-1592
patient preferences for, 3035-3037, 4403-4404 (correspondence)
quality of life in, 1704-1705 (correspondence)
sedation practices and attitudes in Japan, 758-764
Endobronchial carcinoid, of lung, 2747-2748, 4269-4270 (correspondence)
Endocarditis, marantic, in advanced cancer, 4111-4114
Endocrine-related predictive factors, in postmenopausal node-negative breast cancer, 2210-2212 (correspondence)
Endocrine treatment, *vs.* chemotherapy, in premenopausal breast cancer patients, 4611-4614 (editorial), 4621-4627
Endometrial cancer, metastatic, pegylated liposomal doxorubicin for (phase II trial), 2360-2364
rh-Endostatin
in advanced solid tumors (phase I trial), 3792-3803
antiangiogenic activity of
biologic markers in, 3804-3814
potential for (editorial), 3758-3760
intravenous infusion (phase I trial), 3772-3784
media coverage influencing potential trial participants, 3761-3764 (editorial), 3785-3791
Eniluracil, with fluorouracil
for anthracycline- and taxane-resistant advanced breast cancer (phase II trial), 987-993, 3750 (correspondence)
for metastatic/advanced colorectal cancer (phase III trial), 1519-1526
oral 5-FU and continuous infusion 5-FU compared, in solid tumors, 1683-1691
Epidermal growth factor receptor
inhibition by ZD1839, skin as marker for, 110-124
targeting
in cancer therapy (David A. Karnofsky Award Lecture), 1*s*-13*s*
with tyrosine kinase inhibitors, 2217-2219 (editorial)
Epirubicin
for advanced soft tissue sarcomas, 1329-1334
in CEV chemotherapy regimen, etoposide/cisplatin *vs.*, in small-cell lung cancer (phase III trial), 4665-4672
with cisplatin or lonidamine, in advanced breast cancer (phase III trial), 4150-4159
for esophagogastric cancer, 1962-1964 (editorial), 1996-2004, 4124-4126 (correspondence)
with vinorelbine, for metastatic breast cancer, 2689-2694
Epithelial ovarian cancer
BRCA-related survival in, 463-466
recurrent, carboplatin with paclitaxel as second-line therapy for, 1238-1247
Epithelium, Barrett's, angiogenesis in, 2971-2979
Epoetin
alfa, in chemotherapy patients, quality of life and nonplatinum, 601-603 (correspondence)
once-weekly dosing, 3182-3184 (correspondence)
once-weekly *vs.* three-times-weekly dosing, 878 (correspondence), 2757-2758 (correspondence)
ASCO/ASH evidence-based guidelines for use of, 4083-4107
beta, in hematologic malignancy patients, quality of life and, 2486-2494
Epstein-Barr virus, hemophagocytic lymphohistiocytosis associated with, etoposide therapy for, 599-601 (correspondence)
ErbB-1. *See* Epidermal growth factor receptor
ErbB-2. *See* HER-2/*neu*
Errata
adoptive immunotherapy with cytolytic T lymphocytes, in melanoma, 3184
autologous tumor-derived vaccination in metastatic melanoma patients, 4610
breast cancer diagnosis, nutrition and survival after, 3939 (errata)
ET-743 dosage (abstract), 3563
paclitaxel plus gemcitabine in refractory germ cell tumors (phase II trial), 3754 (erratum)
palliative chemotherapy *vs.* watchful waiting, oncologists' preferences between, 4409
temozolomide plus thalidomide in advanced melanoma, 3361
Erythroplakias, oral, long-term follow-up in, 456-462
rh-Erythropoietin, in hematologic malignancy patients, quality of life and, 2486-2494
Esophageal cancer
combined-modality therapy for (phase III trial), 1167-1174
dose escalation in, 1151-1153 (editorial)
oxaliplatin therapy for, 2844-2850
Esophagogastric cancer, chemotherapy trials in, 1962-1964 (editorial), 1996-2004, 4124-4126 (correspondence)
Essential thrombocythemia, polycythemia rubra vera-1 gene in, 4249-4254
Esthesioneuroblastoma, intracranial metastatic, treatment of, 357-358 (correspondence)
Estramustine phosphate, intravenous (phase I trial), 1115-1127
Estrogen
interaction with raloxifene, breast cancer risk and, 1430 (erratum)
letrozole and anastrozole influence on levels in postmenopausal breast cancer patients, 751-757, 3039-3040 (correspondence)
Estrogen receptor-beta expression, in hereditary breast cancer, 3752-3753 (correspondence)
ET-743, dosage for (abstract), 3563 (erratum)
Ethical issues
hospice care and, 2752-2755
off-shore clinical trials and, 3934-3936 (correspondence)

Etoposide
in chemoradiotherapy for pathologic stage IIIB NSCLC, 3454-3460
with cisplatin
CEV chemotherapy regimen *vs.*, in small-cell lung cancer (phase III trial), 4665-4672
and doxorubicin, for small-cell prostate carcinoma (phase II trial), 3072-3080
response rate in childhood low-grade glioma, 4209-4216
with doxorubicin and cisplatin, for small-cell prostate carcinoma (phase II trial), 3072-3080
for EBV-associated hemophagocytic lymphohistiocytosis, 599-601 (correspondence)
with ifosfamide, in pediatric metastatic osteosarcoma (phase II/III trial), 426-433
oral, in AIDS-related Kaposi's sarcoma (phase II trial), 3236-3241
Euthanasia, views in terminally-ill patients, 2134-2141
Evidence-based medicine
recurrent ovarian cancer treatment and, 1161-1163 (editorial)
use and abuse of statistics in, 4122-4124 (correspondence)
Existentialism, oncologists and, 2407-2408
External-beam radiation therapy, for localized prostate cancer, surgery *vs.*, 3363-3364 (editorial), 3376-3385
Extragonadal germ cell tumors, 1864-1873
Extraosseous osteosarcoma, outcomes of, 521-527
Extremity soft tissue sarcoma
high-grade osteosarcoma, prognostic factors in, 776-790, 2910-2911 (correspondence)
radiation timing and health status outcomes in, 4472-4477
stage II-B, adjuvant radiation for, 1643-1650, 3929-3930 (correspondence)
Eyelid, non-Hodgkin's lymphoma of, palliative radiotherapy in, 4601-4602

F

Factorial design, considerations in clinical trials, 3424-3430
Family, of recurrent breast cancer patients, quality of life for, 4050-4064
Family history
in cancer susceptibility identification, 528-537
and prostate cancer screening, 2658-2663
FAP chemotherapy, M-VAC chemotherapy *vs.*, in advanced or metastatic urothelial cancer (phase III trial), 1361-1367
Fatigue, in cancer patients. *See also* Anemic patients
leukemia and non-Hodgkin's lymphoma, 1319-1328
FDG–PET. *See* ^{18}Fluorodeoxyglucose–PET
Fibrosarcoma, juvenile bronchopulmonary, 2745-2746
Filgrastim. *See* Granulocyte colony-stimulating factor
Fingers, paraneoplastic necrotic, in small-cell lung cancer, 4600-4601
FISH (fluorescence in situ hybridization), detection of HER-2/*neu* overexpression in breast cancer, 3095-3105, 4607-4608 (correspondence)
Flavopiridol
daily 1-hour infusion, for advanced neoplasms (phase I trial), 4074-4082
with paclitaxel, in advanced solid tumors (phase I trial), 2157-2170
Fludarabine
for chronic lymphocytic leukemia
alemtuzumab therapy subsequent to, 3891-3897
myeloid leukemia associated with, 3878-3884
for low-grade non-Hodgkin's lymphoma, *vs.* CVP chemotherapy regimen in (phase III trial), 4649-4654
Fluorescence in situ hybridization, detection of HER-2/*neu* overexpression in breast cancer, 3095-3105, 4607-4608 (correspondence)
^{18}Fluorodeoxyglucose–PET
in breast cancer, biology of, 379-387
in colorectal liver metastases, 388-395
in head and neck cancers
diagnostic and prognostic value of, 4199-4208
uptake, 1398-1404
in tumor recurrence detection, after liver metastases surgery, 4453-4458
Fluoropyrimidine drugs, oral, evolving role for, 894-896 (editorial)
Fluorouracil
adjuvant, for advanced colon cancer in elderly patients, 3992-3998
in chemotherapy regimens
biweekly, in metastatic colorectal cancer, 4006-4014
CMF, goserelin *vs.*, in premenopausal breast cancer patients, 4628-4635
tamoxifen and, 4611-4614 (editorial), 4621-4627
FOLFOX6, in advanced/metastatic gastric cancer patients, 4542-4548
triplet, for metastatic colorectal cancer (phase II trial), 2651-2657
for colorectal cancer
metastatic. *See* Fluorouracil, for metastatic colorectal cancer
toxicity of, gender differences in, 1439-1441 (editorial), 1491-1498
TS expression and, 1721-1728
continuous infusion, and oral 5-FU/eniluracil compared, in solid tumors, 1683-1691
with eniluracil
for anthracycline- and taxane-resistant advanced breast cancer (phase II trial), 987-993, 3750 (correspondence)
and leucovorin, for metastatic/advanced colorectal cancer (phase III trial), 1519-1526
for esophagogastric cancer, 1962-1964 (editorial), 1996-2004, 4124-4126 (correspondence)
with gemcitabine, *vs.* gemcitabine alone in advanced pancreatic cancer (phase III trial), 3270-3275
with leucovorin
and eniluracil, for metastatic/advanced colorectal cancer (phase III trial), 1519-1526

irinotecan plus, mortality associated with, 1145-1146 (correspondence)
uracil/tegafur plus leucovorin *vs.*, in metastatic colorectal cancer, 3605-3616 (phase III), 3617-3627
for metastatic colorectal cancer, 1175-1181 (phase II trial), 3937-3939 (correspondence)
biweekly chemotherapy regimen including, 4006-4014
in combined drug therapy, 2545-2550
fluorouracil/leucovorin *vs.* uracil/tegafur plus leucovorin, 3605-3616 (phase III), 3617-3627
prognostic factors in, 2832-2843
triplet chemotherapy regimen including (phase II trial), 2651-2657
with oxaliplatin
for esophageal cancer, 2844-2850
for taxane- and anthracycline-pretreated metastatic breast cancer, 2551-2558
protracted venous infusion with/without mitomycin for inoperable pancreatic cancer (phase III trial), 3130-3136
systemic lupus erythematosus exacerbation induced by, 3032-3034
Fluoxetine, for hot flashes, evaluation of (phase III trial), 1578-1583
FOLFOX6 chemotherapy regimen, in advanced/metastatic gastric cancer patients, 4542-4548
Folinic acid
in FOLFOX6 regimen, in advanced/metastatic gastric cancer patients, 4542-4548
for gestational trophoblastic disease, 1838-1844
for metastatic colorectal cancer (phase II trial), 1175-1181, 3937-3939 (correspondence)
Follicular lymphoma
genomic aberrations in, clinical relevance of, 4523-4530
primary cutaneous, 647-655
radioimmunotherapy for, 2453-2463
5-FU. *See* Fluorouracil
Fulvestrant, *vs.* anastrozole, in postmenopausal women with advanced breast cancer, 3386-3395, 3396-3403

G

Galectin-3, and prognosis in laryngeal squamous cell carcinoma, 3850-3856
Gastric cancer. *See also* Esophagogastric cancer
advanced/metastatic, FOLFOX6 regimen in, 4543-4548
minimal residual disease in, 2005-2016
Gastric carcinoid, metastatic to liver, 2403-2404
Gastric plasmacytoma, hemorrhagic, in multiple myeloma, 344-347
Gastrointestinal stromal tumors, *KIT* mutation type in, 3898-3905
GCSF. *See* Granulocyte colony-stimulating factor
Gemcitabine
with 5-FU, *vs.* gemcitabine alone in advanced pancreatic cancer (phase III trial), 3270-3275
with capecitabine, in advanced cancer (phase I trial), 582-587
with carboplatin/paclitaxel, for carcinoma of unknown primary site, 1651-1656
in combination chemotherapy for advanced NSCLC (phase III trial), 3578-3585
with concurrent radiotherapy, in inoperable NSCLC (phase I trial), 804-810
with docetaxel, in unresectable leiomyosarcoma (phase II trial), 2824-2831
in induction therapy in stage IIIB NSCLC, 4191-4198
intravesical, in transitional-cell carcinoma of bladder (phase I trial), 3185-3186
with irinotecan, for relapsed or refractory leukemia or lymphoma (phase I trial), 2995-3000
with oxaliplatin, for pancreatic adenocarcinoma (phase II trial), 1512-1518
with paclitaxel, in refractory germ cell tumors (phase II trial), 1859-1863, 3754 (erratum)
prolonged infusion
with mitoxantrone, for relapsed or refractory acute leukemia (phase I trial), 674-679
in relapsed acute myelogenous leukemia (phase I trial), 665-673
in salvage chemotherapy for advanced transitional-cell carcinoma (phase II trial), 2965-2970
for solid tumors, dose-finding and pharmacokinetic study of, 1657-1667, 3042-3043 (correspondence)
tumor marker responses induced by, in pancreatic cancer, 1182-1191
with vinorelbine (biweekly), in pretreated advanced breast cancer (phase II trial), 37-41
Gender differences, colorectal cancer and
adjuvant therapy, 1192-1202
fluorouracil toxicity, 1439-1441 (editorial), 1491-1498
Gene transfer, adenovirus-mediated *p53*, in bladder cancer, 957-965
Generic drug names, *vs.* trade names, use of, 1707-1708 (correspondence)
Genomic aberrations, in follicular lymphoma, 4523-4530
Genotyping
and interindividual variability of docetaxel activity in Asians, 3683-3690
vs. immunohistochemistry, in tumors, 897-899 (editorial)
Germ cell cancer, cisplatin-refractory, oxaliplatin for, 2031-2037
Germ cell tumors
intracranial, induction chemotherapy and low-dose involved-field radiotherapy for, 857-865, 2911-2912 (correspondence)
mediastinal, 1864-1873, 3739-3742
refractory, paclitaxel plus gemcitabine in (phase II trial), 1859-1863, 3754 (erratum)
testicular, treatment response in, 1551-1561, 3928-3929 (correspondence)
Germline mutations, *BRCA1*/*BRCA2*, clinical characteristics of individuals with, 1480-1490

Gestational trophoblastic disease, low-risk, methotrexate for, 1838-1844
GF120918, and topotecan bioavailability, 2943-2950
Giant cell plasmacytoma, as intraperitoneal mass, 2405-2406
Glioblastoma multiforme
concomitant temozolomide and radiation therapy for, 1375-1382, 3180-3181 (correspondence)
newly-diagnosed, treatment of, 3179-3180 (correspondence), 3181-3182 (correspondence)
RSR13 and radiotherapy for (phase II trial), 3149-3155
Gliomas
high-grade, survival and failure patterns after conformal radiotherapy in, 1635-1642, 3357-3359 (correspondence)
low-grade, 2223-2224 (editorial)
cerebral, prognostic factors in, 2076-2084
in children
carboplatin for (phase II trial), 2951-2958
cisplatin/etoposide regimen for, 4209-4216
supratentorial, radiotherapy regimes in, 2267-2276
malignant. *See* Malignant glioma
pretreated, and IMT–SPECT diagnosis of recurrent brain tumors, 396-404
survivin levels in, prognostic value of, 1063-1068
Glutathione, modifying oxaliplatin neurotoxicity, 3478-3483
GM-CSF. *See* Granulocyte-macrophage colony-stimulating factor
Godé-Darel, Valentine, Ferdinand Hodler paintings of, 1948-1950
Goserelin, CMF chemotherapy regimen *vs.*, in premenopausal breast cancer patients, 4628-4635
tamoxifen and, 4611-4614 (editorial), 4621-4627
Graft-*vs.*-host disease
acute and chronic, meta-analysis of, 603-606 (correspondence)
relapsed leukemias and, 2756-2757 (correspondence)
Granulocyte colony-stimulating factor, in induction therapy in childhood non-Hodgkin's lymphoma, 441-448
Granulocyte-macrophage colony-stimulating factor
Influenza vaccine with, in cancer patients, 4313-4318
lymphocyte reinfusion with, in metastatic breast cancer, 58-64
Growth hormone replacement therapy, outcomes in childhood ALL, 2959-2964

H

Hairy cell leukemia, second cancer risk in, 638-646
HCL. *See* Hairy cell leukemia
Head
cancer of. *See* Head and neck cancer
radiotherapy on, stroke risk after, 282-288
Head and neck cancer
advanced, radiotherapy with concurrent chemotherapy for, 1405-1410
^{18}FDG uptake predicting outcome in, 1398-1404
squamous cell
docetaxel/cisplatin combination chemotherapy for (phase II trial), 1593-1599
p53 pathways in, 2980-2987
recurrent, FDG-PET in, 4199-4208
Health-related quality of life
after localized prostate cancer therapy, 557-566, 3038-3039 (correspondence)
measurement of
future directions for, 2215-2216 (editorial), 4126-4127 (correspondence)
in hepatobiliary cancers, 2229-2239
in palliative chemotherapy treatment decisions, 1056-1062
Heart disease, in childhood cancer survivors, long-term enalapril therapy for, 4517-4522
Heat shock protein gp96-peptide complexes, autologous tumor-derived, vaccination of metastatic melanoma patients with, 4139-4140 (editorial), 4169-4180, 4610 (erratum)
Hematologic disorders/malignancies
with diarrhea and bony lesions, 3737-3739
epoetin beta and recombinant human erythropoietin effects in, 2486-2494
extramedullary sites of involvement in, 340-347
refractory, PS-341 for, 4420-4427
stem-cell transplantation for, impact of hospitalization on patients with, 1907-1917
unusual, case studies in, 3737-3744
Hematoma, splenic, associated with non-Hodgkin's lymphoma, 1946-1947
Hematopoietic stem-cell transplantation. *See* Stem-cell transplantation
Hemophagocytic lymphohistiocytosis, EBV-associated, etoposide therapy for, 599-601 (correspondence)
Hepatic dysfunction, irinotecan in patients with, 4303-4312
Hepatobiliary cancers, health-related quality-of-life measurements, 2229-2239
Hepatoblastoma, unresectable and metastatic, treatment in pediatric patient (phase II trial), 3438-3444
Hepatocellular carcinoma
in children and adolescents, 2789-2797, 2798-2804
microvessel density in, 1775-1785
simplified staging for, 1527-1536
spontaneous rupture of, 4108-4111
transcatheter arterial chemoembolization *vs.* hepatic resection in, 4459-4465
HER-2/*neu*
gene amplification and overexpression in breast cancer specimens, assay methods compared, 3095-3105, 4607-4608 (correspondence)
predicting response to hormone therapy in metastatic breast cancer, 1467-1472, 3357 (correspondence), 4605-4606 (correspondence)
protein immunity, after peptide immunization, 2624-2632
HER2 expression
in brain metastases, 4130-4133 (correspondence)
in metastatic breast cancer

trastuzumab for, safety and efficacy of, 719-726, 4130-4133 (correspondence)
weekly docetaxel/trastuzumab for (phase II trial), 1800-1808
HercepTest, detection of HER-2/*neu* overexpression in breast cancer, 3095-3105, 4607-4608 (correspondence)
Hereditary nonpolyposis colorectal cancer
molecular screening for, 1705-1707 (correspondence)
suspected, *hMLH1* and *hMSH2* mutations in, 1203-1208, 3178-3179 (correspondence)
High-dose chemotherapy
for "aggressive" lymphoma, 4413-4419
with autologous stem-cell transplantation
for aggressive lymphoma, 2472-2479
for oligometastatic breast cancer, prognosis in, 707-718
for breast cancer, with Ro 25–8315, 24-36
for high-risk neuroblastoma, 2284-2292
for metastatic breast cancer
lymphocyte reinfusion and T-cell recovery after, 58-64
standard chemotherapy *vs.*, 743-750
for peripheral T-cell lymphoma, 1426-1427 (correspondence)
for poor-prognosis small round-cell tumors, 2181-2188
for relapsed osteosarcoma, 2150-2156
salvage therapy with, for Hodgkin's disease, 467-475
for small-cell lung cancer, 3941-3943 (editorial), 3947-3955 (phase III trial)
High-fiber diet, effect on PSA, 3592-3598
Histamine dihydrochloride
with IL-2, for metastatic melanoma (phase III trial), 125-133
metastatic melanoma therapeutic trial, 1431-1433 (editorial), 3558-3559 (correspondence)
Histiocytes, sea-blue, in non-Hodgkin's lymphoma, 1942-1943
Histiocytosis, malignant, 3739-3742
Histopathology, in primary cutaneous follicular lymphoma, 647-655
Hodgkin's disease
breast cancer screening in, 2085-2091
bulky and advanced, Stanford V chemotherapy and radiotherapy for, 630-637
in children and adolescents
chemotherapy without radiotherapy for, 3765-3771
combination chemotherapy for, 3081-3087
quality of life challenges in, 3048-3050 (editorial)
therapy for, new approaches to, 3755-3757 (editorial), 3765-3771
VAMP and low-dose radiation for, 3081-3087
VEPA and low-dose involved-field radiation for, 3088-3094
ChlVPP/EVA hybrid *vs.* VAPEC-B chemotherapy regimen for, 2980-2987
classical form, CD20 expression and Reed-Sternberg cells in, 1278-1287
early-stage
in children and adolescents, VAMP and low-dose radiation for, 3081-3087
long-term competing mortality in, 2092-2100
treatment-related morbidity and mortality in, 2225-2228 (editorial)
in elderly, treatment outcome for, 1087-1093
new treatments for (editorial), 607-609
residual mediastinal mass in, pitfalls of PET assessment of, 3347-3349
salvage therapy with high-dose chemotherapy for, 467-475
survivors of, second malignant neoplasms among, 3484-3494
tracheal compression in, 3344-3347
Hodgkin's lymphoma
COPP/ABV/IMEP *vs.* COPP/ABVD in, 476-484
relapsed, new prognostic score for, 221-230
Hodler, Ferdinand, paintings by, 1948-1950
Home care setting, symptom experiences in, patient and caregiver perceptions of, 3495-3507
Hormone therapy
deciding to use, 616-619 (editorial)
isotretinoin and, in prostate cancer, 538-544
in metastatic breast cancer, HER-2/*neu* predicting response to, 1467-1472, 3357 (correspondence), 4605-4606 (correspondence)
Hospice care, 1419-1424
overcoming obstacles in, 2752-2755
Hospitalization
of cancer patients during last six months of life, 1584-1592
and expenditures for paclitaxel in refractory metastatic breast cancer, 3658-3664, 4409 (erratum)
for stem-cell transplantation, psychiatric morbidity during, 1907-1917
for toxicity of chemotherapy in older breast cancer patients, 4636-4642
Hot flashes
effect of soy phytoestrogens on, 1449-1455, 3040-3042 (correspondence)
fluoxetine evaluation in (phase III trial), 1578-1583
treatment options for (editorial), 1436-1437
House calls, by oncologists, 3745-3746
HRQL. *See* Health-related quality of life
HSCT (hematopoietic stem-cell transplantation). *See* Stem-cell transplantation
HSR. *See* Hypersensitivity reaction
Humoral response, to melanoma vaccine, 3242-3248
Hydration, artificial, in terminally-ill patients, 4699-4704
5-Hydroxytryptamine type 3 receptor antagonists, in patient-tailored antiemetic treatment, 2805-2811
Hypercoagulability, in breast cancer prevention trial, 4133-4134 (correspondence)
Hyperexcitability, peripheral nerve, acute oxaliplatin-induced, 1767-1774, 3561-3562 (correspondence)
Hypersensitivity pneumonitis, and imatinib relationship, 4271-4272 (correspondence)

Hypersensitivity reaction
to carboplatin chemotherapy, oxaliplatin as replacement for, 353 (correspondence)
to docetaxel, 2760-2761 (correspondence)
to oxaliplatin, 1146-1147(correspondence)
radiation recall dermatitis and, 4130 (correspondence)
Hyperthermia, predicting survival in retroperitoneal and visceral soft tissue sarcomas, 3256-3164
Hyperthermic isolated limb perfusion, multidrug resistance genes and, 3282-3292
Hypoxia, in cervix cancer, 610-615 (editorial), 680-687
Hysterectomy, radical, in cervical cancer, 688-693, 2602-2603 (correspondence)

I

Ibandronate therapy, long-term, for advanced multiple myeloma, effects of, 2353-2359
Ibritumomab tiuxetan radioimmunotherapy, yttriun-90-labeled, for lymphoma, 2453-2463
ICI 182,780. *See* Fulvestrant
IFN therapy. *See* Interferon therapy
Ifosfamide
in CIB regimen for squamous cell carcinoma of cervix, 1832-1837
with etoposide, in pediatric metastatic osteosarcoma (phase II/III trial), 426-433
in salvage chemotherapy for advanced transitional-cell carcinoma (phase II trial), 2965-2970
IGF-1 (insulin-like growth factor I), prostate cancer and, 833-841
IGFBP (insulin-like growth factor binding proteins), prostate cancer and, 833-841
IL therapy. *See* Interleukins
Imatinib mesylate
in cancer therapy paradigm, 325-334
and depigmentation in chronic myeloid leukemia patient, 869-870, 1430 (erratum)
hypersensitivity pneumonitis related to, 4271-4272 (correspondence)
for metastatic dermatofibrosarcoma protuberans, 3568-3569 (editorial), 3586-3591
metastatic gastrointestinal stromal tumor response to, 870-872, 1430 (erratum)
tumor lysis syndrome after, 354-355 (correspondence)
Immune response, humoral, to melanoma vaccine, 3242-3248
Immunohistochemistry
in breast cancer, 2310-2318, 3752-3753 (correspondence)
in colorectal tumors, *vs.* microsatellite instability, 1043-1048
genotyping *vs.*, in tumors, 897-899 (editorial)
in lymph node micrometastases detection, 4232-4241
Immunophenotyping, in primary cutaneous follicular lymphoma, 647-655
Immunotherapy, for melanoma. *See also* Vaccine/Vaccination, for melanoma
adjuvant, 2058-2066, 2067-2075, 4181-4190
with cytolytic T lymphocytes, 1075-1086, 3176-3177 (correspondence), 3184 (errata)
humoral response to, 3242-3248
survival after, 4561-4566
Implantable devices
cardiac defibrillators, radiotherapy damaging, 2212-2213 (correspondence)
drug delivery system, for refractory cancer pain, 4040-4049
IMT (iodine-123-alpha-methyl-l-tyrosine)-SPECT, in diagnosis of recurrent brain tumors, 396-404
Induction chemotherapy
for high-risk neuroblastoma, 2284-2292
for intracranial germ cell tumors following low-dose involved-field radiotherapy, 857-865, 2911-2912 (correspondence)
for mantle-cell lymphoma, 1288-1294
for NSCLC, followed by concomitant chemoradiotherapy for, 4191-4198
in pediatric patients
with AML, maintenance therapy added to, 2774-2782
with non-Hodgkin's lymphoma, G-CSF and, 441-448
Infertility, cancer-related, in young males, 1880-1889
Influenza vaccine, with GM-CSF or placebo in cancer patients, 4313-4318
Insulin, in early-stage breast cancer, 42-51
Insulin-like growth factor I, prostate cancer and, 833-841
Insulin-like growth factor binding proteins, prostate cancer and, 833-841
Interferon therapy
alfa
for advanced cutaneous squamous cell cancer (phase II trial), 364-370
for advanced renal cell cancer, 289-296
cessation of, cytogenetic remission in chronic myeloid leukemia and, 214-220
for malignant melanoma, 1818-1825, 4120-4122 (correspondence)
alfa-2a, combined with thalidomide, for metastatic renal cell carcinoma, unexpected toxicity of, 1429-1430 (correspondence)
alfa-2b
high-dose
quality-of-life–adjusted survival analysis of, in melanoma, 1311-1318
radiation recall dermatitis from, 355-357 (correspondence)
toxicities associated with, mechanisms and management of, 3703-3718
pegylated, for solid tumors (phase I/II trial), 3841-3849
for melanoma, tyrosinase mRNA in patients' blood after, 4032-4039
Interleukins
IL-2
metastatic melanoma therapeutic trial, 1431-1433 (editorial), 3558-3559 (correspondence)

with/without histamine dihydrochloride for metastatic melanoma (phase III trial), 125-133
IL-8 mRNA, in NSCLC, *p53* and, 900-910
International Consensus Panel on the Treatment of Primary Breast Cancer, meeting highlights from, 879-880 (correspondence)
Internet, melanoma information on, 134-141
Intracranial esthesioneuroblastoma, metastatic, treatment of, 357-358 (correspondence)
Intraperitoneal chemotherapy, for ovarian cancer, 694-698
Intraperitoneal mass, giant cell plasmacytoma as, 2405-2406
Intraperitoneal therapy, for advanced ovarian carcinoma (editorial), 3944-3946
Intravesical therapy, for superficial bladder cancer, 3185-3186 (editorial)
with gemcitabine (phase I trial), 3185-3186
Intussusception, as mantle-cell lymphoma complication, 4397-4398
Invasive infections, *Aspergillus*, 1898-1906
Iodine ^{131}I lipiodol, in suspended resectable carcinoma trial, 1709 (correspondence)
Iodine-123-alpha-methyl-l-tyrosine–SPECT, in diagnosis of recurrent brain tumors, 396-404
Iodine-131-metaiodobenzylguanidine, for neuroblastoma, 2142-2149
Irinotecan
in cancer patients with hepatic dysfunction, 4303-4312
in chemotherapy regimens
biweekly, in metastatic colorectal cancer, 4006-4014
triplet, for metastatic colorectal cancer (phase II trial), 2651-2657
clearance of, body-surface area and, 81-87
with fluorouracil/leucovorin, mortality association and, 1145-1146 (correspondence)
with gemcitabine, for relapsed or refractory leukemia or lymphoma (phase I trial), 2995-3000
and ketoconazole interaction, 3122-3129
with oxaliplatin, in advanced colorectal cancer (phase II trial), 165-172
pharmacokinetics of, 3293-3301, 4609-4610 (correspondence)
with raltitrexed, pharmacogenetics of, 1425-1426 (correspondence)
tumor marker responses induced by, in pancreatic cancer, 1182-1191
Irradiation. *See also* Radiotherapy
of breast, after breast-conserving therapy, clinical trials evaluating (editorial), 4135-4138
skeletal, with high-dose ^{153}Sm-EDTMP, 189-196, 1953-1954 (correspondence)
Ischemic stroke, risk after radiotherapy on neck, 282-288
Isotretinoin. *See* Retinoic acid

J

Jewish women, ovarian cancer risk in, 1570-1577
Juvenile bronchopulmonary fibrosarcoma, 2745-2746
Juvenile myelomonocytic leukemia, treatment protocol results in, 434-440

K

Kaposi's sarcoma
AIDS-related
COL-3 for (phase I trial), 153-159
oral etoposide for (phase II trial), 3236-3241
familial Mediterranean form, 1415-1418
David A. Karnofsky Award Lecture, targeting epidermal growth factor receptor for cancer therapy, 1*s*-13*s*
Ketoconazole, and irinotecan interaction, 3122-3129
Ki-67, in locally advanced colon cancer, prognostic and predictive values of, 1735-1743
ki-ras polymerase chain reaction, in pancreatic cancer diagnosis, 4331-4337
Kinase-positive anaplastic large-cell lymphoma, molecular biology of, 3691-3702
KIT tyrosine kinase activity, inhibition of, 1692-1703
Koeber phenomenon, 4130 (correspondence)
Kyphoplasty, for myelomatous compression fractures, 2382-2387

L

Large-cell lymphoma
anaplastic
isolated meningeal, 4395-4397
kinase-positive, molecular biology of, 3691-3702
limited-stage diffuse, treatment of, 197-204
Laryngectomy, voice rehabilitation after, 2450-2505
Larynx
preservation of, p53 pathway alteration and, 2980-2987
squamous cell carcinoma of, galectin-3 and prognosis in, 3850-3856
Left ventricular dysfunction, in childhood cancer survivors, long-term enalapril therapy, 4517-4522
Legal issues, of email communication in medical practice, 3352-3355
Leiomyosarcoma
pulmonary vein, 2749-2751
unresectable, gemcitabine plus docetaxel in (phase II trial), 2824-2831
Letrozole
causing reversible pancytopenia in recurrent breast cancer, 3747 (correspondence)
in postmenopausal breast cancer patients
influence on total body aromatization, 751-757, 3039-3040 (correspondence)
tamoxifen *vs.*, 876-878 (correspondence)
Leucovorin
in chemotherapy regimens
biweekly, in metastatic colorectal cancer, 4006-4014

triplet, for metastatic colorectal cancer (phase II trial), 2651-2657
with fluorouracil, for metastatic/advanced colorectal cancer (phase III trial), 1519-1526
for metastatic colorectal cancer, in combined drug therapy, 2545-2550
with uracil/tegafur, in colorectal cancer, 3574-3575 (editorial)
Leukemia
acute forms. *See* Acute leukemias
lymphoblastic. *See* Acute lymphoblastic leukemia
myeloid. *See* Acute myeloid leukemia
cancer-related fatigue in, clinical factors associated with, 1319-1328
chronic forms
lymphocytic. *See* Chronic leukemias, lymphocytic
myelogenous, STI571 therapeutic paradigm in, 325-334
myeloid. *See* Chronic leukemias, myeloid
myelomonocytic, juvenile, treatment protocol results in, 434-440
pretreated T-cell prolymphocytic, Campath-1H treatment of, 205-213
refractory or relapsed. *See* Acute leukemias, relapsed/refractory
Limb perfusion, hyperthermic isolated, multidrug resistance genes and, 3282-3292
Limb salvage, in survivors of pediatric lower-extremity bone tumors, 4493-4501
Liposomal lurtotecan, pharmacokinetics of (phase I trial), 1222-1231
Liver
dysfunctional, irinotecan in patients with, 4303-4312
gastric carcinoid metastatic to, 2403-2404
polymer-bound doxorubicin targeting (phase I trial), 1668-1676
Liver disease, non-Hodgkin's lymphoma presenting as, 1943-1946
Liver metastases
from colorectal cancer, 1442-1445 (editorial)
surgical resection of, 1499-1505
in colorectal cancer, ^{FDG}–PET scan in, 388-395
FDG–PET detecting tumor recurrence after surgery for, 4453-4458
Liver resection
of metastases from colorectal cancer, 1499-1505
transcatheter arterial chemoembolization *vs.*, in hepatocellular carcinoma, 4459-4465
Lonidamine, with epirubicin, in advanced breast cancer (phase III trial), 4150-4159
Low-fat diet, effect on PSA, 3592-3598
Lower-extremity bone tumors, limb salvage and amputation in pediatric survivors of, 4493-4501
Lumpectomy, preventing ipsilateral breast tumor recurrence after, 4141-4149
Lung. *See also* Pulmonary *entries*
endobronchial carcinoid of, 2747-2748, 4269-4270 (correspondence)
Lung cancer
advanced, beneficial effects of ATP on nutritional status in, 371-378
CEACAM1 expression in, 4273-4275 (editorial), 4279-4284
chemotherapy for, impact of referral patterns on use of, 1786-1792
incidence and mortality of, 1973-1983, 3931-3934 (correspondence)
nicotine dependence in, tobacco use outcomes after treatment for, 3461-3469
non–small-cell. *See* Non–small-cell lung cancer
novel therapeutic targets for, 2881-2894 (part I), 3016-3028 (part II)
p53 and angiogenesis link in, 883-884 (editorial)
screening for, 1959-1961 (editorial), 1973-1983, 3931-3934 (correspondence)
with low-dose helical CT, 911-920
small-cell. *See* Small-cell lung cancer
unusual presentation of, case studies, 4597-4602
Lurtotecan, liposomal, pharmacokinetics of (phase I trial), 1222-1231
LV. *See* Leucovorin
Lymph node metastases
in high-risk melanoma, PET mimicking, 3349-3351
volume of, colorectal cancer prognosis and, 1506-1511
Lymph nodes
axillary, eradication in breast cancer, 1304-1310
node-negative patients, 1793-1799
in high-risk melanoma patient
microscopic spread of, 2053-2057
PET mimicking, 3349-3351
micrometastases in
colorectal cancer, detection by RT-PCR, 4232-4241
resected NSCLC and, 2930-2936
of node-negative colorectal cancer patients, CK-20 RT-PCR in, 1049-1055
staging of, in resectable NSCLC, 2604-2605 (correspondence)
Lymphadenectomy, sentinel node. *See* Sentinel lymphadenectomy
Lymphangiogenesis, in Barrett's adenocarcinoma, 2971-2979
Lymphatic mapping, in cervical cancer, 688-693, 2602-2603 (correspondence)
Lymphocytes
reinfusion with GM-CSF, after high-dose chemotherapy for metastatic breast cancer, 58-64
in splenic marginal zone lymphoma, morphology of, 342-344
Lymphohistiocytosis, EBV-associated hemophagocytic, 599-601 (correspondence)
Lymphoma
aggressive, high-dose chemotherapy for, 4413-4419
with autologous stem-cell transplantation, 2472-2479
anaplastic large-cell
isolated meningeal, 4395-4397
kinase-positive, molecular biology of, 3691-3702

B-cell. *See* B-cell lymphoma
Burkitt's, advanced pediatric, 2783-2788
follicular. *See* Follicular lymphoma
Hodgkin's. *See* Hodgkin's lymphoma
kinase-positive anaplastic large-cell, molecular biology of, 3691-3702
large-cell. *See* Large-cell lymphoma
limited-stage diffuse large-cell, treatment of, 197-204
mantle-cell
intussusception as complication of, 4397-4398
isolated orbital relapse after BMT for, 4394-4395
multifocal intracranial involvement with, 340-342
marginal zone, of spleen, 342-344
non-Hodgkin's. *See* Non-Hodgkin's lymphoma
primary CNS. *See* Central nervous system, primary lymphoma of
primary cutaneous follicular, 647-655
pyothorax-associated, 4255-4260
radioimmunotherapy for, 2453-2463
refractory. *See* Refractory lymphoma
relapsed. *See* Relapsed lymphoma
T-cell. *See* T-cell lymphoma
Lymphoproliferative malignancies, nonmyeloablative allogeneic stem-cell transplantation in, 4022-4031

M

M-VAC chemotherapy, FAP chemotherapy *vs.*, in advanced or metastatic urothelial cancer (phase III trial), 1361-1367
Magnetic resonance imaging
brain metastases and, 3445-3453
of breast, effect on early-stage breast cancer management, 3413-3423
Maintenance therapy
in childhood acute myeloblastic leukemia, 2774-2782
in indolent non-Hodgkin's lymphoma, 4261-4267
Males, sperm banking by, prior to cancer treatment, 1880-1889
Malignancy
hematologic. *See* Hematologic disorders/malignancies
KIT-positive, inhibition of KIT tyrosine kinase activity and, 1692-1703
lymphoproliferative, nonmyeloablative allogeneic stem-cell transplantation in, 4022-4031
potential for, in precancers, 456-462
resistant, scheduling of capecitabine and docetaxel in, 2616-2623
second, among Hodgkin's disease survivors, 3484-3494
transformation risk, in MGUS and SMM, 1625-1634
unusual complications of (case examples), 4108-4114
Malignant glioma
carmustine plus O^6-benzylguanine for (phase II trial), 2277-2283
of childhood, temozolomide in, 4684-4691
newly diagnosed, ^{131}I-labeled 81C6 in (phase II trial), 1389-1397
Malignant histiocytosis, 3739-3742
Malignant melanoma
interferon alfa therapy for, 1818-1825, 4120-4122 (correspondence)
sentinel-node techniques in clinical trials in, 2208-2210 (correspondence)
Malignant mesothelioma
pemetrexed-carboplatin activity in (phase I trial), 3533-3544
unresectable, ranpirnase in (phase II trial), 274-281
Malignant mixed mullerian tumor, and tamoxifen association, 2758-2760 (correspondence), 4403 (correspondence)
Malignant transformation, risk in MGUS and SMM, 1625-1634
MALT lymphoma. *See* Mucosa-associated lymphoid tissue lymphoma
Mantle-cell lymphoma
intussusception as complication of, 4397-4398
isolated orbital relapse after BMT for, 4394-4395
multifocal intracranial involvement with, 340-342
rituximab and CHOP induction therapy for, 1288-1294
Marantic endocarditis, in advanced cancer, 4111-4114
Marimastat. *See* Matrix metalloproteinase inhibitors
Markers. *See* Tumor markers
Mastectomy
radiotherapy after, decision-analytic model for, 2713-2725
without radiotherapy, predicting local-regional recurrence of breast cancer after, 17-23
Mastocytosis, systemic, 3737-3739
Matrix metalloproteinase inhibitors
for AIDS-related Kaposi's sarcoma (phase I trial), 153-159
for small-cell lung cancer, 4434-4439
temozolomide plus, for glioblastoma multiforme (phase II trial), 1383-1388
MCF chemotherapy regimen, for esophagogastric cancer, 1962-1964 (editorial), 1996-2004, 4124-4126 (correspondence)
MDA-7 expression, in melanoma, 1069-1074
MDM2, role in testicular germ cell tumor treatment response, 1551-1561, 3928-3929 (correspondence)
MDR1 gene, and hyperthermic isolated limb perfusion, 3282-3292
Mediastinum
germ cell tumors of, 1864-1873, 3739-3742
residual mass in, pitfalls of PET assessment of, 3347-3349
Megestrol acetate, for cancer-associated anorexia, 567-573, 2912-2913 (correspondence)
Melanoma
adoptive T-cell immunotherapy for, 1075-1086, 3176-3177 (correspondence), 3184 (errata)
advanced
chemotherapy for, 2411-2414 (editorial)
temozolomide plus thalidomide in, 2610-2615, 3361 (erratum)
anal-rectal, sphincter-sparing therapy for, 4549-4552
cutaneous

in complete regression, detection of malignant cells by RT-PCR in, 1411-1412
metastases from, dermoscopic features of, 1412-1415
disseminated, survival after resection of, 4561-4566
high-risk
microscopic satellites of lymph node spread in, 2053-2057
PET mimicking lymph node metastases in, 3349-3351
information on Internet about, 134-141
malignant. *See* Malignant melanoma
MDA-7 expression in, 1069-1074
metastatic
biochemotherapy for (phase III trial), 1600-1607, 2045-2052, 3560-3561 (correspondence)
CEACAM1 expression in, 2530-2536
IL-2 with/without histamine dihydrochloride for (phase III trial), 125-133
interleukin-2 therapeutic trial, 1431-1433 (editorial), 3558-3559 (correspondence)
intravenous VNP20009 in (phase I trial), 142-152
temozolomide with docetaxel in (phase II trial), 420-425
vaccination with autologous tumor-derived HSP gp96-peptide complexes in, 4139-4140 (editorial), 4169-4180, 4610 (erratum)
quality-of-life–adjusted survival analysis of adjuvant IFNα2b for, 1311-1318
tyrosinase mRNA and, 4032-4039
vaccine therapy for
adjuvant, 2058-2066, 2067-2075
humoral response to, 3242-3248
Melatonin, actions and potential usefulness of, 2575-2601, 4127-4129 (correspondence)
Meninges, isolated anaplastic large-cell lymphoma of, 4395-4397
Menopause, hormone replacement therapy and, 699-706
Mental health service, cancer survivors use of, 4581-4590
Merkel cell carcinoma, 588-598
Mesorectal adenocarcinoma, excision of, 1714-1715 (editorial), 1729-1734
Mesorectal excision, preoperative radiotherapy with, side effects and complications after, 817-825
Mesothelioma, unresectable malignant, ranpirnase in (phase II trial), 274-281
Meta-analysis
of acute and chronic GVHD, 603-606 (correspondence)
of adjuvant interferon therapy in malignant melanoma, 1818-1825, 4120-4124 (correspondence)
Metachronous contralateral renal cell carcinoma, risk of developing, 2370-2375
Metastases. *See also* Brain metastases; Micrometastases
benign pleomorphic adenoma, 2400-2403
bone
N-/C-telopeptide cross-links in, 850-856
skeletal irradiation with high-dose ^{153}Sm-EDTMP in, 189-196, 1953-1954 (correspondence)
breast cancer. *See* Metastatic breast cancer
colorectal cancer, uracil/tegafur plus leucovorin in, 3605-3616 (phase III), 3617-3627
from cutaneous melanoma, dermoscopic features of, 1412-1415
gastric carcinoid, to liver, 2403-2404
hepatic, from colorectal cancer, 1442-1445 (editorial)
FDG-PET scan in, 388-395
surgical resection of, 1499-1505
intracranial esthesioneuroblastoma, treatment of, 357-358 (correspondence)
lymph node. *See* Lymph nodes, metastatic
melanoma. *See* Melanoma, metastatic
in osteosarcoma
pediatric, etoposide and ifosfamide in (phase II/III trial), 426-433
prognosis of, 3470-3477
renal cell carcinoma, unexpected toxicity of combined thalidomide and INFa2a therapy for, 1429-1430 (correspondence)
Metastatic breast cancer
aromatase inhibitor therapy for, 3365-3368 (editorial)
doxorubicin/paclitaxel *vs.* doxorubicin/cyclophosphamide in, 3114-3121
epirubicin and vinorelbine first-line treatment of, 2689-2694
high-dose chemotherapy for
with autologous stem-cell transplantation, 707-718
lymphocyte reinfusion and T-cell recovery after, 58-64
Ro 25–8315 with, 24-36
standard chemotherapy *vs.*, 743-750
hormone therapy response in, 1467-1472, 3357 (correspondence), 4605-4606 (correspondence)
limited, 620-623 (editorial)
paclitaxel for, nail toxicities and, 4404-4405 (correspondence)
refractory, tumor response to paclitaxel in, 3665-3673
taxane- and anthracycline-pretreated, combination chemotherapy for (phase II trial), 2551-2558
taxane sensitivity in, molecular markers of, 2319-2326
trastuzumab for
effects on quality of life, 3106-3113
safety and efficacy of, 719-726, 4130-4133 (correspondence)
weekly docetaxel/trastuzumab for (phase II trial), 1800-1808
Metastatic colorectal cancer
Bax expression and, 811-816
biweekly chemotherapy regimen in, 4006-4014
capecitabine and oxaliplatin for (phase II trial), 1759-1766
5-FU and *l*-folinic acid for (phase II trial), 1175-1181, 3937-3939 (correspondence)
lymph node micrometastases detection by RT-PCR in, 4232-4241
multidrug treatment for, 2545-2550
first-line triplet chemotherapy regimen (phase II trial), 2651-2657

node volume in, 1506-1511
oral chemotherapy for
efficacy and quality-of-life data after (phase I trial), 4574-4580
intravenous first-line therapy *versus* (phase III trial), 1519-1526
prognostic factors in, 2832-2843
Metastatic gastrointestinal stromal tumor, response to imatinib mesylate, 870-872, 1430 (erratum)
Metastatic hepatoblastoma, treatment in pediatric patient (phase II trial), 3438-3444
Methadone, in opioid rotation, 2409-2410 (correspondence)
Methotrexate
in CMF regimen, goserelin *vs.*, in premenopausal breast cancer patients, 4628-4635
tamoxifen and, 4611-4614 (editorial), 4621-4627
in graft-*vs.*-host disease prophylaxis regimen, 603-606 (correspondence)
low-dose, for gestational trophoblastic disease, 1838-1844
Methylphenidate, cancer patients use of, 335-339
MGMT gene, clinical relevance in cancer treatment, 2388-2399
MGUS (monoclonal gammopathy of undetermined significance), malignant transformation risk in, 1625-1634
Microarrays
as cancer keys, 3165-3175
prognostic value of E-cadherin pathway in NSCLC, 2417-2428
Microassays, DNA, in clinical oncology, 1932-1941
Microcirculation, in tumor, effect of DMXAA on (phase I trial), 3826-3840
Micrometastases
in bone marrow, 2930-2936
in colorectal cancer, 4338-4343
lymph node, 2930-2936, 4232-4241
in NSCLC, 1984-1988, 2930-2936
Microsatellite instability
in colorectal tumors, immunohistochemistry *vs.*, 1043-1048
of tumor phenotyping, 897-899 (editorial)
Microvessel density, in hepatocellular carcinoma, 1775-1785
Minimal residual disease tests, in adult lymphoblastic leukemia, 1094-1104
Minneapolis-Manchester Quality of Life instrument, 4692-4698
Mismatch repair gene mutations, molecular screening for, 1705-1707 (correspondence)
Mitomycin, for inoperable pancreatic cancer (phase III trial), 3130-3136
Mitoxantrone, for relapsed or refractory acute leukemia (phase I trial), 674-679
hMLH1/hMSH2 mutations, in suspected hereditary nonpolyposis colorectal cancer, 1203-1208, 3178-3179 (correspondence)
MLL gene, partial tandem duplication in acute myeloid leukemia, 3254-3261
MMQL (Minneapolis-Manchester Quality of Life) instrument, 4692-4698
Molecular biology, of kinase-positive anaplastic large-cell lymphoma, 3691-3702
Molecular genetics
chromosome segment 11p15.5 in NSCLC, 1353-1360
detection of genomic aberrations in AML, 2480-2485
heterogeneity influencing clinical trials, 2495-2499, 4606-4607 (correspondence)
relationship between multiple tumors, 1105-1114
screening for hereditary nonpolyposis colorectal cancer, 1705-1707 (correspondence)
Molecular markers, of taxane sensitivity in metastatic breast cancer, 2319-2326
Monoclonal antibodies
^{131}I-labeled 81C6 in newly diagnosed malignant gliomas (phase II trial), 1389-1397
radiolabeled anti-CD20, for B-cell lymphoma, 3545-3557
Monoclonal gammopathy of undetermined significance, malignant transformation risk in, 1625-1634
Morbidity
in cardiac disease, after radiotherapy for breast cancer, 1036-1042
chronic arm, after breast cancer treatment, 4242-4248
psychiatric, during hospitalization for stem-cell transplantation, 1907-1917
treatment-related, in early-stage Hodgkin's disease, 2225-2228 (editorial)
Mortality
associated with irinotecan plus bolus fluorouracil/leucovorin, 1145-1146 (correspondence)
in cardiac disease, after radiotherapy for breast cancer, 1036-1042
and long-term survival in treated early-stage Hodgkin disease, 2101-2108
in lung cancer, 1973-1983, 3931-3934 (correspondence)
in prostate cancer, predictors in, 4567-4573
treatment-related, in early-stage Hodgkin's disease, 2225-2228 (editorial)
Motexafin gadolinium, for brain metastases, 3445-3453
MRNA, VEGF and IL-8, in NSCLC, *p53* and, 900-910
MRP1 gene, and hyperthermic isolated limb perfusion, 3282-3292
MTX. *See* Methotrexate
Mucosa-associated lymphoid tissue lymphoma
of bladder, regression after antibiotic therapy, 882 (correspondence)
cladribine therapy in (phase II trial), 3872-3877
Mucositis, radiation-associated, prophylactic antimicrobial lozenge for (phase III trial), 3956-3963
Mullerian tumor, malignant mixed, association of tamoxifen with, 2758-2760 (correspondence), 4403 (correspondence)
Multidrug resistance genes, and hyperthermic isolated limb perfusion, 3282-3292
Multinomial stopping rule (phase II trial), 599 (correspondence)

Multiple myeloma
advanced, effects of long-term ibandronate therapy in, 2353-2359
bisphosphonates role in, ASCO guidelines, 3719-3736
hemorrhagic gastric plasmacytoma in, 344-347
high-risk, allogeneic stem-cell transplantation after nonmyeloablative conditioning in, 1295-1303, 4268-4269 (correspondence)
smoldering, malignant transformation risk in, 1625-1634
thalidomide therapy for, tumor lysis syndrome and, 2212 (correspondence)
vertebral compression fractures in, kyphoplasty for, 2382-2387
Mutations, *BRCA1/BRCA2* germline. *See* *BRCA1/BRCA2* genes, mutation carriers
MVP gene, and hyperthermic isolated limb perfusion, 3282-3292
Myelodysplastic syndrome
azacytidine therapy in
impact on quality of life, 2441-2452
supportive care *vs.*, 2415-2416 (editorial)
in children, treatment results, 434-440
Myeloid malignancies, advanced relapsed, chemotherapy and donor leukocyte infusions for, 405-412, 2756-2757 (correspondence)
Myeloma
human bone marrow, RANKL in, 353-354 (correspndence)
multiple. *See* Multiple myeloma
stridor in patient with, 866
thalidomide plus dexamethasone for, 4319-4323
Myelomonocytic leukemia, juvenile, treatment results in, 434-440
Myelosuppression, chemotherapy-induced, 4713-4721

N

Nail toxicities, with paclitaxel for metastatic breast cancer, 4404-4405 (correspondence)
Nasopharyngeal cancer
advanced, chemoradiation for, 1845-1852
local-regionally advanced, chemotherapy and, 1968-1970 (editorial)
concurrent chemotherapy-radiotherapy (phase III trial), 2038-2044
NCCTG (North Central Cancer Treatment Group), real-time toxicity monitoring program, 4591-4596
Neck
cancer of. *See* Head and neck cancer
radiotherapy on, stroke risk after, 282-288
Neoadjuvant chemotherapy
in breast cancer, 2905-2907 (correspondence)
docetaxel, in breast cancer, 1456-1466
predicting survival in retroperitoneal and visceral soft tissue sarcomas, 3256-3164
and radical surgery, in locally advanced squamous cell cervical cancer, 179-188, 2908-2910 (correspondence)
without radiotherapy, predicting local-regional recurrence of breast cancer after, 17-23
Neoangiogenesis, in NSCLC, *p53* and, 900-910
Nerve-sparing radical prostatectomy, risks associated with, 1853-1858
Neural networks, artificial. *See* Artificial neural networks
Neuroblastoma
^{131}I-MIBG therapy for, 2142-2149
in children, screening for, 1154-1155 (editorial)
incidence and mortality results, 1209-1214
Neuropsychologic impact, of chemotherapy in breast cancer survivors, 485-493
Neurotoxicity, oxaliplatin
acute peripheral nerve hyperexcitability, 1767-1774, 3561-3562 (correspondence)
glutathione modifying, 3478-3483
Nevi, cutaneous melanoma metastases mimicking, dermoscopic features of, 1412-1415
Nicotine dependence, outcomes in lung cancer patients after treatment for, 3461-3469
Node-negative cancers
cervical, tumor hypoxia in, 610-615 (editorial), 680-687
colorectal, CK-20 RT-PCR in lymph nodes of patients with, 1049-1055
Node-positive breast cancer
angiogenesis associated with outcome in (CALB 8541 trial), 732-742
anthracycline-based chemotherapy for, 3637-3643
Non-Hodgkin's lymphoma
aggressive, autologous transplantation for, 2344-2352, 4411-4412 (editorial)
B-cell, CD4+ T-cell immune response to, 2904-2905 (correspondence)
cancer-related fatigue in, clinical factors associated with, 1319-1328
of eyelid, palliative radiotherapy in, 4601-4602
indolent, rituximab for, 4261-4267
low-grade, fludarabine *vs.* CVP chemotherapy regimen in (phase III trial), 4649-4654
in pediatric patient
bone outcomes, 2293-2301
G-CSF induction therapy in, 441-448
presenting as liver disease, 1943-1946
radioimmunotherapy for, 2453-2463
subsequent chemotherapy regimens after, 3885-3890
rituximab-refractory follicular, radioimmunotherapy for, 3262-3269
sea-blue histiocytes in, 1942-1943
splenic hematoma associated with, 1946-1947
unusual sites of involvement in, 4394-4398
Nonmyeloablative conditioning, in high-risk multiple myeloma patients, 1295-1303, 4268-4269 (correspondence)
Nonrhabdomyosarcoma soft tissue sarcoma, pediatric, outcomes in, 3225-3235
Non–small-cell lung cancer
advanced

chemotherapy options for (discussion), 23*s*-33*s*
cisplatin-based combination chemotherapy for, 3565-3567 (editorial)
defined duration *vs.* continuous therapy for (phase III trial), 1335-1343
docetaxel *vs.* best supportive care as second-line therapy of, 1344-1352, 3750-3751 (correspondence)
two-drug combination chemotherapy for, 3565-3567 (editorial), 3578-3585 (phase III trial)
paclitaxel/carboplatin (phase II trial), 2937-2942
paclitaxel/cyclosporine (phase II trial), 4508-4516
platinum-based (phase III trial), 4285-4291
alternative staging strategies for, 263-273
chemotherapy cost-effectiveness in, 3750-3751 (correspondence)
chromosome segment 11p15.5 in, 1353-1360
initial manifestations of
adrenal insufficiency, 4598-4600
diabetes insipidus, 4597-4598
inoperable, gemcitabine and concurrent radiotherapy for (phase I trial), 804-810
long-term survivors of, quality of life in, 2920-2929
p21 expression in, clinical significance of, 3865-3871
p53 correlates in, 900-910
postoperative radiotherapy for, intercurrent disease risk and, 1427-1429 (correspondence)
prognostic value of E-cadherin pathway in, 2417-2428
resectable
combined-modality therapy in, long-term results of, 1989-1995
lymph node staging in, 2604-2605 (correspondence)
postoperative micrometastases in lymph nodes and bone marrow and, 2930-2936
preoperative chemotherapy *vs.* primary surgery in, 247-253, 2603-2604 (correspondence)
sentinel node mapping in, 1984-1988
stage IIIB
chemoradiotherapy in, 3454-3460
induction chemotherapy followed by concomitant chemoradiotherapy for, 4191-4198
telomerase and *p16* expression in, 254-262
and TNP-450/paclitaxel activity in solid tumors, 4440-4447
ZD1839 activity and tolerance in (phase I trial), 3815-3825
North Central Cancer Treatment Group, real-time toxicity monitoring program, 4591-4596
NSCLC. *See* Non–small-cell lung cancer
Nutrition
after breast cancer diagnosis, survival and, 3302-3316, 3939 (errata)
in cancer patients, beneficial effects of ATP on, 371-378

O

Off-shore clinical trials, ethical issues and, 3934-3936 (correspondence)
Oncologists
addressing end-of-life issues with patient, 3035-3037, 4403-4404 (correspondence)
attitudes of
artificial hydration in terminally-ill patients, 4699-4704
disclosing unfavorable medical information to patients, 2189-2196
sperm banking by patients, prior to cancer treatment, 1890-1897
challenges and difficulties facing, 2407-2408
and chemotherapy benefit perceptions, 4603-4604
and clinical trial design principles, 42*s*-46*s*
house calls by, 3745-3746
and palliative chemotherapy *vs.* watchful waiting, 3658-3664, 4409 (erratum)
and patient communication. *See* Patient-physician communication
unanswerable questions posed to, 873-875
Oncology, randomized discontinuation design in, 4478-4484
Oncolytic viruses
in cancer treatment, development of, 2220-2222 (editorial)
PV701, for advanced solid tumors (phase I trial), 2251-2266
ONYX-015, intraperitoneal, in recurrent ovarian cancer (phase I trial), 1562-1569
Oophorectomy
in *BRCA1* mutation carriers, 2092-2100
and tamoxifen adjuvant therapy, for premenopausal breast cancer, 2559-2566, 3934-3936 (correspondence)
Opioids
rotation in palliative therapy, 348-352, 2409-2410 (correspondence)
SSRIs inhibiting, 2409 (correspondence)
Orbital relapse, isolated, after BMT for mantle-cell lymphoma, 4394-4395
Organ preservation
in advanced cancers
of head and neck, 1405-1410
oropharyngeal (phase II trial), 3964-3971
and radiotherapy in bladder cancer, 3048-3050 (editorial), 3061-3071
Oropharyngeal carcinoma, advanced resectable, organ preservation protocols in (phase II trial), 3964-3971
Osteosarcoma
extraosseous, outcomes of, 521-527
high-grade, of extremities or trunk, prognostic factors in, 776-790, 2910-2911 (correspondence)
metastasis in
etoposide and ifosfamide in pediatric patient (phase II/III trial), 426-433
prognosis of, 3470-3477
relapsed, high-dose chemotherapy for, 2150-2156
skeletal irradiation with high-dose ^{153}Sm-EDTMP in, 189-196, 1953-1954 (correspondence)
Outcomes
in acinar cell carcinoma of pancreas, 4673-4678

after Wilms tumor treatment in pregnant patient, 2506-2513
in *BRCA* gene mutation carriers, 1260-1268
in CNS lymphoma, effect of radiotherapy on, 231-236
in ductal carcinoma-in-situ, age at diagnosis and, 2736-2744
of estrogen-raloxifene interaction and breast cancer risk, 1430 (erratum)
in extraosseous osteosarcoma, 521-527
in head and neck cancer, ^{18}FDG uptake predicting, 1398-1404
in Hodgkin's disease
in elderly, 1087-1093
relapsed, prognostic score based on, 221-230
of low-dose methotrexate for gestational trophoblastic disease, 1838-1844
in metastatic renal cell cancer, 2376-2381
MRD tests predicting, in adult lymphoblastic leukemia, 1094-1104
in myeloid leukemia, after BMT
acute form, 4324-4330
chronic form, 2334-2343
in node-positive breast cancer, angiogenesis association with (CALB 8541 trial), 732-742
in non-Hodgkin's lymphoma
B-cell, CD4+ T-cell immune response predicts, 2904-2905 (correspondence)
pediatric bone, 2293-2301
in NSCLC, alternative staging strategies for, 263-273
in pancreatic ductal adenocarcinoma, 4531-4542
in pediatric patients
with ALL
growth hormone replacement therapy, 2959-2964
treatment protocols (Dana-Farber Institute), 237-246
juvenile myelomonocytic leukemia or myelodysplastic syndrome, 434-440
nonrhabdomyosarcoma soft tissue sarcoma, 3225-3235
rhabdomyosarcoma, by race, 4428-4433
in prostate cancer, clinical stage and, 2025-2030
and radiotherapy timing, in extremity soft tissue sarcoma, 4472-4477
in renal cell carcinoma, risk group algorithm predicting, 4553-4560
tobacco use, after nicotine dependence treatment in lung cancer patients, 3461-3469
Ovarian cancer
advanced
chemotherapy variations in elderly patients with, 173-178
cytoreductive surgery for, 1248-1259
intraperitoneal therapy for (editorial), 3944-3946
BRCA-related survival in, 463-466
cerebral metastases from, 982-986
intraperitoneal chemotherapy for, follow-up results in, 694-698
Jewish women at risk for, 1570-1577
oxaliplatin therapy in carboplatin-sensitive patients, 353 (correspndence)
recurrent
evidence-based treatment of, 1161-1163 (editorial)
intraperitoneal ONYX-015 in (phase I trial), 1562-1569
paclitaxel *vs.* cyclophosphamide/doxorubicin/cisplatin for, 1232-1237
second-line treatment of, carboplatin/paclitaxel, 1238-1247
refractory/relapsed, weekly single-agent paclitaxel for (phase II trial), 2365-2369
second-line treatment of, 1158-1160 (editorial)
thalidomide pilot study, 1147-1149 (correspondence)
Oxaliplatin
with capecitabine, in advanced or metastatic colorectal cancer (phase II trial), 1759-1766
in carboplatin-sensitive patients, 353 (correspondence)
in chemotherapy regimens
FOLFOX6, in advanced/metastatic gastric cancer patients, 4542-4548
triplet, for metastatic colorectal cancer (phase II trial), 2651-2657
weekly, in metastatic colorectal cancer, 4006-4014
in cisplatin-refractory germ cell cancer, 2031-2037
cumulative polyneuropathy induced by, treatment of, 3359-3361 (correspondence)
dosing schedule for, 2758 (correspondence), 3753 (correspondence)
for esophageal cancer, 2844-2850
with fluorouracil, for taxane- and anthracycline-pretreated metastatic breast cancer, 2551-2558
with gemcitabine, for pancreatic adenocarcinoma (phase II trial), 1512-1518
hypersensitivity reactions to, 1146-1147(correspondence)
with irinotecan, in advanced colorectal cancer (phase II trial), 165-172
for metastatic colorectal cancer, in combined drug therapy, 2545-2550
neurotoxicity of
acute peripheral nerve hyperexcitability, 1767-1774, 3561-3562 (correspondence)
glutathione modifying, 3478-3483

P

P-glycoprotein
inhibition of, and oral bioavailability of topotecan, 2943-2950
and oral bioavailability of docetaxel and cyclosporine, 1951-1952 (correspondence)
p16, and telomerase in NSCLC, 254-262
p21, in NSCLC, clinical significance of, 3865-3871
p53
adenovirus-mediated gene transfer, in bladder cancer, 957-965
and angiogenesis link, in lung cancer, 883-884 (editorial)

in locally advanced colon cancer, prognostic and predictive values of, 1735-1743
in metastatic colorectal cancer, 2832-2843
in NSCLC, correlates of, 900-910
pathways in squamous cell carcinoma of head and neck, 2980-2987
role in testicular germ cell tumor treatment response, 1551-1561, 3928-3929 (correspondence)
uPA. *See* Urokinase-type plasminogen activator
Paclitaxel
for advanced NSCLC
in carboplatin-based chemotherapy (phase II trial), 2937-2942
in combination chemotherapy (phase III trial), 3578-3585
with cyclosporine (phase II trial), 4508-4516
in induction therapy, 4191-4198
with doxorubicin, *vs.* doxorubicin/cyclophosphamide in metastatic breast cancer, 3114-3121
with flavopiridol, in advanced solid tumors (phase I trial), 2157-2170
with gemcitabine, in refractory germ cell tumors (phase II trial), 1859-1863, 3754 (erratum)
with gemcitabine/carboplatin, for carcinoma of unknown primary site, 1651-1656
for metastatic breast cancer, nail toxicities and, 4404-4405 (correspondence)
in pretreated advanced urothelial cancer (phase II trial), 937-940
with radiotherapy, for pancreatic adenocarcinoma, 2537-2544
for recurrent ovarian cancer
carboplatin with, as second-line therapy, 1238-1247
vs. cyclophosphamide/doxorubicin/cisplatin regimen, 1232-1237
in refractory metastatic breast cancer, tumor response to, 3665-3673
with TNP-470, for solid tumors, safety and pharmacokinetic effects of, 4440-4447
unbound, pharmacokinetics of, 574-581
weekly
with carboplatin, in advanced breast cancer (phase II trial), 3857-3864
single-agent, for refractory ovarian cancer (phase II trial), 2365-2369
Pain
after treatment of locally recurrent rectal cancer, 4361-4367
analgesic regimen adherence and, patients' perspective on, 2907-2908 (correspondence)
drug therapies for, using trade *vs.* generic names of, 1707-1708 (correspondence)
management of. *See* Palliative therapy
refractory
implantable drug delivery system for, 4040-4049
opioid rotation in management of, 348-352, 2409-2410 (correspondence)
Palliative therapy
changing patterns of, 880-882 (correspondence)
chemotherapy
health-related quality of life and, 1056-1062
vs. watchful waiting, oncologists' preferences, 3658-3664, 4409 (erratum)
for eyelid non-Hodgkin's lymphoma, 4601-4602
methylphenidate, 335-339
opioid rotation in, 348-352, 2409-2410 (correspondence)
psychologic symptoms and (editorial), 624-626
quality of life in, 1704-1705 (correspondence)
sedation in terminally-ill patients, 758-764
Pancreas
acinar cell carcinoma of, 4673-4678
endocrine neoplasms of, prognostic factors in, 2633-2642
juice and bile of, *ki-ras* polymerase chain reaction and, 4331-4337
Pancreatic adenocarcinoma
ductal, 4531-4542
gemcitabine and oxaliplatin for (phase II trial), 1512-1518
paclitaxel and radiotherapy for, 2537-2544
Pancreatic cancer
acinar cell, 4673-4678
advanced
gemcitabine with 5-FU *vs.* gemcitabine alone in (phase III trial), 3270-3275
oral capecitabine in (phase II trial), 160-164
anti-gastrin-17 antibodies in (phase II trial), 4225-4231
inoperable, protracted venous infusion 5-FU with/without mitomycin for (phase III trial), 3130-3136
metastatic, oral capecitabine in (phase II trial), 160-164
tumor marker responses in, irinotecan and gemcitabine inducing, 1182-1191
Pancytopenia, reversible, in recurrent breast cancer, 3747 (correspondence)
Papillary-serous peritoneal carcinoma, thalidomide pilot study in, 1147-1149 (correspondence)
Paraneoplastic digital necrosis, in small-cell lung cancer, 4600-4601
Paratesticular rhabdomyosarcoma, 449-455
Parents with cancer, child care and, 4399-4402
Partial tandem duplication, of *MLL* gene in acute myeloid leukemia, 3254-3261
Pathology, of rectal cancer resection specimen, 1714-1715 (editorial), 1729-1734
Patient burden, assessing, 4-6 (editorial), 65-72
Patient-physician communication
about breast cancer treatment in older women, 1008-1016
addressing end-of-life issues and, 3035-3037, 4403-4404 (correspondence)
consultation planning and, 2695-2700
hospice care and, 1419-1424
and unfavorable medical information, oncologists' attitudes on disclosing, 2189-2196
via email, 3352-3355
Patients
with breast cancer. *See* Breast cancer patients

discussing hospice care with, 1419-1424
dying. *See* End-of-life care; Terminally-ill patient
pediatric. *See* Children
and right to decide, 4115-4118
symptom experiences in home care setting, 3495-3507
PAX3-FKHR/PAX7-FKHR gene fusion, in rhabdomyosarcoma, 2672-2679
PCFL. *See* Lymphoma, primary cutaneous follicular
PCNSL. *See* Central nervous system, primary lymphoma of
Pediatric patients. *See* Children
Pegfilgrastim, as adjunct to chemotherapy in advanced breast cancer, 727-731
Pegylated interferon alfa-2b, for solid tumors (phase I/II trial), 3841-3849
Pegylated liposomal doxorubicin, for metastatic endometrial cancer (phase II trial), 2360-2364
Pemetrexed, and carboplatin activity, in malignant mesothelioma (phase I trial), 3533-3544
Peptide-doxorubicin conjugate, PSA-activated, in prostate cancer patients, 1874-1879
Peptide immunization, HER-2/neu protein immunity after, 2624-2632
Peripheral nerve hyperexcitability, acute oxaliplatin-induced, 1767-1774, 3561-3562 (correspondence)
Peripheral T-cell lymphoma, high-dose chemotherapy or allogeneic hematopoietic transplantation for, 1426-1427 (correspondence)
Peritoneal carcinoma, papillary-serous, thalidomide pilot study, 1147-1149 (correspondence)
PET. *See* Positron emission tomography
Pharmacodynamics
docetaxel, interindividual variability in Asians, 3683-3690
EGF receptor inhibition by ZD1839 in skin from cancer patients, 110-124
prolonged gemcitabine infusion, in relapsed acute myelogenous leukemia (phase I trial), 665-673
ZD1839 (phase I trial), 4276-4278 (editorial), 4292-4302
Pharmacogenetics, irinotecan and raltitrexed, 1425-1426 (correspondence)
Pharmacokinetics
antrasentan for refractory adenocarcinomas, 2171-2180
in cancer patients with hepatic dysfunction, 4303-4312
carboplatin and pemetrexed, in malignant mesothelioma (phase I trial), 3533-3544
combination chemotherapy for solid tumors, 1657-1667, 3042-3043 (correspondence)
continuous infusion 5-FU and oral 5-FU/eniluracil compared, in solid tumors, 1683-1691
docetaxel, interindividual variability in Asians, 3683-3690
E7070 (phase I trials), 4065-4073
in advanced cancer (phase I trial), 3508-3521
irinotecan, 3293-3301, 4609-4610 (correspondence)
liposomal lurtotecan (phase I trial), 1222-1231
polymer-bound doxorubicin, hepatic targeting evaluation of (phase I trial), 1668-1676
TAC-101, in advanced cancer, 3522-3532
TNP-470/paclitaxel, in solid tumors, 4440-4447
troxacitabine (phase I trial), 2567-2574
in advanced solid malignancies (phase I trial), 96-109
unbound paclitaxel, 574-581
ZD1839 (phase I trial), 4276-4278 (editorial), 4292-4302
ZD9331 for solid tumors (phase I trial), 1923-1931
Phase I trials
capecitabine
with concurrent radiotherapy, in rectal cancer, 3983-3991
with gemcitabine, in advanced cancer, 582-587
carboplatin/pemetrexed, in malignant mesothelioma, 3533-3544
COL-3, for AIDS-related Kaposi's sarcoma, 153-159
DMXAA, effect on tumor microcirculation, 3826-3840
E7070 pharmacokinetics, 4065-4073
in advanced cancer, 3508-3521
endostatin
in advanced solid tumors, 3792-3803
intravenous infusion of, 3772-3784
media coverage influencing potential participants, 3761-3764 (editorial), 3785-3791
flavopiridol
daily 1-hour infusion, for advanced neoplasms, 4074-4082
with paclitaxel, in advanced solid tumors, 2157-2170
gemcitabine
and concurrent radiotherapy, in inoperable NSCLC, 804-810
with irinotecan, for relapsed or refractory leukemia or lymphoma, 2995-3000
prolonged infusion, in relapsed or refractory acute leukemia, 665-673
with mitoxantrone, 674-679
intraperitoneal ONYX-015, in recurrent ovarian cancer, 1562-1569
intravenous estramustine phosphate, 1115-1127
intravenous VNP20009 in metastatic melanoma, 142-152
intravesical gemcitabine, for transitional-cell bladder carcinoma of bladder, 3185-3186
liposomal lurtotecan pharmacokinetics, 1222-1231
oral chemotherapy for metastatic colorectal cancer, efficacy and quality-of-life data after, 4574-4580
oral ZD9331, for solid tumors, pharmacologic study of, 1923-1931
polymer-bound doxorubicin, hepatic targeting evaluation of, 1668-1676
PV701, for advanced solid tumors, 2251-2266
R115777 in advanced cancers, chronic oral administration of, 2726-2735
temozolomide, in relapsed/refractory acute leukemia, 3249-3253
topotecan/carboplatin, in pediatric solid tumors in, 88-95, 3558 (correspondence)
troxacitabine
in advanced solid malignancies, 96-109
pharmacokinetics of, 2567-2574
ZD1839

activity and tolerance in NSCLC and other solid tumors, 3815-3825
for solid malignant tumors, 2240-2250
Phase I/II trials, pegylated interferon alfa-2b for solid tumors, 3841-3849
Phase II trials
alternating thoracic radiotherapy and chemotherapy, in unresectable stage III NSCLC, 797-803
anti-gastrin-17 antibodies, in pancreatic cancer, 4225-4231
capecitabine
oral, in advanced or metastatic pancreatic cancer, 160-164
with oxaliplatin, in advanced or metastatic colorectal cancer, 1759-1766
carboplatin, for progressive pediatric low-grade gliomas, 2951-2958
carmustine/O^6-benzylguanine, for malignant glioma, 2277-2283
cisplatin/gemcitabine/ifosfamide, for advanced transitional-cell carcinoma, 2965-2970
cladribine therapy in MALT type B-cell lymphoma, 3872-3877
combination chemotherapy regimens
for small-cell prostate carcinoma, 3072-3080
for taxane- and anthracycline-pretreated metastatic breast cancer, 2551-2558
docetaxel
with cisplatin, for head and neck squamous cell carcinoma, 1593-1599
with trastuzumab (weekly), for metastatic breast cancer, 1800-1808
eniluracil/fluorouracil, for anthracycline- and taxane-resistant advanced breast cancer, 987-993, 3750 (correspondence)
5-FU/*l*-folinic acid, for colorectal cancer, 1175-1181, 3937-3939 (correspondence)
gemcitabine
biweekly, with vinorelbine, in pretreated advanced breast cancer, 37-41
with docetaxel, for unresectable leiomyosarcoma, 2824-2831
with oxaliplatin for pancreatic adenocarcinoma, 1512-1518
^{131}I-labeled 81C6 in newly diagnosed malignant gliomas, 1389-1397
multinomial stopping rule, 599 (correspondence)
oral etoposide, in AIDS-related Kaposi's sarcoma, 3236-3241
organ preservation protocols, in advanced resectable oropharyngeal carcinoma, 3964-3971
oxaliplatin/ironotecan *vs.* raltitrexed, in advanced colorectal cancer, 165-172
paclitaxel
and carboplatin-based chemotherapy for advanced non–small-cell lung cancer, 2937-2942
with cyclosporine, in advanced non–small-cell lung cancer, 4508-4516
with gemcitabine, in refractory germ cell tumors, 1859-1863, 3754 (erratum)
for pretreated advanced urothelial cancer, 937-940
weekly
with carboplatin, in advanced breast cancer, 3857-3864
single-agent, for refractory ovarian cancer, 2365-2369
pegylated liposomal doxorubicin, for metastatic endometrial cancer, 2360-2364
preradiation chemotherapy in high-risk pediatric brainstem tumors, 3431-3437
ranpirnase, in unresectable malignant mesothelioma, 274-281
RSR13 and radiotherapy, for glioblastoma multiforme, 3149-3155
temozolomide
with concurrent radiotherapy, in brain metastases, 3644-3650
with docetaxel, in advanced melanoma, 420-425
with marimastat, for glioblastoma multiforme, 1383-1388
thalidomide, in advanced renal cell cancer, 302-306
translational study of advanced cutaneous squamous cell cancer, 364-370
triplet chemotherapy regimen, for metastatic colorectal cancer, 2651-2657
troxacitabine, in refractory leukemia, 656-664, 3356-3357 (correspondence)
in unresectable and metastatic hepatoblastoma in pediatric patient, 3438-3444
vinorelbine and gemcitabine (biweekly), in pretreated advanced breast cancer, 37-41
Phase II/III trials, etoposide and ifosfamide, in pediatric metastatic osteosarcoma, 426-433
Phase III trials
capecitabine/docetaxel combination therapy, survival in advanced breast cancer with, 2812-2823
chemotherapy in advanced NSCLC
combination, 3578-3585
duration, 1335-1343
platinum-based doublets, 4285-4291
epirubicin/cisplatin/lonidamine, in advanced breast cancer, 4150-4159
etoposide/cisplatin *vs.* CEV chemotherapy regimen, in small-cell lung cancer (phase III trial), 4665-4672
FAP *vs.* M-VAC chemotherapy regimens, in advanced or metastatic cancer of urothelial tract, 1361-1367
fludarabine *vs.* CVP chemotherapy regimen, for low-grade non-Hodgkin's lymphoma, 4649-4654
fluorouracil/eniluracil/leucovorin, for metastatic/advanced colorectal cancer, 1519-1526
gemcitabine/5-FU *vs.* gemcitabine alone, in advanced pancreatic cancer, 3270-3275
hot flashes, evaluation of fluoxetine for, 1578-1583
intensified chemotherapy, for small-cell lung cancer, 3941-3943 (editorial), 3947-3955

interleukin-2 with/without histamine dihydrochloride, for metastatic melanoma, 125-133
prophylactic antimicrobial lozenge for radiation mucositis, 3956-3963
protracted venous infusion 5-FU with/without mitomycin for inoperable pancreatic cancer (phase III trial), 3130-3136
radiotherapy
high-dose *vs.* standard-dose radiotherapy, for esophageal cancer, 1167-1174
vs. concurrent chemotherapy-radiotherapy, for nasopharyngeal cancer, 2038-2044
with/without cisplatin, for advanced squamous cell cervical cancer, 966-972
sequential chemoradiotherapy for limited-stage small-cell lung lancer, 3045-3047 (editorial), 3054-3060
systemic treatment for metastatic melanoma, 2045-2052
uracil/tegafur plus leucovorin, in metastatic colorectal cancer, 3605-3616
Phenotyping
of adrenocortical carcinoma, 941-950
of colorectal tumors, immunohistochemistry *vs.* microsatellite instability, 1043-1048
and interindividual variability of docetaxel activity in Asians, 3683-3690
Physician and patient communication. *See* Patient-physician communication
Phytoestrogens, effect on hot flashes in postmenopausal women with breast cancer, 1449-1455, 3040-3042 (correspondence)
PK2, in hepatic drug targeting evaluation (phase I trial), 1668-1676
Placebo, influenza vaccine with, in cancer patients, 4313-4318
Plasmacytoma
giant cell, as intraperitoneal mass, 2405-2406
hemorrhagic gastric, in multiple myeloma, 344-347
Plasminogen activator inhibitor type 1 (PAI-1), in breast cancer, 1000-1007
Platinum-based doublets, in advanced NSCLC (phase III trial), 4285-4291
Pleomorphic adenoma, benign metastasizing, 2400-2403
PNET. *See* Primitive neuroectodermal tumors
Pneumonitis, hypersensitivity, and imatinib relationship, 4271-4272 (correspondence)
Polycythemia rubra vera-1 gene, in essential thrombocythemia, 4249-4254
Polymerase chain reaction
ki-ras, in pancreatic cancer diagnosis, 4331-4337
reverse transcriptase. *See* Reverse transcriptase-PCR
Polyneuropathy, oxaliplatin-induced, 3359-3361 (correspondence)
Positron emission tomography
^{18}fluorodeoxyglucose. *See* ^{18}Fluorodeoxyglucose–PET
mimicking lymph node metastases in high-risk melanoma patient, 3349-3351
for residual mediastinal mass assessment in Hodgkin's disease, pitfalls of, 3347-3349
Postmenopausal women, breast cancer in
advanced
anastrozole *vs.* tamoxifen for, 3748-3750 (correspondence)
fulvestrant *vs.* anastrozole for, 3386-3395, 3396-3403
letrozole *vs.* tamoxifen for, 876-878 (correspondence)
effect of soy phytoestrogens on hot flashes in, 1449-1455, 3040-3042 (correspondence)
letrozole/anastrozole cross-over study in, 751-757, 3039-3040 (correspondence)
tamoxifen and vorozole effects compared in, 1026-1035
Postoperative radiotherapy, for NSCLC, intercurrent disease risk and, 1427-1429 (correspondence)
Practice patterns, of community physicians, in adjuvant therapy for breast cancer, 1809-1817
Predictive factors
in carcinoma of unknown primary site, 4679-4683
death in hospital *vs.* at home, 2127-2133
dietary change after breast cancer and, 1017-1025
^{18}FDG uptake, in head and neck cancer, 1398-1404
for local-regional recurrence of breast cancer, 17-23
microvessel density in hepatocellular carcinoma, 1775-1785
MRD tests, in adult lymphoblastic leukemia, 1094-1104
N-/C-telopeptide crosslinks in bone metastases, 850-856
in node-negative cervical cancer, 680-687
in prostate cancer mortality, 4567-4573
recursive partitioning, ipsilateral breast tumor recurrence and, 4015-4021
renal cell carcinoma survival, mathematical model for, 1368-1374
in retroperitoneal and visceral soft tissue sarcomas, 3256-3164
risk group algorithm, for renal cell carcinoma outcomes, 4553-4560
seminoma surveillance, relapse and, 4448-4452
of smoking initiation and cessation among childhood cancer survivors, 1608-1616
thymidylate synthase levels (editorial), 1711-1713
in colorectal cancer, 1721-1728
in locally advanced colon cancer, 1735-1743
Prednisone, in CVP chemotherapy regimen, for low-grade non-Hodgkin's lymphoma (phase III trial), 4649-4654
Pregnancy, outcome after Wilms tumor treatment, 2506-2513
Premalignancies, malignant potential of, 456-462
Prevention strategies
cancer prevention clinical trials (American Cancer Society Award Lecture), 14*s*-22*s*
and decision analysis for *BRCA1*/*BRCA2* mutation carriers, 2420-2529
Primary CNS lymphoma. *See* Central nervous system, primary lymphoma of
Primitive neuroectodermal tumors, supratentorial, in childhood, radiotherapy of, 842-849

Prognostic factors. *See also* Survival
axillary lymph node eradication in breast cancer, 1304-1310
in node-negative patients, 1793-1799
c-met expression, in transitional cell carcinoma of urinary bladder, 1544-1550
in carcinoma of unknown primary site, 4679-4683
CEACAM1 expression, in lung cancer, 4273-4275 (editorial), 4279-4284
in cerebral low-grade glioma, 2076-2084
chromosome segment 11p15.5, in NSCLC, 1353-1360
CK-19$^+$ cells, in peripheral blood of patients with operable breast cancer, 3404-3412
CK-20 RT-PCR, in lymph nodes of node-negative colorectal cancer patients, 1049-1055
COX-2, in cervical cancer, 973-981
E-cadherin pathway, in NSCLC, 2417-2428
FDG-PET, in recurrent head and neck squamous cell carcinoma, 4199-4208
galectin-3, in laryngeal squamous cell carcinoma, 3850-3856
gene fusions, in rhabdomyosarcoma, 2672-2679
in high-grade osteosarcoma of extremities or trunk, 776-790, 2910-2911 (correspondence)
KIT mutation type, in gastrointestinal stromal tumors, 3898-3905
malignant transformation risk in MGUS and SMM, 1625-1634
in metastatic colorectal cancer, 2832-2843
metastatic lymph node volume in colorectal cancer, 1506-1511
MLL gene partial tandem duplication, in acute myeloid leukemia, 3254-3261
in oligometastatic breast cancer, after high-dose chemotherapy with autologous stem-cell transplantation, 707-718
in pancreatic endocrine neoplasms, 2633-2642
u-PAR, in gastric cancer, 2005-2016
pulmonary metastases identification in osteosarcoma, 3470-3477
in relapsed Hodgkin's disease, 221-230
for sarcomas, 627-629
survivin, in glioma, 1063-1068
thymidylate synthase levels (editorial), 1711-1713
in colorectal cancer, 1721-1728
in locally advanced colon cancer, 1735-1743
tumor vascularity, in primary cutaneous melanoma, 1826-1831
Progression, in multinomial stopping rule (phase II trial), 599 (correspondence)
Prophylaxis
antimicrobial lozenge for radiation mucositis (phase III trial), 3956-3963
methotrexate regimen in graft-*vs.*-host disease, 603-606 (correspondence)
surgical, for *BRCA1* mutation carriers, 2092-2100
Prostate cancer
advanced, suramin, 3369-3375
androgen receptor CAG repeat and, 3572-3573 (editorial)
racial variations in, 3599-3604
artificial neural network detecting, 921-929
clinical stage and outcome in, 2025-2030
early-stage, radiotherapy *vs.* radical prostatectomy costs, 2869-2875
excision of. *See* Radical prostatectomy
IGF-I, IGFBP-2, and IGFBP-3 and, 833-841
isotretinoin and hormone therapy in, 538-544
localized, surgery *vs.* external-beam radiotherapy for, 3363-3364 (editorial), 3376-3385
localized therapy for, health-related quality of life after, 557-566, 3038-3039 (correspondence)
locally persistent
challenge of (editorial), 3187
nested RT-PCR for PSA and PSM in, 3213-3218
radical radiation and late metastases in, 3199-3205
mortality predictors in, 4567-4573
PSA-activated peptide-doxorubicin conjugate in, 1874-1879
recurrent
postoperative, nomogram for, 951-956, 3206-3212
salvage cryotherapy for, 2664-2671
risk in, 3570-3571 (editorial)
screening for, family history and, 2658-2663
small-cell, combination chemotherapy for (phase II trial), 3072-3080
survival after castration in, 3972-3982
Prostate-specific antigen
effect of diet on, 3570-3571 (editorial), 3592-3598
peptide-doxorubicin conjugate activated by, 1874-1879
predicting recurrence of (editorial), 3188-3190
in prostate cancer screening, family history and, 2658-2663
in radical prostatectomy
impact of race on outcome after, 2863-2868, 4129-4130 (correspondence)
nested RT-PCR for, 3213-3218
Prostate-specific membrane antigen, in radical prostatectomy, nested RT-PCR for, 3213-3218
Prostatectomy. *See* Radical prostatectomy
Proteosome inhibitor (PS-341), for refractory hematologic malignancies, (phase I trial), 4420-4427
PRV-1, in essential thrombocythemia, 4249-4254
PS-341, for refractory hematologic malignancies, (phase I trial), 4420-4427
PSA. *See* Prostate-specific antigen
PSM (prostate-specific membrane antigen), in radical prostatectomy, nested RT-PCR for, 3213-3218
Psychiatric morbidity, during hospitalization for stem-cell transplantation, 1907-1917
Psychologic distress
BRCA1/BRCA2 mutation testing and, 514-520
dietary change after breast cancer and, 1017-1025
Psychologic symptoms, and palliative care (editorial), 624-626

Pulmonary lesions
metastatic, in osteosarcoma, prognosis of, 3470-3477
unusual presentations of, 2745-2751. *See also specific lesions*
Pulmonary vein leiomyosarcoma, 2749-2751
PV701, for advanced solid tumors (phase I trial), 2251-2266
Pyothorax-associated lymphoma, 4255-4260

Q

Quality of cancer care
in breast cancer patients, 4381-4393
measurement challenge in, 4353-4360
regulatory burdens of (ASCO Presidential Initiative 2001), 4722-4726
Quality of life
and anxiety disorders in cancer patients, 3137-3148
with azacytidine therapy in myelodysplastic syndrome, 2441-2452
in *BRCA1/BRCA2* mutation carriers, effect of prevention strategies on, 2420-2529
in childhood cancer survivors, measurement tool for, 4692-4698
and chronic arm morbidity after breast cancer treatment, 4242-4248
in chronic myeloid leukemia after BMT, 2334-2343
effects of epoetin alfa on
nonplatinum therapy and, 601-603 (correspondence)
once-weekly dosing, 3182-3184 (correspondence)
once-weekly *vs.* three-times-weekly dosing, 878 (correspondence), 2757-2758 (correspondence)
in elderly cancer patients, 2915-2917 (editorial)
epoetin beta and recombinant human erythropoietin and, 2486-2494
health-related. *See* Health-related quality of life
in locally recurrent rectal cancer, 4361-4367
in metastatic breast cancer
refractory, tumor response to paclitaxel and, 3665-3673
trastuzumab and chemotherapy effects on, 3106-3113
in metastatic colorectal cancer, after oral chemotherapy for (phase I trial), 4574-4580
in NSCLC survivors, 2920-2929
in palliative cancer care, 1704-1705 (correspondence)
chemotherapy treatment decisions and, 1056-1062
and sphincter preservation for rectal cancer, 1971-1972 (editorial), 3930-3931 (correspondence)
survival analysis and, of adjuvant IFNα2b for high-risk melanoma, 1311-1318
in testicular cancer survivors, 73-80
of women with recurrent breast cancer, 4050-4064

R

R115777, in advanced cancer (phase I trial), 2726-2735
Race
adjuvant therapy for colorectal cancer and, 1192-1202
androgen receptor CAG repeat variations in prostate cancer and, 3599-3604
pediatric rhabdomyosarcoma outcomes by, 4428-4433
PSA outcome after radical prostatectomy and, 2863-2868, 4129-4130 (correspondence)
Radiation mucositis, prophylactic antimicrobial lozenge for (phase III trial), 3956-3963
Radiation recall phenomenon
after capecitabine administration, 3029-3030, 4130 (correspondence)
docetaxel and, 867-869
from high-dose IFN alfa-2b, 355-357 (correspondence)
Radiation therapy. *See* Radiotherapy
Radical hysterectomy, in cervical cancer, 688-693, 2602-2603 (correspondence)
Radical prostatectomy
for localized prostate cancer, external-beam radiotherapy *vs.*, 3363-3364 (editorial), 3376-3385
nerve-sparing, risks associated with, 1853-1858
PSA in
and impact of race on outcome, 2863-2868, 4129-4130 (correspondence)
nested RT-PCR for PSA, 3213-3218
PSM in, nested RT-PCR for, 3213-3218
radiotherapy costs *vs.*, in early-stage prostate cancer, 2869-2875
recurrence of prostate cancer after, 951-956, 3206-3212
Radical surgery, in locally advanced squamous cell cervical cancer, 179-188, 2908-2910 (correspondence)
Radioimmunotherapy
for B-cell lymphoma, 3545-3557
for lymphoma, 2453-2463
for non-Hodgkin's lymphoma, subsequent chemotherapy regimens after, 3885-3890
rituximab tiuxetan, for rituximab-refractory follicular non-Hodgkin's lymphoma, 3262-3269
Radiotherapy. *See also* Chemoradiotherapy; Irradiation
for brain metastases, motexafin gadolinium administration prior to, 3445-3453
for breast cancer, cardiac disease morbidity and mortality after, 1036-1042
carbon ion, in bone and soft tissue sarcomas, 4466-4471
in cervical cancer
locally advanced squamous cell, 179-188, 2908-2910 (correspondence)
for pelvic complications associated with smoking history in, 3651-3657
with cisplatin
for advanced squamous cell cervical cancer (phase III trial), 966-972
for limited-stage small-cell lung cancer (phase III trial), 3045-3047 (editorial), 3054-3060
with concurrent chemotherapy, for advanced head and neck cancer, 1405-1410
conformal 3-D, for high-grade gliomas, 1635-1642, 3357-3359 (correspondence)

external-beam, for localized prostate cancer, surgery *vs.*, 3363-3364 (editorial), 3376-3385
for extremity soft tissue sarcoma, timing of, 4472-4477
high-dose *vs.* standard-dose, for esophageal cancer (phase III trial), 1167-1174
in Hodgkin's disease, 630-637
early-stage pediatric, 3081-3087
unfavorable pediatric, 3088-3094
in Hodgkin's lymphoma, with combined chemotherapy, 476-484
implantable cardiac defibrillators damaged by, 2212-2213 (correspondence)
in inoperable NSCLC
gemcitabine concurrent with (phase I trial), 804-810
thoracic radiotherapy alternating with chemotherapy (phase II trial), 797-803
ipsilateral breast tumor and
for prevention, 4141-4149
recurrence after, 4015-4021
low- *vs.* high-dose, in supratentorial low-grade glioma, 2267-2276
low-dose involved-field
for early-stage Hodgkin's disease in children and adolescents, 3081-3087
induction chemotherapy for intracranial germ cell tumors following, 857-865, 2911-2912 (correspondence)
for unfavorable childhood Hodgkin's disease, 3088-3094
for nasopharyngeal cancer, *vs.* concurrent chemotherapy-radiotherapy (phase III trial), 2038-2044
on neck, stroke risk after, 282-288
and organ preservation in bladder cancer, 3048-3050 (editorial), 3061-3071
with oxaliplatin, for esophageal cancer, 2844-2850
with paclitaxel, for pancreatic adenocarcinoma, 2537-2544
palliative, for eyelid non-Hodgkin's lymphoma, 4601-4602
post-laryngectomy, voice rehabilitation after, 2450-2505
postmastectomy, decision-analytic model for, 2713-2725
preoperative, in rectal cancer, side effects and complications after, 817-825
in primary CNS lymphoma protocols, 231-236
in prostate cancer
early-stage, radical prostatectomy costs *vs.*, 2869-2875
locally persistent, 3199-3205
survival after, 4567-4573
in rectal cancer, capecitabine concurrent with (phase I trial), 3983-3991
RSR13 and, for glioblastoma multiforme (phase II trial), 3149-3155
of supratentorial PNET in childhood, 842-849
temozolomide concurrent with
for brain metastases (phase II trial), 3644-3650
for glioblastoma multiforme, 1375-1382, 3180-3181 (correspondence)
for testicular carcinoma-in-situ, 1537-1543, 3559-3560 (correspondence)
thoracic, in unresectable stage III NSCLC, alternating with chemotherapy (phase II trial), 797-803
Radiotherapy protectants, ASCO guidelines on use of (2002 update), 2895-2903
Raloxifene
breast cancer risk reduction with (ASCO update 2002), 3328-3343
estrogen interaction with, breast cancer risk and, 1430 (erratum)
Raltitrexed
in advanced colorectal cancer (phase II trial), 165-172
irinotecan and, pharmacogenetics of, 1425-1426 (correspondence)
RANKL, in human bone marrow myeloma, 353-354 (correspndence)
Ranpirnase, in unresectable malignant mesothelioma (phase II trial), 274-281
Recombinant human erythropoietin, in hematologic malignancy patients, 2486-2494
Rectal cancer
adjuvant chemotherapy in
stage, sex, and local control analysis, 1744-1750
stage II and III, 1751-1758
concurrent radiotherapy and capecitabine in (phase I trial), 3983-3991
in elderly, adjuvant chemotherapy and radiation therapy for, 2643-2650
locally recurrent, pain and quality of life after treatment of, 4361-4367
preoperative radiotherapy in, side effects and complications after, 817-825
resection specimen, macroscopic evaluation of, 1714-1715 (editorial), 1729-1734
sphincter preservation for, 1971-1972 (editorial), 3930-3931 (correspondence)
Recurrence
of brain tumors in pretreated glioma patients, diagnosis of, 396-404
of breast cancer. *See* Recurrent breast cancer
of head and neck squamous cell carcinoma, diagnostic and prognostic values of FDG-PET in, 4199-4208
of ipsilateral breast tumor, 4015-4021
of ovarian cancer, intraperitoneal ONYX-015 in (phase I trial), 1562-1569
of prostate cancer
after radical prostatectomy, nomogram for, 951-956, 3206-3212
salvage cryotherapy for, 2664-2671
Recurrent breast cancer
letrozole causing reversible pancytopenia in, 3747 (correspondence)
local-regional, predicting, 17-23
quality of life of patients and their family members, 4050-4064
Ro 25–8315 with combination chemotherapy for, 24-36
Recursive partitioning, ipsilateral breast tumor recurrence and, 4015-4021

Reed-Sternberg cells, in classical Hodgkin's disease, 1278-1287
Referral, to medical oncologists, 1716-1718 (editorial)
Referral patterns, impact on chemotherapy use for lung cancer, 1786-1792
Refractory cancers
adenocarcinoma, antrasentan for, 2171-2180
germ cell, paclitaxel plus gemcitabine in (phase II trial), 1859-1863, 3754 (erratum)
ovarian, weekly single-agent paclitaxel for (phase II trial), 2365-2369
Refractory leukemia. *See* Acute leukemias, relapsed/refractory
Refractory lymphoma
gemcitabine and irinotecan for (phase I trial), 2995-3000
non-Hodgkin's, rituximab tiuxetan radioimmunotherapy for, 3262-3269
radioimmunotherapy for, 2453-2463
Refractory pain
implantable drug delivery system for, 4040-4049
opioid rotation in management of, 348-352
Relapse
in acute leukemias. *See* Acute leukemias, relapsed/refractory
in Hodgkin's disease, salvage therapy with high-dose chemotherapy for, 467-475
in myeloid malignancies, chemotherapy and donor leukocyte infusions for, 405-412, 2756-2757 (correspondence)
in oligometastatic breast cancer after high-dose chemotherapy with autologous stem-cell transplantation, prognosis for, 707-718
seminoma surveillance predicting, 4448-4452
Relapsed lymphoma
gemcitabine and irinotecan for (phase I trial), 2995-3000
radioimmunotherapy for, 2453-2463
T-cell, trimetrexate in, 2876-2880
Remission, cytogenetic, in chronic myeloid leukemia, 214-220
Renal cell carcinoma
advanced
IFN-α for, 289-296
thalidomide in (phase II trial), 302-306
individual survival in, mathematical model predicting, 1368-1374
metachronous contralateral, risk of developing, 2370-2375
metastatic
outcome and survival in, 2376-2381
unexpected toxicity of combined thalidomide and INFα2a therapy for, 1429-1430 (correspondence)
risk group algorithm predicting outcome in, 4553-4560
sensitivity t o nonmyeloablative allogeneic hematopoietic cell transplantation, 1965-1967 (editorial), 2017-2024
Research
on cancer survivors/survivorship, 888-890 (editorial)
melatonin, 2575-2601, 4127-4129 (correspondence)
Resection
of disseminated melanoma, survival after, 4561-4566
of liver. *See* Liver resection
Response, in multinomial stopping rule (phase II trial), 599 (correspondence)
Retinoic acid
in advanced cutaneous squamous cell cancer (phase II trial), 364-370
hormone therapy and, in prostate cancer, 538-544
Retroperitoneal soft tissue sarcomas, survival predictions in, 3256-3164
Retroperitoneum, germ cell tumors of, 1864-1873
Reverse transcriptase-PCR
CK-20, in lymph nodes of node-negative colorectal cancer patients, 1049-1055
detecting circulating malignant cells in cutaneous melanoma in complete regression, 1411-1412
lymph node micrometastases detection by, 4232-4241
for PSA and PSM in radical prostatectomy, 3213-3218
Rhabdomyosarcoma
paratesticular, 449-455
pediatric therapeutic outcomes by race, 4428-4433
prognostic gene fusions in, 2672-2679
Rituximab
for indolent non-Hodgkin's lymphoma, 4261-4267
for lymphoma, radioimmunotherapy *vs.*, 2453-2463
for mantle-cell lymphoma, 1288-1294
for Waldenström's macroglobulinemia, 2327-2333
Rituximab tiuxetan radioimmunotherapy, for rituximab-refractory follicular non-Hodgkin's lymphoma, 3262-3269
Ro 25–8315, with combination chemotherapy, for metastatic or recurrent breast cancer patients, 24-36
RSR13, and radiotherapy, for glioblastoma multiforme (phase II trial), 3149-3155
RT. *See* Radiotherapy

S

Safety
of carbon ion radiotherapy, in bone and soft tissue sarcomas, 4466-4471
of chemotherapy, multidisciplinary approach to, 4705-4712
of complementary and alternative medicine use (ASCO/American Cancer Society Symposium), 39*s*-41*s*
of TAC-101, in advanced cancer, 3522-3532
of TNP-470/paclitaxel, in solid tumors, 4440-4447
of ZD1839 (phase I trial), 4276-4278 (editorial), 4292-4302
Salvage cryotherapy, for recurrent prostate cancer, 2664-2671
Salvage therapy
for advanced pure seminoma, 297-301
cisplatin/gemcitabine/ifosfamide, for advanced transitional-cell carcinoma (phase II trial), 2965-2970

with high-dose chemotherapy, for Hodgkin's disease, 467-475
Samarium-153 ethylene diamine tetramethylene phosphonate, skeletal irradiation with, 189-196, 1953-1954 (correspondence)
Sarcoma
bone, carbon ion radiotherapy in, 4466-4471
death from, risk factor analysis, 791-796
Kaposi's. *See* Kaposi's sarcoma
prognostic factors for, 627-629
soft tissue
advanced, epirubicin dosing in, 1329-1334
carbon ion radiotherapy in, 4466-4471
of extremity. *See* Extremity soft tissue sarcoma
pediatric nonrhabdomyosarcoma, 3225-3235
retroperitoneal and visceral, survival predictions in, 3256-3164
time-dependent prognostic variables in, 4344-4352
uterine, and tamoxifen association, 2758-2760 (correspondence), 4403 (correspondence)
Screening
for *BRCA* gene mutation carriers, outcome in, 1260-1268
for breast cancer
in *BRCA1* mutation carriers, 2092-2100
in women with previous Hodgkin's disease, 2085-2091
for hereditary nonpolyposis colorectal cancer, 1705-1707 (correspondence)
for lung cancer, 1959-1961 (editorial), 1973-1983, 3931-3934 (correspondence)
with low-dose helical CT, 911-920
for pediatric neuroblastoma, 1154-1155 (editorial)
incidence and mortality results, 1209-1214
for prostate cancer, family history and, 2658-2663
Sedation, in terminally-ill patients, 758-764
Selective serotonin reuptake inhibitors, opioid analgesia and, 2409 (correspondence)
Self-assessment, by elderly cancer patients, 770-775
Self-rated health, predicting survival in advanced cancer patients, 2514-1519
Seminoma
advanced pure, salvage chemotherapy for, 297-301
surveillance in, relapse prediction and, 4448-4452
Sentinel lymphadenectomy, in cervical cancer, 688-693, 2602-2603 (correspondence)
Sentinel node
in cervical cancer, identification of, 688-693, 2602-2603 (correspondence)
mapping in NSCLC, 1984-1988
techniques in malignant melanoma clinical trials, 2208-2210 (correspondence)
Side effects, of treatment, case examples of, 3029-3034, 4130 (correspondence)
Single-photon emission tomography, and diagnosis of recurrent brain tumors, 396-404
Skeleton
irradiation with high-dose ^{153}Sm-EDTMP, 189-196, 1953-1954 (correspondence)
long-term ibandronate therapy effects on, in advanced multiple myeloma, 2353-2359
Skin. *See also* Cutaneous *entries*
as marker of EGF receptor inhibition by ZD1839, 110-124
^{153}Sm-EDTMP (samarium-153 ethylene diamine tetramethylene phosphonate), skeletal irradiation with, 189-196, 1953-1954 (correspondence)
Small-cell lung cancer
chemotherapeutic regimens compared in (phase III trial), 4665-4672
intensified chemotherapy for, 3941-3943 (editorial), 3947-3955 (phase III trial)
limited-stage, sequential chemoradiotherapy for (phase III trial), 3045-3047 (editorial), 3054-3060
management of, progress in (editorial), 4618-4620
marimastat for, 4434-4439
paraneoplastic digital necrosis in, 4600-4601
Small-cell prostate carcinoma, combination chemotherapy for (phase II trial), 3072-3080
Small round-cell tumors, poor-prognosis, high-dose chemotherapy for, 2181-2188
SMM (smoldering multiple myeloma), malignant transformation risk in, 1625-1634
Smoking
among childhood cancer survivors, initiation and cessation predictors, 1608-1616
and complications of pelvic irradiation, 3651-3657
outcomes after nicotine dependence treatment in lung cancer patients, 3461-3469
Smoldering multiple myeloma, malignant transformation risk in, 1625-1634
Socioeconomic factors, impact on accrual in cancer treatment trials, 2109-2117
Soft tissue tumors
rhabdomyosarcoma. *See* Rhabdomyosarcoma
sarcoma. *See* Extremity soft tissue Sarcoma; Sarcoma, soft tissue
Solid malignancies, thalidomide in, 2607-2609 (editorial)
Solid tumors
advanced
endostatin for (phase I trial), 3792-3803
flavopiridol and paclitaxel (phase I trial), 2157-2170
combination chemotherapy for, dose-finding and pharmacokinetic study of, 1657-1667, 3042-3043 (correspondence)
continuous infusion 5-FU and oral 5-FU/eniluracil compared, in solid tumors, 1683-1691
malignant, efficacy and tolerability of ZD1839 in (phase I trial), 2240-2250
pediatric, combined topotecan and carboplatin in (phase I trial), 88-95, 3558 (correspondence)
pegylated interferon alfa-2b for (phase I/II trial), 3841-3849
TNP-470/paclitaxel for, safety and pharmacokinetic effects of, 4440-4447
troxacitabine for (phase I trial), 96-109
ZD1839 activity and tolerance in (phase I trial), 3815-3825

ZD9331 for, pharmacologic study of (phase I trial), 1923-1931
Soy phytoestrogens, effect on hot flashes in postmenopausal women with breast cancer, 1449-1455, 3040-3042 (correspondence)
SPECT (single-photon emission tomography), and diagnosis of recurrent brain tumors, 396-404
Sperm banking, prior to cancer treatment
oncologists' attitudes toward, 1890-1897
patients' attitudes toward, 1880-1889
Sphincter-sparing therapy, for anal-rectal melanoma, 4549-4552
Spleen
hematoma, associated with non-Hodgkin's lymphoma, 1946-1947
marginal zone lymphoma of, 342-344
Squamous cell carcinoma
cutaneous advanced, 359-361 (editorial)
translational study of (phase II trial), 364-370
of head and neck
docetaxel/cisplatin combination chemotherapy for (phase II trial), 1593-1599
p53 pathways in, 2980-2987
recurrent, FDG-PET in, 4199-4208
laryngeal, galectin-3 and prognosis in, 3850-3856
uterine cervix
neoadjuvant chemotherapy plus radical surgery *vs.* exclusive radiotherapy for, 179-188, 2908-2910 (correspondence)
radiotherapy with/without cisplatin for (phase III trial), 966-972
SSRIs (selective serotonin reuptake inhibitors), opioid analgesia and, 2409 (correspondence)
Staging
lymph node, in resectable NSCLC, 2604-2605 (correspondence)
of NSCLC, alternative strategies for, 263-273
of pediatric Wilms' tumor by chest CT, 2763-2764 (editorial), 2768-2773
Staging systems
in breast cancer, AJCC update on, 3576-3577 (editorial), 3628-3636
in prostate cancer, outcomes and, 2025-2030
simplified, for hepatocellular carcinoma, 1527-1536
Stanford V chemotherapy regimen, for Hodgkin's disease, 630-637
Statistical prediction models, artificial neural networks and, 885-887 (editorial)
Stem-cell rescue, in high-risk neuroblastoma, 2284-2292
Stem-cell transplantation. *See also* Bone marrow transplantation
allogeneic
acute and chronic GVHD after, meta-analysis of, 603-606 (correspondence)
for acute leukemias, 4655-4664
in high-risk multiple myeloma patients after nonmyeloablative conditioning, 1295-1303, 4268-4269 (correspondence)
myeloid relapse after, chemotherapy and donor leukocyte infusion for, 405-412, 2756-2757 (correspondence)
nonmyeloablative, 1965-1967 (editorial), 2017-2024, 4022-4031
for peripheral T-cell lymphoma, 1426-1427 (correspondence)
autologous
for aggressive non-Hodgkin's lymphoma, 2344-2352, 4411-4412 (editorial)
high-dose chemotherapy with
for aggressive lymphoma, 2472-2479
for oligometastatic breast cancer, prognosis in, 707-718
nonmyeloablative allogeneic, 4022-4031
sensitivity of renal cell cancer to, 1965-1967 (editorial), 2017-2024
psychiatric morbidity associated with
depressive symptoms and survival after, 2118-2126
during hospitalization for, 1907-1917
STI571. *See* Imatinib mesylate
Stomach
cancer of. *See* Gastric cancer
MALT lymphoma of. *See* Mucosa-associated lymphoid tissue lymphoma
Stopping rule, multinomial (phase II trial), 599 (correspondence)
Stress management training, for patients undergoing chemotherapy, 2851-2862
Stridor, in myeloma patient, 866-867
Stroke risk, after radiotherapy on neck, 282-288
Stromal tumor, gastrointestinal
KIT mutation type in, 3898-3905
metastatic, response to imatinib mesylate, 870-872, 1430 (erratum)
SU5416, for solid tumors, dose-finding and pharmacokinetic study of, 1657-1667, 3042-3043 (correspondence)
Superficial bladder cancer, intravesical therapy for (editorial), 3185-3186
Supportive care
azacytidine therapy *vs.*, in myelodysplastic syndrome, 2415-2416 (editorial), 2429-2440
individualized, 2765-2767 (editorial)
Suramin, for advanced prostate cancer, 3369-3375
Surgery. *See also specific procedures*
cytoreductive, for advanced ovarian cancer, 1248-1259
preoperative chemotherapy *vs.*, in resectable NSCLC, 247-253, 2603-2604 (correspondence)
radical, in locally advanced squamous cell cervical cancer, 179-188
resection
of disseminated melanoma, survival after, 4561-4566
hepatic. *See* Liver resection
Surveillance, in seminoma, relapse prediction and, 4448-4452

Survival. *See also* Survivors
in advanced cancers
of breast, with capecitabine/docetaxel combination therapy (phase III trial), 2812-2823
multiple myeloma, effects of long-term ibandronate therapy on, 2353-2359
nasopharyngeal, treated with chemoradiation, 1845-1852
patient self-rated health predicting, 2514-1519
in *BRCA1*/*BRCA2* mutation carriers, effect of prevention strategies on, 2420-2529
in breast cancer. *See* Breast cancer survivors
in carcinoma of unknown primary site, prognostic model and, 4679-4683
in cervical cancer, COX-2 prognostic role and, 973-981
depressive symptoms and, after hematopoietic stem-cell transplantation for malignant disorders, 2118-2126
in glioblastoma multiforme
concomitant temozolomide and radiation therapy for, 1375-1382, 3180-3181 (correspondence)
RSR13 and radiotherapy for (phase II trial), 3149-3155
in glioma
cerebral low-grade, prognostic factors for, 2076-2084
high-grade, after conformal radiotherapy, 1635-1642, 3357-3359 (correspondence)
long-term
of cancer patients, analysis of, 826-832, 4405-4409 (correspondence)
in NSCLC, quality of life and, 2920-2929
in melanoma
adjuvant IFNα2b for, quality-of-life–adjusted analysis of, 1311-1318
disseminated, after complete resection, 4561-4566
in NSCLC
after combined-modality therapy, 1989-1995
long-term, quality of life and, 2920-2929
nutrition after breast cancer diagnosis and, 3302-3316, 3939 (errata)
in ovarian cancer
advanced, after cytoreductive surgery for, 1248-1259
BRCA-related, 463-466
in prostate cancer
after castration, nomogram for, 3972-3982
after radiation therapy, 4567-4573
in renal cell cancer
mathematical model predicting, 1368-1374
metastatic, 2376-2381
in retroperitoneal and visceral soft tissue sarcomas, predicting, 3256-3164
Survivin expression, in glioma, prognostic value of, 1063-1068
Survivors
of breast cancer, neuropsychologic impact of chemotherapy in, 485-493
of childhood cancer. *See* Childhood cancer survivors
children as. *See* Childhood cancer survivors
of Hodgkin's disease, second malignant neoplasms in, 3484-3494
mental health service use among, 4581-4590
research on, 888-890 (editorial)
testicular, quality of life in, 73-80
young male, infertility and sperm banking and, 1880-1889
Symptoms
control of, changing patterns in, 880-882 (correspondence)
experiences with, patient and caregiver perceptions in home-care setting, 3495-3507
Systemic lupus erythematosus, fluorouracil-induced exacerbation of, 3032-3034
Systemic mastocytosis, 3737-3739

T

T-cell immunity, after peptide immunization, 2624-2632
T-cell lymphoma
intestinal gamma/delta, CNS involvement in, 3742-3744
peripheral, high-dose chemotherapy or allogeneic hematopoietic transplantation for, 1426-1427 (correspondence)
relapsed, trimetrexate in, 2876-2880
T-cell prolymphocytic leukemia, pretreated, Campath-1H treatment of, 205-213
T-cell recovery, with lymphocyte reinfusion in metastatic breast cancer, 58-64
T lymphocytes, cytolytic, toxicity against a single melanoma epitope, 1075-1086, 3176-3177 (correspondence), 3184 (errata)
t(9;11), impact in childhood AML, 2302-2309
TAC-101, in advanced cancer, safety, toxicity, and pharmacokinetics of, 3522-3532
Tamoxifen
anastrozole *vs.*, in advanced breast cancer, 3748-3750 (correspondence)
for breast cancer risk reduction
ASCO update (2002) on, 3328-3343
in highest-risk groups, cost-effectiveness analysis, 1-3 (editorial), 9-16
for ipsilateral breast tumor prevention, 4141-4149
in older women with breast cancer, 2680-2688
in postmenopausal women
letrozole *vs.*, 876-878 (correspondence)
and vorozole effects compared, 1026-1035
in premenopausal women
with goserelin, *vs.* CMF regimen, 4611-4614 (editorial), 4621-4627
oophorectomy and, 2559-2566, 3934-3936 (correspondence)
and uterine sarcoma association, 2758-2760 (correspondence), 4403 (correspondence)
TAX 317 trial, for advanced NSCLC, economic analysis of, 1344-1352, 3750-3751 (correspondence)
Taxane sensitivity, in metastatic breast cancer, molecular markers of, 2319-2326

Tegafur, uracil with, plus leucovorin in colorectal cancer, 3574-3575 (editorial), 3605-3616 (phase III), 3617-3627
Telomerase, and *p16* expression in NSCLC, 254-262
Telopeptide, N-/C-, crosslinks in bone metastases, 850-856
Temozolomide
with concurrent radiotherapy in brain metastases (phase II trial), 3644-3650
with docetaxel, in advanced melanoma (phase II trial), 420-425
for glioblastoma multiforme
with marimastat (phase II trial), 1383-1388
radiation therapy concomitant with, 1375-1382, 3180-3181 (correspondence)
in malignant childhood gliomas, 4684-4691
in relapsed/refractory acute leukemia (phase I trial), 3249-3253
with thalidomide, in advanced melanoma, 2610-2615, 3361 (erratum)
Terminally-ill patient
artificial hydration in, 4699-4704
care of. *See* End-of-life care
euthanasia views in, 2134-2141
Valentine Godé-Darel, Ferdinand Hodler paintings of, 1948-1950
TESE (testis sperm extraction), in postchemotherapy azoospermic men, 930-936
Testicular cancer
carcinoma-in-situ, radiotherapy for, 1537-1543, 3559-3560 (correspondence)
quality of life in long-term survivors, 73-80
Testis
germ cell tumors of, 1551-1561, 3928-3929 (correspondence)
sperm extraction, in postchemotherapy azoospermic men, 930-936
Thalidomide
in advanced renal cell cancer (phase II trial), 302-306
with dexamethasone, for myeloma, 4319-4323
for multiple myeloma, tumor lysis syndrome and, 2212 (correspondence)
for ovarian and papillary-serous peritoneal carcinoma, pilot study in, 1147-1149 (correspondence)
in solid malignancies, 2607-2609 (editorial)
with temozolomide, in advanced melanoma, 2610-2615, 3361 (erratum)
Thrombocythemia, essential, polycythemia rubra vera-1 gene in, 4249-4254
Thrombosis
antiangiogenesis-associated, 1657-1667, 2605-2606 (correspondence)
Port-a-Cath–induced, follow-up after, 2605-2606 (correspondence)
Thymidylate synthase
oral ZD9331 inhibiting, in solid tumors (phase I trial), 1923-1931
prognostic and predictive values of (editorial), 1711-1713
in colorectal cancer, 1721-1728
in locally advanced colon cancer, 1735-1743
TS and p53 protein, in metastatic colorectal cancer, 2832-2843
Tiredness. *See* Anemic patients; Fatigue
Tissue microarray analysis. *See* Microarrays
TNM (tumor-necrosis-metastasis) staging system, recording accuracy of, 413-419
TNP-470, with paclitaxel, for solid tumors, 4440-4447
Tobacco use. *See* Smoking
Topotecan
bioavailability of, 2918-2919 (editorial), 2943-2950
with carboplatin, in pediatric solid tumors (phase I trial), 88-95, 3558 (correspondence)
in pediatric refractory acute leukemia, 1617-1624
Toxicity
of chemotherapy
and antiangiogenic combinations (editorial), 1446-1447
in breast cancer, assessing and reporting, 52-57, 4636-4642
of combination thalidomide and INFα2a, for metastatic renal cell carcinoma, 1429-1430 (correspondence)
early detection of, NCCTG real-time monitoring program, 4591-4596
of fluorouracil in colorectal cancer, gender differences in, 1439-1441 (editorial), 1491-1498
in high-dose interferon alfa-2b therapy, mechanisms and management of, 3703-3718
irinotecan dosing and (editorial), 7-8
measuring, patient burden and, 4-6 (editorial), 65-72
nail, with paclitaxel for metastatic breast cancer, 4404-4405 (correspondence)
of TAC-101, in advanced cancer, 3522-3532
Tracheal compression, in Hodgkin's disease, 3344-3347
Trade names, *vs.* generic drug name, use of, 1707-1708 (correspondence)
Transcatheter arterial chemoembolization, *vs.* hepatic resection in hepatocellular carcinoma, 4459-4465
Transitional-cell carcinoma
advanced, salvage chemotherapy for (phase II trial), 2965-2970
of urinary bladder
c-met expression in, 1544-1550
intravesical gemcitabine in (phase I trial), 3185-3186
Transplantation. *See* Bone marrow transplantation; Stem-cell transplantation
Trastuzumab
cardiac dysfunction experienced with, 1156-1157 (editorial), 1215-1221, 4119-4120 (correspondence)
for metastatic breast cancer
with docetaxel (phase II trial), 1800-1808
effects on quality of life in, 3106-3113
safety and efficacy of, 719-726, 4130-4133 (correspondence)
Treatment burden, patient's estimation of, 4-6 (editorial), 65-72

Treatment decisions
by cancer patients, 503-513
early-stage breast cancer, patients' role in, 1473-1479
hormone replacement therapy, 616-619 (editorial)
palliative chemotherapy, health-related quality of life and, 1056-1062
patient's right to make, 4115-4118
Treatment side effects, case examples of, 3029-3034, 4130 (correspondence)
Trimetrexate, in relapsed T-cell lymphoma, 2876-2880
Troxacitabine
in advanced solid malignancies (phase I trial), 96-109
pharmacokinetic study of (phase I trial), 2567-2574
in refractory leukemia, 656-664 (phase II trial), 3356-3357 (correspondence)
Trunk, high-grade osteosarcoma of, prognostic factors in, 776-790, 2910-2911 (correspondence)
TS. *See* Thymidylate synthase
Tumor angiogenesis. *See* Angiogenesis
Tumor burden, bisphosphonates and (editorial), 3191-3192
Tumor hypoxia, in cervical cancer, 610-615 (editorial), 680-687
Tumor lysis syndrome
after STI571 in ALL, 354-355 (correspondence)
and thalidomide therapy for multiple myeloma, 2212 (correspondence)
Tumor markers, in pancreatic cancer, irinotecan and gemcitabine inducing, 1182-1191
Tumor-necrosis-metastasis staging system, recording accuracy of, 413-419
Tumors. *See also individual tumors*
microcirculation in, effect of DMXAA on (phase I trial), 3826-3840
microsatellite instability phenotype of, 897-899 (editorial)
multiple, molecular relationship between, 1105-1114
response to paclitaxel in refractory metastatic breast cancer, 3665-3673
uncommon, unusual presentations of, 2400-2406
vascularity of, in primary cutaneous melanoma, 1826-1831
Tyrosinase mRNA, in melanoma patients after Adjuvant IFN therapy, 4032-4039
Tyrosine kinase inhibitors. *See also* ZD1839
targeting epidermal growth factor receptor with, 2217-2219 (editorial)

U

uPA. *See* Urokinase-type plasminogen activator
Uracil, with tegafur plus leucovorin in colorectal cancer, 3574-3575 (editorial), 3605-3616 (phase III), 3617-3627
Urinary bladder, cancer of. *See* Bladder cancer
Urokinase-type plasminogen activator
in breast cancer, clinical relevance of, 1000-1007
prognostic impact in gastric cancer, 2005-2016
Urothelial tract, advanced cancer of. *See also* Bladder cancer
FAP *vs.* M-VAC chemotherapy in (phase III trial), 1361-1367
pretreated, weekly paclitaxel for (phase II trial), 937-940
Uterine cervix, cancer of. *See* Cervical cancer
Uterine sarcoma, and tamoxifen association, 2758-2760 (correspondence), 4403 (correspondence)

V

Vaccine/Vaccination
carcinoembryonic antigen as target of, 2197-2207
HER-2/neu peptide-based, T-cell immunity and, 2624-2632
Influenza, with GM-CSF or placebo in cancer patients, 4313-4318
for melanoma. *See also* Immunotherapy
adjuvant, 2058-2066, 2067-2075, 4181-4190
humoral response to, 3242-3248
metastatic, with autologous tumor-derived HSP gp96-peptide complexes, 4139-4140 (editorial), 4169-4180, 4610 (erratum)
survival and, 4561-4566
Vaccinia viral lysates, in high-risk melanoma, 4181-4190
VAMP chemotherapy regimen, for early-stage Hodgkin's disease in children and adolescents, 3081-3087
VAPEC-B chemotherapy regimen, *vs.* ChlVPP/EVA hybrid regimen for Hodgkin's disease, 2980-2987
Vascular endothelial growth factor
in NSCLC, *p53* and, 900-910
and tumor angiogenesis, 4368-4380
Vasomotor symptoms, treatment options for (editorial), 1436-1437
Venous catheters, occluded, alteplase for, 317-324, 1918-1922
Ventricular dysfunction, in childhood cancer survivors, long-term enalapril therapy, 4517-4522
VEPA chemotherapy regimen, for unfavorable childhood Hodgkin's disease, 3088-3094
Vincristine
in CEV chemotherapy regimen, etoposide/cisplatin *vs.*, in small-cell lung cancer (phase III trial), 4665-4672
in CVP chemotherapy regimen, fludarabine *vs.*, for low-grade non-Hodgkin's lymphoma (phase III trial), 4649-4654
Vinorelbine
with epirubicin, for metastatic breast cancer, 2689-2694
with gemcitabine (biweekly), in pretreated advanced breast cancer (phase II trial), 37-41
in induction therapy in stage IIIB NSCLC, 4191-4198
Viruses, oncolytic. *See* Oncolytic viruses
Visceral soft tissue sarcomas, survival predictions in, 3256-3164
VNP20009, intravenous administration in metastatic melanoma (phase I trial), 142-152
Voice rehabilitation, after total laryngectomy and radiation therapy, 2450-2505
Vorozole, and tamoxifen effects compared, in postmenopausal breast cancer, 1026-1035

W

Waldenström's macroglobulinemia, rituximab for, 2327-2333
Weight loss, in breast cancer patient management, 1128-1143
Wilms' tumor
  in children, staging by chest CT, 2763-2764 (editorial), 2768-2773
  pregnancy outcome after treatment of, 2506-2513

X-Y

Yttriun-90-labeled ibritumomab tiuxetan radioimmunotherapy, for non-Hodgkin's lymphoma, 2453-2463
  subsequent chemotherapy regimens after, 3885-3890

Z

ZD1839
  EGF receptor inhibition by
    in NSCLC and other solid tumors (phase I trial), 3815-3825
    in skin, 110-124
    in solid malignant tumors (phase I trial), 2240-2250
  pharmacokinetics and pharmacodynamics of (phase I trial), 4276-4278 (editorial), 4292-4302
ZD9331, oral, for solid tumors, pharmacologic study of (phase I trial), 1923-1931